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Abstract
Breast cancer is a clinically and molecularly heterogeneous disease displaying distinct
therapeutic responses. Although recent studies have explored the genomic and
transcriptomic landscapes of breast cancer, the epigenetic architecture has received
less attention.
To address this, an optimised Reduced Representation Bisulfite Sequencing protocol
was performed on 1482 primary breast tumours (and 237 matched adjacent normal
tissues). This constitutes the largest breast cancer methylome yet, and this thesis
describes the bioinformatics and statistical analysis of this study.
Noticeable epigenetic drift (both gain and loss of homogeneous DNA methylation
patterns) was observed in breast tumours when compared to normal tissues, with
markedly higher differences in late replicating genomic regions. The extent of
epigenetic drift was also found to be highly heterogeneous between the breast tumours
and was sharply correlated with the tumour’s mitotic index, indicating that epigenetic
drift is largely a consequence of the accumulation of passive cell division related
errors.
A novel algorithm called DMARC (Directed Methylation Altered Regions in Cancer)
was developed that utilised the tumour-specific drift rates to discriminate between
methylation alterations attained as a consequence of stochastic cell division errors
(background) and those reflecting a more instructive biological process (directed).
Directed methylation alterations were significantly enriched for gene expression
changes in breast cancer, compared to background alterations. Characterising these
methylation aberrations with gene expression led to the identification of breast cancer
subtype-specific epigenetic genes with consequences on transcription and prognosis.
Cancer genes may be deregulated by multiple mechanisms. By integrating with
existing copy number and gene expression profiles for these tumours, DNA methylation
alterations were revealed as the predominant mechanism correlated with differentially
expressed genes in breast cancer. The crucial role of DNA methylation as a mechanism
to target the silencing of specific genes within copy number amplifications is also
explored which led to the identification of a putative tumour suppressor gene, THSZ2.
Finally, the first genome-wide assessment of epigenomic evolution in breast cancer is
conducted. Both, the level of intratumoural heterogeneity, and the extent of epiallelic
burden were found to be prognostic, and revealed an extraordinary distinction in the
role of epiclonal dynamics in different breast cancer subtypes.
Collectively, the results presented in this thesis have shed light on the somatic DNA
methylation basis of inter-patient as well as intra-tumour heterogeneity in breast cancer.
This complements our genetic knowledge of the disease, and will help move us towards
tailoring treatments to the patient’s molecular profile.
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1.1. Cancer
1.1 Cancer
Cancer has been notably described by Peter Nowell as an evolutionary process in
which clones (groups of cells arising from a common descendent) that offer a selective
advantage, are pushed towards rapid growth [Nowell, 2012]. Cancer progression,
therefore, can be explained as a process of clonal diversification and adaptation under
selective pressures [Greaves and Maley, 2012]. However, this inherently Darwinian-
style evolution likely leads to the advancement of potent treatment resistant clones and
may explain the failure of current cancer therapies [Aparicio and Caldas, 2013; Nowell,
2012]. Consideration of the evolutionary processes involved in cancer suggests that
tumorigenesis is a multistep process [Foulds, 1958], determined by the acquisition
of alterations leading to disruption of cell cycle regulation and attainment of self-
sufficiency in cell proliferation. A linear evolution model associated with common
initiating genetic mutations followed by a cumulative increase in alterations was
proposed by Fearon and Volgestein [1990] in colorectal cancer. However, these
findings have been challenged in breast cancer, with recent studies prescribing a more
heterogeneous evolutionary model, where neighbouring clones within a tumour share
common progenitor mutations but progressively acquire independent alterations in
parallel [Shah et al., 2012].
The delineation of the evolutionary forces disrupted in cancer has also led to the
classification of cancer driver genes into oncogenes and tumour suppressor genes.
Genes whose alterations cause gain of function effects enabling autonomous and
uncontrolled cell proliferation leading to the transformation of normal cells into
cancer are known as proto-oncogenes [Adamson, 1987]. Proto-oncogenes encode
proteins involved in normal cellular functions such as activating cell division and
suppressing cell death. However, in the event of a gain of function alteration in these
genes, they form mutated version of themselves known as oncogenes that are
aberrantly expressed and drive tumorigenesis. The mechanisms associated with
activating proto-oncogenes are varied. For instance, a chromosomal aberration
involving reciprocal translocation between chromosome 9 and 22 leads to the
formation of the BCR-ABL gene fusion [Rowley, 1973], popularly known as the
Philadelphia chromosome [Nowell and Hungerford, 1960]. This oncogenic variant is
associated with uncontrollable cell division and has been detected in various
leukemias [Kurzrock et al., 2003]. Another example is the Ras proto-oncogene,
involved in cell growth and division, which is activated by somatic point mutations in
several adenocarcinomas including the pancreas, colon and the lung [Bos, 1989].
Additionally, copy number amplifications of the 17q12 amplicon harbouring ERRB2,
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a growth factor receptor, causes overexpression of HER2 resulting in an aggressive
form of breast cancer [Hynes and Stern, 1994].
In contrast, genes whose alterations cause loss of function effects contributing to
the dysregulation in cell behaviour such as evasion of apoptosis are known as tumour
suppressor genes. Tumour suppressor genes can be characterised as gatekeepers
involved in regulating cell cycle checkpoints and inhibiting cell division in normal cells,
or as caretakers involved in maintaining genome integrity [Kinzler and Vogelstein,
1997]. Alfred Knudson is credited with the first detection of a classical tumour
suppressor gene, when he suggested that two independent mutational events within
the same gene were required for the development of retinoblastoma [Knudson, 1971].
Subsequently, RB1, involved in cell cycle regulation, was identified as the target gene
with the discovery that a somatic inactivating mutation often followed an inherited
defective copy of the gene, ultimately leading to retinoblastoma in children [Cavenee
et al., 1983; Comings, 1973]. Prominent examples of tumour suppressor genes in
breast cancer include TP53 [Ananiev et al., 2011] and PTEN [Li et al., 1997] that are
also involved in cell cycle regulation. The breast cancer susceptibility genes, BRCA1
and BRCA2 with recognised roles in double-strand DNA break repair [Merajver et al.,
1995], as well as CDH1 which encodes E-cadherin, a protein involved in cell adhesion
[Berx et al., 1998].
Historically, the main focus of cancer evolution has been on the acquisition of
genetic alterations at oncogenes and tumour suppressor genes. However, in addition to
genetic modifications such as somatic mutations and copy number alterations (CNAs),
epigenetic aberrations (that are also heritable modifications) have been identified as
molecular drivers of tumorigenesis [Baylin and Jones, 2011; Esteller, 2008; Jones and
Baylin, 2002].
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1.2 The role of DNA methylation in cancer
The term epigenetics was first coined by Conrad Waddington to describe how cells
with the same genotype can differentiate into multiple phenotypes [Waddington, 1942,
1957]. Although, this description still holds true more than half a century later, the
definition of epigenetic mechanisms has been updated to include mitotically heritable
variations in transcription that do not modify the underlying DNA sequence. Several
pioneering studies revealed that regulation of normal cellular processes is typically
driven in a cell type-dependent manner, requiring a complex interplay between
different layers of epigenetic information, including DNA methylation, nucleosome
positions, histone modifications, and expression of noncoding RNA. These epigenetic
mechanisms, together, help establish and consolidate the correct higher-order
chromatin structures and gene-expression patterns during differentiation and
development. Of these, DNA methylation remains the most studied epigenetic
alteration in normal mammalian cells as well as in cancer. This is primarily due to two
reasons: a) its strong and validated role in mammalian development, cellular
differentiation and manifestation of some cancers; b) rapid technological
advancements that have allowed systematic and high throughput DNA methylation
analyses on a genome-scale..
1.2.1 DNA methylation is a well-balanced process in mammalian
cells
DNA methylation was first discovered in 1948 [Hotchkiss, 1948] as a covalent
modification of the cytosine base where a single methyl group is added to the
carbon-5 position of the pyrimidine ring in post-replicative DNA. This reaction uses
S-adenosyl-methionine as a methyl group donor, and is catalysed by the action of
DNA methyltransferase enzymes, yielding 5-methylcytosine (5mC, DNA methylation)
[Ehrlich et al., 1982], as depicted in Figure 1.1. Cytosine methylation is a widespread
modification in the genome of mammalian cells that is imposed predominantly on
CpG sites [Ziller et al., 2011], although non-CpG methylation is also found in certain
tissues such as embryonic stem cells [Lister et al., 2009]. The human genome contains
approximately 28 million CpG sites, but these are not evenly distributed [Deaton and
Bird, 2011]. Rather, bulk of the genome is largely depleted of CpG sites with less than
25% of the expected frequency, due to increased mutability of methylated CpGs by
spontaneous deamination [Coulondre et al., 1978]. By contrast, CpG sites can cluster
in short (approximately 1 kb) CpG-rich regions, called CpG islands, which are located
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in about 60% of transcription start sites of human genes (promoters), or in large
repetitive DNA regions (such as centromeres and retro transposons) [Jones and Takai,
2001]. CpG islands are flanked by regions of comparatively lower CpG density, called
CpG shores [Irizarry et al., 2009].
Figure 1.1: DNA methylation of cytosine in the mammalian genome. Figure adapted
from Herman and Baylin [2003]. CH3 = methyl group.
In 1975, two seminal papers [Holliday, R. & Pugh, 1975; Riggs, 1975] were
the first to propose that DNA methylation could function as a potential epigenetic
modification. They reported that precise DNA methylation patterns are established de
novo during embryonic development and are mitotically heritable through multiple
somatic cellular divisions in vertebrates. Since then the functional role of DNA
methylation has been elucidated through a large number of studies that have shown
that DNA methylation is necessary for cell development [Deaton and Bird, 2011;
Suzuki and Bird, 2008], stem cell differentiation [Meissner, 2010], and control of
some tissue-specific gene expression, with widespread effects on cellular growth
and genomic stability [Jones and Takai, 2001]. DNA methylation is also involved in
genomic imprinting, in which certain genes bypass epigenetic reprogramming resulting
in their methylation states to be preserved in a parent-of-origin specific manner [Li
et al., 1993].
In human genomes, the pattern of DNA methylation is cell-specific due to the
tissue specific distribution of methylated and unmethylated CpG sites. However,
several studies have revealed that promoter CpG islands are typically resistant to
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methylation in normal cells and are associated with active gene expression during
differentiation [Jones, 2012; Jones and Takai, 2001]. Unlike CpG island promoters,
the role of DNA methylation within the gene body is yet to be understood. Although,
extensive exonic methylation has been associated with active gene expression [Portela
and Esteller, 2010], a recent report demonstrates that intragenic DNA methylation can
protect the genebody from erroneous transcription initiation [Neri et al., 2017]. Beyond
CpG islands, CpG-poor regions that are enriched in intergenic elements with the
exception of enhancers, are typically methylated in normal cells. Similarly, CpG-poor
promoters are silenced by DNA methylation and exhibit a closed chromatin structure
unless gene expression is required [Stirzaker et al., 2014]. Repetitive sequences are
usually methylated as well and involved in maintaining genome integrity [Jones, 2012].
As a result, DNA methylation has been increasingly recognised as a critical
epigenetic alteration influencing gene regulation. Early studies established promoter
DNA methylation as a key gene expression inhibitor after the discovery of two
mechanisms. First, methyl-binding proteins that are recruited by the methyl group
block the binding of transcriptional factors, thus acting as transcription inhibitors
[Bird and Wolffe, 1999]. Second, methyl-binding proteins also recruit
chromatin-remodelling factors possessing transcriptional repression domains that bind
to these methylated promoters [Hendrich and Bird, 1998]. Recent evidence has also
implicated non-promoter methylation such as intragenic methylation with increased
transcription [Suzuki and Bird, 2008]. However, recent studies have indicated that the
relationship between DNA methylation and transcription is much more nuanced than
originally presumed. Which event -- DNA methylation or transcriptional regulation --
precedes the other, is still debatable. Although, some transcription factors have been
demonstrated as methylation sensitive in the sense that they are inhibited from binding
in the presence of DNA methylation (e.g. NRF), this mechanism is highly
transcription factor and genome-context specific [Domcke et al., 2015; Feldmann
et al., 2013]. Moreover, the binding (or absence) of other transcription factors (e.g.
CTCF) have been shown to locally mediate altered DNA methylation levels [Lienert
et al., 2011; Stadler et al., 2011]. Furthermore, experiments by Lock in the late 1980s
[Lock et al., 1986, 1987] demonstrated that although DNA methylation of the Hprt
gene followed inactivation of the X chromosome, methylation played a critical but
secondary role in locking this inactive state. Therefore, depending on the context,
DNA methylation may play an initiating or a reinforcing role in gene regulation.
However, either way, DNA methylation provides an extremely informative readout of
the epigenetic state of the tissue.
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1.2.2 DNA methylation patterns are disrupted in cancer cells
Although, DNA methylation is a well-balanced process that exquisitely regulates gene
expression in mammalian cells, the disruption of these normal epigenetic processes
can have devastating consequences leading to developmental disorders as well as the
initiation and progression of cancer [Gopalakrishnan et al., 2008; Robertson, 2005;
Robertson and Wolffe, 2000]. Cancer was one of the first diseases in which the
regulatory role of DNA methylation was determined, and altered DNA methylation
patterns is a fundamental attribute observed in nearly all human cancers [Baylin and
Jones, 2011; Esteller, 2008]. A schematic representation (adapted from [Stirzaker et al.,
2014]) summarising DNA methylation patterns in normal cells and the deregulation
observed in cancer cells is presented in Figure 1.2.
Figure 1.2: Summary of DNA methylation patterns in normal cells and the
deregulation observed in cancer cells. Green squiggle = active gene expression. Red
cross = Gene silencing. White circle = unmethylated CpG. Black circle = methylated
CpG. Figure obtained from [Stirzaker et al., 2014].
In 1983, Feinberg and Vogelstein [1983a] observed that genomes of cancer cells
have reduced levels of DNA methylation (hypomethylation) compared to normal
tissues which represented the first link between DNA methylation and cancer.
Promoters that were methylated and repressed in normal tissues were also found to be
hypomethylated in human cancers leading to the reactivation of oncogenes including
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the ras oncogenes [Feinberg and Vogelstein, 1983b] and CCND2 [Oshimo et al.,
2003]. Hypomethylation in tumour cells is also enriched in repetitive elements and
has been shown to result in genomic instability through the expression and
chromosomal rearrangements of repetitive DNA sequences, which is one of the
hallmarks of cancer [Ehrlich, 2002, 2009]. In contrast, promoter CpG islands are
prone to DNA hypermethylation in cancer, and often associated with the silencing of
key tumour suppressor genes (such as BRCA1 involved in DNA repair and p16INK4a
involved in cell cycle control) [Esteller, 2000; Herman and Baylin, 2003; Jones and
Baylin, 2007] which represents another hallmark of cancer. Promoter CpG shores also
exhibit cancer-specific differential methylation and are associated with repression of
genes including HOX2A [Rodríguez-Paredes and Esteller, 2011].
Although a majority of cancer studies have focused on promoter regions due
to their established significance as an epigenetic transcriptional repressor, recently
several reports have progressed to investigating the role of DNA methylation in other
regions as well. DNA methylation in gene bodies has been shown to cause aberrant
gene activation and may have an influence on deregulating alternative splicing [Kulis
et al., 2012; Neri et al., 2017; Shukla et al., 2011]. Genome-scale analysis have
also identified loss of methylation at enhancers in cancers presumably associated
with increased transcription factor binding which can have varied transcriptional
consequences for the target genes [Heyn et al., 2016; Kulis et al., 2012; Pellacani
et al., 2016]. Additionally, polycomb repressive complexes (a group of repressive
chromatin proteins), have also been found take part in epigenetic switching with DNA
methylation; however, the exact role of DNA methylation in these regions in cancer is
not clear [Baylin and Jones, 2011; Cedar and Bergman, 2009].
1.2.3 Epigenetic drift in cancer
It is well established that the DNA methylation landscape of normal cells gets altered
gradually with age, and this phenomenon has been termed as epigenetic drift [Ahuja
et al., 1998; Issa, 2014; Teschendorff et al., 2013]. High genome-coverage studies
showed that these age-related methylation changes occurred genome-wide [Fraga et al.,
2005], but are not randomly distributed [Day et al., 2013; Teschendorff et al., 2010].
A large component of this epigenetic drift has been shown to be a universal feature,
independent of tissue type [Horvath et al., 2012; Teschendorff et al., 2013], and has
been detected in cancer as well [Zheng et al., 2016]. But this imposes the question –
what is the biological mechanism underpinning this epigenetic drift? Key experiments
conducted by Yatabe et al. [2001] investigating DNA methylation patterns at neutral
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loci in the stem cell population of colorectal cancer indicated an accumulation of errors
in the maintenance of DNA methylation in line with the number of cell divisions.
These neutral loci were specifically chosen to not have any functional consequences
and were unlikely to be under selective pressures, which suggested that the accrual
of DNA methylation replication errors largely contributed to the observed epigenetic
drift [Kim et al., 2005; Siegmund et al., 2009].
Epigenetic drift in a tumour represents the divergence in its epigenome over time,
and consequently, a higher level of epigenetic drift fuels epigenetic cellular
heterogeneity which could enhance phenotypic plasticity enabling superior tumour
evolution [Feinberg et al., 2006; Issa, 2011]. Consequently, this stochastic
accumulation of methylation errors is also associated with increased proliferation rates
and adverse clinical outcomes such as relapse or death [Teschendorff et al., 2016a].
In fact, the rate of DNA methylation replication errors (either gain or loss of
methylation) has been estimated to be approximately 100 times higher than the rate of
somatic mutations (Rate of DNA methylation errors within CpG dinucleotide = ∼10-5
per CpG site per cell division; Rate of somatic mutation within CpG dinucleotide =
∼10-7) [Siegmund et al., 2009]. Consequently, compared to somatic mutations, DNA
methylation errors have been proposed as a superior molecular mark to serve as a
mitotic clock to provide an estimate of the number of cell divisions in cancer [Issa,
2014; Kim et al., 2005]. However, although epigenetic drift is related to the number
of cell divisions, it may also be acquired due to environmental exposures including
inflammatory conditions and/or underlying genetic traits such as genome instability
[Fraga et al., 2005; Jones et al., 2015; Teschendorff et al., 2013].
These observations collectively indicate that precancerous malignancies could
carry DNA methylation signatures (called epigenetic field defects) which continue
to intensify in line with the rate of mitotic divisions accompanying the initiation and
progression of the cancer [Chai and Brown, 2009; Teschendorff et al., 2016a]. This has
opened up the exciting possibility to use DNA methylation signatures in normal cells
as a predictor of cancer risk, with promising results in cervical cancer [Teschendorff
et al., 2012] and lung cancer [Teschendorff et al., 2015] among others. Recently,
Yang et al. [2016] constructed a mitotic-index based epigenetic signature that was
universally accelerated in cancer, in pre-invasive lesions and in normal cells at risk of
neoplastic transformation, and thus could have a potential utility in diagnosis.
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1.2.4 Deregulation of epigenetic modifiers in cancer
A significant discovery of genome-scale cancer studies has been the detection of
mutations in epigenetic modifiers in multiple tumour types [Feinberg et al., 2016].
These include genes that are critical protagonists in the DNA methylation machinery,
and therefore are associated with many downstream epigenetic alterations. For
example, DNMT3A, which encodes a de novo DNA methyltransferase, is affected by
somatic mutations in approximately 25% of acute myelogenous leukaemia (AML)
cases [The Cancer Genome Atlas Research Network, 2013b]. These mutations have
been shown to result in hypomethylation within the gene body, gene neighbourhood,
and intergenic regions [Glass et al., 2017]. Moreover, mutations in ten-eleven
translocation 2 (TET2), and isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) genes
have been detected in gliomas and AML which resulted in a global hypermethylation
phenotype [Abdel-Wahab et al., 2009; Figueroa et al., 2010; Noushmehr et al., 2010].
Remarkably, the mutations in TET2 and IDH1/ IDH2 were mutually exclusive in
AML. These findings indicated involvement of these genes in a mechanism of active
DNA methylation change. About the same time, seminal work discovered that the
TET family of proteins are hydroxylating enzymes responsible for active DNA
demethylation through enzymatic conversion of 5-methylcytosine (5mC) to
5-hydroxymethylcytosine (5hmC) [Iyer et al., 2009; Kriaucionis and Heintz, 2009;
Tahiliani et al., 2009]. TET enzymes and 5-hydroxymethylcytosine have since been
established to play crucial roles in embryonic development, cellular differentiation
and stem cell reprogramming [Hackett et al., 2013; Ito et al., 2010; Koh et al., 2011].
Loss of hydroxymethylcytosine is an epigenetic hallmark of cancers and both IDH
and TET family of proteins have been implicated in the mechanism underlying this
epigenetic deregulation [Figueroa et al., 2010; Lian et al., 2012].
1.2.5 Advancements in methylation profiling
Cancer studies focusing on methylation aberrations were initially restricted to relatively
localised regions of the genome (predominantly promoter CpG rich regions). With
the emergence of microarrays and next-generation sequencing (NGS) technologies,
methylation-profiling strategies have been developed to perform systematic and high
throughput DNA methylation analyses on a genomic-wide scale. Today, three broad
genome-wide strategies for methylome profiling stand out as the most useful and
popular. Each has different sample requirements, merits and challenges that are
dictated by the research hypothesis, sample types and feasibility. These are discussed
in depth below, and summarised in Table 1.1.
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Table 1.1: Comparison between the three broad types of DNA methylation profiling
technologies. C = unmethylated cytosine. 5mC = methylated cytosine. NGS = Next
Generation Sequencing.
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1.2.5.1 Bisulphite microarrays
Array-based methods have been the popular choice for genome-wide DNA
methylation analyses in a variety of cell types. These methylation assays commence
with the bisulphite conversion of genomic DNA, followed by hybridisation to arrays
that contain predesigned probes to distinguish methylated (cytosine) and
unmethylated (converted to uracil) DNA fragments [Bibikova et al., 2009, 2006]. The
Illumina GoldenGate Assay [Bibikova et al., 2006] and the Infinium Human
Methylation 27 (HM27) BeadChip [Bibikova et al., 2009] were the first popular
iterations of the microarray-based technologies that included 1536 and >27,000
cytosines respectively. However, they were quickly superseded by the widely used
Infinium Human Methylation 450 (HM450) BeadChip that interrogates >480,000
cytosines across the human genome. This represents only approximately 1.7% of all
CpG sites in the human genome, substantially less than other methods. These sites are
enriched for CpG residues (99.3%) and located in 99% of (Reference Sequence)
RefSeq gene promoters, gene bodies, and also some intergenic space [Bibikova et al.,
2011]. However, the HM450 microarrays suffer from a lack of coverage at distal
regulatory regions. In 2016, Illumina launched the Infinium Methylation EPIC (EPIC)
BeadChip which interrogates >850,000 cytosines comprising of 90% of the HM450
probes, but significantly also including more than 350,000 probes representing
potential enhancers [Pidsley et al., 2016] identified by FANTOM5 [Lizio et al., 2015]
and ENCODE [Siggens and Ekwall, 2014].
With the advantage of requiring low amounts of input material,
cost-effectiveness, suitability for high-throughput and ease of bioinformatics analysis,
microarrays have been the most popular choice amongst researchers studying DNA
methylation. However, these benefits come with the price of certain limitations.
Firstly, the design is heavily biased due to preselection and inclusion of probes that
interrogate only specific CpG sites that have been previously identified in
methylation-based assays. Secondly, it is assumed that CpG sites located adjacent to
those interrogated by the probes will be similarly methylated, which is known as the
co-methylation assumption [Eckhardt et al., 2006]. Additionally, their use in cancer
studies may also lead to biases since single nucleotide polymorphisms (SNPs) and
mutations can affect the hybridisation step [Pidsley et al., 2013].
1.2.5.2 Immunoprecipitation-based technologies
Genome-wide immunoprecipitation-based methods rely on enrichment of a fraction of
methylated DNA, followed by quantification by sequencing. Two common
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immunoprecipitation-based approaches include using a monoclonal antibody specific
for 5-methylcytosine (called methyl-DNA immunoprecipitation (MeDIP)) [Weber
et al., 2005]; and affinity capture using Methyl-CpG-binding domain (MBD) proteins
[Rauch and Pfeifer, 2005]. Due to biases in the different immunoprecipitation-based
technologies, distinctive genomic regions are interrogated [Nair et al., 2011]. MeDIP
is based on immunoprecipitation of single-stranded methylated DNA fragments and
targets regions of low CpG density (e.g., intergenic regions). On the contrary, MBD
isolates double-stranded fragments and favours enrichment of CpG-dense regions
(e.g., CpG islands) [Robinson et al., 2010]. MBD-Seq performed on fully methylated
DNA can yield approximately 18% coverage of the genome because it captures
approximately 5 million methylated CpG sites [Stirzaker et al., 2014]. Approximately
30 million single-end reads are required for accurate interpretation of data.
The two key merits of immunoprecipitation-based technologies are a) achieving
genome-wide coverage is relatively cheap; and b) enabling differentiation between
types of DNA methylation (such as 5mC and 5hmC) by using antibodies that
specifically detect one and not the other [Bock, 2012]. Conversely, a notable
disadvantage of s that these techniques do not provide single-nucleotide resolution.
Rather, they identify regions containing multiple methylated CpG sites typically at
CpG-rich regions (for MeDIP) similar to chromatin immunoprecipitation sequencing
(ChIP-Seq). Furthermore, these techniques are only marginally quantitative because
the number of reads mapping to a particular region of the genome depends on the
density of methylated CpG sites and is also highly susceptible to experimental biases
[Stirzaker et al., 2014]. Consequently, it is more challenging to compare methylation
levels between samples. Additionally, the immunoprecipitation-based techniques are
prone to copy number biases, making them less suitable for cancer analyses,
particularly breast and ovarian, that are dominated by CNAs.
1.2.5.3 Bisulfite sequencing techniques
Bisulphite-sequencing is considered the gold standard for DNA methylation analyses
because it enables quantification of CpG methylation at single-base resolution
[Frommer et al., 1992]. Briefly, the protocol involves treatment of the DNA with
sodium bisulphite to convert cytosine to uracil, which is converted to thymine after
polymerase chain reaction (PCR) amplification, whereas methylated cytosine residues
are not converted and remain as cytosines due to a protective effect of their methyl
group [Susan et al., 1994]. This is then followed by sequencing that enables the
generation of genome-wide, single-base resolution DNA methylation maps from
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bisulphite-converted DNA. After bisulphite conversion and sequencing, methylated
and unmethylated cytosines will be distinguished as C and T, respectively [Frommer
et al., 1992; Susan et al., 1994].
Whole Genome Bisulphite Sequencing (WGBS) is a well-established protocol
that facilitates profiling of approximately 95% of all the CpG sites (28 million) in
the human genome. WGBS has the advantage of whole-genome coverage, excellent
reproducibility and of providing single-nucleotide resolution and thus high quantitative
accuracy [Stirzaker et al., 2014]. Moreover, reads from WGBS data could be used
to not only measure methylation at individual CpGs, but also to detect SNPs and
mutations. Additionally, since multiple CpG sites are profiled for a large number
of individual reads per sample, this sequencing method allows for estimation of
intratumour heterogeneity in cancer studies [Landan et al., 2012]. Disadvantages of
WGBS include the high cost and the inability to easily discriminate between 5mC
and 5hmC [Booth et al., 2012]. Moreover, more than 500 million paired-end reads
are required to achieve approximately 30-fold coverage [Stirzaker et al., 2014], and
consequently conducting WGBS is extremely expensive. Bioinformatics analysis
and accurate interpretation of bisulphite sequencing requires computational expertise
[Stirzaker et al., 2014]. As a result, relatively few WGBS human cancer or related
methylomes have been generated.
The increasing momentum of methylation studies, coupled with the considerable
cost of whole epigenome technologies has sparked interest in the conception of more
cost-effective methods. This has led to the development of genome-wide methylation
analyses that are directed at specific genomic regions of interest (such as CpG rich
regions) by using enrichment strategies. The archetype of this method is Reduced
Representation Bisulphite Sequencing (RRBS), an efficient and high-throughput
technique to analyse methylation profiles in which an enrichment strategy using
restriction enzymes is combined with bisulphite sequencing to target a specific
fraction of the genome, thereby reducing the per-sample cost of sequencing [Gu et al.,
2010, 2011; Meissner et al., 2005]. A restriction enzyme such as MspI recognises and
cuts the CCGG motifs that are overrepresented in high CpG content regions of the
genome. Thus, RRBS is able to investigate methylation profiles at a majority of CpG
islands and gene promoters, but does not interrogate intergenic or lowly methylated
regions of the genome. This reduced representation of the genome is sequenced
similarly to WGBS to generate a single-base pair resolution DNA methylation map. A
minimum of 10 million sequencing reads are required for the downstream analysis of
RRBS data sets, leading to approximately 3.7% actual coverage of CpG dinucleotides
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genome-wide or approximately 1 million CpG sites [Gu et al., 2011; Stirzaker et al.,
2014]. However, using enhanced RRBS protocols such as eRRBS described in
Garrett-Bakelman et al. [2015] can yield approximately 3-4 million CpG sites.
RRBS offers most of the advantages of WGBS. Furthermore, it is more cost-
effective since it targets bisulphite sequencing in an enriched population of the genome,
while retaining single-nucleotide resolution. RRBS also requires significantly lower
input DNA than WGBS, and can be extensively applied to model systems with limited
DNA material availability [Bock, 2012]. Despite being biased towards CpG-rich
regions, it has allowed discovery of novel biomarkers in addition to those identified
using methylation arrays. Provided the coverage is sufficient, reads from RRBS
data could also be used to detect single nucleotide variants (SNVs) [Gu et al., 2010],
allowing simultaneous detection of genetic and epigenetic information in important
regulatory regions of the genome that RRBS covers. Being a sequencing-based
technology similar to WGBS, it can also capture epiallelic composition of the samples
allowing the estimation of intratumour heterogeneity in cancer studies [Landan et al.,
2012]. However, a lack of coverage at CpG-poor intergenic and distal regulatory
elements is a potential disadvantage of the method. Similar to WGBS, it also suffers
from a difficulty to differentiate between 5mC and 5hmC.
A limitation of bisulphite sequencing techniques is that the bisulphite treatment
leads to considerable fragmentation of DNA, and therefore it typically requires
relatively large quantities of DNA (1–5 µg for WGBS, lower for RRBS) followed by
PCR amplification. Bisulphite conversion followed by PCR amplification also results
in a highly skewed AT/GC composition which can introduce biases in the
quantification of methylation [McInroy et al., 2016]. In RRBS, this bias is magnified
due to the inability to discriminate between PCR-induced duplication artefacts or
distinct molecular copies of fragments since the start and end sites of reads are largely
driven by restriction enzyme digestion. However, two PCR-free protocols have since
been established: post-bisulphite adaptor tagging (PBAT) [Miura et al., 2012] and
recovery after bisulphite treatment (ReBuilT) [McInroy et al., 2016]. Consequently,
these protocols result in lower levels of duplication as well as reduced biases in
sequence context compared to bisulphite sequencing experiments that require PCR
amplification. The PCR-duplicate predicament in RRBS can also be circumvented
through the use of unique molecular identifiers (UMI) as demonstrated in the
quantitative RRBS (Q-RRBS) method established by Wang et al. [2015]. These
methods have also enabled the development of single-cell genome-wide bisulphite
sequencing techniques [Farlik et al., 2015; Guo et al., 2013; Smallwood et al., 2014].
16
1.3. Heterogeneity in breast cancer
1.3 Heterogeneity in breast cancer
Breast cancer is an uncontrolled growth of cells that originates from the breast tissue.
If left untreated, the tumour can invade surrounding tissues or metastasise to distant
areas of the body leading to death. Breast cancer is one of the leading causes of
mortality in women with greater than 450,000 deaths each year worldwide [Cancer
Genome Atlas Network, 2012]. Most breast cancer patients (80%) are above the age of
fifty, but younger women, and very rarely, men, are also diagnosed with breast cancer.
Over the past 25 years, there have been substantial improvements in overall
survival outcomes, primarily due to developments in early diagnosis, early surgical
interventions and efficacy of cytotoxic and targeted biological therapies [Peto et al.,
2000]. Despite these advancements, a great challenge in the clinic is that breast cancer
is not one single disease, but a group of heterogeneous entities with diverse variations
in molecular and clinical outcomes [Dawson et al., 2013]. As a result, therapies that
are not targeted may subject some patients to unnecessary toxicity and inferior efficacy.
In fact, present clinical management causes overtreatment of 50% of breast cancer
patients [Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005], with
implications on quality of life of patients as well as healthcare costs. At the same
time, intrinsic or acquired tumour resistance to treatment leads to disease progression
towards incurable metastatic disease in a significant proportion of patients.
There is a pressing need to expand our knowledge of the genetic and epigenetic
aberrations underlying breast cancer, which would be vital in delineating inter-patient
as well as intra-tumour heterogeneity. Successful translation of these findings into the
clinic will move us closer towards the implementation of a more targeted, personalised
approach to breast cancer medicine.
1.3.1 Histopathological evaluation of breast cancer
The current clinical management of breast cancer involves surgical excision of the
tumour in combination with therapies administered either before (neoadjuvant) or
after (adjuvant) the surgery. Therapies include radiotherapy, cytotoxic chemotherapy,
endocrine therapy or molecular targeted therapies. Following surgery, therapeutic
decisions are predominantly based on histopathological assessments of the surgical
biopsy that involve a combination of morphological examinations alongside identifying
immuno-histochemical (IHC) markers [Ali et al., 2014; Dawson et al., 2013]. These
histopathological examinations have proven to have prognostic and predictive power,
and hence remain the foundation of current clinical management of breast cancer.
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1.3.1.1 Morphological and anatomical classification
Morphological features such as tumour grade and anatomical features such as tumour
size and lymph node status, all form key tools as part of the histopathological arsenal.
Tumour grade provides an assessment of its intrinsic characteristics including
differentiation and proliferative activity [Elston et al., 1999]. Breast tumours are
scored on a scale of 1-3, with 3 representing high-grade tumours. High-grade tumours
have been shown to be correlated with high levels of the nuclear antigen Ki-67, a
marker of cell proliferation and is associated with worse survival [Contesso et al.,
1987]. Lymph node status and tumour size provide information related to the extent
and stage of the disease. Lymph node status is typically defined as the number of
lymph nodes in which the breast cancer has invaded, and is presently the most
powerful prognostic factor in breast cancer [Carter et al., 1989]. Tumour size has also
been shown to be a robust and independent prognostic factor in breast cancer [Carter
et al., 1989]. Younger patient age at diagnosis has also been shown to be associated
with worse prognosis for premenopausal women, independent of other
histopathological parameters.
The morphological assessment also includes allocation of the histological subtype
according to the tumour’s architectural patterns and a semi-quantitative evaluation of
its cytological characteristics [Elston et al., 1999]. A majority (75%) of breast cancers
show no special characteristics and are defined as invasive carcinomas of no special
type (NST) [Sinn and Kreipe, 2013]. There at least 17 special histological subtypes
that are characterised by distinct microscopic appearances, histological growth patterns
and diverse clinical courses [Wellings SR, Jensen HM, 1975]. They are relatively
uncommon and include ductal carcinoma in situ; lobular carcinoma in situ; invasive
lobular carcinoma; tubular carcinoma; medullary carcinoma; and mucinous carcinoma.
1.3.1.2 Histological molecular markers
The discovery of two key IHC markers, oestrogen receptor (ER) and human epidermal
growth factor receptor 2 (HER2) provided a breakthrough in breast cancer research,
and set the stage for the first targeted therapies in cancer.
Oestrogen receptor status
Oestrogen receptor (ER) expression status is a keystone of breast cancer
management [Knight et al., 1977; Riggs and Hartmann, 2003], and is typically
assessed using IHC [Harvey et al., 1999]. Most breast cancer patients have high levels
of ER (75%, ER+ breast cancer), and are generally older patients with smaller
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tumours [Anderson et al., 2002]. On the contrary, ER- breast cancers are more
commonly diagnosed in younger patients. ER markers are widely applied to aid the
selection of breast cancer patients for adjuvant hormonal based treatments such as
tamoxifen, a non-steroid oestrogen antagonist in breast tissues [Fisher et al., 1998;
Jensen et al., 1971]; and aromatase inhibitors that reduce the levels of oestrogen by
interfering with its production [Bonneterre et al., 2000; Riggs and Hartmann, 2003].
These endocrine therapies have been associated with a striking improvement in
survival predominantly in ER+ patients [Early Breast Cancer Trialists’ Collaborative
Group (EBCTCG), 1998, 2005]. ER+ patients generally experience a consistent risk
of mortality over time, whereas ER- patients have a much higher risk of relapse and
death within the first five years after diagnosis, after which the risk diminishes [Dent
et al., 2007]. The rationale for this time-dependence is still unclear.
Progesterone receptor status
Progesterone receptor (PR) is an oestrogen-regulated hormone [Lee and Gorski,
1996] which has been shown to inhibit oestrogen-fuelled growth and tumour
progression [Mohammed et al., 2015]. Most ER+ tumours are also PR+, although
about 25% of all breast tumours are ER+/PR-, and is has been argued that this
represents a distinct clinical and biological entity compared to ER-/ PR+ tumours
[Rakha et al., 2007].
HER2 status
The overexpression and/ or amplification of the protein Human Epidermal growth
factor Receptor 2 (HER2) is found in 12-15% of breast cancers with approximately
half of these co-expressing hormone receptors [Curtis et al., 2012; King CR, Kraus
MH, 1985; Konecny et al., 2003]. HER2 belongs to a family of transmembrane
receptor tyrosine kinases that are activated by the binding of growth factor ligands
such as the epidermal growth factor (EGF), which triggers receptor dimerization and
activation of downstream cellular processes including proliferation [Baselga, 2010;
Rowinsky, 2004]. Not only do HER2 amplifications have great prognostic value in
predicting survival and time to relapse [Dressman et al., 2003], this discovery also led
to the development of anti-HER2 based therapies. The most prominent is trastuzumab
(Herceptin), a monoclonal antibody that interferes with the HER2 receptor, which in
combination with chemotherapy provides significant clinical benefit to HER2-positive
breast cancer patients [Tan, 2003].
Breast cancers that are hormone receptor negative (ER- and PR-) as well as HER2
negative are classified as Triple Negative Breast Cancers (TNBCs) and account for
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the remaining 12-17% of cancers [Foulkes et al., 2010]. TNBCs represent the least
favourable IHC-based subtype of breast cancer in terms of prognosis due to the lack of
therapeutic options available today [Ali et al., 2014; Dawson et al., 2013; Dent et al.,
2007].
1.3.2 Molecular classification of breast cancer
The use of the histopathological assessments in conjunction with prognostic indices
such as the Nottingham prognostic index (NPI) [Galea et al., 1992] and PREDICT
[Wishart et al., 2010] are routinely performed in the clinic and provide great prognostic
and predictive value in clinical management. However, despite these advancements,
breast cancer patients with similar histopathological/ clinical features still exhibited
significant variation in therapeutic response and survival [Dawson et al., 2013]. A
probable explanation for this is that these assessments provide inadequate insight
into the underlying molecular mechanisms and biological pathways that drives breast
cancer heterogeneity.
1.3.2.1 Gene expression profiling - the Intrinsic subtypes
The emergence of microarray technology heralded the way for comprehensive
molecular profiling of breast cancer towards the aim of revealing the unexplained
heterogeneity. Pioneer gene expression profiling studies in breast cancer led to the
identification of four distinct Intrinsic subtypes -- Luminal A, Luminal B, Basal-like
and HER2-enriched -- and a normal breast-like group (called Normal-like) [Perou
et al., 2000; Sorlie et al., 2001, 2003]. These molecular subtypes of breast cancer were
discovered by focusing on an intrinsic gene set of 500 unique genes (initially 1753
genes), that had significantly higher variation between tumours from different patients
than between successive samples from the same patient’s tumour [Sorlie et al., 2003],
and then performing unsupervised hierarchical clustering. These Intrinsic subtypes not
only reflected pervasive transcriptomic differences underlying the cell biology of
breast cancer, but importantly also showed significant variation in clinical outcomes
including incidence, survival and therapeutic response [Sorlie et al., 2003]. A
noteworthy finding of this study was that ER+ breast carcinomas (that arise from
luminal epithelial cells), actually encompass two separate biological subtypes:
Luminal A and Luminal B. They have distinctive gene expression profiles, with the
Luminal A subtype having higher expression of ESR1 and GATA3, whereas the
Luminal B subtype had lower expression of luminal cell genes and exhibited higher
levels of proliferation. Luminal B tumours also associated with higher grade and
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appreciably worse prognosis [Sorlie et al., 2003; Sotiriou et al., 2003]. The other two
Intrinsic Subtypes were characterised by ER-negativity with poor patient outcomes.
HER2-enriched subtype is defined by dominant HER2 expression, whereas the
Basal-like subtype shows characteristics of basal cells in the mammary epithelium.
The Normal-like subtype is most similar to the normal mammary tissue with respect
to its gene expression profile.
The evolution of gene expression studies has led to many similar analyses that
have proposed additional subtypes and molecular signatures that could accurately
predict disease outcome [Melisko, 2005; Teschendorff et al., 2007; van ’t Veer et al.,
2002]. Particularly, a sixth breast cancer subtype was discovered called Claudinlow that
closely resembles mammary epithelial stem cells and is characterised by low expression
levels of claudins and CDH1 [Herschkowitz et al., 2007; Prat et al., 2010]. These
tumours are predominantly ER, PR and HER2-negative, and reflect an intermediate
prognosis between Luminal and Basal-like tumours. Parker et al. [2009] developed
a single sample classifier called the Prediction Analysis of microarrays 50 (PAM50)
to prospectively classify breast cancer tumours into the aforementioned Intrinsic
subtypes. The PAM50 classifier uses a quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR) assay to measure the expression of 50 genes followed by the
centroid-based Prediction Analysis of Microarrays (PAM) method [Tibshirani et al.,
2002]. It’s utility as a single sample classifier, the ability to apply it on formalin-fixed,
paraffin-embedded (FFPE) tissue, as well as the reduced number of genes to consider
has led to the widespread adoption of the Intrinsic subtype classification in breast
cancer management.
These efforts have also prompted the development of multigene tests that employ
distinct prognostic signatures for individual risk assessment in the clinic. In addition
to PAM50, other prognostic tools include Mammaprint, OncotypeDX and Breast
Cancer Index, that have been validated in clinical trials to establish their use in the
clinic [Cardoso et al., 2008; Melisko, 2005; Sotiriou et al., 2006; Sparano and Paik,
2008; van de Vijver et al., 2002]. Although these attempts provided early insights into
the molecular heterogeneity, they did not take into account the underlying molecular
aberrations that might explain these transcriptomic variations, and ultimately subtype
specificity. This prompted the development of multi-level genomic characterisation of
breast cancer.
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1.3.2.2 Profiling genomic alterations in breast cancer
Tumorigenesis as well as subtype-specific variations in gene expression profiles are
heavily influenced by the underlying genomic architecture of breast cancers. Both
inherited genetic variants and acquired genetic alterations contribute to the tumours’
genetic diversity. However, it is the accumulation of somatic genomic changes
(including somatic mutations and copy number aberrations) that enable the initiation
and progression of breast carcinomas [Albertson et al., 2003]. Recurrent genomic
aberrations can contribute to tumorigenesis by deregulating genes linked with the
development of cancer pathophysiology such as evasion of apoptosis, sustained
angiogenesis and limitless potential for proliferation [Aguirre-Ghiso et al., 2003;
Hanahan and Weinberg, 2011]. Discovery of these somatic alterations, followed by
differentiation between driver and passenger events amongst them would prove to be a
key strategy in identifying these genes related to the initiation and progression of
breast cancer.
The advent and rapid development of NGS technologies, combined with the
continued use of older microarray technologies led to the realisation of a plethora
of cancer genomics projects. These projects were designed to evaluate multi-level
molecular characterisation of several cancer types, including breast cancer with the aim
of fulfilling the aforementioned strategy of identifying driver genes, and are delineated
below.
In breast cancer, the landscape of somatic alterations is dominated by copy
number alterations; and well-defined genomic rearrangements have been characterised
in breast cancer [Ciriello et al., 2013; Stephens et al., 2009]. Copy number profiling
has also been linked with gene expression changes to improve the classification of
the Intrinsic subtypes of breast cancer [Chin et al., 2006, 2007]. The emergence of
low cost and deep whole-genome and whole-exome sequencing has also enabled the
comprehensive characterisation of the mutational landscape of breast cancer, leading
to the identification of genes previously implicated in breast cancer as well as novel
frequently mutated genes [Banerji et al., 2012; Cancer Genome Atlas Network, 2012;
Ellis et al., 2012; Nik-Zainal et al., 2016; Pereira et al., 2016; Shah et al., 2012;
Stephens et al., 2012]. Several of these genes displayed Intrinsic subtype specific
mutation patterns that could be linked into cellular pathways underlying tumour biology
and clinical outcomes. Investigating the landscape of somatic alterations also enabled
characterisation of the distribution of clonally dominant somatic mutations [Eirew
et al., 2014; Nik-Zainal et al., 2012; Shah et al., 2012]. This allowed exploration into
the dynamics of genomic clones and the role of intratumour heterogeneity in evolution.
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1.3.2.3 Integrated analysis of copy number and gene expression - the
Integrative clusters
The discovery efforts of the first-generation sequencing studies mentioned above
signaled the move to identifying driver events in breast cancer as the optimum strategy
for molecular classification. An extensive examination of 2000 breast cancers as part of
the METABRIC (MolEcular TAxonomy of BReast cancer International Consortium)
consortium involved the integration of the genomic (copy number) and transcriptomic
landscapes of the disease [Curtis et al., 2012]. METABRIC represents the largest
cohort of breast tumours on which molecular profiling has been undertaken, and
this seminal study illuminated the profound impact that somatic CNAs have on gene
expression in breast cancer. This strategy led to the identification of 1000 genes with
cis-acting CNA (on gene expression) and used the integrative cluster method [Shen
et al., 2009, iCluster] and internal validation to reveal 10 Integrative clusters (IntClusts
1-10). These clusters yielded a refinement of the molecular classification of the
disease towards a driver-based taxonomy and demonstrated the extensive heterogeneity
present within tumours classified according to IHC-subtypes and Intrinsic subtypes.
Furthermore, each Integrative cluster was associated with different clinical features and
survival outcomes. A complete description of the molecular and clinical characteristics
of the Integrative clusters are provided in Dawson et al. [2013], and summarised
in Table 1.2 (modified from [Dawson et al., 2013]). Since then, the tumours in
IntClust 4, a genomically quiet cluster, have been further stratified based on ER status
(IntClust 4ER+ and IntClust 4ER-), increasing the total number of clusters to 11. To
allow for single-sample prediction of the Integrative clusters in external datasets, Ali
et al. [2014] developed a 614 gene-based classifier to assign breast cancer IntClust
classifications solely from gene expression data. Classifying the original METABRIC
dataset (validation cohort: 983 patients) into the Integrative clusters using this gene
expression-based approach produced a concordance of 98% when compared to the
original integrative copy number and gene expression method described in Curtis et al.
[2012].
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Subsequently, the contributions of microRNAs [Dvinge et al., 2013] and somatic
point mutations [Dawson et al., 2013; Pereira et al., 2016] towards explaining the
heterogeneity of breast cancer have also been explored in the METABRIC dataset. It
has become quite clear that breast cancer subtypes possess different molecular wiring,
but insights into the mechanism of tumorigenesis need to be extended beyond genomic
alterations. The epigenome has long been understood as compelling regulators of
tumorigenesis [Jones and Baylin, 2002, 2007]. However, the epigenetic landscape of
breast cancer has received far less attention in comparison to its genomic counterparts.
1.3.3 Methylome studies in breast cancer
Epigenetic cancer studies prior to the recent technological advances in DNA
methylation profiling focused on a small number of genes (such as BRCA1), and
provided a limited representation of the breast cancer methylome [Berman et al.,
2005; Dickinson et al., 2004; Esteller, 2000]. They demonstrated that methylation
configurations are varied in different types of tumours, as well as between cancerous
and stromal tissues. The advent of superior DNA methylation technologies, coupled
with advances in bioinformatics, have enabled genome-wide investigation of DNA
methylation patterns in breast cancer, which has further led to a quest for epigenetic
regulators of tumorigenesis and prognostic/ predictive biomarkers.
Several studies have successfully examined the relationship between the breast
cancer methylome and disease taxonomy and prognosis. Li et al. [2010] discovered
that ER/ PR status was associated with the methylation levels of four genes. Fackler
et al. [2011] further illustrated the potential of DNA methylation patterns to accurately
predict the ER status of a tumour, besides identifying a CpG methylation signature
that was significantly associated with breast cancer progression . Three studies using
selected gene promoter panels revealed that the some of the Intrinsic subtypes (gene
expression-based) of breast cancer harbour characteristic DNA methylation profiles
[Bediaga et al., 2010; Holm et al., 2010; Rønneberg et al., 2011]. In particular, Luminal
B tumours were associated with highest promoter methylation, Luminal A tumours
with intermediate methylation, and Basal-like tumours harboured the lowest promoter
methylation. HER2-enriched and Normal-like tumours did not exhibit a significant
association with methylation derived subtypes in these studies. Eventually, these
Intrinsic subtype-specific methylation patterns were largely verified in genome-wide
studies with significantly higher sample sizes [Cancer Genome Atlas Network, 2012;
Stefansson et al., 2015].
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A study by Flanagan et al. [2010] determined that genome-wide methylation
profiles could accurately predict the mutation status of breast cancer tumours, and
identified a global hypomethylation signature that was associated with a novel subgroup
of BRCA1 mutated tumours. Conversely, BRCA2 mutations were linked with promoter
hypermethylation [Holm et al., 2010] suggesting that the BRCA family of proteins
may participate in the regulation of DNA methylation.
Further DNA methylation profiling in breast cancers led to the discovery of
new methylation-based subtypes with strong prognostic potential. Fang et al. [2011]
identified a breast CpG island methylator phenotype (denoted by CIMP), characterised
by coordinated methylation of a group of CpG islands, which was a strong determinant
of breast cancer metastasis. The CIMP-positive phenotype was later found to be
enriched in invasive lobular breast tumours [Roessler et al., 2015].
In 2011, Dedeurwaerder et al. [2011] examined genome-wide DNA methylation
profiles in the largest breast cancer methylome study conducted up until that point (248
tumours), that revealed the existence of novel breast cancer subtypes not classified
by current expression subtypes suggesting that methylation profiling might reflect the
cellular origin of breast cancer cells. Furthermore, it highlighted an immune gene
set associated with high prognostic value. A similar immune signature was revealed
in a pathway-based integrated approach in breast cancer combining genome wide
DNA methylation patterns with gene expression, microRNA and DNA copy number
[Kristensen et al., 2012]. However, this study determined that the contribution of DNA
methylation profiles was minimal, potentially due to the choice of the methylation
platform which only profiled 1505 CpG sites.
The studies discussed above were able to expand the breast cancer classification
to identify unique features that were not considered relevant through gene expression
analysis, but they suffered from a lack of sufficient power. Most of the studies
reported up until 2012 profiled less than 100 breast tissues (Dedeurwaerder et al.
[2011] was the exception with 248 samples), and employed methylation profiling
technologies that assayed only a limited number of CpG sites (up to ∼27,000) in the
genome. However, in 2012, The Cancer Genome Atlas (TCGA) Network assayed
802 breast tumours using Infinium DNA HM450 methylation arrays, in addition to
copy number, gene expression, exome-sequencing and microRNA profiling [Cancer
Genome Atlas Network, 2012; Ciriello et al., 2015]. This represented the first large
multiplatform analysis with epigenetic and genetic data in breast cancer, and was
followed by an ER+ breast cancer study (n = 560) conducted by the International
Cancer Genome Consortium (ICGC) in 2015 [Nik-Zainal et al., 2016]. Although, the
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breast cancer methylome was not explored in depth in either of these two studies, the
public availability of the TCGA data in particular, sparked an interest in integrating data
across multiple molecular platforms to identify epigenetic drivers of tumorigenesis.
In 2015, Gao et al. [2015] performed a novel systems-level integrative analysis
of the DNA methylation and transcriptomic landscapes using ER+ tumours from
the TCGA breast cancer consortium dataset [Cancer Genome Atlas Network, 2012].
They identified nine epigenetic hotspots that were functionally deregulated in ER+
tumours including the W NT bone morphogenetic protein (BMP) signalling pathways.
Although, the ER+ tumours were found to be remarkably homogeneous with respect
to these epigenetic hotspots, Luminal B tumours exhibited higher deregulation. In
the same year, investigation of the gene expression and methylation profiles in the
TNBC sub-cohort of the TCGA dataset revealed three clusters with distinct prognosis
[Stirzaker et al., 2015]. Aure et al. [2013] additionally examined microRNA expression
in the TCGA breast cancer dataset, and revealed that DNA methylation along with
copy number alterations influence mechanisms underlying microRNA dysregulation.
A shortcoming of the vast majority of the breast cancer methylome studies
mentioned above, is that the focus has largely been retained on promoter regions due
to their established significance as an epigenetic transcriptional repressor. Recent
reports in breast cancer have progressed to investigating gene body methylation as
well [Fleischer et al., 2014; Györffy et al., 2016]. These studies generally
demonstrated a positive correlation between DNA methylation and gene expression in
the gene body regions; however, they restricted their analysis to a selected panel of
genes. Additionally, recent investigations have also explored the role of DNA
methylation in enhancers in normal mammary tissues [Pellacani et al., 2016] and
breast tumours [Fleischer et al., 2017; Heyn et al., 2016]. These studies demonstrated
that reduced DNA methylation at enhancers was associated with increased
transcription factor binding which can have transcriptional consequences for the target
genes. Furthermore, Holm et al. [2016] identified seven novel breast cancer clusters
with distinct methylation patterns that were correlated with the underlying chromatin
states in normal mammary cells. This study suggested that DNA methylation profiles
are informative indicators of the overall epigenetic state of breast tissues.
Despite multiple studies attempting to map breast cancer-associated epigenetic
changes at the genome-wide level, not much evidence of the dynamics of methylation
change and intratumour heterogeneity have been provided in breast cancer. Studies in
chronic lymphocytic leukaemia (CLL) and diffuse large B-cell lymphomas (DLBCL)
have emerged that have indicated that methylation patterns within cancer tissues are
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highly heterogeneous and polymorphic [Landau et al., 2014; Pan et al., 2015]. This
epipolymorphism has also been linked to adverse clinical outcomes such as relapse.
Further, Li et al. [2014] developed a combinatorial entropy change calculation to
identify loci that alter significantly in epiallelic compositions between two time points
in the same sample. They applied this method to acute myeloid leukemia (AML)
patients with paired observations at diagnosis and relapse, and observed that epiallelic
compositions varied considerably during disease progression, and that a high degree
of epigenetic allelic burden within a tumour was linked with adverse clinical outcomes
[Li et al., 2016b]. However, due to the lack of NGS methylomes in epithelial tumours,
the role of methylation disorder and intratumour heterogeneity in tumour evolution is
poorly understood.
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1.4 Scope of this thesis
Breast cancer is one of the leading causes of cancer death in women, and is a
heterogeneous disease displaying distinct therapeutic responses. Accordingly, there
has been a push to catalogue and characterise the molecular drivers in breast cancer to
bring us closer towards the goal of personalised medicine. Recent efforts have focused
on high-throughput genomic and transcriptomic profiling in large breast cancer
datasets [Cancer Genome Atlas Network, 2012; Curtis et al., 2012; Dvinge et al.,
2013; Nik-Zainal et al., 2016; Pereira et al., 2016], and revealed that breast cancer
subtypes possess distinct molecular wiring. However, insights into the mechanism of
tumorigenesis need to be extended beyond genomic alterations. Although, two large
breast cancer consortiums, TCGA [Cancer Genome Atlas Network, 2012] and ICGC
[Nik-Zainal et al., 2016], have included DNA methylation profiles as part of their
multiplatform investigations, these breast cancer methylomes were not explored
in-depth. Consequently, the methylomic basis of breast cancer heterogeneity is not
fully understood, and this limitation in the literature can be explained by four
fundamental reasons. Firstly, breast cancer is one of the most heterogeneous cancers
at the molecular level, and in order to comprehensively reveal the contribution of
DNA methylation in tumorigenesis and heterogeneity, a significantly large number of
tumours needs to be investigated. Secondly, the abundant use of microarrays in which
the selection of CpG probes is hypothesis driven has forbidden the discovery of novel
methylation events in cancer, and has restricted focus primarily to promoter regions.
Thirdly, the lack of long-term survival data in these studies, has stunted the
investigation of the prognostic value of DNA methylation signatures in breast cancer.
And finally, the absence of large NGS-based breast cancer methylomes has made it
almost impossible to evaluate the role of intratumour heterogeneity in tumour
evolution.
From this perspective, the METABRIC consortium dataset [Curtis et al., 2012]
provides a vital resource for studying the epigenetic landscape of breast cancer.
METABRIC represents the largest cohort of primary breast tumours available for
observational study, and has excellent clinical annotation as well as long-term survival
information. Additionally, the availability of multi-dimensional molecular profiles
including copy number, gene expression, and somatic mutations in cancer driver genes
enables the possibility to integrate DNA methylation into combined epigenomic and
genomic pathways.
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In order to expand our knowledge of the DNA methylation aberrations
underlying human breast pathogenesis, the laboratory has conducted an NGS-based
breast cancer methylome study of 1482 breast tumours and 237 adjacent matched
normal tissues drawn from the METABRIC cohort. Such a large sample size
guarantees adequate statistical power and appropriate representation of inter-patient
heterogeneity to illuminate the full complexity of epigenetic aberrations in breast
cancer. As described earlier, several genome-wide strategies for methylome profiling
are currently available with different sample requirements, merits and challenges.
RRBS was selected as the DNA methylation platform of choice since it allows
quantification of DNA methylation at single nucleotide resolution and would also
enable the exploration of intratumour methylation heterogeneity and epiclonal
dynamics. Other advantages include the lower input DNA requirement and cost
effectiveness compared to WGBS. The RRBS library preparation was performed by
Dr Ana Tufegdzic Vidakovic, Dr Suet-Feung Chin, and Ankita Sati Batra; and
sequencing was conducted by the Cancer Research UK Cambridge Institute (CRUK
CI) Genomics Core.
This thesis largely delineates the bioinformatics and statistical analysis of the
genome wide sequencing-based breast cancer methylomes of 1482 breast tumours and
237 adjacent matched normal tissues drawn from the METABRIC cohort. The current
chapter (Chapter 1) provides a literature review illustrating the discovery of DNA
methylation as an epigenetic mark, and its role in embryonic development and cancer
(with a focus on breast cancer), along with an account of the significant efforts that
have already been conducted to refine the taxonomy of breast cancer. The subsequent
four chapters present four distinct fundamental features of the methylome analysis.
Each of these four chapters commences with a focused introduction, reviewing the
relevant literature and summarising the questions investigated in it; and concludes with
a discussion of the results generated in the respective chapter.
Chapter 2 presents a detailed outline of the development of a robust RRBS
pipeline that is not only suitable for high-throughput, but also maximises the
information content yield while keeping feasibility in mind. An NGS-based cancer
methylome study of this scale is unprecedented. Accordingly, several strategies have
been implemented including optimising the sequencing parameters and bioinformatics
methods with the ultimate aim of boosting the information yield. Furthermore, since
methylation profiling has gained relative importance only recently, there are still
unmet challenges in terms of the bioinformatics tools to analyse bisulphite sequencing
data. In particular, quantitative methods for RRBS are currently undeveloped due to
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the specific complexities of this protocol. Currently available statistical methods are
reviewed and a novel algorithm called SCCRUB (Spatially Coordinated CpG-sites
within RRBS Universe in Breast cancer) is constructed and implemented to define a
functionally relevant RRBS universe of regions comprising of spatially coordinated
CpG sites in breast cancer. Validation of the RRBS pipeline as well as a preliminary
overview of the DNA methylation landscape generated from the 1482 breast tumours
and 237 adjacent normal tissues is presented.
The primary objective of Chapter 3 is to quantify the extent of DNA
methylation alterations that have putative functional roles in a) tumorigenesis; b)
and/or explaining inter-tumour heterogeneity in breast cancer. However, as described
previously, cancers accumulate epigenetic drift over time. The presence of these
methylation alterations, that are largely stochastic and not gene-specific in nature, can
make the identification of epigenetic alterations truely associated with the initiation
and progression of tumours quite challenging; an obstacle that is rarely considered in
previous cancer methylome studies. Accordingly, in this chapter, background
methylation differences in tumours (compared to normal tissues), that are a
consequence of epigenetic drift, are first quantified. The genomic context and
inter-tumour heterogeneity of these background methylation differences are also
investigated, and are then utilised to feed the development of a novel algorithm called
DMARC (Directed Methylation Altered regions in Cancer) to detect directed and
background DNA methylation alterations in tumours. In addition, to illuminating the
mechanism underlying an observed methylation difference in a tumour, this algorithm
can also enrich for putative functional (expression-associated) methylation events.
Finally, the heterogeneity in epigenetic programming in distinct breast cancer
subtypes, and its consequences on transcriptional networks and survival is explored.
Chapter 4 extends the findings of the previous chapter, and compares the
independent contributions of DNA methylation and copy number alterations in
deregulating gene expression in breast cancer. The large number of samples in this
study allows for the detection of mutually exclusive or co-occurring patterns between
epigenetic (DNA methylation) and genomic (CNA) alterations, that can lead to the
identification of genes with putative tumour suppressive or oncogenic roles.
Interestingly, the crucial role of DNA methylation as a mechanism to target the
silencing of specific genes within copy number amplifications is also investigated.
While the previous chapters investigated the inter-tumour DNA methylation
heterogeneity in breast cancer, in Chapter 5, the 1482 RRBS breast cancer and 237
normal methylomes are reanalysed at the single read level to provide the first genome-
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wide assessment of the role of epigenetic intra-tumour heterogeneity in breast cancer,
and the largest for any single cancer type. Two previously established measures were
implemented in the breast tumours. The Proportion of Discordant Reads (PDR) score
represents the intratumour epigenetic diversity [Landau et al., 2014]; while the Eloci
Per Milion (EPM) score represents the magnitude of dynamic epiallele shifting in
a tumour compared to the normal tissue [Li et al., 2014]. These two orthogonal
scores represent distinct properties of the epigenome and the relationship between
them is explored for the first time. The link between intratumour heterogeneity
measures inferred from epigenetic and genetic profiles is also examined, and finally,
the prognostic potential of the DNA methylation intratumour diversity (PDR) and the
magnitude of dynamic epiallele composition shifts (EPM) is explored.
The future directions of this project are also outlined in the final chapter
(Chapter 6). With the wealth of data available, the possibilities are abundant. A
comprehensive genome-wide profiling of hydroxymethylcytosine in breast cancer is
warranted since it is a distinct epigenetic modification to methylcytosine with an
alternate role in pathogenesis. Additionally, the investigation of DNA methylation
signatures in i) a panel of breast Patient Derived Tumour Xenografts (PDTXs),
representing one of the best preclinical models available today [Bruna et al., 2016];
and ii) in circulating tumour DNA, enabling the possibility of a liquid biopsy, is also
proposed. These cohorts are already established in the Caldas laboratory and would
enable the exploration of the potential of DNA methylation biomarkers to be used as
tools for early predictors of breast cancer, monitoring, prognosis and stratification for
different therapeutic approaches.
32
Chapter 2
DNA methylation profiling of a large
breast cancer cohort
Contents
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.1.1 Summary of aims . . . . . . . . . . . . . . . . . . . . . . 37
2.2 Sample overview . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.2.1 Gene expression data . . . . . . . . . . . . . . . . . . . . 38
2.2.2 Copy number data . . . . . . . . . . . . . . . . . . . . . 38
2.2.3 Mutation data . . . . . . . . . . . . . . . . . . . . . . . . 40
2.2.4 Clinical data . . . . . . . . . . . . . . . . . . . . . . . . 40
2.3 Optimising the RRBS Pipeline . . . . . . . . . . . . . . . . . . 41
2.3.1 RRBS library preparation protocol . . . . . . . . . . . . . 41
2.3.1.1 Input DNA . . . . . . . . . . . . . . . . . . . . 41
2.3.1.2 Unbalanced libraries . . . . . . . . . . . . . . . 41
2.3.1.3 RRBS library preparation workflow . . . . . . . 42
2.3.2 Sequencing parameters . . . . . . . . . . . . . . . . . . . 44
2.3.2.1 Illumina technology . . . . . . . . . . . . . . . 44
2.3.2.2 Single-end vs. paired-end sequencing . . . . . . 44
2.3.2.3 Read length . . . . . . . . . . . . . . . . . . . 46
2.3.2.4 Sequencing depth . . . . . . . . . . . . . . . . 46
33
Chapter 2. DNA methylation profiling of a large breast cancer cohort
2.3.2.5 Final Sequencing Parameters . . . . . . . . . . 50
2.3.3 Bioinformatics pipeline . . . . . . . . . . . . . . . . . . 50
2.3.3.1 Trimming . . . . . . . . . . . . . . . . . . . . 50
2.3.3.2 Alignment . . . . . . . . . . . . . . . . . . . . 50
2.3.3.3 Methylation calling . . . . . . . . . . . . . . . 52
2.3.3.4 Merging strands . . . . . . . . . . . . . . . . . 53
2.3.4 Quality assessment and sample filtering . . . . . . . . . . 55
2.3.4.1 Read quality control . . . . . . . . . . . . . . 55
2.3.4.2 Genotyping . . . . . . . . . . . . . . . . . . . 56
2.3.4.3 Read counts and depth of coverage . . . . . . . 56
2.3.4.4 Bisulphite conversion . . . . . . . . . . . . . . 58
2.3.4.5 Sample inclusion criteria . . . . . . . . . . . . 58
2.3.5 Determination of CpG sites . . . . . . . . . . . . . . . . 58
2.3.5.1 CpG site filtering . . . . . . . . . . . . . . . . 58
2.3.5.2 Annotation . . . . . . . . . . . . . . . . . . . . 60
2.4 Analysing DNA methylation using RRBS . . . . . . . . . . . . 65
2.4.1 Existing approaches to analyse bisulphite sequencing data 65
2.4.1.1 Single CpG resolution . . . . . . . . . . . . . . 65
2.4.1.2 Annotated region-level analysis . . . . . . . . . 66
2.4.1.3 Defining differentially methylated regions based
on clustering of spatially correlated CpGs . . . 67
2.4.1.4 Smoothed gene unit analysis . . . . . . . . . . 67
2.4.2 Novel Method – Spatially Coordinated CpG-sites within
the RRBS Universe in Breast cancer (SCCRUB) . . . . . 68
2.4.2.1 STEP 1: Determination of empirical region
boundaries . . . . . . . . . . . . . . . . . . . . 69
2.4.2.2 STEP 2: Defining regions . . . . . . . . . . . . 69
2.4.2.3 STEP 3: Filtering regions based on
autocorrelation of CpG sites . . . . . . . . . . . 71
2.4.2.4 STEP 4: Annotation . . . . . . . . . . . . . . . 72
2.5 Pipeline validation . . . . . . . . . . . . . . . . . . . . . . . . . 74
2.5.1 Tumour and normal methylation statuses . . . . . . . . . 74
2.5.2 Technical variability and clinicopathological factors . . . 76
2.5.3 Validation with HM450 data . . . . . . . . . . . . . . . . 76
2.6 The breast cancer methylome in METABRIC . . . . . . . . . . 80
2.6.1 The global methylation landscape of breast cancer . . . . 80
2.6.2 Comparison with the TCGA breast cancer methylome . . 80
2.7 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
34
2.1. Introduction
2.1 Introduction
Recent technological advances have allowed the characterisation of not only genetic
aberrations such as somatic mutations and copy number alterations in cancer, but
also allowed exploration of the epigenetic landscape including DNA methylation and
its role in tumorigenesis. A majority of the previous studies of the breast cancer
methylome have been limited by platforms that analyse only a very small fraction
of the epigenome or have low resolution, and/ or insufficient power to unravel the
epigenetic basis of breast cancer heterogeneity (Chapter 1). However, in 2012, 800
breast tumours were profiled with the Infinium HumanMethylation450 BeadChip
(HM450) microarray by the TCGA consortium [Cancer Genome Atlas Network, 2012]
and this represents the largest breast cancer methylome study conducted thus far.
Multiple reports since then have used the HM450 platform in breast tumours leading
to key findings including the identification of tumour subgroups with distinct DNA
methylation patterns that were shown to have diverse molecular characteristics and
prognosis [Györffy et al., 2016; Stefansson et al., 2015]. These studies delineated
specific genomic regions that are epigenetically disrupted in breast cancer and had
associations with other molecular events such as mRNA expression and copy number
events [Gao et al., 2015; Holm et al., 2016; Teschendorff et al., 2016b].
The investigation of the DNA methylation landscape in the METABRIC
(Molecular Taxonomy of Breast Cancer International Consortium) cohort comprising
of approximately 1500 breast tumours represents a significant development in the field
and will enable the confirmation of previous findings as well as improve the
understanding of the genome-wide patterns of DNA methylation in breast cancer. For
the METABRIC study, Reduced Representation Bisulphite Sequencing (RRBS) has
been chosen as the DNA methylation platform for a variety of reasons. Firstly,
HM450 and RRBS represent complementary genome-wide techniques, profiling
distinct sets of CpG sites in the genome, and this allows the discovery of novel
methylation biomarkers. Moreover, being a next-generation sequencing (NGS)
technique, it allows quantification of DNA methylation at single nucleotide resolution
and also enables the exploration of intratumour methylation heterogeneity and
epiclonal dynamics in breast cancer. Another advantage of RRBS is the possibility of
DNA methylation profiling using very low input DNA amounts, since the need to
characterise tumours at multiple levels puts tumour DNA at a premium.
While RRBS has been shown to be suitable for methylome profiling of cancer
samples [Li et al., 2016b; Pan et al., 2015], most studies that have implemented this
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strategy have relatively small sample sizes, probably due to the challenging nature
of this protocol. The methylome study of approximately 1500 tumours presented in
this thesis represents the largest bisulphite sequencing study in cancer. Accordingly,
it was imperative to design a robust RRBS pipeline that is not only suitable for
high-throughput, but also maximises the information content yield, while considering
feasibility in terms of cost and input DNA material. This chapter presents several
strategies that have been implemented including optimising the library preparation
protocol, sequencing parameters and bioinformatics methods with the ultimate aim of
boosting the information yield, which in the case of RRBS is the number of CpG sites
detected with sufficient depth across all samples. A description of the filtering steps
and quality control procedures are also provided.
Bisulphite sequencing technologies, in particular RRBS, present substantial
challenges in the statistical analysis and biological interpretation of methylation
differences between samples or groups of samples. In fact, only a few computational
tools to analyse RRBS data exist. Since functional methylation alterations usually
involve clusters of multiple CpG sites, an important consideration is the need to deal
with methylation information at single nucleotide resolution. Currently available
methods are explored, and a novel algorithm is developed and implemented to define a
RRBS universe of regions comprising of spatially coordinated CpG sites in breast
cancer.
Next, validation of the RRBS pipeline is performed. Specifically, the extent
of technical variability in the methylome dataset is investigated. A comparison of
methylation profiles in METABRIC samples mapped using two distinct platforms,
RRBS and the universally used HM450 microarray, is also conducted to check whether
the two technologies produce similar methylation estimates for the same tumour and
same genomic region.
Finally, a preliminary overview of the DNA methylation landscape in 1482 breast
tumours and 237 adjacent normal tissues is presented. An unsupervised analysis based
on methylation profiles is also conducted in the METABRIC samples and compared
with that obtained from the external TCGA breast cancer study [Cancer Genome Atlas
Network, 2012].
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2.1.1 Summary of aims
This chapter describes the generation of a sequencing-based genome-wide methylome
breast cancer dataset comprising of 1482 tumours and 237 adjacent normal tissues
drawn from the METABRIC cohort. This is achieved through the following steps:
1. An overview of the samples that are part of the METABRIC cohort, and a
description of the multidimensional molecular and clinical data available for
these samples.
2. Optimisation of the RRBS pipeline including determination of the sequencing
parameters, and development of the bioinformatics pipeline. Quality assessment
and filtering procedures are also detailed.
3. A review of existing methods to analyse single nucleotide methylation
information as generated by bisulphite sequencing techniques. Construction and
implementation of a novel algorithm to define an RRBS universe of regions
comprising of spatially coordinated CpG sites in breast cancer.
4. Validation of the RRBS pipeline including investigating the extent of technical
variability, and a comparison of RRBS and HM450 generated methylation
profiles in the METABRIC study.
5. A preliminary overview of the DNA methylation landscape in the METABRIC
samples, including comparison with the external TCGA breast cancer
methylome.
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2.2 Sample overview
METABRIC is a collection of over 2,000 primary fresh-frozen invasive breast cancer
specimens and 473 matched normal tissues from tumour banks in the UK and Canada,
associated with extensive clinical annotation and follow up [Curtis et al., 2012]. For
DNA methylation profiling, a total of 1719 samples were characterised (following
quality control procedures described in Section 2.3.4) including 1482 primary breast
tumours and 237 adjacent normal samples. 1367 out of the 1980 tumours from the
original METABRIC study [Curtis et al., 2012] were utilised, with insufficient DNA
accounting for the missing samples. The additional 113 tumours were not published
as part of the original METABRIC study despite belonging to the METABRIC cohort.
These samples had either failed quality checks on the platforms used at the time, lacked
corresponding gene expression data, or were processed after the initial publication was
completed.
Multi-dimensional molecular data including gene expression (Illumina HT-12 v3
microarray), copy number aberrations (Affymetrix SNP 6.0 arrays), mutations in key
cancer driver genes (targeted sequencing on 173 genes) as well as extensive clinical
annotation were also available, and described below.
2.2.1 Gene expression data
Gene expression profiling of the METABRIC cohort was conducted using Illumina
HT-12 v3 microarrays [Curtis et al., 2012]. Gene expression data was pre-processed
and annotated using custom scripts relying on the beadarray package [Dunning et al.,
2007] resulting in normalised relative log2 intensities for each probe. Details are
described in, and the gene expression data was obtained from the original publication
[Curtis et al., 2012]. Since Illumina microarrays use multiple probes localised at
distinct loci to represent the expression of a single gene, low-quality probes were
removed and the probe with the highest variation was chosen in order to determine
gene-level expression data.
2.2.2 Copy number data
Copy number profiling of the METABRIC cohort was conducted using Affymetrix
SNP 6.0 arrays [Curtis et al., 2012]. The raw data was pre-processed using
aroma.affymetrix [Bengtsson et al., 2009] to obtain normalised relative log2 ratios for
each probe, and B-allele fractions at SNP loci, as described in Curtis et al. [2012].
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Two distinct analytical approaches were employed to generate continuous and
allele-specific discrete estimates for copy number alterations respectively.
1. Continuous approach: The ratios were segmented using the circular binary
segmentation (CBS) algorithm [Venkatraman and Olshen, 2007] implemented
in the DNAcopy bioconductor package [Lipson and Liebert, 2006], as described
in Curtis et al. [2012]. The segmented data was obtained from the original paper
[Curtis et al., 2012]. Subsequently, the genome coordinates were converted from
hg18 to hg19 using the LiftOver bioconductor package [Hinrichs, 2006]. Where
continuous copy number estimates were required, the segmented mean log2
ratios were used. Overall, 1389 out of the 1482 tumour samples had associated
DNAcopy number data available.
2. Allele-specific approach: The Allele-Specific Copy number Analysis of
Tumours (ASCAT) algorithm [Van Loo et al., 2010] was implemented to obtain
tumour-specific estimates of ploidy and aberrant cell fraction (tumour purity).
Consequently, segmented allele-specific estimates of absolute copy number
corrected for normal contamination were generated as described in Pereira et al.
[2016]. The ASCAT data was obtained from Pereira et al. [2016]. Subsequently,
the total copy number estimates were adjusted for ploidy as follows:
CNcorr = round(
2×CNtot
π
) (2.1)
where CNtot and CNcorr refer to the total and corrected copy number calls
respectively, and π is the estimated tumour ploidy. The corrected copy number
was rounded to the nearest integer. Where allele-specific or discrete copy number
data was required, these ASCAT estimates were used. Overall, 1345 out of the
1482 tumour samples had associated ASCAT copy number data available.
The downstream analysis described below was conducted for both
DNAcopy-derived and ASCAT-derived copy number data. Germline copy
number variants were removed using copy number data from the combination
of HapMap populations and the adjacent matched normal tissues as described in
Curtis et al. [2012]. Only somatic copy number alterations (CNA) were
considered for which a diploid copy number state was assumed for the normal
tissues. Gene annotation was conducted using coordinates obtained from
RefSeqGene (Reference Sequence Gene) [Karolchik et al., 2014, hg19]. In
order to summarise copy number at the gene-level, segmented copy number
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alterations were overlapped with gene regions. Where multiple copy number
segments were available for the same gene, the copy number state of the
segment with maximal severity was assigned.
2.2.3 Mutation data
Targeted sequencing of the exons of 173 genes (panel of key cancer genes) was
performed on the METABRIC cohort [Pereira et al., 2016]. The bioinformatics
pipeline is described in Pereira et al. [2016] and summarised below. Variant calling
was performed using MuTect [Cibulskis et al., 2013] for single nucleotide variants
(SNVs), and Haplotype Caller for indels [McKenna et al., 2010]. Custom pipelines
were utilised for filtering. Candidate driver genes in breast cancer were identified
by looking for genes that harboured multiple recurrent or inactivating mutations, as
these patterns are characteristic of oncogenes and tumour suppressors respectively as
proposed by Vogelstein et al. [2013]. As described in Pereira et al. [2016], inactivating
mutations included nonsense SNVs, frameshift substitutions, splice sites mutations;
whereas recurrent mutations were defined as missense SNVs and in-frame substitutions
that occur in the same codon. The proportions of recurrent mutations (oncogene score)
or inactivating mutations (tumour suppressor score) observed for each gene were
scored, and a threshold of 20% was used. Further details are described in, and the
mutation data was obtained from Pereira et al. [2016].
2.2.4 Clinical data
Clinical data for the METABRIC cohort was obtained from published and
in-preparation manuscripts [Curtis et al., 2012; Pereira et al., 2016; Rueda et al., 2017,
in preparation]. Clinical data includes age at diagnosis; tumour-specific variables such
as grade, size, number of lymph nodes, ER and HER2 status; as well as breast cancer
classification into Intrinsic subtypes and Integrative clusters. Pathology-based mitotic
indices for the tumours (scored by Dr Elena Provenzano) and digital lymphocytic
infiltration scores (created by Dr Raza Ali) were also available. Long-term follow-up
data including overall survival, breast cancer-specific survival, local and distant
relapse was also available with a median follow-up time of 11 years.
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2.3 Optimising the RRBS Pipeline
The preliminary goal of the project was to design a robust RRBS pipeline that was
suitable for high-throughput, and that ensured accurate methylation calling as well as
maximised the information content yield i.e. the number of CpG sites detected per
sample. Previous work in the laboratory (conducted by Dr Ana Tufegdzic Vidakovic)
led to the optimisation of the RRBS library preparation protocol (summarised in
Vidakovic [2014], Section 2.3.1). Determination of the ideal sequencing parameters
and optimisation of the RRBS bioinformatics pipeline was conducted as part of this
thesis and described in Section 2.3.2 - 2.3.5.
2.3.1 RRBS library preparation protocol
Optimisations to the RRBS library preparation protocol implemented in this study are
described in Vidakovic [2014], and are summarised briefly in this section.
A gel-free multiplexed RRBS method was adapted from Boyle et al. [2012] with
modifications discussed below. Briefly, the original Boyle protocol commences with
DNA digestion with the restriction endonuclease MspI, followed by end repair and
A-tailing of the fragments. This is followed by ligation with methylated adapters.
Subsequently, the DNA is bisulphite converted, after which the RRBS libraries are
amplified. Finally, a purification step is conducted to size-select for fragments
between 200-700 base pairs (bp). Typically multiplexing of samples is performed
using barcoded DNA adaptors and pooled before the bisulphite conversion step.
2.3.1.1 Input DNA
The recommended DNA input for RRBS is 200ng of DNA [Boyle et al., 2012] .
However, this amount can be considerably scaled down (to 5 ng), as determined
by experiments performed in the laboratory [Vidakovic, 2014]. This is of particular
significance for methylation profiling of the METABRIC samples, since the input DNA
obtained from these tissues is low due to previous multiple molecular characterisations.
2.3.1.2 Unbalanced libraries
Typically, each RRBS library consists of 6-12 barcoded samples. In spite of starting
from equal amounts of DNA, the original RRBS protocol suffers from an imbalance
in the sequencing reads assigned to each sample within the pool [Boyle et al., 2012].
The imbalance appears to occur upstream of the Polymerase chain reaction (PCR)
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amplification step where using equivalent volume did not represent equal input. A
quantification step, pre-PCR and prior to sample pooling was introduced to normalise
the input DNA which has positively affected library balancing and the final number of
CpG loci detected [Vidakovic, 2014] .
2.3.1.3 RRBS library preparation workflow
The workflow of the modified RRBS library preparation protocol used in this study is
shown in Figure 2.1. Further details are given in Vidakovic [2014].
Tissue processing was performed by Dr Suet-Feung Chin. In brief, DNA was
extracted from 10x30micron sections using Qiagen QIAmp DNeasy Kits (Qiagen,
Germany) and quantified fluorometrically by Qubit dsDNA High Sensitivity
Quantification Reagent (ThermoFisher, USA). The DNA were normalised and plated
into 96 well plates.
The RRBS libraries were generated by Dr Ana Tufegdzic Vidakovic, Dr Suet-
Feung Chin, and Ankita Sati Batra.
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Figure 2.1: Schematic outline of the RRBS library preparation protocol. Figure is
modified from Vidakovic [2014]. SPRI = Solid Phase Reversible Immobilisation.
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2.3.2 Sequencing parameters
Multiple RRBS experiments were performed using DNA derived from MDA-MB-231
breast cancer cell lines (library preparation conducted by Dr Ana Tufegdzic Vidakovic)
to determine the optimal sequencing parameters including the Illumina chemistry, read
lengths, necessary sequencing depth, and comparison of single-end and paired-end
sequencing. The aim was to maximize CpG site detection while considering feasibility
and cost.
2.3.2.1 Illumina technology
The launch of v4 Illumina chemistry on the HiSeq 2500 machines (to replace the v3
chemistry on the HiSeq 2000 machines) in 2014 promised an increase in sequencing
yield, and thus number of reads, as well as offering a reduction in run time and price. A
12 sample-multiplexed RRBS library sequenced with HiSeq 2500 yielded on average
13.2 million aligned reads per sample, whereas the same library on HiSeq 2000 yielded
8.8 million reads on average (p-value = 0.0018; t-test; Figure 2.2a). Importantly this
also translated in an increase in CpG sites detected at 1×, 5×, and 10× coverage
(Figure 2.2a).
2.3.2.2 Single-end vs. paired-end sequencing
Sequencing both ends of each read is a more efficient use of a library. Paired-end (PE)
improves the ability to identify the relative positions of reads in the genome, making it
much more effective than single-end (SE) in resolving structural rearrangements such
as gene insertions, deletions, or inversions; and improving the assembly of repetitive
regions. However, PE sequencing is approximately 50% more expensive and time-
consuming to perform than SE [Genomics Core Cancer Research UK Cambridge
Institute, 2015]. The key question is whether PE reads yield significantly more data
than SE reads to justify this difference in price and cost.
PE reads are informative for the same DNA fragment (representing one DNA
strand), but captures information from both sides of the fragment. In Whole Genome
Bisulphite Sequencing (WGBS) experiments, the DNA fragments are randomly
distributed across the genome, and can be selected to be large enough, and therefore
PE sequencing yields considerably more unique CpG sites than SE. However, in
RRBS, DNA digestion with Msp1 results in fragments that start and end at the same
sites of the genome, and the size-selection can often lead to fairly small fragments in
contrast to a read length of 125bp [Babraham Bioinformatics, 2016b]. As a
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Figure 2.2: Single end sequencing was performed on the Illumina HiSeq 2500. (a)
Comparison of yield between Illumina HiSeq 2000 and Illumina HiSeq 2500 within
samples of a 12-sample library pool. (b) Comparison of yield between SE and PE within
samples of a 12- sample library pool. In both comparisons, number of total reads
detected, number of unique CpG sites detected at 1×, 5× and 10× coverage were
compared. For both plots, boxplots indicate the interquartile range with 25th percentile,
median and 75th percentile values illustrated. Whiskers indicate 1.5× of the interquartile
range. T-tests were used for statistical comparison. M=million. (. = FDR p-value < 0.1, *
= FDR p-value < 0.05, ** = FDR p-value < 0.01, *** = FDR p-value < 0.001, **** =
FDR p-value < 0.0001).
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consequence, PE reads overlap in the middle and yield redundant methylation
information for the same strand and thus, do not yield twice the amount of
methylation data as anticipated [Babraham Bioinformatics, 2016b]. In fact, SE
sequencing with the same number of reads as a PE run is more likely to yield more
methylation information in terms of unique CpG sites detected.
Notably, preliminary RRBS experiments revealed that only 27.6% more unique
CpG sites at 5× coverage (p-value = .0040; t-test), and 36.6% more unique CpG sites
at 10× coverage (p-value = 0.0009; t-test) were detected using PE vs. SE sequencing
(Figure 2.2b). Keeping in mind the large number of samples in the METABRIC study,
this finding strongly indicates that it is not cost-effective to use PE sequencing which
is 50% more expensive than SE.
2.3.2.3 Read length
Most RRBS protocols have recommended 36-50 bp read runs for sequencing [Akalin
et al., 2012a; Boyle et al., 2012] . The suggested reason for this is that the quality of
base calling drops with an increase in read length and as a result, increasing the read
length of RRBS sequences may not necessarily translate into a linear increase in CpG
sites yield [Krueger et al., 2012]. Accordingly, many methylome studies use short
reads sequencing for RRBS reads [Akalin et al., 2012a; Landau et al., 2014; Pan et al.,
2015]. However, since RRBS library fragment sizes range from 200-700 bp, it is
apparent that longer sequencing reads could increase both the number of CpGs detected
and their coverage as long as sequencing quality does not drop. To investigate whether
longer sequencing reads would improve high quality yield, a 12 sample-multiplexed
RRBS library was sequenced with 125 bp read length. The reads were then trimmed
in silico to 50 bp to obtain an in silico shorter sequencing output, and the quality of
base calls and the yield in terms of number of CpGs detected were assessed. This
experiment revealed that the quality of base calls remains high in longer sequenced
reads (125 bp), substantiating the effectiveness of the enhanced RRBS protocol (Figure
2.3a). Moreover, increasing the read length from 50 bp to 125 bp allowed for detection
of significantly more CpG sites (Figure 2.3b). This suggests a shift to longer read
sequencing for RRBS libraries, contrary to what has been recommended in previous
studies.
2.3.2.4 Sequencing depth
The success of the methylome study is contingent on each of the approximately 2000
samples yielding sufficient methylation information (unique CpG sites at adequate
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Figure 2.3: : Increased read length improves CpG detection and coverage. (a)
Phred-scaled quality of base calls remains high for 125 bp reads. y-axis represent quality
scores for a 12- sample library pool and x-axis represents the position in the read up to
125 bp. Phred-scaled quality > 20 constitute acceptable scores and Phred-scaled quality
≥ 30 represent good scores. (b) Comparison of yield between 50 bp and 125 bp reads
within samples of a 12-library pool. Number of unique CpG sites detected with 1×, 5×
and 10× coverage were compared. Boxplots indicate the interquartile range with 25th
percentile, median and 75th percentile values illustrated. Whiskers indicate 1.5× of the
interquartile range. T-tests were used for statistical comparison. M=million. (. = FDR
p-value < 0.1, * = FDR p-value < 0.05, ** = FDR p-value < 0.01, *** = FDR p-value <
0.001, **** = FDR p-value < 0.0001).
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depth). The target number of unique CpG sites to be profiled per sample was set to 2.5
million for the purpose of this study. A minimum of 5 read coverage is recommended
to accurately estimate the methylation at each CpG site [Bock et al., 2010; Boyle
et al., 2012; Meissner et al., 2008]. It is apparent that a higher number of reads would
yield a higher number of CpG sites, however sequencing can quickly reach saturation
depending on the required depth. Feasibility constraints necessitates the calculation of
the optimal number of reads required to be sequenced per sample to reach the target
number of CpG sites at the required depth, and consequently the determination of
the extent of multiplexing. The extent of multiplexing has obvious consequence on
the read yield and cost for each sample: pooling less samples leads to a higher read
yield and higher costs while pooling more samples is more cost effective albeit with
an associated compromise on read yield.
Data from preliminary RRBS experiments (multiplexed at 12 samples) was
investigated, and in silico experimentation was performed to investigate the read yield
for other levels multiplexing. The average sequencing yield per lane for the preliminary
RRBS experiments was 160-180 million reads. Figure 2.4a reveals that the optimal
extent of multiplexing is 8 samples, at which point the number of unique CpG sites
detected on average per sample starts reaching saturation. Multiplexing at 8 samples
results in approximately 20 million reads yield and results in detection of more than
2.5 million unique CpG sites at 5× coverage for each sample (interquartile range
is higher than 25 million CpG sites, Figure 2.4a). Multiplexing less and increasing
sequencing read depth is associated with higher costs, but with not a high reward in
terms of additional unique CpG sites detected, whereas multiplexing more does not
generate sufficient CpG sites. Interestingly, the number of unique CpG sites detected at
10× coverage does not reach saturation at 8-sample multiplexing, and a higher reward
ratio is observed by multiplexing less (Figure 2.4b). However, the number of unique
CpG sites detected at 1× coverage quickly approaches saturation (Figure 2.4c).
These findings reinforce the notion that RRBS is focused on a well-defined CpG-
rich reduced representation of the genome which leads to relatively early saturation in
detecting unique CpG sites with deeper sequencing. Profiled CpG sites are deemed
beneficial for methylome studies only if they have sufficient coverage for accurate
estimation of methylation levels (minimum 5× coverage). Deeper sequencing boosts
the coverage of these detected CpG sites, but does not yield considerably more unique
CpG sites.
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Figure 2.4: Multiplexing at the level of 8 samples provides a good balance between
yield and feasibility. (a) The blue line represents the average number of CpG sites
detected at 5× per sample as a function of the extent of multiplexing. Shaded area
represents the interquartile range for the above relationship. Higher values on the y-axis
represents lower multiplexing which yields a higher number of reads per sample and
consequently a higher number of unique CpG sites detect at 5×. However, this starts
reaching saturation at 8-sample multiplexing. (b) Average number of CpG sites detected
at 10× per sample as a function of the extent of multiplexing. Does not reach saturation
at 8-sample multiplexing. (c) Average number of CpG sites detected at 1× per sample as
a function of the extent of multiplexing. Reaches saturation earlier than 8-sample
multiplexing. In (a) (b) and (c) 8-sample multiplexing is indicated by the vertical dotted
line. M=million.
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2.3.2.5 Final Sequencing Parameters
For the METABRIC samples, sequencing was performed on the Illumina HiSeq 2500
(v4 chemistry), with single-end reads of 125 bp length. Multiplexing was conducted at
the level of 8 samples per lane. Sequencing was performed by the Cancer Research
Cambridge Institute (CRUK CI) Genomics Core and de-multiplexing by the CRUK CI
Bioinformatics Core.
2.3.3 Bioinformatics pipeline
The RRBS bioinformatics pipeline for alignment and methylation calling has been well
established [Babraham Bioinformatics, 2016a,b]. However, it was adapted to meet the
specific challenges of the project. Moreover, as with all high throughput sequencing
applications, it is critical to perform quality control (QC) to detect and account for
sequencing and methylation calling errors. The modified RRBS bioinformatics pipeline
and QC are detailed below. The schematic outline of the pipeline is illustrated in Figure
2.5.
2.3.3.1 Trimming
RRBS libraries with long read lengths (125 bp in this case) suffer from a variety of
complications. As with all high throughput sequencing, long reads can be associated
with poor qualities towards the 3’ end. Moreover, DNA fragments generated from
RRBS libraries are often shorter than 125 bp, and hence the sequencing reads may
continue into the adapter sequence on the 3’ end (Section 2.3.2). An additional
characteristic of RRBS is that unmethylated cytosines (Cs) that are introduced during
the enzymatic end repair step may also be sequenced if they are not trimmed
appropriately. Trimming of the 3’ ends was performed using Trim Galore! (version
0.3.7: powered by cutadapt) to i) remove bases with Phred-scaled quality score < 20,
ii) remove adaptor contamination, and iii) remove the additional unmethylated Cs
introduced during the end repair step.
2.3.3.2 Alignment
DNA treatment with the bisulphite chemical results in converting unmethylated
cytosines (Cs) to thymines (Ts), whereas methylated Cs are largely protected from
bisulphite-induced conversion. Aligning to the traditional human reference genome is
problematic since after bisulphite conversion, a large number of Cs are not Cs any
more, and consequently the DNA sequences will align with less concordance to the
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Figure 2.5: Schematic outline of the RRBS bioinformatics pipeline. Purple boxes
indicate steps involved in the bioinformatics pipeline. Green boxes indicate steps
involved in quality assessment and sample filtering. Red boxes indicate steps involved in
CpG site filtering and annotation. Gold stars indicate steps included in addition to the
RRBS bioinformatics pipeline established by Babraham Bioinformatics [2016a,b].
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reference sequence. Additionally, the complexity of the bisulphite-treated library is
also reduced [Bock et al., 2010]. Consequently, utilising standard aligners to align
bisulphite converted reads to the human reference genome will result in a bias towards
reads covering methylated Cs against unmethylated Cs. To complicate matters further,
a single CpG site can have a different methylation state in different cells, and so
building a reference human methylome is challenging [Krueger et al., 2012].
Algorithms have been proposed that avoid the bias towards methylation by
removing the penalty associated with aligning a C or T in the read to a C in the
reference genome. Three-letter aligners such as Bismark and BS-Seeker simplify
bisulphite alignment by converting all Cs into Ts in the reads and for both strands of
the genomic DNA sequence prior to alignment [Chen et al., 2010; Krueger and
Andrews, 2011]. This way, they can carry out the alignment exclusively on a
three-letter alphabet (namely, A, G and T) using standard aligners, such as Bowtie and
Bowtie2 [Langmead and Salzberg, 2012; Langmead et al., 2009]. As a result of the
reduced sequencing complexity with only three letters remaining, a larger number of
reads align to more than one position in the reference sequence and are discarded.
Consequently, three letter aligners such as Bismark can be expected to achieve a lower
genomic coverage than wild-card aligners such as BSMAP [Xi and Li, 2009] and
RRBSMAP [Xi et al., 2012], but is free from the bias towards increased DNA
methylation levels [Bock, 2012]. Additionally, Bismark is less likely to report
non-unique alignments compared to the other popular three-card aligner, BS-Seeker
[Chen et al., 2010; Krueger and Andrews, 2011].
Reads were aligned to the Human Genome Assembly GRCh37 [Lander et al.,
2001, UCSC release hg19] using Bismark (version 0.13.1). Bowtie2 (version 2.2.4)
was chosen over Bowtie as the standard aligner due to improvements in speed, fraction
of reads aligned and ability to perform gapped alignments [Langmead and Salzberg,
2012].
2.3.3.3 Methylation calling
To quantify absolute DNA methylation levels from bisulphite-sequencing data, the
percentage of Cs and Ts are calculated among all reads aligned to each C in the genomic
DNA sequence [Bock, 2012]. Single-base-pair methylation estimates were determined
by quantifying evidence for methylated (unconverted) and unmethylated (converted)
Cs at all CpG positions. Two approaches can be used to estimate methylation at a CpG
site
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1. Beta-value
A Beta-value is defined as the proportion of Cs (methylated CpGs) at a particular CpG
site. Beta-value methylation estimates range from 0% to 100% where a value of 0%
indicates that the CpG site was unmethylated in all assayed cells originating from the
sample (i.e. no methylated molecules were measured) and a value of 100% indicates
that every cell was methylated at that CpG site.
1. M-value
Beta-value methylation calls are largely bimodal at 0% and 100% (completely
unmethylated and completely methylated respectively). The M-value is an alternate
estimate that is calculated by applying the logistic transformation to Beta-values. This
transformation results in a continuous methylation estimate from –∞ to ∞ that expands
the Beta-value distribution at 0% and 100% (Figure 2.6), and thus is more suitable for
many quantitative statistical analyses [Irizarry et al., 2008]. Analogous to Beta-values,
larger M-values also represent more evidence of methylation. The mathematical
relationship between M-values and Beta-values is detailed in these two equations.
Beta =
2M
2M +1
(2.2)
M = log2(
Beta
1−Beta) (2.3)
Both Beta-values [Hovestadt et al., 2014; Kulis et al., 2012] and M-values
[Stirzaker et al., 2014; Stone et al., 2015] have been commonly used as metrics to
measure methylation levels. However, Beta-values have a more intuitive biological
interpretation and their use is recommended for reporting results, while M-value
methylation estimates are more statistically valid, and accordingly recommended for
downstream statistical analyses such as differential methylation [Du et al., 2010].
Beta-value methylation estimates were called using bismark_methylation_extractor
[Babraham Bioinformatics, 2016a], and M-values were generated in R using the
Equation 2.3.
2.3.3.4 Merging strands
In mammals, the Cs at CpG dinucleotides on the two complementary DNA (+ and -)
strands are symmetric with respect to methylation [Ehrlich et al., 1982]. If the C on
one strand is methylated, so is the other. However, the 2 complementary Cs do not
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Figure 2.6: Relationship between M-value and Beta-value for methylation calling.
Data points represent methylation Beta-values of 20%, 50% and 80%.
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represent the exact same nucleotide location, but rather two consecutive nucleotides
on separate strands. Consequently, this would result in methylation calls from the
two consecutive bases, one from the + strand and one from the – strand. Standard
bisulphite sequencing bioinformatics pipelines do not control for this and potentially
different methylation estimates may be detected for the two bases since the random
nature of directional RRBS libraries does not guarantee that reads originating from
the + and – strands are represented equally, or even represent the same cells. However,
due to the aforementioned symmetry in mammalian methylomes, it is necessary to
merge the methylation information from the two complementary strands, since they
truly represent the same CpG dinucleotide.
In the METABRIC dataset, methylation calls from complementary strands
originating from the same CpG dinucleotide were highly correlated (median
correlation = 0.89, 25th percentile = 0.86, 75th percentile = 0.91), and consequently
the methylation information was merged using coverage2cytosine [Babraham
Bioinformatics, 2016a].
2.3.4 Quality assessment and sample filtering
Systematic sequencing and base-calling errors that adversely affect downstream results
are common and increasingly well characterised in high-throughput sequencing studies
[Taub et al., 2010]. This is even more crucial for the METABRIC methylome study
presented in this thesis, given the large number of samples involved and the unique
features of RRBS libraries that make it susceptible to a variety of biases. While several
of these biases (such as DNA fragments being shorter than the read length, have been
described and controlled in Section 2.3.2), several other biases can arise and need to
be detected. At each individual stage of the bioinformatics pipeline, a quality control
(QC) step is introduced to guide the identification of the error-prone stage so that quick
steps that can be taken to mitigate these errors. These steps are described below.
2.3.4.1 Read quality control
Quality control reports were generated for the raw sequence data using FASTQC
(version 0.11.2) [Andrews Simon, 2015]. If base quality and base composition of the
reads are not as expected, then trimming of the reads was performed as detailed in
Section 2.3.3.1.
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2.3.4.2 Genotyping
Single Nucleotide Polymorphism (SNP) data obtained from the Affymetrix SNP 6.0
arrays from the original METABRIC publication [Curtis et al., 2012] was used as the
original genotyping data, and remapped from the genome assembly hg18 (on which
genotyping was originally performed) to hg19 using the LiftOver package [Hinrichs,
2006]. Genotypes from the RRBS sequencing data was obtained by using GATK’s
Unified Genotyper with default parameters to call SNPs at the loci shared with the SNP
6.0 array. C/T and G/A SNPs were removed to prevent confounding with unmethylated
cytosines. For each sample, the percentage of SNPs with the same genotype across
the two platforms was used to confirm sample identity. Dr Harry Clifford performed
genotyping on the samples in order to identify potential sampling or plating errors.
The identities of 24 samples were corrected as a consequence of genotyping.
2.3.4.3 Read counts and depth of coverage
Multiplexing leads to a potential imbalance of samples within the library pools, which
could result in decreased sequencing coverage in some samples. Although, the RBBS
library preparation protocol has been optimised to reduce this imbalance (Section
2.3.1), some samples may not yield a sufficient number of unique CpG sites with
adequate coverage due to insufficient input DNA. Figure 2.7a displays the number of
aligned reads obtained for the METABRIC samples retained after filtering (median
= 16.98 million reads, 25th percentile = 13.63 million reads, 75th percentile = 20.11
million reads). The mapping median mapping efficiency was 77.0% (25th percentile
= 75.3%, 75th percentile = 78.1%; Figure 2.7b). As a reference, average mapping
efficiency for an RRBS library is typically around 60%-65% [Garrett-Bakelman et al.,
2015; Li et al., 2016b].
Only samples with more than 1.5 million unique CpGs at a minimum 5× coverage
were retained. 100 samples (96 tumours and 4 normals) were discarded as a result of
failing this criterion. After filtering, the number of unique CpGs with 1×, 5× and 10×
coverage were computed for each sample (Figure 2.7d-f). The METABRIC samples
had a median of 2.82 unique million CpGs at 5× (25th percentile = 2.52 million CpGs,
75th percentile = 3.05 M CpGs); median of 4.82 million unique CpGs at 1× (25th
percentile = 4.54 million CpGs, 75th percentile = 5.20 M CpGs); and 1.88 million
unique CpGs at 10× (25th percentile = 1.58 million CpGs, 75th percentile = 2.13
million CpGs).
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Figure 2.7: Sample filtering was based on the number of CpG sites detected at 5×
coverage and non-CpG methylation %. (a) No. of aligned reads for all samples. (b)
Mapping efficieny (%) for all samples. (c) Non-CpG methylation (%) for all samples.
Dashed lines at 0.3% and 0.6% represent the thresholds used for sample filtering. (d) No.
of CpG sites detected at 1× coverage. (e) No. of unique CpG sites detected at 5×
coverage. Dashed lines at 1.5 M unique CpG sites represents the threshold used for
sample filtering. (f) No. of CpG sites detected at 10× coverage. In (a) – (f) all
METABRIC samples retained after filtering are plotted. Boxplots (red) indicate the
interquartile range with 25th percentile, median and 75th percentile values illustrated.
Whiskers indicate 1.5× of the interquartile range. M = million. No. = Number.
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2.3.4.4 Bisulphite conversion
After methylation calling, the sensitivity and specificity of the bisulphite conversion is
monitored. Elevated levels of observed non-CpG methylation can provide an indication
of incomplete bisulphite conversion since non-CpG dinucleotides are rarely methylated
in mammalian cells [Ziller et al., 2011].
Traditionally, non-CpG methylation levels of > 1% are used as a threshold to
identify and discard samples that suffered from incomplete bisulphite conversion
[Gu et al., 2010; Kulis et al., 2015]. However, one of the aims of the METABRIC
project is to investigate and compare epiclonal compositions of the samples, and
epiclonal estimates are extremely sensitive to variations in bisulphite conversion [Li
et al., 2016b]. Consequently, a more stringent interval of [0.3%-0.6%] was used as a
quality control criteria to retain samples. 122 samples (101 tumours and 21 normals)
were discarded as a result of failing this criterion. Figure 2.7c portrays the global
non-CpG methylation % for each retained sample.
2.3.4.5 Sample inclusion criteria
Only primary invasive breast tumours and adjacent normal breast tissues from female
patients were retained. Ductal carcinoma in situ (DCIS, n=12), Non-invasive tumours
(n=6), and recurrent tumours (n=13), and tumours from male patients (n=8) were
removed. Where replicates or bilateral tumours exist, the sample with the highest
number of CpGs at 5× coverage was picked to represent the patient. 7 replicates and
5 bilateral tumours were discarded as a consequence.
Overall 1719 METABRIC samples (1482 breast tumours and 237 adjacent normal
tissues) were retained after quality control. Stratifying the breast tumours by three
established taxonomies (see Chapter 1) – ER Status, Intrinsic subtypes and Integrative
clusters – revealed that distinct breast cancer subtypes are also very well represented
(Figure 2.8).
2.3.5 Determination of CpG sites
2.3.5.1 CpG site filtering
The starting sites of reads generated from RRBS are not random, but are dictated by
MspI digestion, and hence this leads to an inability to distinguish PCR duplicates from
two cancer cells having the same genotype and methylation information. Consequently,
if experiments suffer from a high degree of PCR duplication, some reads will be
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Figure 2.8: Breast cancer subtypes are well represented in the METABRIC
methylome study. (a) Number of tumour and normal tissues retained in the study. (b)
Distribution of tumours based on ER status. (c) Distribution of tumours based on
Intrinsic subtype membership. (d) Distribution of tumours based on Integrative cluster
membership.
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preferentially over-amplified and will impair accurate determination of methylation
estimates for these regions.
Read coverage per base distribution is an important metric that aids in filtering
CpG sites that suffer from PCR duplication bias and consequently have very high read
coverage [Akalin et al., 2012a]. CpG sites that have more than 99.99 percentile of
coverage in each sample were discarded, as long as they are not located on known
copy number amplifications (based on copy number estimates, see Section 2.2). This
filtering step also avoids the inclusion of centromeric or telomeric repetitive regions
[Kulis et al., 2015].
Furthermore, sufficient read coverage is required for providing adequate power
of statistical tests, and accordingly CpG sites with low read coverage were also
discarded. The number of CpG sites covered at various minimum depths and by
different proportions of samples were also computed (Figure 2.9a). Increasing the
minimum depth required, decreased the number of total number of CpG sites profiled,
but increased the median coverage for the cohort. 1.25 CpG universe represents the
set of 5.41 million CpG sites with a minimum 1× coverage that are profiled in at
least 25% of METABRIC samples. 5.50 CpG universe represents the set of 2.72
million CpG sites with a minimum 5× coverage that are profiled in at least 50%
of METABRIC samples. For this CpG universe, CpG sites covered by less than 5
reads were discarded due to insufficient confidence in their methylation estimates.
1506 METABRIC samples (87.6%) harboured more than 2 million CpG sites within
the 5.50 CpG universe (Figure 2.9b). 10.50 CpG universe represents the set of 1.79
million CpG sites with a minimum 10× coverage that are profiled in at least 50% of
METABRIC samples. Where single CpG information is analysed in this thesis, the
5.50 CpG universe is used, with the exception of Chapter 5 in which a different CpG
selection criterion is applied for the investigation of intratumour heterogeneity.
2.3.5.2 Annotation
RefSeq transcript annotation for hg19 was obtained from UCSC genome browser
[Karolchik et al., 2014] to define TSS, exons and introns for each gene. Promoters
were defined as 2 Kbp upstream and 500bp downstream of the transcription start site
(TSS). One gene may be associated with more than one promoter. Intergenic regions
were defined as regions complementing promoter and gene body regions. CpG island,
CpG shore and open sea definitions for hg19 were also obtained from the UCSC
genome browser [Karolchik et al., 2014].
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Figure 2.9: 5.50 CpG universe represents the set of 2.7 M CpG sites at ≥5×coverage
profiled in ≥ 50% of METABRIC samples. (a) Comparison of coverage distribution
for 3 CpG universes: (left) 1.25 CpG universe, (middle) 5.50 CpG universe (right) 10.50
CpG universe. Definition of universes given in text. (b) Distribution of the number of
unique CpG sites assayed as part of the 5.50 CpG universe in the METABRIC samples.
Dashed vertical grey line represents 2 M unique CpG sites. M=million.
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Human Mammary Epithelial Cell (HMEC) ChromHMM annotations for hg19
were downloaded from ENCODE to define the chromatin states based on
genome-wide histone marks [Ernst et al., 2011]. The chromatin states summarised
regions with coordinated chromatin modification patterns and included enhancers,
polycomb-repressed chromatin (PRC) regions, insulators, heterochromatin and
repetitive regions. Figure 2.10a illustrates the distribution of the CpG sites within the
5.50 CpG universe according to RefSeq definitions, CpG content definitions and
chromatin state definitions. Figure 2.10b compares the total number of CpG sites
covered in the RRBS 5.50 CpG universe with that covered in the Illumina HM450
microarray panel and the Illumina EPIC microarray panel. The RRBS 5.50 CpG
universe clearly interrogates a larger number of CpG sites in promoters, enhancers and
PRC regions. Figure 2.10c illustrates the proportion of each genomic feature that is
assayed as part of the 5.50 CpG universe. For instance, approximately 75% of
promoters present in the genome are covered by at least 1 CpG sites in the 5.50 CpG
universe. However, only 66% of promoters present in the genome are covered by at
least 5 CpG sites in the 5.50 CpG universe. Similarly, the gene bodies (comprising of
all introns and exons of a gene) of 70% of all genes are covered by at least 5 CpG sites
in the 5.50 CpG universe.
Genes were also annotated by their known biological function (if any) by using
gene-family annotation obtained from the Molecular Signatures Database
[Subramanian et al., 2005, MSigDB]. Gene-family categories included tumour
suppressors, oncogenes, translocated cancer genes, protein kinases, cell differentiation
markers, homeodomain proteins, transcription factors and cytokines/ growth factors.
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Figure 2.10: (Caption on next page.)
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Figure 2.10: (Previous page.) Proportion of promoters, exons, introns, enhancers
and PRC regions interrogated by RRBS. (a) illustrates the distribution of the CpG sites
within the 5.50 CpG universe according to RefSeq definitions, CpG content definitions
and chromatin state definitions. (b) compares the total number of CpG sites covered in
the 5.50 CpG universe with that covered in the Illumina HM450 microarray panel and
the Illumina EPIC microarray panel, according to RefSeq definitions, CpG content
definitions and chromatin state definitions. (c) illustrates the proportion of each genomic
feature that is assayed as part of the 5.50 CpG universe at different overlap thresholds
(CpG overlap at 1+, 5+, 10+, 20+, 50+ are denoted with different shades of green).
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2.4 Analysing DNA methylation using RRBS
With recent advances in NGS technologies for methylation profiling such as WGBS
and RRBS, there is an increasing demand for statistical tools to analyse bisulphite
sequencing data. However, bisulphite sequencing technologies present substantial
challenges in terms of data processing, statistical analysis and biological interpretation
of observed differences, which are addressed below.
2.4.1 Existing approaches to analyse bisulphite sequencing data
There are a number of approaches that can be used to analyse methylation information
obtained through RRBS profiling. Four distinct approaches can be used in bisulphite
sequencing experiments and are detailed below.
2.4.1.1 Single CpG resolution
Previous publications have focused on estimating and comparing precise methylation
levels at single-base resolution. For instance, Fisher’s exact test [Lister et al., 2009]
and logistic regression [Akalin et al., 2012b] have been used to identify single CpGs
that are differentially methylated across two samples or groups of samples respectively.
However, comparing methylation levels over single base resolution, as described in
these studies, has a few disadvantages.
Firstly, methods such as Fisher’s exact test and logistic regression either
completely ignore biological variability within the conditions tested or underestimate
it. Methylation levels between tumours are known to be highly variable [Györffy et al.,
2016; Holm et al., 2016], and defining differentially methylated CpG sites in tumours
versus normal tissues using these two approaches leads to overdispersion. As a result,
the overall variability is underestimated resulting in overestimation of significantly
differentially methylated CpG sites in tumours. The beta-binomial model is a more
appropriate statistical method for identifying differentially methylated CpGs in
bisulphite sequencing studies [Hebestreit et al., 2013].
Secondly, any statistical method that tests for differences in DNA methylation at
a large number of genomic loci needs to correct for multiple hypothesis testing. This
correction is usually done by controlling the false discovery rate (FDR)1, in which the
1 False discovery rate (FDR). The false discovery rate is an estimate of the proportion of significant
results (usually at alpha = 0.05) that are false positives. Originally developed by Benjamini and
Hochberg [1995], FDR procedures essentially correct for this number of expected false discoveries,
providing an estimate of the number of true results among those called significant.
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distribution of uncorrected p-values is analysed and an FDR is inferred for each DMR.
Because of the large number of CpGs in the genome, only the strongest single-CpG
differences tend to remain significant after multiple testing corrections [Kuan and
Chiang, 2012]. The result is often a high false-negative rate, especially when sample
numbers and effect sizes are small.
Thirdly, the standard error of the single-CpG methylation estimate is inversely
proportional to the number of reads covering the CpG. A high coverage of at least
30x per CpG site is required to minimise the standard error to an adequate level for
accurate detection [Hansen et al., 2012]. However, such a high coverage design is
unfeasible in particular for studies with high sample sizes.
2.4.1.2 Annotated region-level analysis
The regulatory role of DNA methylation at different genomic features has been
discussed at length in Chapter 1. For instance, hypermethylated promoters in cancer
have been associated with a strong repressive effect [Esteller, 2000], whereas loss of
gene body methylation has been associated with both the suppresson and stimulation
of genes [Kulis et al., 2012]. Therefore, delineating the role of DNA methylation at
different genomic features should be of interest for DNA methylation based analyses.
Furthermore, functionally relevant findings are generally associated with multiple
CpG sites rather than a single CpG site, and methylation properties of the region as a
whole determines its function [Eckhardt et al., 2006; Laird, 2010].
Therefore, an alternate option to single nucleotide analysis would be to carry out
comparisons on predefined large genomic regions by averaging methylation levels over
all CpG sites within individual genomic features, and then proceeding with statistical
tests. Genomic features included in the analysis are i) CpG-density related regions
such as CpG islands and CpG shores; ii) gene related regions such as promoters, gene
bodies, and intergenic regions; iii) regulatory regions such as enhancers and PRC
regions. This delivers an improvement over a single CpG analysis since neighbouring
CpGs with similar differences in DNA methylation reinforce each other and improve
the statistical power for detecting weak differences.
However, a limitation of using pre-defined genomic regions is that they may not
exactly overlap functional differentially methylated regions. For instance, if a large
fraction of a differentially methylated region extends beyond the annotation-defined
region or is significantly smaller, then averaging methylation differences over all CpGs
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within the annotation-defined region would effectively dilute this signal and potentially
lead to a high false-negative rate (loss of detection).
2.4.1.3 Defining differentially methylated regions based on clustering of
spatially correlated CpGs
The approach detailed in the previous subsection operates by first defining regions,
and then conducting downstream analysis. Due to the aforementioned limitations of
this approach, methods that detect differentially methylated regions unconstrained by
a priori region definitions are more suitable. However, explicitly defining differentially
methylated regions (DMRs) using single CpG information is difficult since controlling
the FDR at the region-level whilst simultaneously defining the region poses a statistical
challenge due to the spatial correlation of CpG sites [Bock, 2012; Robinson et al.,
2014]. A number of methods have been developed that adjust for the correlation
in neighbouring CpG sites such as the Stouffer-Liptak test [Dolzhenko and Smith,
2014; Li et al., 2013]. This additional step allows identification of precise differentially
methylated regions with appropriate FDR control over single CpG sites. Other methods
that attempt to control this FDR including a module for block finding for microarrays
[Aryee et al., 2014]; cluster-wise weighted FDR strategy [Hebestreit et al., 2013]; and
a tool called comb-p for DMR detection by combining spatially correlated p-values
[Pedersen et al., 2012].
Although these approaches are statistically appropriate for RRBS analysis, they
are only suitable for defining differentially methylated regions between two samples
or between two groups of samples [Dolzhenko and Smith, 2014; Li et al., 2013].
Consequently, distinct region universes are constructed for each tumour and every
comparison tested. This does not allow interrogation of methylation profiles over a
common set of regions across all samples.
2.4.1.4 Smoothed gene unit analysis
The distribution of the epigenetic marks in the genome depends on distinct genomic
features. Methylation that occurs directly on genes (promoter and gene bodies) is
intuitively associated with regulation of the underlying gene itself and so it might be
beneficial to focus the statistical analysis on genes separately. Furthermore, DNA
methylation levels at neighbouring CpG sites have been shown to be strongly correlated
[Zhang et al., 2015]. This implies that the probability that a CpG site is methylated
can be assumed to vary smoothly along a gene, without distorting signal or losing
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functional information [Hansen et al., 2012]. Precision can be improved by the use of
modern statistical techniques such as local likelihood smoothing or smoothing splines.
A statistical method that combines the two concepts discussed above – a gene-
centric analysis; and smoothing over CpG sites – has been developed in parallel to this
thesis [Batra, 2015; Rueda, 2014, private communication] with the aim of increasing
the statistical power as well as allowing gene-by-gene analyses. This method would
enable testing of the role of individual genes between cancer and normal tissues (as well
as between subtype-specific cancers), and also comparison of gene-by-gene differential
patterns within the same tissue. However, this method is unsuitable for RRBS due to
the disjointed nature of the profiled epigenome and is far more appropriate for WGBS
and MBD-seq. Consequently, the smoothed gene unit analysis has not been utilised
for quantifying methylation in this thesis.
2.4.2 Novel Method – Spatially Coordinated CpG-sites within the
RRBS Universe in Breast cancer (SCCRUB)
One of the reasons that the microarray platform has been popular compared to
bisulphite sequencing experiments is the relative ease in bioinformatics analysis. Each
probe in a microarray analysis can be treated independently; conversely single CpG
analysis in bisulphite experiments suffers from inadequate power and low functional
relevance. Moreover, the unsuitability of the smoothed gene approach (previous
subsection) in RRBS necessitates the need for a suitable method to delineate distinct
regions for analysis. However, using predefined annotated regions for analysis results
in the dilution of signal; and although explicitly defining differentially methylated
regions overcomes this obstacle (discussed in Section 2.4.1.3), it does not yield a
common set of regions for all tumours.
A novel algorithm called Spatially Coordinated CpG-sites within the RRBS
Universe in Breast cancer (SCCRUB) is introduced that attempts to transform the
RRBS data into distinct regions comprising of multiple CpG sites coordinated in
their methylation behaviours2. The objective of this effort is to generate a universe
of regions that is potentially functionally relevant and is smaller in size than the
number of single CpG sites. This SCCRUB algorithm specifically identifies clusters
of spatially correlated CpG sites across tumours and normal tissues by leveraging: a)
2 This novel approach stemmed from discussions with Dr Cem Meydan during a travel fellowship to
Professor Ari Melnick and Professor Chris Mason’s laboratory at Weill Cornell Medicine, New York.
The two principal investigators are incidentally the authors of Li et al. [2013], a method that defines
DMRs based on clustering of spatially correlated CpG sites.
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the large number of samples available (both tumours and normal tissues); and b) the
single nucleotide resolution methylation estimates obtained from RRBS profiling. The
algorithm consists of four components that are described below.
2.4.2.1 STEP 1: Determination of empirical region boundaries
In order to identify a set of regions comprising of neighbouring CpGs in close spatial
proximity, an optimal threshold of genomic distance has to be estimated to determine
the minimum gap between two distinct regions. This threshold is used to separate
two adjacent CpG sites so that they are not considered in the same region. This is
particularly vital for RRBS data since it is based on restriction enzyme digestion; and
consequently, the profiled CpGs are not evenly distributed across the genome. The
method and tool presented in Li et al. [2013] was used to determine this optimum
boundary cut-off; however, the method was implemented on the 5.50 CpG universe
(which is a common universe of CpGs covered at ≥ 5× in at least 50% of all samples;
n = 2.7 million; Section 2.3.5), and not on a per sample basis as described in the
original publication. Another key distinction is that method was originally used on
differentially methylated CpG sites, whereas in this case it is implemented on all
CpG sites. The distribution of the distance between consecutive CpG sites (using the
5.50 CpG universe; n = 2.7 million) was examined. Log2 transforming revealed a
bimodal normal distribution (Figure 2.11a), with the assumption being that the first
normal distribution represents distances between CpG sites belonging to the same
functional region, whereas the second normal distribution represents the distance
between boundary CpGs of distinct regions. An expectation maximisation (EM)
algorithm was used to fit the bimodal normal distribution, and the weighted combined
probability function was minimised to determine the appropriate boundary cut-off (D
= e8.2 = 294 bp) as described in Li et al. [2013]. This threshold represents the best
separation point between the two distributions, and thus determines the minimum gap
between consecutive functional region boundaries.
2.4.2.2 STEP 2: Defining regions
Once the boundary threshold (D=294 bp) was determined, regions comprising of
neighbouring CpG sites were identified based on two criteria:
1. Distances between adjacent CpG sites were examined, and consecutive CpG
sites with distances less than 294 bp were clustered into the same region. A
distance of greater than 294 bp between consecutive CpG sites was used to mark
the boundary point of two distinct regions.
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Figure 2.11: Generation of the novel SCCRUB universe. (a) The distribution of the
distance between consecutive CpG sites within the 5.50 CpG universe. x-axis is log2
transformed. The first normal distribution (red) represents distances between CpG sites
belonging to the same functional region. The second normal distribution (green)
represents the distance between boundary CpGs of distinct regions. The boundary cut-off
is empirically estimated to be 294 bp and is used to determine the minimum gap between
consecutive region boundaries. (b) Distribution of the number of CpG sites in each
region in SCCRUB. (c) Distribution of the width of each region in SCCRUB. In (b) and
(c), boxplots indicate the interquartile range with 25th percentile, median and 75th
percentile values illustrated. Whiskers indicate 1.5× of the interquartile range.
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2. Regions with at least 3 CpG sites were included, and the rest were discarded.
2.4.2.3 STEP 3: Filtering regions based on autocorrelation of CpG sites
CpG sites in the regions defined in STEP2 were further refined based on whether
the CpG sites within a region were spatially correlated with each other. For each
region, the following steps were implemented to obtain spatially correlated filtered
sub-regions.
1. Spatial autocorrelations of methylation (M-values) between CpG sites were
calculated using both tumour and normal samples. Two autocorrelations were
calculated using lags of i) 1 CpG site, and ii) 2 CpG sites respectively, to account
for inconsistencies in single CpG estimates. The maximum of the two was
recorded for each CpG site.
2. A correlation threshold of 0.7 was used to mark a CpG site as PASS.
3. A forward sliding CpG approach (starting with the CpG with lowest base position
and going higher) and backward sliding CpG approach (starting with CpG with
highest position and going lower) were used to detect maximal sub-regions
such that at least 60% of its CpG sites are marked as PASS. If the forward and
backward approaches yield overlapping sub-regions, then the union is recorded;
otherwise the sub-regions are recorded as two distinct regions.
4. Sub-regions with at least 3 CpG sites were included.
5. Step 2-4 were repeated with tiered correlation thresholds of 0.6, 0.5, 0.4, 0.3 and
0.2.
6. Sub-regions obtained from the 6 distinct correlation thresholds were compared.
For overlapping sub-regions, a preference for the sub-region passing the most
stringent (highest) correlation threshold (and consequently comprising the lowest
number of CpG sites) was recorded. Non-overlapping sub-regions were recorded
as distinct entities. Consequently, each region defined in STEP2 can yield more
than one spatially correlated filtered sub-regions.
7. For each filtered sub-region, samples methylation estimates were obtained by
aggregating estimates (Beta-values) over all CpG sites within the region.
Methylation estimates were marked as unknown for samples that harboured less
than 3 CpG sites for a sub-region since this constitutes insufficient data.
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2.4.2.4 STEP 4: Annotation
Finally, the universe of spatially correlated filtered regions was comprehensively
annotated using i) RefSeq gene coordinates: promoters, exons, introns and intergenic
regions; ii) CpG content; and iii) chromatin based marks such as enhancers and PRC
regions (see Section 2.3.5).
Figure 2.12: Schematic diagram of the SCCRUB algorithm.
A schematic diagram of the SCCRUB algorithm is shown in Figure 2.12.
Implementing the SCCRUB algorithm on the 5.50 CpG universe yielded 289,265
regions comprising of 4 CpG sites on average (median = 4, 25th percentile = 3, 75th
percentile = 6; Figure 2.11b), and with an average width of 88bp (median = 88, 25th
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percentile = 47, 75th percentile = 150; Figure 2.11c). The underlying premise of this
universe of regions is that it potentially delineates all the regions within the
RRBS-universe in which there is strong evidence that multiple CpGs (at least 3) are
spatially coordinated in their methylation statuses. This has led to the identification of
a novel set of regions that are potentially more functionally relevant than single CpG
sites, but also represent a significantly smaller universe leading to lower false positives
(SCCRUB: n = 289 K, 5.50 CpG universe: n = 2,700 K = 2.7 M). Moreover, the
SCCRUB algorithm is an unsupervised method unconstrained by any particular
comparison, and consequently the resulting fixed set of SCCRUB regions can be used
for any downstream analysis much like microarray probes. 289K distinct regions are
assessed in SCCRUB, a manageable number for downstream statistical analysis, that
can be compared to current and previous microarray technologies (HM27 = 27K
probes; HM450 = 450K; EPIC = 850K probes). However, these regions comprise of
methylation statuses of 1.7M spatially correlated CpG sites (and are constructed from
the 5.50 CpG universe of universe of 2.7M CpG sites). In this thesis, the SCCRUB
universe of regions will be utilised exclusively in those downstream analyses that are
involved in identifying regions of ordered (comprising of coordinated CpG sites)
methylation alterations that have potential to be functional, such as the differential
methylation analysis in Chapter 3. However, analyses in which stochastic methylation
changes are examined will require single CpG investigations, and in these cases the
5.50 CpG universe will be employed. Although, the SCCRUB universe provides many
advantages (as described above), it is important to note that a large number of samples
(both tumours and normal tissues) as well as large inter-tumour representation is
necessary to accurately estimate CpG autocorrelations per region to feed accurate
region definitions.
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2.5 Pipeline validation
2.5.1 Tumour and normal methylation statuses
In order to conduct an unsupervised global assessment of the methylation profiles of
the samples, the top 50% variably methylated SCCRUB regions (n=144632 regions)
were chosen. t-Distributed Stochastic Neighbour Embedding (t-SNE), a technique for
dimensionality reduction [Maaten and Hinton, 2008] was conducted on the pairwise
Euclidean distance matrix obtained from the 1719 x 144632 matrix of methylation
estimates over all 1719 samples and 144632 selected SCCRUB regions. Consequently,
the methylation landscape of each sample (consisting of 144632 SCCRUB regions)
could be largely represented by its two t-SNE components. Figure 2.13a illustrates
the first two t-SNE components for each sample, and this allows easy visualisation
and examination of the high dimensional methylation profiles for each sample. The
normal tissues (grey crosses) exhibit a spectacular divergence from the tumours (red
dots) implying distinct methylation profiles for the two groups.
Finally, tumours were classified according to ER status, as this classification
encompasses significant differences in the fundamental biology of breast tumours;
further, the normal tissues were also classified according to the ER status of the
corresponding adjacent matched tumours (Figure 2.13b). The top two t-SNE
components (representing sample-specific DNA methylation profiles) were tested for
association with ER Status in the tumours and normal tissues separately (multinomial
linear regression; Figure 2.13c). The DNA methylation profiles of the tumours are
highly significantly associated with ER status which indicates that in addition to
tumour-normal differences in breast cancer (Figure 2.13b, c) it would also be
beneficial to test for subtype-specific differences in ER+ and ER- tumours separately.
Crucially, normal samples have homogeneous methylation profiles with respect to the
corresponding adjacent tumours’ ER status (Figure 2.13b, c) which implies that unlike
tumours, it is not necessary to divorce normal tissues by their respective matched
subtypes. Accordingly, for all the analyses in this thesis, all normal tissues were
pooled together, with the exception of intra-sample investigation in Chapter 5. Similar
dichotomies between tumour and normal samples were noted for the Intrinsic subtype
and Integrative cluster classifications (Figure 2.13c).
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Figure 2.13: (Caption on next page.)
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Figure 2.13: (Previous page.) DNA methylation profiles of breast samples separate
by tumour-normal classification and by tumour subtypes. (a) The top 2 t-SNE
components representing the sample specific methylation profile are plotted for each
sample. Each point represents a breast tissue sample. Colour and shape of points
represent tumour or normal classification. (b) The top 2 t-SNE components representing
the sample specific methylation profile are plotted for each sample. Each point represents
a breast tissue sample. Shape of points represent tumour or normal classification. Colour
of points represent ER status in the case of tumours, and ER status of the adjacent
matched tumour in the case of the normal tissues. (c) For three tumour subtype
classifications (ER status, Intrinsic subtypes and Integrative clusters), the association
between the tumour subtype and the 2 t-SNE components were investigated (multinomial
linear regression). Similar associations were tested between the normal subtype (as
defined by adjacent matched tumour subtype) and the 2 t-SNE components. Colour of
the squares represent the level of significance of the association as detailed in the legend.
adj = adjacent to tumour.
2.5.2 Technical variability and clinicopathological factors
In order to test whether technical effects and tumour-related clinicopathological factors
were associated with DNA methylation profiles, a similar analysis (as above) was
conducted for all 1482 tumours. The top two t-SNE components were tested with
clinicopathological factors including age at diagnosis, tumour size, tumour grade
and number of lymph nodes; and technical effects including METABRIC plate and
RRBS batch (multiple plates were processed together and formed one batch). ER
status was added as a confounder in the models. All clinicopathological factors were
significantly associated with at least one t-SNE component suggesting that established
clinical phenotypes have distinctive methylation profiles (linear regression; Figure
2.14). Conversely neither of the technical factors were associated with the 2 t-SNE
components, implying that technical variability is not associated with the tumours’
methylation profiles, and that a majority of the variation in methylation is explained
by clinical/ biological variation.
2.5.3 Validation with HM450 data
To validate the RRBS pipeline, methylation calls from RRBS were compared to
previous methylation estimates obtained previously using the HM450 microarray
analysis of 12 METABRIC tumour samples (study conducted by Associate Professor
Christina Curtis, Stanford University). Thirteen samples had data from both RRBS and
HM450. Approximately 78.7K CpG sites were commonly covered in both HM450 and
RRBS (read coverage≥ 10). Sample-specific correlations were performed across these
CpG sites yielding a median correlation of 0.93 (25th percentile = 0.90, 75th percentile
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Figure 2.14: Clinicopathological variables but not technical variables are associated
with DNA methylation profiles of the breast tumours. Associations between
clinicopathological variables for the tumours and the 2 t-SNE components were
investigated. Similarly, associations between technical variables and the 2 t-SNE
components were investigated. Linear regression was used for continuous variables and
multinomial regression was used for categorical variables. Colour of the squares
represent the level of significance of the association as detailed in the legend.
= 0.94; Figure 2.15a). As expected, correlations between the two technologies increase
with higher coverage in RRBS (Figure 2.15b). The high reproducibility between
the RRBS platform and the HM450 platform indicates the robustness of these two
technologies.
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Figure 2.15: (Caption on next page.)
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Figure 2.15: (Previous page.) High reproducibility of DNA methylation calls between
RRBS and HM450 platforms indicates the robustness of these procedures. (a)
Scatter plots of the RRBS and HM450 DNA methylation calls for thirteen breast
tumours. Only CpG sites with RRBS read coverage ≥ 10× and overlapping HM450
probes were plotted. Colours represent density of CpG sites. Median spearman
correlation coefficients estimating the agreement between the RRBS and HM450 DNA
methylation calls for each tumour were noted in the top left corner of the plots. (b)
Distribution of the thirteen sample-specific median spearman correlation coefficients
between the two methylation platforms, conducted for sets of CpG sites at different
RRBS coverages that also overlap the HM450 probes. Median (red line) represents the
average spearman correlation between the methylation calls from two platforms for the
13 breast tumours, and is noted above the boxplots. Size of the blue circle represents the
number of CpG sites that were considered at the different RRBS read coverages, and the
number is noted below the circle.
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2.6 The breast cancer methylome in METABRIC
2.6.1 The global methylation landscape of breast cancer
The global methylation landscape is explored in tumour and normal samples.
Investigating all CpG sites within the 5.50 CpG universe revealed that on average,
tumours have lower methylation levels genome-wide than normal tissues (Figure
2.16a, b). Stratifying the genome into relevant genomic features, also revealed
differences (Figure 2.16a, b). An aggregate gain of methylation is observed in
promoters (though difference was not significant in this study) and exons in breast
tumours as observed in previous breast cancer studies [Fleischer et al., 2014; Györffy
et al., 2016; Rønneberg et al., 2011]. On the contrary, a loss of methylation is
observed in introns and heterochromatin in the tumours when compared to the normal
tissue. In addition, enhancers and PRC regions are dramatically hypermethylated in
breast tumours, agreeing with previous reports in other cancers [Ohm et al., 2007;
Schlesinger et al., 2007; Widschwendter et al., 2007].
Comparing the aggregate methylation levels in the two predominant breast cancer
subtypes, ER+ and ER-, tumours revealed that the global directionality of epigenetic
change for a given genomic feature is the same in both subtypes (Figure 2.16c). Similar
findings were observed when stratifying breast tumours by the Intrinsic subtypes and
Integrative clusters (Appendix A.1). For example, all breast tumour subtypes have
significantly increased global methylation in exons, enhancers and PRC regions. This
indicates that the same fundamental mechanisms of epigenome control are breached
in breast cancer resulting in the redistribution of DNA methylation across the genome.
However, the extent of these changes vary across the different breast cancer subtypes,
suggesting that the epigenome does contribute to defining these subtypes as distinct
biological entities. A more formal investigation of tumour versus normal methylation
alterations and subtype-specific methylation alterations is conducted in Chapter 3.
2.6.2 Comparison with the TCGA breast cancer methylome
The largest breast cancer methylome study preceding the METABRIC study described
in this thesis was conducted by TCGA (The Cancer Genome Atlas) [Cancer Genome
Atlas Network, 2012]. TCGA is a publically available collection of 1000 invasive
breast cancer samples (and matched normal tissues), with multidimensional molecular
characterisation (mRNA expression microarrays, DNA methylation microarrays, whole
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Figure 2.16: (Caption on next page.)
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Figure 2.16: (Previous page.) Supervised analysis of DNA methylation profiles reveal
distinct epigenetic landscapes in tumours and normal tissues. (a) Scatter plots of the
average DNA methylation estimates for tumour and normal tissues for CpG sites within
the 5.50 CpG universe stratified by genomic feature. Colours represent density of CpG
sites. Number of CpG sites within each genomic feature is noted in the bottom right
corner of the plots. (b) Distribution of average methylation estimates for tumour and
normal tissues stratified by genomic feature. For each sample, the median methylation
level across each genomic feature, and the resulting distributions were plotted. For each
genomic feature, methylation estimates between tumour and normal tissues were
compared using the Wilcoxon rank-sum test. FDR p-values were denoted. (c)
Distribution of average methylation estimates for ER+, ER- and normal tissues stratified
by genomic feature. For each sample, the median methylation level across each genomic
feature, and the resulting distributions were plotted. For each genomic feature,
methylation estimates between these three categories were compared using the Kruskal
Wallis test. FDR p-values were denoted. (N.S.= FDR p-value < 0.1, * = FDR p-value <
0.05, ** = FDR p-value < 0.01, *** = FDR p-value < 0.001, **** = FDR p-value <
0.0001). Heterochrmtn = Heterochromatin.
exome sequencing, SNP arrays, microRNA sequencing and reverse-phase protein
arrays (RPPA)), as well as clinical annotation.
In the original TCGA study, Infinium Human Methylation 27 (HM27) and
Infinium Human Methylation 450 (HM450) arrays were used to profile methylation in
800 samples. Unsupervised analysis using a Recursively Partitioned Mixture Model
(RPMM) was performed on 466 breast tumours using a set of 574 selected probes that
were present in the HM27 microarray, as detailed in the original publication. This
identified five clusters of tumours with distinct DNA methylation profiles [Cancer
Genome Atlas Network, 2012].
In order to conduct a comparison of the METABRIC methylome with the TCGA
methylome, a similar unsupervised analysis was conducted in the METABRIC samples.
Since a vast majority of the probes in the HM27 microarray (used in the TCGA
clustering analysis) localise to promoters (88%), only promoter SCCRUB regions
were considered for this analysis. On aggregate, 42517 SCCRUB promoter regions
were identified (out of which 4589 (11%) also overlapped with the HM27 microarray
probes). For each region, z-scores were calculated for the 1482 tumours with respect to
the methylation estimates of the 237 normal tissues. The top 50% variable regions were
selected and a Partitioning Around Medoids (also known as K-medoids) clustering,
which is a more robust version of K-means clustering [Kaufman and Rousseeuw,
1987] was conducted to cluster the tumours into 5 groups (same depth of clustering
as conducted in the TCGA dataset). Table 2.1 (top panel) details the 5 methylation-
groups identified in METABRIC, and they show remarkable concordance with the
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5 methylation-clusters identified in the TCGA tumours. For instance, Groups 1 and
2 derived from both TCGA and METABRIC clustering efforts were revealed to
be significantly enriched for the Luminal A subtype. Methylation group 3 derived
from both TCGA and METABRIC clustering analyses demonstrated the strongest
hypermethylation phenotype among all groups; they were depleted for PIK3CA,
MAP3K1 and MAP2K4 mutations; and they largely overlapped with the Luminal B
subtype. Group 5 showed the lowest aggregate methylation levels, highest frequency of
TP53 mutations and largely consisted of Basal-like tumours in both METABRIC and
TCGA analyses. Moreover, the methylation subtypes derived from both METABRIC
and TCGA analyses did not exhibit a significant association with the HER2-enriched
breast cancer subtype. This remarkable agreement between the two sets of methylation-
clusters that were independently derived from two completely distinct breast cancer
datasets (TCGA and METABRIC tumours), and using distinct methylation platforms,
strongly demonstrate the validity of the RRBS methylome data in METABRIC.
A 5-member unsupervised clustering solution derived from the METABRIC
dataset was described above to conduct a like-for-like comparison with the TCGA
cluster analysis (in which 5 methylation groups had been identified). In order to select
the number of clusters that provides the most consistent clustering solution, the Dunn
index was calculated for different number of clusters. The Dunn index aims to identify
sets of clusters in which members of the same cluster have a small variance i.e. they
are compact, while the means of distinct clusters are far apart i.e. they are separated.
The 8-cluster solution had the highest Dunn index (compared with 3-9 member cluster
solutions). Table 2.1 (bottom panel) details these 8 methylation-clusters identified in
METABRIC. Remarkably many Intrinsic subtypes were split into 2 or more groups,
and strong associations with the Integrative clusters were observed. For instance,
the Luminal B subtype has been divorced into 2 methylation groups: i) Methylation
group 3, which is enriched for IntClust 1, and has a dramatically hypermethylated
phenotype, and ii) Methylation group 7, which is enriched for IntClust 7, and has a
lesser hypermethylated phenotype. Similarly, the Basal-like subtype has also been
split into three methylation groups: i) and ii) Methylation groups 4 and 8 which
were both enriched for IntClust 10, had the lowest aggregate methylation levels,
and highest frequencies of TP53 mutations; and iii) Methylation group 5 which was
enriched for IntClust 4ER- and the Claudin-low subtype, had moderate methylation
levels and moderate prevalence of TP53 mutations. Moreover, this clustering also
identified a HER2-enriched subtype (Methylation group 6). This demonstrates how
increased sample size provided by the METABRIC cohort enabled the refinement of the
epigenetic taxonomy of breast cancer into 8 clusters, compared to the 5-cluster solution
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obtained in the TCGA cohort [Cancer Genome Atlas Network, 2012]. In addition, these
preliminary results substantiate the biological significance of the Integrative clusters
and indicate that besides carrying distinct genetic rearrangements, these Integrative
clusters might carry distinct epigenetic alterations as well.
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2.7 Discussion
The investigation of the DNA methylation landscape in the METABRIC dataset
comprising of approximately 1500 breast tumours constitutes the largest single cancer
methylome cohort yet, and represents a significant development in the field of breast
cancer. In addition to methylation profiling, the availability of gene expression,
copy number and somatic mutation data allows a comprehensive investigation of the
molecular multi-omic basis of breast cancer. Moreover, patients from the METABRIC
cohort have rich clinical annotation and long follow-up times compared to other recent
breast cancer studies, thus enabling the identification of prognostic biomarkers.
RRBS was selected as the DNA methylation platform of choice since it allows
quantification of DNA methylation at single nucleotide resolution and enables the
exploration of intratumour methylation heterogeneity and epiclonal dynamics. Other
advantages include the lower input DNA requirement and cost effectiveness compared
to WGBS. However, the RRBS technique described and implemented in this thesis
requires PCR amplification, which can introduce biases in the uniformity of coverage
as well as the confidence in the quantification of DNA methylation over the epigenome
[McInroy et al., 2016] (see Chapter 1). Moreover, the inability to discriminate between
PCR-induced duplication artefacts or distinct molecular copies of fragments in RRBS
can distort DNA methylation estimates as well. Recently, advanced protocols have
been established that can circumvent these limitations such as post-bisulphite adaptor
tagging (PBAT) [Miura et al., 2012], quantitative RRBS (Q-RRBS) [Wang et al., 2015],
and recovery after bisulphite treatment (ReBuilT) [McInroy et al., 2016]. One of the
follow-up goals of this project is to perform a sensitivity analysis by implementing the
PBAT technique on a subset of the breast tumours described in this thesis.
Despite numerous advancements in bisulphite sequencing chemistries and the
bioinformatics pipeline over the last few years, considerable steps were implemented
to maximise yield and ensure the accurate calling of methylation estimates in this
massively parallel sequencing effort. In addition to improvements to the RRBS
protocol conducted in the laboratory previously [Vidakovic, 2014], switching to
Illumina v4 chemistry and increasing the length of sequencing reads improved the
number of unique CpG sites detected from RRBS libraries. Although, data alignment
and methylation calling procedures to analyse RRBS methylomes are well established
[Babraham Bioinformatics, 2016b], the bioinformatics pipelines were also modified.
For instance, methylation information was merged from the + and – strands since
DNA methylation is symmetric in mammals. This not only provides a tremendous
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boost in coverage, but consequently also results in a more accurate estimate of the
DNA methylation status at CpG dinucleotides. Furthermore, following quality
assessment procedures and CpG filtering, a universe of 2.72 million CpG sites with a
minimum 5× coverage that are profiled in at least 50% of METABRIC samples was
established (5.50 CpG Universe).
Statistical analysis of bisulphite sequencing data is challenging, predominantly
due to the high false positives associated with analysing a large number of CpG
sites profiled, and the difficulty of interpreting single CpG data when cancer specific
methylation alterations usually involve multiple CpG sites [Bock, 2012]. In order to
counter these limitations, a novel algorithm called Spatially Coordinated CpG-sites
within the RRBS Universe in Breast cancer (SCCRUB) is developed and implemented
that attempts to transform the RRBS data into distinct regions comprising of multiple
CpG sites coordinated in their methylation behaviours. This led to the identification of
a universe of regions that are functionally relevant, and also provides a significantly
lower multiple testing problem than single CpG analysis due to the smaller size of the
universe. In this thesis, the SCCRUB universe consisting of ∼ 289,000 regions was
used exclusively for those analyses in which the predominant aim is to detect functional
methylation alterations that are likely to involve multiple CpG sites that are altered in a
coordinated manner. However, the SCCRUB universe cannot employed for analyses in
which stochastic methylation changes at the single CpG site level are quantified. Two
key investigations of this nature presented in this thesis include i) Section 3.1 (Chapter
3), in which single CpG specific information was utilised to describe the genomic
context of epigenetic drift and estimate tumour-specific background methylation rates;
and ii) Chapter 5 in which RRBS methylation information was reanalysed at the read
level to investigate intratumour methylation heterogeneity.
An unsupervised clustering analysis over the 1482 breast tumours identified
subgroups of tumours with distinct methylation profiles. The 5-group clustering
solution demonstrated remarkable concordance with a clustering solution obtained in
an external dataset, the TCGA breast cancer study [Cancer Genome Atlas Network,
2012]. The agreement between these Furthermore, most bioinformatics packages
that are available for analysing bisulphite sequencing data are not optimised for large
sample sizes. Consequently, a vast majority of the statistical methods and analyses
presented in this thesis have been constructed using bespoke statistical algorithms,
unless mentioned otherwise.
Next, validation of the RRBS pipeline was performed. An unsupervised t-SNE
analysis established that the variation in DNA methylation profiles was predominantly
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explained by the tumour/ normal classification, established breast cancer subtype
taxonomies and clinicopathological variables, but notably not technical factors. The
high reproducibility of DNA methylation calls between the RRBS platform and the
universally used HM450 platform further established the robustness of the RRBS
pipeline detailed in this chapter. two sets of methylation-clusters that were
independently derived from two completely distinct breast cancer datasets (TCGA and
METABRIC tumours), largely unique promoter regions (only 11% overlap between
the SCCRUB promoter regions and HM27 probes), and two different methylation
platforms (RRBS and HM27 microarrays) strongly substantiates the validity of the
RRBS methylome data in METABRIC. Moreover, ∼ 240,000 SCCRUB regions lie
outside promoters in this RRBS-derived methylome, and can be used to redefine and/
or refine the DNA methylation based epigenetic subtypes in breast cancer.
Finally, a supervised analysis demonstrated that tumours and normal tissues
have distinct methylation profiles across various genomic features; and also revealed
that the extent of methylation changes in tumours is subtype specific. A formal
investigation delineating the precise locations of epigenetic deregulation (within the
SCCRUB universe) between tumour and normal tissues as well as between breast
tumour subtypes, and examination of their functional roles is conducted in Chapter 3.
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3.1 Introduction
The establishment and maintenance of precise epigenetic programs such as DNA
methylation are essential for embryonic development and differentiation, and different
tissues and cell types adopt characteristic methylation patterns that serve to determine
and preserve specific biological processes (Chapter 1) [Holliday, R. & Pugh, 1975;
Jones, 2012; Okano et al., 1999; Riggs, 1975]. While DNA methylation is a well-
balanced process that regulates gene expression in mammalian cells, these normal
DNA methylation patterns are largely disrupted during the initiation and progression
of cancer. The first link between DNA methylation and cancer was reported by
Feinberg and Vogelstein [1983a] who observed that genomes of cancer cells had
reduced levels of DNA methylation (hypomethylation) compared to normal tissues.
Repetitive elements were found to be enriched in hypomethylation and this was shown
to result in genomic instability, which is one of the hallmarks of cancer [Ehrlich, 2002,
2009]. On the other hand, DNA hypermethylation of gene promoter has also been
studied extensively and shown to favour tumorigenesis by repressing transcription in
key tumour suppressor genes in many cancers [Esteller, 2000; Herman and Baylin,
2003; Kawaoi et al., 1992] which represents another hallmark of cancer. Consequently,
there has been a drive to map these cancer-associated epigenetic changes with putative
functional roles in gene transcriptional regulation. Recently, major international
projects have identified key locations of divergent epigenetic changes between cancers
and their normal counterparts [Cancer Genome Atlas Network, 2012; Hovestadt et al.,
2014; Weisenberger, 2014], as well as between tumour subtypes [Figueroa et al., 2010;
Kretzmer et al., 2015]. Moreover, these regions of differential methylation can serve as
prognostic and predictive biomarkers [Gyparaki et al., 2013; Nikolaidis et al., 2012].
However, despite extensive profiling of cancer methylomes, there is insufficient
evidence of the dynamics of the process driving methylation change in cancer tissues.
For instance, if the promoter of a tumour suppressor gene is methylated, the key
question is – how did this region gain methylation in tumour cells versus the normal
tissue? Two distinct models have been put forward to explain this phenomenon: the
stochastic model and the instructive model [Struhl, 2014; Tanay, 2017, private
communication]. The fundamental distinction between these two models is whether
this altered methylation is specifically targeted to the tumour suppressor gene
(instructive model) or instead non-specifically over the whole genome (stochastic
model). In the stochastic model, random changes in methylation occur independently
and in parallel at different regions in different cells of the tumour as a consequence of
DNA methylation replication errors (largely associated with cell division, see
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Epigenetic drift, introduced in Chapter 1). One of these stochastic errors may result in
the methylation increase of a specific tumour suppressor gene, and consequently give
a cell a growth advantage (for instance, by silencing the tumour suppressor gene). For
example, age-related DNA methylation linked with the epigenetic silencing of
antagonists of the WNT-signalling pathway has been observed which was potentially
implicated with stem-cell and progenitor expansion and survival [Baylin and Ohm,
2006; West et al., 2013; Zheng et al., 2016]. Conversely, in the instructive model, a
genomic event such as a mutation in an oncogene triggers a transcriptional regulatory
pathway that results in the DNA methylation of a tumour suppressor gene. For
example, recent work in human colorectal cancer cell lines revealed that a KRAS
mutation led to a surge in the concentration of the transcription factor, ZNF304, in the
nucleus [Serra et al., 2014]. This transcription factor in turn recruits a co-repressor
complex including DNA methylase leading to the concomitant DNA methylation and
repression of specific loci including the INK4-ARF tumour suppressor. Although a
few reports including those mentioned above have been able to identify the relevant
mechanism culminating in tumour-specific methylation alterations in a few genes or
pathways, this effort has been largely ignored in most high throughput cancer
methylome studies.
The aim of genome-wide cancer methylome studies is to identify malignancy-
associated epigenetic changes with putative functional roles in gene transcriptional
regulation. Although instructive methylation changes are by definition linked with
instructive regulatory pathways upstream of the methylation event, on the other hand
stochastic methylation changes generally affect gene function, only if they hit a
key gene maintaining healthy homeostasis (such as specific transcription factors or
tumour suppressor genes). However, as discussed above, stochastic DNA methylation
errors in tumours (collectively termed as epigenetic drift) are widespread all over the
genome and do not target functional genes only; and thus, might be less likely to have
relevance to tumorigenesis than instructive methylation differences. This imposes
the question – can genome-wide cancer methylome studies accurately discriminate
between methylation alterations with potential functional significance versus stochastic
methylation changes that are not selected for? Unfortunately, this line of investigation
has rarely been considered in cancer methylome studies and the relevant mechanism
underlying observed methylation changes are usually not explicitly delineated. Indeed,
with increasing sample sizes, larger genomic coverage and higher resolution profiling
of cancer methylomes, it is extremely likely that a large contribution of the detected
cancer-normal differentially methylated regions is a consequence of cell-division
DNA replication errors. This is largely because the analytical approaches widely
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available today employ a uniform methylation difference threshold (such as 20%) to
identify differentially methylated regions irrespective of genomic context or cancer
type [Akalin et al., 2012b; Hebestreit et al., 2013; Robinson et al., 2014]. However, this
assumption is flawed. Firstly, it has been well established that methylation gain and
loss rates are exceptionally dependent on CpG density [Horvath et al., 2012; Rakyan
et al., 2010]. Regions that gain DNA methylation over time are enriched for CpG
content, while low CpG regions tend to lose DNA methylation as a consequence of
epigenetic drift. Subsequently key experiments investigating clonal dynamics of DNA
methylation in somatic fibroblast populations revealed that higher methylation error
rates are associated with late time of replication in the cell cycle and nuclear lamina
interaction [Shipony et al., 2014]. In addition, stochastic epigenetic events result in
increasing discordance in a tumour’s epigenome and consequently, highly variable
methylome profiles have been observed between different individuals and tissue types
[Jones et al., 2015; Talens et al., 2012]. Based on this collective evidence, it is clear
that the assumption of a uniform background methylation difference for all tumours
and over the whole genome is erroneous, and can lead to widespread false positive
findings that might overshadow those epigenetic events involved in transcriptional
pathways.
One of the key objectives of this chapter is to quantify the extent of DNA
methylation alterations with putative functional roles in tumorigenesis and/ or
explaining inter-tumour heterogeneity in breast cancer. I aim to do this by first,
linking detected methylation alterations with their presumed underlying mechanism,
and secondly, identifying any relevant genes or pathways exhibiting concomitant
modifications (as measured via gene expression). However, in order to shed light on
the mechanisms underlying tumour-specific methylation alterations, it is necessary to
first quantify the variation in Epigenetic drift in tumours (background DNA
methylation alterations compared to normal tissues). The genomic context of these
background methylation changes is investigated, as well as the inter-patient
heterogeneity in what represents the first genome-wide characterisation of epigenetic
drift in a large cohort of primary breast tumours. Finally, two epigenetic drift-related
indices are introduced that allow evaluation of the extent and direction of epigenetic
drift in the METABRIC dataset including their respective prognostic potentials.
The next section of this chapter involves the construction of a novel algorithm
called DMARC (Directed Methylation Altered regions in Cancer) to detect directed
and background DNA methylation alterations in tumours. Directed methylation
comprise of all instructive methylation alterations as well as stochastic alterations that
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are selected for and consequently observed more frequently in the tumour cell
population. In contrast, background methylation alterations essentially comprise of all
stochastic alterations that are not under selection. The algorithm incorporates the
background methylation heterogeneity (estimated above) into the traditional
differential methylation analysis resulting in the added functionality of being able to
discern whether the identified methylation alterations are background or directed. The
underlying premise of this discrimination is based on the assumption that directed
methylation alterations will exhibit a larger methylation difference compared to that
expected based on the estimated background differences. If developed effectively,
DMARC would enable i) illumination of the mechanisms underlying these epigenetic
events; and ii) enrichment of methylation events with potential functional roles.
The development of the novel algorithm DMARC is followed by its
implementation in the 1482 breast cancer and 237 normal tissues to identify directed
and background differentially methylated regions (DMRs) in the breast tumours
compared to normal tissues. An analogous strategy is also used to detect methylation
alterations at an individual tumour resolution to assemble a catalogue of
tumour-specific directed and background methylation alterations. Finally, both
directed and background methylation alterations were functionally characterised by
linking them with concomitant modifications in gene expression and identifying the
relevant biological pathways that are affected using gene set enrichment analysis. This
line of analysis is conducted to achieve two goals. Firstly, it would determine whether
the detected directed methylation alterations in breast cancer are more likely to have
functional consequences than background methylation alterations as hypothesised.
Secondly, it would validate the prominence of previously reported epigenetically
altered genes in breast cancer, as well as revealing novel genes that have not yet been
implicated.
Given the well-established distinct methylation landscapes between ER+ and
ER- breast tumours (see Chapter 1), separate analyses on these two subtypes are also
conducted. In addition, tumour vs. tumour methylation differences are identified to
explicitly explore the distinct epigenetic profiles of ER+ and ER- tumours.
Finally, the functional differential methylation analysis described above was
repeated in each of the previously defined breast cancer subtypes: 11 Integrative
clusters (IntClusts) and 6 Intrinsic subtypes to examine the role of tumour-normal and
tumour-tumour epigenetic differences in each subtype. Although a limited
investigation has been conducted across the Intrinsic subtypes in previous reports
[Bediaga et al., 2010; Holm et al., 2010], the large sample size of this study permits a
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detailed genome-wide investigation that would enable the identification of
subtype-specific epigenetic events involved in breast cancer transcriptional
deregulation. This analysis would be crucial in assessing the contribution of DNA
methylation alterations in explaining inter-tumour breast cancer heterogeneity.
3.1.1 Summary of aims
The previous chapter involved the generation of a large sequencing based breast cancer
methylome comprising of 1482 breast tumours and 237 matched adjacent normal
tissues. This chapter aims to identify DNA methylation alterations with putative
functional roles in tumorigenesis and/or in explaining inter-tumour heterogeneity in
breast cancer. This is achieved through the following steps:
1. Characterisation of epigenetic drift in breast tumours. Spatial-dependency
and inter-tumour heterogeneity of background methylation alterations were
investigated to elucidate the biological mechanisms underlying epigenetic drift.
2. Identification of class-specific and tumour-specific differential methylation
alterations in breast cancer versus normal tissue.
3. Development and implementation of a novel algorithm that utilises background
methylation heterogeneity to classify cancer methylation alterations as
background or directed.
4. Assessment of the contribution of directed and background methylation
alterations in regulating transcription.
5. Exploration of the heterogeneity in epigenetic programming in distinct breast
cancer subtypes and its consequences on transcriptional networks and survival.
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3.2 Epigenetic drift in breast cancer
As described in Chapter 1, epigenetic drift largely comprises of stochastic DNA
methylation changes that lead to deregulation of normal methylation patterns. In order
to elucidate the biological mechanisms underlying epigenetic drift, the spatial variation
as well as the inter-patient heterogeneity in epigenetic drift was first quantified in the
METABRIC breast cancer methylome cohort and then integrated with gene expression
changes1.
The extent of epigenetic drift in the breast tumours versus the normal tissues was
examined. For the purpose of characterising epigenetic drift, only regions of the
genome with methylation statuses unlikely to be under selection were considered
[Yatabe et al., 2001]. Accordingly, regions of the genome were removed that have
previously been implicated in neoplastic transformation through epigenetic processes.
This strategy enriches for neutral methylation modifications by minimising
confounding with alterations that are not stochastically or environmentally acquired.
Specifically, a background set of CpG sites was established by eliminating CpG sites
lying in promoter, enhancers or PRC region from the previously defined 5.50 CpG
universe. This newly constructed Background CpG universe comprised of 1.8 million
CpG sites (5.50 CpG universe = 2.7 million CpG sites) that were covered in 50% of
samples with at least 5 read coverage.
For each CpG site included in the Background CpG universe, average normal
methylation levels were calculated by taking the mean across all 237 normal tissues.
Subsequently, CpG site-specific methylation differences from the mean normal levels
were calculated for each of the 1482 breast tumours separately. As discussed in
Section 3.1, the extent and direction of methylation differences have been shown
to be conditional on CpG density in cancer [Horvath et al., 2012], and on Time of
Replication (TOR) and nuclear laminal interaction in fibroblast populations [Shipony
et al., 2014]. Drift related methylation gains and losses have also been associated with
PRC-marked promoter and enhancer regions [Day et al., 2013; Teschendorff et al.,
2010]. However, as noted previously, these chromatin domains have been eliminated
from the analysis to minimise bias attributed to functional methylation alterations that
are likely to lie in these regions. For the sake of model parsimony, epigenetic drift
related spatial dependency was assessed for only two genomic factors: CpG density
and TOR. CpG density was estimated by quantifying the number of CpG dinucleotides
1The analysis described in Section 3.2 stemmed from discussions with Professor Amos Tanay
and Aviezer Lifschitz during a fruitful travel fellowship to Professor Amos Tanay’s laboratory at the
Weizmann Institute of Science, Rehovot, Israel.
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in the immediate 1Kbp surrounding each CpG. TOR status for the CpG sites was
obtained from previously published Repli-seq experiments conducted on the Michigan
Cancer Foundation-7 (MCF-7) breast cancer cell lines [Pope et al., 2014]. Although
the TOR status observed in MCF-7 breast cancer cell lines may not be completely
conserved across all breast cancer subtypes, it should give a reasonable indication of it.
The CpG sites were first stratified into 25 bins based on CpG density (1st 24 bins
= 0 CpG/kbp to 120 CpG/kbp; bin size = 5 CpG/kbp; 25th bin = 120+ CpG/kbp) and
then further stratified into 5 bins based on TOR (based on 20th percentiles) resulting
in 125 bins with distinct CpG density and TOR profiles. The distribution of CpG
sites across CpG density and TOR are illustrated in Figure 3.1a and 3.1b respectively.
For each tumour, background methylation differences were aggregated across CpG
sites lying within each bin. The mean background methylation difference between
all tumours and all normals (across all CpG sites), and the number of CpG sites is
calculated for each of the CpG density/ TOR bins and detailed in Appendix B.1.
3.2.1 Epigenetic drift is genomic-context dependent
In normal tissues, high background DNA methylation levels are observed at CpG-poor
regions and low DNA methylation at CpG-rich regions (Figure 3.1c). It is likely
that background methylation alterations in tumours will regress this strong bipolarity.
As expected from previous reports [Jones and Baylin, 2002, 2007; Stirzaker et al.,
2014; Teschendorff et al., 2013], breast tumours clearly gain methylation in CpG rich
regions (methylation difference = 6.05%, FDR p-value < 1×10-300;Wilcoxon–Mann–
Whitney test; CpGs with density > 100 CpGs/kbp) and lose methylation in CpG poor
regions (methylation difference = -2.96%, FDR p-value < 1×10-300; Wilcoxon–Mann–
Whitney test; CpGs with density < 25 CpGs/kbp) when compared to normal tissues
in the background epigenome (Figure 3.1c). Furthermore, tumours exhibit a marked
increase in the variance of methylation statuses in CpG sites that replicate late/ very
late in the cell cycle compared to CpG sites that replicate early/ very early (Ratio
of variances in tumours = 3.86, FDR p-value = 1×10-300; F-test), whereas this was
not observed in normal tissues (Ratio of variances in normals = 1.07, FDR p-value =
0.4685; F-test) (Figure 3.1d).
Figure 3.2 (top panel) illustrates the tumour-normal methylation background
differences at a tumour-specific resolution, and the association of epigenetic drift with
CpG density and TOR (described above) is undeniable. Although the relationship of
methylation gains with CpG-rich regions and losses with CpG-poor regions is already
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Figure 3.1: Background DNA methylation levels are dependent on CpG density and
time of replication. Distribution of CpG sites in the background epigenome based on (a)
25 CpG density bins; and (b) 5 Time of Replication categories. (c) Mean methylation of
tumour and normal tissues stratified by CpG density bins. Firstly, mean methylation
levels of all background CpG sites per density bin were calculated for each sample. Next,
for each CpG density bin, these sample-specific values were averaged over all normal
tissues and tumour tissues respectively. (d) Variance in methylation of tumour and
normal tissues stratified by time of replication. Firstly, mean methylation levels of all
background CpG sites per TOR category were calculated for each sample. Next, for each
TOR class, the variance of the sample-specific values was calculated over all normal
tissues and tumour tissues respectively. V Early = Very Early. Neut= Neutral. V Late =
Very Late.
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well established in cancer, these findings demonstrate the remarkable predisposition
of late TOR regions for accumulating both methylation changes (gains and losses)
in breast cancer. A global loss of methylation has previously been hypothesised
to be a consequence of replication-associated hypomethylation in late replicating
regions in breast cancer cell lines [Hon et al., 2012] and prostate cancer [Berman
et al., 2011]. However, the findings in this section strongly suggest that the direction
of methylation change in late replicating regions is noticeably dependent on the
underlying CpG density; nevertheless, an aggregate loss in these regions is observed
since late replicating regions are generally CpG poor (as is the whole epigenome,
Figure 3.2 – bottom panel). Late-replicating compartments of the genome have been
functionally associated with heterochromatin and laminal associated domains [Hansen
et al., 2010], which have been shown to be evolutionarily conserved [Pickersgill et al.,
2006]. This suggests that mechanisms facilitating methylation errors in these regions
involve the higher-order chromatin architecture within the cell nucleus as well as DNA
replication timing.
3.2.2 Epigenetic drift is highly heterogeneous across breast
tumours
Figure 3.2 also demonstrates that breast tumours exhibit extraordinary variations in
their capacities to gain or lose methylation. Based on these estimated background
methylation differences, two tumour-specific indices were developed to describe the
extent and direction of epigenetic drift.
1. Accumulation index: Accumulation of epigenetic drift, represents the absolute
extent of methylation alterations in the tumour compared to the normal. The
accumulation index for each tumour was calculated by averaging absolute
background methylation differences (irrespective of gain or loss) over all CpG
sites. Higher values signify a larger extent of epigenetic divergence from the
normal tissue with 0 being the lowest theoretical score.
2. Direction index: Direction of epigenetic drift, represents the tendency of a
tumour to gain or lose methylation over the background epigenome. The
direction index for each tumour calculated by averaging methylation differences
across all CpG sites. Tumours tend to lose methylation globally due to higher
proportion of CpG poor sites than CpG rich sites, and so the direction index
would tend to be negative for most tumours. Accordingly, the index was
normalised according to CpG density such that a value of 0 represents a tumour
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Figure 3.2: Epigenetic drift is genomic context-dependent and tumour-specific. (top
panel) The five panels represent the TOR classes from Very Early to Very Late. In each
panel, the x-axis represents CpG density bins. For each of the 125 CpG density/ TOR
categories, mean tumour-normal methylation differences were calculated by averaging
over background CpG sites and plotted. Colours represent the extent of tumour-normal
methylation difference (gain denoted by red, loss denoted by blue; legend on far left).
The y-axis represents the tumours. The tumours were ordered by average methylation
difference aggregated over all 125 CpG density/ TOR bins, and not by breast cancer
subtype. The legend on the far right indicates the ER status of the tumours. (bottom
panel) Distribution of CpG sites in the background epigenome based on CpG density
bins; stratified by the TOR classes. Figure conceptualised by Professor Amos Tanay,
Weizmann Institute of Science, Rehovot, Israel.
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that doesn’t exhibit an aggregate increase or decrease in methylation
(conditional on its underlying genomic context). Positive values represent an
aggregate gain in methylation over the background genome while negative
values represent an aggregate loss in methylation.
Examination of the accumulation and the direction indices of the 1482 breast tumours
stratified by ER status showed that ER+ tumours on average tend to accumulate more
methylation alterations than ER- tumours (mean accumulation: ER+ = 3.23, ER- =
2.64, p-value = 8.0×10-16; t-test), implying that the former could have more divergent
epigenomes (Figure 3.3a). However, since higher accumulation of epigenetic drift was
associated with higher age (p-value = 3.1×10-16, linear regression adjusted for tumour
cellularity), this could also reflect the average younger ages of ER- patients (mean
age: ER+ = 63 years, ER- = 54 years, p-value = 3.10×10-28; t-test). Interestingly, ER+
tumours are also quite balanced in terms of the direction of these alterations, while the
small fraction of ER- tumours that exhibit high accumulation also revealed a tendency
for hypomethylation (mean Direction: ER+ = -0.17, ER- = -0.534, p-value = 1.4×10-6;
t-test).
Two epigenetic drift indices were formally examined across the previously
established breast cancer molecular subtypes: 6 Intrinsic subtypes (Figure 3.3b) and
11 Integrative clusters (Figure 3.3c). The accumulation index was significantly
associated with the Integrative cluster definition (p-value = 5.7×10-64; Analysis of
Variance) and the Intrinsic subtype definition (p = 7.7×10-71; Analysis of Variance);
while the direction index was less so (Direction vs. Integrative clusters: p-value =
1.8×10-7; Direction vs. Intrinsic subtype: p-value = 3.2×10-6; Analysis of Variance).
The strong relationship of the two purely epigenetic based scores (accumulation and
direction) with genetic and transcriptomic-defined subtypes of breast cancer confirms
its biological significance as well as the relationship between genetic and epigenetic
dysregulation in tumorigenesis. Moreover, further analysis also revealed tremendous
variability in the epigenetic drift within ER+ and ER- tumours as well. For instance,
tumours in IntClust 1 accumulates significantly more methylation alterations than
IntClust 3 (mean accumulation: IntClust 1 = 4.35, IntClust 3 = 2.57, p-value =
1.2×10-20; t-test) despite both clusters being predominantly composed of ER+
tumours. Similarly, two ER- enriched clusters, IntClust 4ER- and 10, exhibited
distinct levels of epigenetic divergence (mean accumulation: IntClust 4ER- = 2.17,
IntClust 10 = 2.63, p-value = 0.001; t-test).
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Figure 3.3: Epigenetic drift is highly heterogeneous across breast tumours. The
Accumulation and Direction indices are plotted for each tumour (coloured points)
stratified by breast cancer subtypes (a) ER Status; (b) Intrinsic subtypes; (c) Integrative
clusters. Light grey points represent other tumours. Black points represent normal
tissues. LUMA = Luminal A. LUMB = Luminal B. HER2 = HER2-enriched. BASAL =
Basal-like. CLAUDIN = Claudin-low. NORMAL = Normal-like.
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3.2.3 Accumulation of epigenetic drift is largely a consequence of
mitotic errors
Epigenetic drift has largely been considered to comprise of alterations acquired as a
consequence of stochastic DNA methylation maintenance errors [Kim et al., 2005;
Teschendorff et al., 2013]. This hypothesis was explored in the METABRIC breast
cancer methylome. Firstly, for each gene, a linear regression model was used to
evaluate the association between a tumour’s expression for the corresponding gene
(dependent variable) and its accumulation index (independent variable). Tumour
cellularity (as measured by ASCAT (Chapter 2) was significantly associated with the
Accumulation index (p-value = 7.6×10-23), and therefore it was added as a confounder
in the model. Next, the genes were ranked based on the relationship (β coefficients)
between their expression and the accumulation index, and a Gene Set Enrichment
Analysis (GSEA) was used to identify relevant mechanisms associated with a higher
accumulation index using the fgsea package [Sergushichev, 2016]. The top 2 pathways
associated with a tumour’s capacity to accumulate methylation alterations were cell
cycle (enrichment score = 2.18, FDR p-value = 0.0214; GSEA) and mitotic cell
cycle (enrichment score = 2.06, FDR p-value = 0.0214; GSEA). Evidence for this
relationship was reinforced with a strong association of a tumour’s accumulation index
with its mitotic index, a pathology-based score exclusively in ER+ tumours (ER+:
p-value = 5.1×10-8, ER-: p-value = 0.5820; linear regression; Figure 3.4a). A sharp
correlation was also revealed with the expression of the proliferation-related genes,
Aurora Kinase A, AURKA (ER+: FDR p-value = 2.0×10-46, ER-: FDR p-value =
0.0213; linear regression; Figure 3.4b), and MKI67 (ER+: FDR p-value = 3.4×10-28;
ER-: FDR p-value = 0.8591; linear regression), in ER+ tumours. Although a higher
accumulation index was also associated with higher age of the patients (Section 3.2.2),
the relationship with mitotic index and proliferation was much sharper. These results
collectively confirm the acquisition of background DNA methylation alterations in the
epigenome is largely a consequence of the accumulation of passive replication related
errors related to the number of cell divisions (mitotic clock), as initially hypothesised
by Yatabe et al. [2001].
However, the relationship between epigenetic drift and mitotic clock (as measured
by mitotic index and gene expression of AURKA) was much stronger in ER+ tumours
than ER- tumours. In fact, in ER+ tumours, the accumulation index was significantly
associated with Breast Cancer-Specific Survival (BCSS) indicating that ER+ tumours
that accumulate more methylation alterations have lower survival times (univariable
p-value = 2.6×10-5, multivariable p-value = 0.0190; Cox-proportional hazards model:
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Figure 3.4: Accumulation of epigenetic drift is largely a consequence of mitotic
errors. (a) Relationship between the Accumulation index and the mitotic index which is
pathology-based score for ER+ and ER- tumours separately. (b) Relationship between
the Accumulation index and expression of proliferation-related gene, AURKA, which is
pathology-based score for ER+ and ER- tumours separately.
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independent variable = BCSS, dependent variable = Accumulation index stratified into
tertiles: with and without adjusting for clinical variables; Figure 3.5a). The dampened
relationship in ER- patients may be explained by the fact that not all epigenetic drift
related DNA methylation alterations are a consequence of stochastic cell division
errors. Instead, background methylation alterations in ER- tumours may also be
acquired due to environmental exposures including inflammatory conditions and/or
underlying genetic traits such as genome instability [Jones et al., 2015; Teschendorff
et al., 2013]. Moreover, deregulation of epigenetic modifiers have been shown to
alter the global methylation landscape in ER- breast cancer (particularly in BRCA-
like tumours) [Flanagan et al., 2010; Holm et al., 2010]. Although this is certainly
an example of an instructive (and not stochastic) methylation event, these global
changes would confound estimates of tumour background methylation differences,
and therefore could be another explanation of the reduced association between the
accumulation index and proliferation.
Remarkably, in ER- tumours, the Direction index was mildly but significantly
associated with BCSS indicating that ER- tumours that undergo a global gain of
background methylation have adverse clinical outcomes compared to those that lose
methylation (univariable p-value = 0.1413, multivariable p-value = 0.0492; Cox-
proportional hazards model: independent variable = BCSS, dependent variable =
Direction index stratified into tertiles: with and without adjusting for clinical variables;
Figure 3.5b). However, conducting a Gene Set Enrichment Analysis on the Direction
index did not reveal any interesting pathways associated with a tumour’s tendency to
gain or lose methylation making interpretating this finding challenging. The global loss
of background methylation in tumours could perhaps be explained by the contribution
of lymphocytic infiltration in the tumour since they harbour lower DNA methylation
estimates on average than epithelial cells [Dedeurwaerder et al., 2011]; however,
examining a measure of the tumour’s lymphocytic infiltration (digital pathology scores,
see Chapter 2) revealed no such association with the Direction metric.
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Figure 3.5: Accumulation index is prognostic in ER+ tumours and Direction index
is prognostic in ER- tumours. (a) Kaplan-Meier survival estimates on BCSS stratified
by Accumulation index (tertiles) for ER+ and ER- tumours. (b) Kaplan-Meier survival
estimates on BCSS stratified by Direction index (tertiles) for ER+ and ER- tumours.
Multivariable Cox proportional hazards models as described in the text. Significant
analyses (alpha = 0.05) are labelled by an ‘*’, and non-significant analyses by ‘N.S.’.
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3.3 Detecting class-specific and tumour-specific DNA
methylation alterations
Genomic features such as promoter, enhancers and PRC region show increased DNA
methylation in tumours whilst intron and intergenic regions show decreased
methylation (Chapter 2). However, these global changes detected in tumours represent
the aggregate of multiple specific hyper- and hypomethylation events, and it is
essential to identify individual focal methylation events that may be associated with
tumorigenesis. The analysis strategy presented below involves determining the
genomic regions that exhibit statistically different methylation statuses when
comparing all breast tumours with normal tissues (Section 3.3.1); followed by
identifying individual tumour-specific methylation aberrations (Section 3.3.2).
3.3.1 Detecting Differential Methylation Regions (DMRs): Class-
specific alterations
A Differentially Methylated Region (DMR) is a region of neighbouring CpG sites
harbouring large methylation change in the same orientation (gain or loss) between two
classes of multiple samples, such as between tumour and normal samples; or between
two different tumour subtypes. These regions are likely to represent important locations
of divergent epigenetic changes between these two classes with a potential regulatory
role. To detect focal regions of methylation alterations, a differential methylation
analysis was used to derive DMRs for the tumours compared to the normal tissue.
Being a genome-wide method, RRBS enables the identification of methylation changes
in a variety of different genomic features, thus providing an insight into epigenetic
changes beyond the oft studied promoter.
SCCRUB is a set of coordinated regions defined based on correlations of proximal
CpG sites (see Chapter 2). The underlying premise of SCCRUB is that it captures
all regions within the RRBS-universe comprising of at least 3 CpGs that are spatially
coordinated in their methylation behaviours. Therefore, SCCRUB represents a set
of potentially functionally relevant regions over the genome. For the purpose of
differential methylation analysis, only promoter, exon, intron, enhancer and PRC
region were considered since they can be linked with 1 or more target genes to allow
for investigation of the role of DMRs in explaining gene expression (Section 3.5).
SCCRUB regions in other genomic features such as intergenic elements (excluding
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enhancer and PRC region) and repetitive regions were excluded. This led to analysing
a subset of the SCCRUB universe (187,095 out of 289,265 regions).
In this section, observed sample methylation estimates were used for the
calculation of DMRs between the tumours and the normal tissues to obtain an overall
perspective of the extent and precise locations of DMRs over the epigenome. The
strategy of analysis is detailed below.
1. Regression
For each region under consideration, a linear regression model was constructed
using the observed methylation of the region as the independent variable and the
2-group classification as the predictor. The methylation values were
transformed from Beta-values into M-values prior to fitting the model using a
logistic transformation (see Chapter 2) leading to a distribution which is more
appropriate for Gaussian-approaches.
2. Adjusting for Multiple comparisons
An additional multiple-testing correction was applied to the p-values using FDR
to account for the large number of genomic regions tested in parallel.
3. Filtering
For the two classes being compared, mean methylation predictions from the
linear regression models were transformed back to Beta-values. The average
methylation difference between the two classes was calculated by subtracting
these two estimates for each region. Subsequently, the genomic regions were
filtered based on an absolute methylation difference exceeding 20% and a FDR
p-value < 0.05. Hyper and hypo DMRs were identified separately depending on
the orientation of the difference.
4. Annotation
Regions were annotated into 5 genomic features (promoter, exon, intron,
enhancer and PRC region) based on the definitions mentioned in Chapter 2.
Altogether, 13517 DMRs were identified in breast tumours compared to normal
tissues (from within the 187,095 SCCRUB regions assessed). In addition to
discriminating between the orientation of methylation differences (hyper and hypo),
the DMRs were further stratified into 3 CpG density categories (low = CpG Density <
40 CpGs/kbp; high = CpG Density ≥ 80 CPGs/kbp; medium = remaining CpGs) to
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Figure 3.6: DMRs detected in breast tumours versus normal tissues. (a) Number of
hyper DMRs. (b) Proportion of SCCRUB regions that are hyper DMRs. (c) Number of
hypo DMRs detected. (d) Proportion of SCCRUB regions that are hypo DMRs. All plots
are stratified by CpG density.
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highlight context specific differences. The number of hyper and hypo DMRs
identified per CpG classification are depicted in Figure 3.6a and 3.6c. whilst Figure
3.6b and 3.6d represent these numbers as a proportion of SCCRUB regions in each
CpG classification separately. A higher number of hypo DMRs (n = 7180, 3.8% of all
SCCRUB regions) were identified than hyper DMRs (n = 6337, 3.4% of all SCCRUB
regions). A striking majority of hypo DMRs were identified in low CpG regions (6715
out of 7180, 93.5%; Figure 3.6c), suggesting a predisposition to lose methylation in
low CpG regions (% of SCCRUB regions hypomethylated by CpG density: low =
5.60%, medium = 1.08%, high = 0.04%; Figure 3.6d). The CpG distribution of hyper
DMRs also indicated that the majority were harboured in low CpG regions (3537 out
of 6337, 55.8%; Figure 3.6a), although this was clearly due to the larger number of
low CpG regions in the genome. Relatively speaking, medium and high CpG density
regions had a greater propensity for gaining methylation (Percentage of SCCRUB
regions hypermethylated stratified by CpG density: low = 2.95%, medium = 4.60%,
high = 3.41%; Figure 3.6b).
The extent of hyper and hypo DMRs in breast cancer across different genomic
features was quantified in Section 3.6. But before that analysis, tumour-specific
methylation alterations are detected.
3.3.2 Detecting Methylation Altered Regions (MARs): Tumour-
specific alterations
In the literature, DMRs have been used interchangeably as class-specific or tumour-
specific methylation alterations. To avoid confusion between the two in this thesis,
DMRs are used specifically to describe class-specific methylation alterations (as
described in Section 3.3.1). For the purpose of identifying tumour-specific DNA
methylation alterations versus the normal tissue, the concept of methylation altered
regions (MARs) is introduced. A MAR is defined as a precise region of neighbouring
CpGs that is significantly differentially methylated in an individual tumour compared
to the normal tissue(s). Table 3.1 describes the difference between DMRs and MARs.
The selection of regions used to define MARs can vary from i) universes such as the
unsupervised-defined set of regions such as SCCRUB, or the set of all promoter; or ii)
a supervised-comparison based filtered set of regions such as tumour DMRs.
SCCRUB is used as the universe of regions within which MARs were determined.
In order to identify the set of tumours with a MAR for a particular region, the following
two criteria were applied.
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1. Outlier test (Statistical significance). This test attempts to address whether
the methylation of the tumour is a significant outlier compared to the distribution
of normal tissues for a specific region. A z-score is derived for each tumour
by comparing its methylation estimate with the mean and standard deviation of
methylation evaluated over all normal tissues. M-value methylation estimates
were used for this calculation since they are more statistically valid than Beta-
values in Gaussian analysis such as z-scores (Chapter 2). Specifically, if r labels
the SCCRUB region under consideration; µMr and σMr represent the mean and
standard deviation of methylation (M-value) of this region over the normal
samples. If the methylation estimate (M-value) of the tumour t is XMrt , then the
z-score of region r in tumour t is defined by ZMrt = (X
M
rt −µMr )/σMr . Tumours
with |ZMrt |≥1.96, corresponding to a FDR p-value of ≤ 0.05 were deemed to be
statistical outlier with respect to the methylation of normal tissues for the region,
r.
2. Absolute difference test (Biological significance). This test attempts to
address whether the methylation difference between the tumour and the average
normal tissue is biologically meaningful. The methylation difference for each
tumour and the mean of the normal tissues was determined for this region.
Beta-value methylation estimates were used for this calculation due to its
intuitive biological interpretation (Chapter 2). Specifically, the mean normal
methylation µMr calculated above is transformed using the inverse-logit function
to derive a Beta-converted methylation value µBr . If the methylation estimate
(Beta-value) of the tumour t for region r is labelled as XBrt , then the methylation
difference is defined as DBrt = (X
B
rt − µBr ). Tumours that pass the 1st criteria
(significant z-score, |ZMrt |≥1.96) and with |DBrt |≥0.20, were deemed to have a
MAR at this region. If both the ZMrt (z-score) and D
B
rt (methylation difference)
were positive, the MAR was classified as a hyper MAR, and if they were
negative, the MAR was classified as a hypo MAR.
Using only the first criteria to determine methylation changes in relation to the
normal tissue could generate large z-scores without necessarily a big change in absolute
methylation value, particularly if the normal tissues are highly homogeneous with
respect to methylation of that region. The combination of these two criteria ensures
that tumours with MARs are not only statistical outliers with respect to the normal
distribution, but the difference between the DNA methylation values are biologically
relevant as well.
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Differentially Methylated Region
(DMR)
Methylation Altered Region (MAR)
A DMR is defined as a precise region
of neighbouring CpGs that is on
average significantly differentially
methylated between two classes of
multiple samples. It can be
characterised as a hyper or hypo
DMR depending on orientation.
A MAR is defined as a precise region
of neighbouring CpGs that is
significantly differentially methylated
in an individual tumour compared to
the matched normal tissue (or the
pool of all normal tissues). It can be
characterised as a hyper or hypo
MAR depending on orientation.
A DMR represents a region of
averaged methylation differences
between a fixed group of tumours and
a fixed group of normal tissues or
between two fixed groups of tumours.
DMRs can be subtype-specific.
A MAR and represents a region of
acquired methylation alteration in a
single tumour versus the normal
tissue(s). MARs are tumour-specific.
At least one (usually more, but rarely
all) tumour(s) used in the definition of
a DMR must also harbour a MAR at
the defined region.
A MAR for an individual tumour may
occur within or outside a region
defined by a DMR.
Table 3.1: Comparison between a DMR and MAR.
Tumour MARs can be detected in all SCCRUB regions of the epigenome.
However, for the purpose of the following analysis, MARs were filtered such that only
MARs within tumour DMR regions were considered. As explained previously, a
DMR is a population-averaged methylation difference compared to normal tissue.
Consequently, not all tumours necessarily harbour MARs within a DMR; and a
tumour does not necessarily harbour MARs in all DMRs. For instance, if n DMRs are
identified between breast tumour and normal tissues, each tumour could theoretically
harbour between 0 and n MARs within these n regions. To illustrate this point, Figure
3.7a represents the proportion of hyper MARs detected in individual tumours within
hyper DMRs stratified by CpG density; and Figure 3.7b represents the proportion of
hypo MARs within hypo DMRs stratified by CpG density. Proportions of tumours
were calculated instead of absolute numbers since the total number of tumours with
methylation information varied depending on the region considered. This analysis
revealed that there is considerable heterogeneity observed in the extent and location of
MARs within the 1482 breast tumours. The recurrence of MARs in breast tumours is
formally investigated in the next section.
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Figure 3.7: MARs detected within DMRs for all breast tumours. (a) Hyper MARs.
Analysis conducted separately for 3 CpG density categories. The dotted line at 100%
(y-axis) represents the total number of hyper DMRs detected in the CpG density category.
The monotonic red lines represent the extent of hyper MARs as a proportion of the
detected hyper DMRs (y-axis) for each of the 1482 tumours (x-axis). The tumours
(x-axis) are ordered by increasing number of hyper MARs for each of the CpG density
category separately. (b) Repeated for hypo MARs. The monotonic blue lines represent
the extent of hypo MARs as a proportion of the detected hypo DMRs (y-axis).
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3.4 DMARC – a novel algorithm for the identification
of Directed Methylation Altered Regions in
Cancer
The overarching goal of this chapter is to identify regions of functional methylation
alterations over the breast cancer methylome. In Section 3.2 it was revealed that breast
cancers have extraordinary variation in their background methylation differences that
are not only tumour-dependent but also highly sequence-specific (CpG density and
TOR). However, the detection of breast tumour DMRs and tumour-specific MARs (in
Section 3.3) utilised uniform methylation difference thresholds on observed tumour
methylation estimates (unadjusted for background differences) across the genome and
for all tumours, as is standard practice in most current cancer methylome studies
[Akalin et al., 2012b; Kulis et al., 2015; Robinson et al., 2014]. Consequently, it is
highly likely that a considerable contribution of the DMRs and MARs are a
consequence of background methylation differences ascertained in Section 3.2. It is
necessary to deconvolute the contribution of background methylation differences and
directed methylation differences. As defined earlier, directed methylation comprise of
all instructive methylation alterations as well as stochastic alterations that are selected
for and consequently observed more frequently in the tumour cell population. In
contrast, background methylation alterations essentially comprise of all stochastic
alterations that are not under selection. Discrimination between the two processes
would shed light into methylation mechanisms with the hypothesis being that
stochastic methylation differences are less likely to have functional consequences than
directed methylation differences (Section 3.1).
A novel algorithm called DMARC (Directed Methylation Altered Regions in
Cancer) is presented here. DMARC is able to characterise MARs and subsequently,
DMRs into directed and background by incorporating the observed heterogeneity in
background differences.
3.4.1 Directed Methylation Altered Regions
Given that MARs are tumour-specific as well as region-specific, they represent ideal
candidates for adjustment using background methylation differences (which have
already been established as tumour and context-specific), hence they were analysed
first. As previously described, tumour-specific MARs within a region were determined
if they passed the statistical outlier test as well as the absolute difference test (using a
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uniform difference threshold of 20%) on comparison with the methylation distribution
of normal tissues. While it is obvious that testing for an absolute methylation difference
that is too low will lead to significant findings that are likely to be biologically
irrelevant [Teschendorff et al., 2016b], it is less appreciated that failing to account
for heterogeneity in the process of accumulating methylation differences can also
lead to spurious results. A similar argument has been made in the case of mutations
[Lawrence et al., 2013]. This point can be illustrated by the following example. Hyper
MARs with an observed methylation difference DBrt of 25% were detected for a tumour
in two distinct promoter regions. The first promoter region lies within the highest
CpG density decile and highest TOR decile of the genome, and the second lies within
median CpG density and TOR deciles. The critical question is – are the mechanisms
underlying the increase in promoter methylation the same for both regions? Has
methylation been purposely deposited to the promoter to fulfil some potential function
that is under selection (directed), or is the hyper methylation merely a consequence of
an accumulation of methylation errors that is occurring in regions with similar genomic
frameworks over the genome (background)? Solely, by virtue of sequence context, a
background methylation increase of 8% to 17% (inter-quartile range of background
methylation difference for genomic context of the first region) can be expected in
the first promoter region due to epigenetic drift, while a background difference of
-2% to 1% (inter-quartile range of background methylation difference for genomic
context of second region) is expected in the second promoter region. Therefore, if a
constant methylation threshold of 20% is used, both promoter regions may be assumed
to be associated with directed irregularity in the epigenetic machinery in that region.
However, in this scenario it is apparent that the hyper MAR detected in the first
region has a considerable contribution due to accumulation of cell-division associated
methylation errors (linked to the background methylation difference); and the hyper
MAR second region is more likely to be a consequence of directed deposition of
methylation. Furthermore, heterogeneity in background methylation differences across
different tumours can also lead to erroneous interpretations of methylation alterations.
Tumours undergoing excessive cell proliferation will demonstrate additional accretion
of methylation errors.
Thus, it is clear that background methylation differences need to be considered to
make inferences on the methylation mechanism underlying a MAR. The background
methylation differences (vs. normal tissues, M-values used), bMgt have already been
approximated for different genomic contexts, g by using genomic covariates (such as
CpG density and DNA replication timing) and tumours, t (see Section 3.2). In order to
account for these background methylation differences, additional steps are proposed
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post detection of MARs. Specifically, the genomic context, g, based on CpG density
and DNA replication timing is identified for the region under consideration, r and a
background adjusted methylation estimate is calculated as XˆMrt = X
M
rt − bMgt , where
XMrt represents the observed methylation estimate, as noted in Section 3.4.2.
Beta-values, XˆBrt as well as M-values, Xˆ
M
rt for background adjusted methylation
estimates can be calculated using the respective observed methylation estimates, XBrt or
XMrt . Outlier tests (|ZˆMrt |≥1.96); and the absolute difference test (|DˆBrt |≥0.20) were
calculated using the background adjusted methylation estimates (XˆBrt and Xˆ
M
rt ) instead
of the observed methylation estimates (XBrt and X
M
rt , as described in Section 3.3.2), and
if the MAR passed both these criteria it was characterised as a directed methylation
altered region (directed-MAR), and if not then as a background methylation altered
region (background-MAR). A schematic diagram of the DMARC algorithm is shown
in Figure 3.17.
To illustrate the difference between directed-MARs and background-MARs,
Figure 3.9a represents the proportion of hyper directed-MARs detected in individual
tumours within hyper DMRs. This is similar to Figures 3.7a with the addition of grey
dots to represent the proportion of directed-MARs. Background-MARs are defined as
MARs that are not directed-MARs and are thus represented by the distance between
total MARs and directed-MARs. Hypo directed-MARs and background-MARs are
indicated in Figure 3.9b. This analysis revealed that most of the hyper background-
MARs occur in CpG-rich regions (mean number of background-MARs per tumour
stratified by CpG Density: low = 3, medium = 53, high = 116, p-value < 1×10-300;
Analysis of Variance), while most of the hypo background-MARs occur in low CpG
regions (mean number of hyper background-MARs per tumour by CpG Density:
low = 1081, medium = 34, high = 0, p-value < 1×10-300; Analysis of Variance).
However, due to the considerably larger number of CpG-poor DMRs (as a result of an
average low CpG density globally), a vast majority of the identified background-MARs
represent losses rather than gains in methylation (mean number of background-MARs
per tumour by direction of methylation alterations: hyper = 170, hypo = 1115, p-value
= 1.2×10-232; Wilcoxon signed rank test).
As explained previously, the vast majority of CpG sites in high CpG density
and late TOR are unmethylated in normal tissues and will gradually gain methylation
randomly in tumours due to DNA replication errors. Accordingly, the DMARC
algorithm adjusts (increases) the threshold for directed methylation gains in these
regions. However, since methylation losses in high CpG density sites in tumours
represent a departure from what is expected based on its genomic context, all losses
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Figure 3.8: Schematic diagram of the DMARC algorithm. DMARC allows the
discrimination between directed and background methylation altered regions in cancer.
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Figure 3.9: Directed-MARs detected within DMRs for all breast tumours. (a) Hyper
MARs. Analysis conducted separately for 3 CpG density categories. The dotted line at
100% (y-axis) represents the total number of hyper DMRs detected in the CpG density
category. The monotonic red lines represent the extent of hyper MARs as a proportion of
the detected hyper DMRs (y-axis) for each of the 1482 tumours (x-axis). The black dots
represent the proportion of tumour-specific hyper directed-MARs, and accordingly hyper
background-MARs are represented by the distance between the hyper MARs (red line)
and hyper directed-MARs (black dot). The tumours (x-axis) are ordered by increasing
number of hyper MARs for each of the CpG density category separately. (b) Analysis
repeated for hypo MARs. The monotonic blue lines represent the extent of hypo MARs
as a proportion of the detected hypo DMRs (y-axis). The black dots represent the
proportion of tumour-specific hypo directed-MARs.
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Figure 3.10: Recurrence of MARs. Regions that are altered in different proportions of
tumours (x-axis) were enumerated as explained in the text and the resulting distribution
was plotted for hyper and hypo regions separately. The solid lines and solid colours
represent all MARs (background and directed), whereas the dashed lines and translucent
colours represent directed-MARs. Red and blue curves represent the number of hyper
and hypo regions respectively per frequency group of tumours. The vertical dotted line
delimits the number of regions in which at least 25% of tumours harbour MARs and
directed-MARs.
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within high CpG density sites are assessed as directed MARs. This is why most hyper
MARs in CpG-poor regions are classified as directed MARs, and most hypo MARS in
CpG-rich regions are classified as directed MARs. This is a limitation of the DMARC
algorithm, and a future version of the algorithm is being developed to address this.
Next, the recurrence of all MARs (background and directed) as well as specifically
directed-MARs were investigated. For each region (all detected hyper and hypo DMRs
are considered), the proportion of tumours that harboured a MAR (i.e. the proportion
of tumours in which the region was aberrantly methylated) and the proportion of
tumours that harboured directed-MARs were enumerated. This was done separately
for hyper and hypo MARs. Proportions of tumours were calculated instead of absolute
numbers since the total number of tumours with assayed methylation information
varied depending on the region considered. The regions were ordered according to
proportion of tumours with directed-MARs and the resulting distribution was plotted
(Figure 3.10; solid colours, solid lines). A similarly constructed distribution for
all MARs (directed and background) was plotted (Figure 3.10; translucent colours,
dashed lines). Approximately 88% of the considered regions are altered (MARs) in
at least 25% of tumours, and 76% of these regions have directed-MARs in the same
fraction of tumours. Overall, these results indicate that there are thousands of recurrent
methylation alterations in a substantial fraction of human breast cancers.
3.4.2 Directed Differentially Methylated Regions
The background estimates of methylation differences are sequence specific, and the
corresponding CpG density and TOR are available for each DMR. However, there is
also vast inter-tumour heterogeneity in the background methylation difference. DMRs
are population-averaged difference (for instance, the identification of DMRs in tumours
versus normal tissues involved comparison of 1482 breast tumours and 237 normal
samples), and therefore, adjusting for tumour specific estimates directly is not trivial.
However, once MARs are classified into directed-MARs and background-MARs it
becomes straightforward to characterise DMRs into directed and background DMRs
as well. For each DMR, the proportion of tumours with directed-MARs (out of total
number tumours with MARs) was calculated. A threshold of 70% was used. If more
than 70% of the MARs detected within the region were directed-MARs, then the DMR
was denoted as a directed-DMR. The rest were classified as background-DMRs. Using
this threshold, 67% of all DMRs were categorised as directed-DMRs, and 33% as
background-DMRs. However, hypomethylation in low CpG density regions accounted
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for a striking majority of background-DMRs (Figure 3.11) for reasons explained
previously in Section 3.4.1.
Next, the potential regulatory roles of directed and background DNA methylation
alteration in breast cancer pathogenesis was studied.
Figure 3.11: Directed and background DMRs detected in breast tumours versus
normal tissues. (a) Number of directed and background hyper DMRs. (b) Number of
directed and background hypo DMRs detected. Both plots are stratified by CpG density.
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3.5 Altered DNA methylation is a regulatory
mechanism in breast cancer
To explore the functional relevance of the identified DNA methylation alterations, the
relationship between the expression and the methylation estimates of genes harbouring
DMRs was evaluated. 11729 DMRs (both directed and background DMRs) were
identified between breast tumours and normal tissues. But how many of these DMRs
are potentially involved in gene silencing or activation?
3.5.1 Identification of expression-DMRs
Methylation that occurs directly on genes such as promoter, exon and intron is
intuitively associated with potential regulation of the underlying gene itself and so
DMRs within these 3 genomic features were examined to explore intragenic
associations with expression, whereas, enhancer and PRC region DMRs were
explored for distal cis-regulation. However, identification of the specific target gene or
genes whose expression is modulated by distal regulatory elements can be challenging
since the target gene is not necessarily the closest gene. In a Chromatin Interaction
Analysis by Paired-End Tag Sequencing (ChIA-PET) study to examine
promoter-enhancer interactions in human cell lines including the MCF-7 breast cancer
cells, Li et al. [2012] observed that almost half (40%) of enhancers bypass several
genes to interact with their target promoter [Gao et al., 2015]. In fact, the median
distance between the enhancer and promoter was 50kb, although a small proportion
(less than 10%) of long distance enhancer-promoter interactions were observed up to
millions of base pairs away from the enhancer. In order to identify candidate target
genes modulated by a particular enhancer or PRC region DMR, nearby genes within a
400kb genomic window centred around the DMR were selected. Although target
genes further than 200kb than the distal-regulatory DMRs would not be included,
most regulatory DMR-gene pairs would be considered. DMRs for which a target gene
could not be identified were excluded from further analysis.
To investigate the functional roles of both intragenic and distal methylation
alterations, associations between methylation and gene expression was explored in the
breast cancer samples for each DMR-target gene pair as defined above. A multivariable
linear regression framework of gene expression (normalised log2 relative intensities)
as the independent variable and using both DNA methylation (M-value) and CNA
(segmented mean log2 ratios, see Chapter 2) as covariates was explored for each
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DMR-gene pair. Gao and Teschendorff [2017] used a similar approach and noted
that the inclusion of CNA in the model ensures that the relationship between gene
expression and DNA methylation was due to concomitant alterations within the same
set of tumours; and that the observed change in gene expression was not explained
by concurrent copy number alterations in the tumours . For each DMR-target gene
pair, two statistics were noted: i) the partial correlation (rhometh-independent) between
methylation of the DMR and expression of the target gene which is a measure of
the independent strength and direction of this relationship whilst controlling for the
effect of CNA; and ii) the regression p-value (t-test) of the methylation coefficient
which indicates the strength of evidence for its association with gene expression. Only
samples utilised in the identification of the DMRs were included in the analysis. For
instance, for ER+ vs. normal DMRs, all ER+ and normal samples were used. However,
not all 1719 METABRIC samples (1482 tumours and 237 normal tissues) had matched
gene expression and CNA data. The 1342 tumours and 108 normal tissues that had
matched gene expression (microarray; Chapter 2), CNA (array) and DNA methylation
data were considered for this analysis.
A region-centric approach was desired to ensure a single DMR is represented only
once in the analysis and the following two strategies were implemented to accomplish
this.
1. For DMRs associated with more than one genomic feature, a biologically
plausible priority ranking was employed: Promoter > Exon > Intron > Enhancer
> PRC region. Using this approach, a DMR detected in an intragenic enhancer
was considered simply as an intragenic (exon or intron) DMR and was only
linked with the target gene that it lies within.
2. For distal regulatory DMRs that have more than one target gene, regression
p-values were corrected for multiple testing (using the Benjamini-Hochberg
procedure) for each of these DMRs separately. This controls the false discovery
rate (FDR) for multiple genes tested per DMR. Subsequently, for each DMR,
the target gene with the highest partial methylation-expression correlation was
selected.
Although this filtering step ensured each DMR is represented only once, it is
important to note that two distinct DMRs could be linked with the same gene. An
additional round of FDR correction was conducted over all unique DMR-target gene
pairs to control for the number of DMRs tested. DMR-target gene pairs with
|rhometh-independent|≥0.40 and FDR p-value < 0.05 were considered to be significantly
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associated and denoted as expression-DMRs. The orientation of the DMR (hyper or
hypo methylation) and the direction of concomitant change in expression
(upregulation or repression) was utilised to classify the expression-DMRs into four
categories: i) hyper expression-DMR associated with gene repression; ii) hyper
expression-DMR associated with gene upregulation; iii) hypo expression-DMR
associated with gene repression; iv) hypo expression-DMR associated with gene
upregulation. The direction of rhometh-independent was used to characterise the direction
of the methylation-expression relationship. A negative correlation denotes the
well-studied view of increased methylation being associated with repression; however,
positive correlations in which increased (decreased) methylation is associated with
upregulation (downregulation) of the gene were also recorded.
3.5.2 Directed-DMRs are enriched for concomitant expression
changes
Using this approach, a total of 1653 expression-DMRs were identified across the 5
genomic features assessed. The first line of analysis was to investigate the hypothesis
that directed methylation alterations in breast cancer are more likely to have
functional consequences (as measured by concomitant gene expression changes) than
background methylation alterations. A Fisher’s exact test was used to assess the
relationship between directed-DMRs AND expression associated DMRs
(expression-DMRs). 15.4% of all directed-DMRs were associated with expression
changes. Reassuringly, directed-DMRs were significantly more likely to be associated
with gene expression changes in breast cancer than background-DMRs (log2 odds of
expression-DMR being directed = 0.155, background = -0.358; Odds Ratio = 1.43;
p-value = 1.2×10-9; Figure 3.12a).
Gene Set Enrichment Analysis (GSEA: pathways tested included Hallmark gene
sets obtained from the Molecular Signatures Database [Subramanian et al., 2005,
MSigDB]) were performed on genes that were significantly up and down regulated
(expression-DMRs) to identify relevant mechanisms that are disrupted due to
methylation alterations. Enrichment scores were calculated and significantly enriched
pathways (enrichment = observed/ expected > 5; FDR p-value < 0.05; hypergeometric
test) were identified. Pathways that were simultaneously significantly enriched for
both up and down regulated genes were also noted and their enrichment scores were
added to reflect this dual role. The analysis was conducted separately on directed and
background expression-DMRs, and significantly enriched pathways were listed for the
two methylation mechanisms (Figure 3.12b). Interestingly, gene expression
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Figure 3.12: Directed DMRs are enriched for concomitant expression changes. (a)
Odds of an expression-DMR being directed or background. Fisher’s exact test used for
calculation of p-value. (b) Significantly enriched gene sets comprising of at least 4 genes
that are regulated by directed and background DMRs (Enrichment (observed/ expected) >
5, FDR p-value < 0.05; hypergeometric test, as explained in text). Colour of points
represent direction of regulation. Size of points represent level of enrichment.
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programmes disturbed by background expression-DMRs included many pathways
elicited by specific cell-extrinsic stresses. Particularly response to ultraviolet radiation
as well as interleukin-2 stimulation, a type of cytokine signalling in the immune
system, were associated with both up and downregulated genes. Background DMRs
were also implicated in the aberrant upregulation of genes in response to low oxygen
levels (hypoxia). Conversely, directed DMRs were more likely to be linked with
cell-intrinsic biological signalling pathways such as ER and NOTCH signalling,
further substantiating the conclusion that the mechanisms underlying background and
directed DMRs are distinct.
Therefore, discerning between directed DMRs and background DMRs has not
only enabled enrichment for expression-related consequences (directed-DMRs, Figure
3.12a), but also separation of methylation-related functional modifications that are
involved in cellular stress pathways in response to extrinsic exposures
(background-DMRs, Figure 3.12b). Moreover, a component of background DMRs are
also likely to be a consequence of DNA methylation maintenance errors as a result of
mitotic division that disrupt the epigenome in a non-targeted manner (Section 3.2 and
DMARC model). Based on this evidence, it is tempting to speculate that alterations
associated with epigenetic drift (background DMRs) are not functionally relevant.
However, these stochastic alterations may occasionally hit key genes in
cancer-relevant pathways such as ER-signalling, androgen-signalling,
hedgehog-signalling and KRAS signalling pathways. Consequently, although
discrimination between directed and background DMRs (and expression-DMRs) has
proved extremely valuable for a better understanding of methylation processes, it
would be erroneous to ignore background DMRs entirely. Therefore, for the
remainder of this thesis, both background and directed DMRs (and expression-DMRs)
are considered, and in some investigations, the distinction between the two
mechanisms is highlighted.
The regulatory role of hyper and hypo DMRs across different genomic features
was investigated separately in ER+ and ER- tumours in Section 3.6.
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3.6 Subtype-specific epigenetic programming in
breast cancer
3.6.1 Tumour-normal differences in ER+ and ER- breast cancer
The extent of aggregate DNA methylation changes varies greatly across the breast
cancer subtypes (Figure 2.6c, Appendix A.1), suggesting that breast tumours harbour
subtype-specific methylation alterations as well. Hyper and hypo DMRs (versus the
normal tissues; methylation difference ≥ 20%; FDR p-value ≤ 0.05) were identified
in ER+ and ER- tumours separately as this classification encompasses significant
differences in the fundamental biology of breast tumours. The extent of hyper and
hypo DMRs (versus normal tissues) in each of ER+ and ER- breast tumours across
5 different genomic features: promoter, exon, intron, enhancers and PRC region was
quantified. Both directed and background DMRs were considered. Multiple 2-class
comparisons are possible within the same classification. For example, ER status
divides the samples into three categories (ER+ tumours, ER- tumours and normal
tissues), and thus three 2-class comparisons are possible: ER+ vs. normals, ER-
vs. normals and ER+ vs. ER-). To account for this, standard errors for the classes
(and hence p-values) were adjusted following a multiple comparison procedure for
simultaneous inference using the changepoint contrast [Hothorn et al., 2008].
Figure 3.13 (top panel) displays the proportion of hyper and hypo DMRs within
each genomic feature (relative to the total number of SCCRUB regions within the
respective genomic feature) detected across both tumour subtypes. Since the total
number of SCCRUB regions assessed within a genomic feature are constant for ER+
and ER- tumours, this allows comparison between the 2 subtypes, and consequently,
identification of the one that has stronger tendencies towards directing their epigenetic
changes to specific regions of the genome. Figure 3.13 (middle panel) displays the
ratio between the number of hyper and hypo DMRs for each genomic feature. This
allows determination of the inclination of a tumour subtype to significantly gain
or lose methylation in a specific genomic feature. Finally, an enrichment analysis
(enrichment = observed/ expected, hypergeometric test) was conducted across hyper
and hypo DMRs separately, to investigate whether any of these 5 genomic features
are preferentially targeted within that particular subtype. For example, are promoter
more likely to be hyper methylated (compared with other genomic features) within
ER+ tumours? For this purpose, a hypergeometric test was conducted independently
for each of the 5 genomic features: promoter, exon, intron, enhancers and PRC region;
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Figure 3.13: (Caption on next page.)
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Figure 3.13: (Previous page.) Hyper and hypo DMRs detected in ER+ and ER-
tumours. (top panel) The proportion of hyper and hypo DMRs within each genomic
feature, relative to the total number of SCCRUB regions within the respective genomic
feature (the total number is noted in the boxes at the top), detected across ER+ and ER-
tumours. x-axis represents the tumour subtype (orange is ER+, purple is ER-) and the five
panels represent the individual genomic features. Analyses were conducted separately
for the 2 tumour subtypes and 5 genomic features resulting in 10 bars. Positive bars on
y-axis represents hyper DMRs and negative bars represents hypo DMRs. (middle panel)
The ratio between the number of hyper and hypo DMRs detected for each genomic
feature which represents the inclination of a tumour subtype to significantly gain or lose
methylation in a specific genomic feature. (bottom panel) Enrichment analysis of hyper
and hypo DMRs across the 5 genomic features conducted separately for each tumour
subtype, as explained in the text (hypergeometric test). Top squares represent enrichment
of hyper DMRs and bottom represent enrichment of hypo DMRs. Colour of the squares
represent level of enrichment (observed/ expected). Red represents enriched (enrichment
> 1), blue represents depleted (enrichment < 1) and white represents no enrichment
(enrichment = 1). Square boundaries represent whether the enrichment was significant
(solid lines = FDR p-value < 0.05; dotted lines = FDR p-value > 0.05).
and across the 2 DMR orientation classifications: hyper and hypo. This was repeated
across the 2 tumour subtypes separately: ER+ and ER- tumours.
This analysis revealed that the most enriched methylation events across all breast
tumours in general (both ER+ and ER- tumours) are hyper methylation of PRC region
with 14.2% of PRC region in ER+ being differentially hypermethylated (enrichment
= 4.08, FDR p-value < 1.0×10-255) and 7.7% in ER- tumours (enrichment = 3.61,
FDR p-value < 1.0×10-255). Previous studies have noted hypermethylation of PRC
region in cancer [Ohm et al., 2007; Schlesinger et al., 2007; Widschwendter et al.,
2007], and more recently in chronic lymphocytic leukemia (CLL) [Kulis et al., 2012].
Epigenetic switching from polycomb-repressive complex mediated gene silencing to a
more stable silencing conveyed by DNA methylation has been proposed as a likely
explanation [Baylin and Jones, 2011]. Nevertheless, the observation that hyper DMRs
are most enriched in PRC region is a first for breast cancer.
Hypermethylation of enhancer regions (9.3% in ER+; 5.6% in ER-), promoter
regions (5.6% in ER+; 2.9% in ER-) and exonic regions (5.2% in ER+; 3.2% in
ER-) were also significantly enriched (enrichment > 1.3, FDR p-value < 0.0001; all
comparisons mentioned). Enrichment of hypermethylation in these genomic features
concurs with findings from the previous section since these regions lie largely in
medium/ high CpG dense regions and thus are more likely to undergo hypermethylation
in tumours. Promoter and exonic hypermethylation has been reported previously in
ER+ and ER- tumours [Fleischer et al., 2014; Györffy et al., 2016; Rønneberg et al.,
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2011], however, methylation alterations in enhancer regions have been understudied in
breast cancer. In addition, the most underrepresented events in breast cancer (both ER+
and ER- tumours) were hypomethylation of promoter and exon, suggesting that that
these regions hardly undergo demethylation, possibly because they are unmethylated
in normal tissue (see Chapter 2). Conversely, intron undergo both hyper and hypo
methylation to a similar extent in both tumour subtypes. In fact, regions within intron
were neither significantly enriched/ depleted for hyper DMRs nor hypo DMRs.
On aggregate, ER+ tumours amass more hyper as well as hypo DMRs than ER-
tumours (Hyper DMRs: ER+ = 12310, ER- = 7392; Hypo DMRs: ER+ = 10814, ER-
= 5047). Although this may be in part due to smaller sample size for ER- tumours,
this observation is consistent with the analysis of epigenetic drift in Section 3.2 where
ER+ tumours were found to accumulate more background methylation differences
(both gains and losses) than ER- tumours. This suggests that the epigenetic machinery
is deregulated to a higher degree in ER+ tumours, although this could also be a
consequence of ER+ patients being older than ER- patients.
This raises the interesting question – how many breast cancer DMRs (vs. normal
tissue) are shared between ER+ and ER- tumours, and how many are subtype-specific?
Jaccard indices (size of intersection over size of union), which is a statistic used for
comparing similarity and diversity of sample sets was used to measure the extent
of shared DMRs between ER+ and ER- tumours. A higher value indicates that a
larger proportion of DMRs are shared between the two subtypes, while a lower value
indicates subtype-specificity. 3577 hyper DMRs (Jaccard index = 0.43) and 2387 hypo
DMRs (Jaccard index = 0.22) were commonly detected across the two breast subtypes
(Figure 3.14). For these DMRs, the same fundamental mechanisms of epigenome
control are hijacked in breast cancer irrespective of subtype. This was prevalent to a
higher degree for gains rather than losses in methylation, indicating that losses in DNA
methylation are more subtype-specific. The analysis was repeated for each genomic
feature separately. Enhancer DMRs had the lowest Jaccard index among all genomic
features indicating that that hypo and hypermethylated regions in enhancers are largely
distinct in ER+ and ER- tumours.
Using the differential methylation and enrichment strategies applied above, DMRs
were identified for the 6 Intrinsic subtypes (Appendix A.2) and the 11 Integrative
clusters as well (Appendix A.3).
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Figure 3.14: Subtype-specific DMRs detected in ER+ and ER- tumours. (a) Venn
diagram of hyper DMRs detected in ER+ and ER- tumours. ER+ specific hyper DMRs
are represented in orange. ER- specific hyper DMRs are represented in purple. Hyper
DMRs shared by the two subtypes are represented in orangish-purple. The number of
DMRs belonging to each of the three categories are denoted. (b) Same as (a) but for
hypo DMRs.
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3.6.2 Associations with gene expression
The distribution of the cancer-specific disrupted methylation marks in the genome,
such as DMRs, is clearly dependent on the underlying genomic feature as noted in the
previous section. However, a key question is whether these DMRs identified in breast
cancer are potentially involved in gene silencing or upregulation, and do they differ
by genomic feature? The regulatory role of hypermethylation in promoter has been
discussed at length in the literature, but recent studies have expanded this investigation
to explore the function of altered methylation in the gene body [Kulis et al., 2012]
and enhancers [Heyn et al., 2016] in cancer. The detection of both hyper and hypo
DMRs, across a variety of genomic features, encompassing both gene-associated
and intergenic elements (Section 3.3) has allowed a comprehensive investigation of
the regulatory role of altered methylation in ER+ and ER- breast tumours (methods
described in Section 3.5.1).
In ER+ tumours, 799 (5.6%) of all expression-DMRS were associated with
upregulation of the respective genes and 1599 (11.2%) with repression suggesting
that DNA methylation plays a stronger role in silencing genes in this subtype (Figure
3.15a – top panel). Interestingly, stratifying DMRs by orientation of methylation
change revealed that both hyper and hypo DMRs were more likely to be associated
with repression of gene expression (hyper DMRs: upregulated = 5.4%, downregulated
= 11.5%; hypo DMRs: upregulated = 5.6%, downregulated = 10.9%) in ER+ tumours.
However, the consequences of hyper or hypo methylation on gene expression were
markedly dependent on which genomic feature they occurred. Twenty independent
enrichment analyses (enrichment = observed/ expected) were conducted to test these
associations formally across hyper and hypo DMRs in the 5 genomic features (Figure
3.15a - bottom panel). Specifically, hypergeometric tests were performed to investigate
whether, hyper promoter DMRs, for instance, had a preferential association with
upregulation or downregulation of the respective target genes compared to other
DMRs. Promoter DMRs exhibit the most glaring directional associations with gene
expression. 13.4% hypermethylated promoter were significantly associated with gene
repression, and this coordinated pattern was highly enriched (enrichment = 1.20; FDR
p-value = 5.1×10-3) while only 2.5% hypermethylated promoter were associated
with gene upregulation (enrichment = 0.44; FDR p-value = 2.7×10-8). Conversely,
hypomethylated ones were strongly enriched for gene upregulation (17.1%; enrichment
= 3.06; FDR p-value = 1.1×10-15). These results demonstrate the repressive role of
methylation in promoter in cancer, and confirms conclusions from multiple cancer
epigenomics studies [Hovestadt et al., 2014; Teschendorff et al., 2016b].
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Hyper or hypo DMRs in exon and intron were not enriched for significant gene
expression changes in ER+ tumours. However, filtering for gene body regions that
localise with intragenic enhancers led to the noteworthy discovery that these
hypomethylated intragenic enhancers were significantly enriched for upregulation of
genes (14.4%; enrichment = 2.58; FDR p-value = 8.9×10-16). This result is consistent
with a report in CLL in which gene-body hypomethylation related with enhancers was
revealed as a major cause of aberrant gene stimulation [Kulis et al., 2012]. Further
investigations in distal-regulatory elements such as enhancers and PRC region in ER+
tumours, revealed that the associations between methylation and expression were not
exclusively neagtive. A considerable fraction of distal-regulatory (both enhancer and
PRC region) hyper DMRs and hypo DMRs were significantly associated with gene
upregulation as well as repression (Figure 3.15a). The higher proportion of distal
regulatory expression-DMRs (15.1%) than intragenic expression-DMRs (7.5%) is
partially due to the fact that each enhancer or PRC region is tested with more than one
target gene increasing the likelihood of finding a significant correlation. On aggregate,
significantly fewer hypo DMRs were detected in enhancers compared to hyper DMRs
(Figure 3.13); nevertheless, hypo DMRs were significantly more likely to be
associated with gene expression changes (Figure 3.15a). And hypo DMRs were
significantly more likely to be associated with upregulation (enrichment = 2.83; FDR
p-value < 1×10-255), than down regulation (enrichment = 1.65; FDR p-value =
4.4×10-7). Collectively these results indicate a strong gene regulatory role for
hypomethylated enhancers in ER+ tumours, both within the gene body and further
away. A likely mechanism is that reduced methylation at enhancers is associated with
increased transcription factor binding which has transcriptional consequences for the
target genes [Heyn et al., 2016; Pellacani et al., 2016]. Hyper DMRs in PRC region
were the most enriched methylation events observed across the genome in ER+
tumours (Figure 3.15a). Surprisingly, hypermethylated PRC region were not
associated with gene silencing, suggesting that these regions reflected the pre-existing
repressed chromatin state at silenced genes in the normal tissue from which the cancer
originates.
In ER- tumours, approximately equal proportions of all expression-DMRS were
associated with upregulation (8.4%) and repression (8.9%) of the respective target
genes (Figure 3.15b). This was in sharp juxtaposition to ER+ tumours in which there
was a stronger tendency for methylation-associated silencing (gene repression = 11.2%,
gene activation = 5.6%). This discrepancy can largely be attributed to the contrasting
roles of enhancer DMRs in ER+ and ER- tumours, that have already been confirmed to
be largely subtype specific (Section 3.6.1). A significantly higher proportion of hypo
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Figure 3.15: (Caption on next page.)
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Figure 3.15: (Previous page.) Expression-DMRs detected in ER+ and ER- tumours.
(a) ER+ tumours. (top panel) The proportion of expression-DMRs detected relative to
the total number of direction-specific (hyper or hypo) DMRs identified within a genomic
feature. x-axis represents the methylation direction (hyper and hypo) and the five panels
represent the individual genomic features. Analyses were conducted separately for the 2
methylation directions and 5 genomic features resulting in 10 bars. Positive bars (orange)
on the y-axis represents upregulating expression-DMRs and negative bars (green)
represents downregulating expression-DMRs. (bottom panel) Enrichment analysis of up
and downregulating expression-DMRs across the 5 genomic features conducted
separately for each methylation direction, as explained in the text (hypergeometric test).
Top squares represent enrichment of upregulating expression-DMRs and bottom
represent enrichment of downregulating expression-DMRs. Colour of the squares
represent level of enrichment (observed/ expected). Red represents enriched (enrichment
> 1), blue represents depleted (enrichment < 1) and white represents no enrichment
(enrichment = 1). Square boundaries represent whether the enrichment was significant
(solid lines = FDR p-value < 0.05; dotted lines = FDR p-value > 0.05). (b) ER- tumours.
Same as (a) but for ER- tumours.
DMRs in enhancers were correlated with gene upregulation in ER- tumours (24.0%)
compared to ER+ tumours (15.8%); and far fewer enhancer DMRs were associated
with gene silencing in ER- tumours (7.9%) than ER+ tumours (16.5%). Transcriptional
consequences of hyper or hypo methylation localising in other genomic features such
as promoter and the gene bodies were largely similar between the two breast cancer
subtypes (Figure 3.15).
Next GSEA (pathways tested included Hallmark MSigDB gene sets) were
conducted on genes that were significantly dysregulated and had concomitant
methylation alterations (expression-DMRs). Pathways that were significantly enriched
(enrichment = observed/ expected > 1, FDR p-value < 0.05; hypergeometric test) in
upregulating and downregulating expression-DMRs represent pathways whose
components are potentially epigenetically regulated (upregulated and suppressed
respectively). The analysis was conducted separately in ER+ and ER- tumours to
classify epigenetically mediated pathways as subtype-specific and shared. Specifically,
if a pathway was enriched only in one subtype then it was classified as
subtype-specific. If a pathway was enriched in both breast cancer subtypes but the
ratio of the enrichment scores for the two subtypes was greater than 1.5, then the
pathway was classified as subtype-specific for the subtype with the higher enrichment
score. Finally, if a pathway was enriched in both breast cancer subtypes but the ratio
of the enrichment scores for the two subtypes was less than 1.5, then the pathway was
classified as shared between ER+ and ER- tumours. Enriched pathways that were
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upregulated or suppressed and classified as subtype-specific or shared were listed in
Figure 3.16.
Figure 3.16: Cancer pathways are epigenetically regulated in a subtype-specific
manner. Significantly enriched gene sets comprising of at least 4 genes that are regulated
by DMRs (Enrichment (observed/ expected) > 5, FDR p-value < 0.05; hypergeometric
test, as explained in text) were identified. This was conducted for upregulating
expression-DMRs (activated gene sets - top) and downregulating expression-DMRs
(suppressed gene sets - bottom). Separate analysis for ER+ and ER- tumours. Enriched
gene sets were classified as subtype-specific or shared as described in the text. Colour of
points represent direction of regulation. Size of points represent level of enrichment.
G2M checkpoint genes and E2F targets are upregulated and associated with
expression-DMRs in both ER+ and ER- tumours, suggesting that DNA methylation is
involved in cell cycle activity. For instance, promoter hypomethylation is associated
with activation of WEE1 in ER+ tumours (correlation = 0.42, FDR p-value = 3.0×10-8),
a nuclear kinase that acts as a mitotic gatekeeper [Nurse, 2004]. Moreover, WEE1
has also been to shown play a key role in controlling histone synthesis [Mahajan
et al., 2012]. This provides further evidence for a direct link between epigenetics and
cell cycle progression. Conversely, genes defining epithelial-mesenchymal transition
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(EMT) as well as those involved in NOTCH signalling were downregulated in both
ER+ and ER- tissues. This is an intriguing discovery since both EMT and NOTCH
signalling are associated with breast cancer progression [Reedijk, 2012; Tomaskovic-
Crook et al., 2009], and additional work is required to tease out the context in which
these pathways are downregulated.
Both early and late oestrogen response stand out as significantly activated
pathways in ER+ tumours, and conversely are suppressed in ER- tumours (only early
ER response), implying that the most evident phenotypic differences in the two breast
cancer subtypes (ER signalling) are strongly linked with epigenetic deregulation.
Androgen response was also upregulated in ER+ tumours (associated with only
promoter and genebody expression-DMRs; Pathways enriched via expression-DMRs
in specific genomic features for ER+ and ER- tumours were listed in Appendix A.4
and Appendix A.5 respectively), which is a fascinating finding since oestrogen gene
expression programmes have been shown to be recapitulated by androgen signalling
[Robinson et al., 2012]. However, it is uncertain whether ER signalling is a
consequence of the aberrant DNA methylation, or if ER signalling converges on and
actively shapes the epigenome.
Furthermore, genes belonging to the p53 pathway are downregulated exclusively
in ER- tumours. Interestingly, TP53, a tumour suppressor involved in cell cycle
regulation, DNA damage response and apoptosis [Gasco et al., 2002], has been shown
to be the most frequently mutated gene in ER- tumours [Cancer Genome Atlas Network,
2012; Pereira et al., 2016]. This imposes the question whether aberrant methylation in
components of the p53 pathway is an alternative pathway to tumorigenesis where there
is no p53 gene mutation, and is an avenue for future investigations. Another possibility
is that methylation of downstream genes ensued as a consequence of genetically-
directed pathway inactivity. In contrast, predominantly ER+ tumours (and not ER-
tumours) harbour expression-DMRs associated with downregulation of genes in the
TGFβ pathway among others. This corroborates previous findings in the lab that
TGFβ had context specific effects on breast tumour initiating cells that were subtype
dependent [Bruna et al., 2012] with further work indicating that the methylome plays a
central role in moulding the context-specific effect of TGFβ in breast cancer [Tufegdzic
Vidakovic et al., 2015]. Collectively, these results strongly suggest that ER+ and ER-
tumours require different degrees of epigenomic programming to achieve a breast
cancer phenotype.
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3.6.3 Subtype specific epigenetic regulators in breast cancer
The previous section revealed specific cellular pathways that are epigenetically
regulated in ER+ and ER- tumours. This theme is explored further by explicitly
identifying genes with sub-type specific expression-DMRs in ER+ and ER- tumours.
Specifically, regions that are differentially methylated compared to the normal tissues
as well as other tumours (in the same direction) are identified; and if concomitant
alterations in expression of the target gene are observed in the tumour subtype
compared to normal tissue as well as other tumours (in the same direction), then these
regions are denoted as subtype specific epigenetic regulators in breast cancer. This
strategy led to the identification of potential oncogene and tumour suppressor gene
candidates that are specific to either ER+ (Table 3.2, Table 3.3) or ER- breast cancer
(Table 3.4, Table 3.5). Survival analysis was also conducted for these genes using a
Cox-proportional hazards model adjusted for clinical variables including grade, size,
lymph node status, and age at diagnosis. Methylation status of regions that were
independently and significantly predictive of BCSS were identified.
A striking example of regional hypomethylation across 10 consecutive CpG
sites was identified in one of the intron of BMPR1B in ER+ tumours (methylation
difference: ER+ vs. normal tissue = -34.8%, ER+ vs. ER- = -35.8%) is shown in Figure
3.17a. The methylation status of the tumours was also significantly associated with
expression resulting in higher expression of BMPR1B in ER+ tumours (correlation
= 0.49, FDR p-value = 3.3×10-51). Interestingly, promoter associated epigenetic
upregulation of BMPR1B has been noted in a report integrating the methylomic and
transcriptomic architectures in ER+ breast cancer [Gao et al., 2015]. Although in
the METABRIC dataset, a ER+ specific expression-DMR was also detected in the
promoter of BMPR1B, the methylation status of the intron (and not the promoter) was
significantly associated with BCSS. Therefore, data presented in this thesis not only
confirms the epigenetic upregulation of BMPR1B, it also provides evidence of the
subtype specificity of this feature. And its value as a prognostic biomarker is revealed
for the first time in breast cancer. Furthermore, luminal tumours (that are largely ER+)
have recently been proposed to arise from an amplified BMP2/ BMPR1B mediated
normal response [Chapellier et al., 2015]. This indicates that this methylation event
might play an oncogenic role in ER+ tumours. Other examples of subtype specific
epigenetic associated upregulation include SIAH2, a transcription factor involved in
hypoxia and hippo signalling [Adam et al., 2015]; AFF3, a mediator of the oncogenic
effects of β -catenin signalling [Von Bergh et al., 2002]; SPDEF (Sam-pointed domain
containing Ets transcription factor), a known transcription factor with a proposed role
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Gene Feature DMR Avg. Meth. Difference Expression Prognostic
Direction Mechanism vs. N vs. T |rho| FDR p
ZNF552 intron Hypo Background -53.8 -47.5 0.45 <0.0001 Strong (Bad)
AGR3 intron Hypo Directed -47.2 -45.6 0.65 <0.0001 No
TBC1D9 intron (Enh) Hypo Background -34.7 -41.4 0.47 <0.0001 Strong (Bad)
CHCHD5 exon Hypo Background -21.5 -39.0 0.50 <0.0001 Weak (Bad)
BAIAP2 intron (Enh) Hypo Directed -24.4 -37.7 0.48 <0.0001 Weak (Bad)
GRTP1 exon Hypo Directed -30.0 -37.6 0.56 <0.0001 No
C1orf64 promoter Hypo Directed -34.9 -36.9 0.59 <0.0001 No
MUC1 exon Hypo Directed -42.6 -36.2 0.50 <0.0001 Weak (Bad)
C3orf52 intron Hypo Background -35.8 -36.2 0.56 <0.0001 Strong (Bad)
BMPR1B intron Hypo Directed -34.8 -35.8 0.49 <0.0001 Strong (Bad)
SPDEF intron Hypo Directed -37.0 -34.4 0.67 <0.0001 Strong (Bad)
GATA3 intron Hypo Directed -35.3 -32.8 0.71 <0.0001 No
MSI2 intron (Enh) Hypo Background -32.4 -32.5 0.57 <0.0001 No
EEF1A2 exon Hyper Directed 47.5 32.5 0.49 <0.0001 Strong (Bad)
ASB13 intron Hypo Directed -30.8 -31.7 0.49 <0.0001 No
SIAH2 intron Hypo Directed -38.7 -31.0 0.58 <0.0001 Weak (Bad)
MLPH intron (Enh) Hypo Directed -39.9 -30.2 0.61 <0.0001 Strong (Bad)
AFF3 intron Hypo Directed -31.8 -29.8 0.58 <0.0001 No
NSMCE1 exon Hypo Background -26.7 -28.4 0.47 <0.0001 Strong (Bad)
TFF3 promoter Hypo Directed -24.7 -28.4 0.45 <0.0001 Strong (Bad)
ENTPD5 intron Hypo Directed -26.0 -27.2 0.46 <0.0001 No
TPRN intron Hypo Directed -29.2 -26.9 0.65 <0.0001 No
ESR1 intron Hypo Directed -27.7 -26.4 0.65 <0.0001 No
C19orf33 promoter Hypo Directed -26.3 -26.0 0.71 <0.0001 No
SCNN1A intron Hypo Directed -34.0 -25.8 0.44 <0.0001 No
MYO6 intron Hypo Directed -32.2 -25.5 0.45 <0.0001 Strong (Bad)
DEGS2 intron Hypo Directed -36.6 -24.5 0.72 <0.0001 No
PVRL2 intron Hypo Directed -35.7 -24.0 0.56 <0.0001 No
STARD10 intron Hypo Directed -25.5 -23.9 0.56 <0.0001 Strong (Bad)
TFF1 promoter Hypo Directed -26.1 -23.5 0.47 <0.0001 No
RBM47 intron Hypo Directed -31.9 -23.2 0.44 <0.0001 Strong (Bad)
EVL intron Hypo Directed -24.7 -22.9 0.43 <0.0001 Strong (Bad)
TUBA3D exon Hypo Directed -31.6 -22.8 0.43 <0.0001 No
SLC2A10 intron Hypo Background -23.1 -22.8 0.43 <0.0001 No
EXOC6 enhancer Hyper Directed 33.1 22.7 0.47 <0.0001 Weak (Bad)
SREBF1 intron (Enh) Hypo Directed -33.2 -22.5 0.42 <0.0001 No
KRT8 intron (Enh) Hypo Directed -43.7 -21.6 0.60 <0.0001 Strong (Bad)
HPN exon Hypo Directed -38.5 -20.4 0.56 <0.0001 No
NAT1 PRC region Hyper Directed 26.7 20.2 0.41 <0.0001 Strong (Bad)
Table 3.2: Upregulated genes with subtype-specific expression-DMRs in ER+
tumours. ER+ expression-DMRs that fulfilled three criteria were listed: i) they had a
methylation difference of at least 20% vs. normal tissue (vs. N); ii) they had a
methylation difference of at least 20% versus ER- tumours (vs. T); and iii) they were
associated with upregulation of the gene: |rhometh-independent| > 0.40 (|rho| in table), and
FDR p-value < 0.05 (FDR p in table). Analyses were performed as described in the text.
For genes with 2 or more expression-DMRs fulfilling the criteria, the region with the
largest ER+ vs ER- methylation difference was recorded. Expression-DMRs that were
independently predictive of BCSS (multivariable Cox-proportional hazards model as
described in the text; FDR p-value < 0.1) were identified as strong prognostic biomarkers.
DMRs with FDR p-value < 0.2 were marked as weak prognostic biomarkers. DMRs that
were prognostic were marked as ‘(Bad)’if they were associated with worse BCSS, and
‘(Good)’otherwise. Genes listed in decreasing order of ER+ vs. ER- methylation
difference. Exonic and intronic DMRs overlapping enhancers are marked with ‘(Enh)’.
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Gene Feature DMR Avg. Meth. Difference Expression Prognostic
Direction Mechanism vs. N vs. T |rho| FDR p
TBC1D4 intron Hypo Directed -47.7 -41.9 0.58 <0.0001 Weak (Bad)
RSU1 intron Hypo Background -52.2 -41.1 0.65 <0.0001 Strong (Bad)
SIRPA intron Hypo Directed -46.7 -37.3 0.65 <0.0001 No
PDXK exon Hyper Directed 34.8 36.5 0.47 0.0003 No
PGM1 enhancer Hyper Directed 26.3 36.4 0.44 0.0002 No
NCK2 enhancer Hypo Background -50.3 -30.9 0.43 <0.0001 Strong (Bad)
EPHB1 intron Hypo Background -41.7 -27.8 0.53 <0.0001 No
FAM171A1 intron Hypo Directed -39.8 -25.8 0.70 <0.0001 Strong (Bad)
TCF7L1 intron Hyper Directed 39.2 25.4 0.58 <0.0001 Strong (Bad)
EGFR enhancer Hypo Background -38.3 -25.2 0.66 <0.0001 No
FZD9 promoter Hyper Directed 27.2 25.1 0.57 <0.0001 Strong (Bad)
MID1 intron Hypo Background -33.9 -25.1 0.68 <0.0001 No
GPM6B intron Hypo Directed -33.4 -24.4 0.66 <0.0001 No
S100A9 enhancer Hypo Directed -21.4 -24.0 0.43 <0.0001 No
PRKCA intron Hypo Directed -30.3 -22.6 0.57 <0.0001 Strong (Bad)
CX3CL1 promoter Hyper Directed 39.3 21.6 0.68 <0.0001 Strong (Bad)
GPT2 promoter Hyper Directed 22.3 20.7 0.55 <0.0001 Strong (Bad)
SFRP1 enhancer Hypo Directed -34.4 -20.2 0.63 <0.0001 No
Table 3.3: Downregulated genes with subtype-specific expression-DMRs in ER+
tumours. ER+ expression-DMRs that fulfilled three criteria were listed: i) they had a
methylation difference of at least 20% vs. normal tissue (vs. N); ii) they had a
methylation difference of at least 20% versus ER- tumours (vs. T); and iii) they were
associated with downregulation of the gene: |rhometh-independent| > 0.40 (|rho| in table),
and FDR p-value < 0.05 (FDR p in table). Analyses were performed as described in the
text. For genes with 2 or more expression-DMRs fulfilling the criteria, the region with the
largest ER+ vs ER- methylation difference was recorded. Expression-DMRs that were
independently predictive of BCSS (multivariable Cox-proportional hazards model as
described in the text; FDR p-value < 0.1) were identified as strong prognostic biomarkers.
DMRs with FDR p-value < 0.2 were marked as weak prognostic biomarkers. DMRs that
were prognostic were marked as ‘(Bad)’if they were associated with worse BCSS, and
‘(Good)’otherwise. Genes listed in decreasing order of ER+ vs. ER- methylation
difference. Exonic and intronic DMRs overlapping enhancers are marked with ‘(Enh)’.
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Gene Feature DMR Avg. Meth. Difference Expression Prognostic
Direction Mechanism vs. N vs. T |rho| FDR p
ENO1 intron Hypo Background -31.2 -43.2 0.64 0.0025 No
IDH2 enhancer Hypo Directed -36.7 -41.3 0.69 <0.0001 No
NMI intron Hypo Background -33.9 -34.0 0.59 <0.0001 No
CLIC3 exon (Enh) Hypo Directed -27.2 -31.1 0.54 0.0051 No
CARD9 promoter Hypo Directed -25.6 -29.2 0.58 0.0021 Weak (Bad)
STIL intron Hypo Directed -32.2 -28.0 0.71 <0.0001 No
P2RY8 intron Hypo Directed -32.7 -27.9 0.46 0.0006 No
AFG3L2 intron Hypo Directed -24.5 -27.3 0.62 <0.0001 No
SNX8 intron Hypo Directed -24.7 -26.8 0.61 0.0257 No
GPSM2 enhancer Hypo Directed -28.4 -25.8 0.65 0.0069 No
SLC7A5 intron Hypo Directed -47.8 -25.6 0.79 <0.0001 Weak (Bad)
TYMP enhancer Hypo Background -27.5 -24.3 0.75 <0.0001 No
LAMP3 PRC region Hyper Directed 40.4 24.2 0.64 <0.0001 No
PLK1 intron (Enh) Hypo Background -31.3 -24.2 0.69 <0.0001 No
TMC6 exon Hypo Directed -22.1 -23.9 0.54 0.0196 No
HSPA14 enhancer Hypo Directed -20.8 -23.1 0.61 <0.0001 No
TRIP13 PRC region Hypo Directed -27.2 -22.6 0.76 <0.0001 No
NFE2L3 intron (Enh) Hypo Directed -30.6 -22.3 0.76 <0.0001 No
XPO5 promoter Hypo Directed -25.1 -21.9 0.70 <0.0001 No
CSK promoter Hypo Directed -22.6 -21.9 0.69 0.0236 No
C1orf106 promoter Hypo Background -24.0 -21.6 0.77 <0.0001 No
FAM83D intron Hypo Directed -24.1 -21.6 0.78 <0.0001 No
GSDMC exon (Enh) Hypo Directed -22.4 -21.5 0.66 <0.0001 No
TOMM5 intron Hypo Directed -21.0 -21.4 0.40 0.0096 No
EVI2B intron Hypo Directed -30.6 -20.6 0.65 <0.0001 No
PTPRCAP promoter Hypo Directed -20.9 -20.2 0.69 <0.0001 No
Table 3.4: Upregulated genes with subtype-specific expression-DMRs in ER-
tumours. ER- expression-DMRs that fulfilled three criteria were listed: i) they had a
methylation difference of at least 20% vs. normal tissue (vs. N); ii) they had a
methylation difference of at least 20% versus ER+ tumours (vs. T); and iii) they were
associated with upregulation of the gene: |rhometh-independent| > 0.40 (|rho| in table), and
FDR p-value < 0.05 (FDR p in table). Analyses were performed as described in the text.
For genes with 2 or more expression-DMRs fulfilling the criteria, the region with the
largest ER+ vs ER- methylation difference was recorded. Expression-DMRs that were
independently predictive of BCSS (multivariable Cox-proportional hazards model as
described in the text; FDR p-value < 0.1) were identified as strong prognostic biomarkers.
DMRs with FDR p-value < 0.2 were marked as weak prognostic biomarkers. DMRs that
were prognostic were marked as ‘(Bad)’if they were associated with worse BCSS, and
‘(Good)’otherwise. Genes listed in decreasing order of ER+ vs. ER- methylation
difference. Exonic and intronic DMRs overlapping enhancers are marked with ‘(Enh)’.
141
Chapter 3. Identification of DNA methylation alterations in breast cancer
Gene Feature DMR Avg. Meth. Difference Expression Prognostic
Direction Mechanism vs. N vs. T |rho| FDR p
DNALI1 promoter Hyper Directed 51.5 45.3 0.75 <0.0001 No
GATA3 exon (Enh) Hyper Directed 33.7 37.2 0.47 <0.0001 No
MAST4 promoter Hyper Directed 30.5 29.7 0.55 0.0113 No
IRS1 exon Hyper Directed 26.4 28.4 0.78 <0.0001 No
PTPRT intron Hypo Directed -28.3 -25.2 0.52 <0.0001 No
WFS1 intron (Enh) Hyper Directed 30.3 23.9 0.59 <0.0001 No
APBB3 enhancer Hypo Directed -28.5 -20.8 0.73 0.0078 Weak (Bad)
ARRB1 intron Hyper Directed 22.7 20.4 0.65 0.0003 No
Table 3.5: Downregulated genes with subtype-specific expression-DMRs in ER-
tumours. ER- expression-DMRs that fulfilled three criteria were listed: i) they had a
methylation difference of at least 20% vs. normal tissue (vs. N); ii) they had a
methylation difference of at least 20% versus ER+ tumours (vs. T); and iii) they were
associated with downregulation of the gene: |rhometh-independent| > 0.40 (|rho| in table),
and FDR p-value < 0.05 (FDR p in table). Analyses were performed as described in the
text. For genes with 2 or more expression-DMRs fulfilling the criteria, the region with the
largest ER+ vs ER- methylation difference was recorded. Expression-DMRs that were
independently predictive of BCSS (multivariable Cox-proportional hazards model as
described in the text; FDR p-value < 0.1) were identified a strong prognostic biomarkers.
DMRs with FDR p-value < 0.2 were marked as weak prognostic biomarkers. DMRs that
were prognostic were marked as ‘(Bad)’if they were associated with worse BCSS, and
‘(Good)’otherwise. Genes listed in decreasing order of ER+ vs. ER- methylation
difference. Exonic and intronic DMRs overlapping enhancers are marked with ‘(Enh)’.
in breast tumour progression [Sood et al., 2009]; and TFF3 which has been shown to
stimulate invasion and angiogenesis in advanced cancer [Ahmed et al., 2012]. The
methylation status of the latter two genes also demonstrated significant prognostic
potential in breast tumours (Table 3.2).
Promoter hypermethylation and epigenetic inactivation of SFRP1 and FZD9
(Figure 3.17b) was also observed in ER+ tumours, but not in ER- tumours. These
genes are antagonists of the WNT signalling pathway which has been recognised as an
oncogenic regulator of cancer development [Polakis, 2000] . Therefore, the epigenetic
silencing of these genes could result in higher activity of the WNT pathway leading to
cancer progression [Ohm et al., 2007]. Although epigenetic silencing of these genes
has recently been implicated in breast cancer [Gao et al., 2015; Györffy et al., 2016],
the results here also demonstrate that this is specific to only ER+ tumours. Furthermore,
promoter methylation of FZD9 was also revealed as a novel prognostic biomarker
with potential value in clinical management. Interestingly, hypermethylation of a
WNT-inhibitor, DKK3, has previously been shown to be associated with the patient’s
age [Veeck et al., 2009], and Gao et al. [2015] hypothesised that epigenetic silencing
of WNT-antagonists including SFRP1 and FZD9 might also be a consequence of
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Figure 3.17: Examples of genes with subtype-specific expression-DMRs in ER+ and
ER- tumours. (a) BMPR1B (left) Average methylation levels for ER+ tumours, ER-
tumours, and normal tissues across all CpGs at this locus. (right) Scatter plot between
DNA methylation and expression levels at this locus across all samples. Black line
represents the loess smoothed relationship between methylation and expression. Blue
vertical dashed line denotes boundary for hypo MAR definition. Red vertical dashed line
denotes boundary for hyper MAR definition. Repeated for (b) FZD9 (c) IDH2 and (d)
MAST4.
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age-related epigenetic drift initiated early in the pathogenesis of cancer. However,
the promoter of both SFRP1 and FZD9 exhibited larger methylation departures than
expected based on the background model (both were directed alterations; Table 3.3),
indicating that although these regions may have accumulated background methylation
differences, it is likely that they were selected for.
Remarkably, in ER- tumours, enhancer hypo methylation of IDH2 was
associated with its upregulation (Figure 3.17c). IDH2 is one the key epigenetic
modifiers involved in the TET-mediated DNA demethylation in cancer. Recurrent
hotspot IDH2 mutations have also been found in a rare subtype of breast cancer (Solid
papillary carcinoma with reverse polarity) that are largely ER- [Chiang et al., 2016].
Other than this rare subtype, mutations in IDH2 are rarely detected in breast tumours
[Chiang et al., 2016] suggesting that the functional disruption of epigenetic enzymes
such as IDH2 in breast cancer may be caused by a mechanism other than mutations,
such as epigenetic events. This suggests that the aberrant methylation observed in ER-
cancers may be a consequence of activation of IDH2 which indeed could be a result of
an epigenetic alteration. This potentially may also confound the estimation of
background methylation differences in ER- tumours which might explain the
dampened association between the accumulation index and proliferation in ER-
tumours.
The subtype-specific epigenetic regulation of GATA3, a known cofactor in the ER
transcription complex, which is activated in ER+ tumours and silenced in ER- tumours
offers a fascinating insight into context-dependent behaviour of DNA methylation and
is explored in detail in Chapter 4. Promoter hypermethylation associated epigenetic
silencing of MAST4, a protein kinase, was also observed specifically in ER- tumours
(Figure 3.17d).
Subtype specific expression-DMRs were also identified for the 6 Intrinsic
subtypes (Appendix B.2) and the 11 Integrative clusters (Appendix B.3).
144
3.7. Discussion
3.7 Discussion
The aim of genome-wide cancer methylome studies is to identify
malignancy-associated epigenetic changes with putative functional roles in gene
transcriptional regulation. This would help in better understanding of the mechanisms
underlying tumorigenesis, and also in developing rational approaches to therapy
stratification. However, a fundamental problem facing cancer methylome studies
today and in the future, is that widespread false positive findings might overshadow
those epigenetic events involved in transcriptional pathways. This is particularly true
for WGBS methylomes, since theoretically every single CpG is profiled. However,
despite the fact that methylome profiling technologies such as microarrays (27K,
450K and EPIC) are enriched for functional regions, not all detected methylation
changes are directed or selected for. It is likely that a large contribution of the detected
cancer-normal differential methylation regions is a consequence of cell-division DNA
replication errors that may not contribute to cancer biology. However, this issue is
rarely considered, and consequently the relevant mechanism underlying observed
methylation changes are not delineated explicitly in genome-wide cancer methylome
studies.
In order to shed light on the mechanisms underlying tumour-specific methylation
alterations, first, the extent of background or neutral DNA methylation changes in
breast tumours (compared to the normal tissues) was quantified. This represents the
first characterisation of genome-wide epigenetic drift in a large cohort of primary
breast tumours, and was found to be highly context specific with methylation gains
largely observed in CpG rich regions and losses in low CpG regions. Moreover,
late TOR regions demonstrated a remarkable predisposition for accumulating both
methylation changes (gains and losses) in breast cancer. This corroborates similar
findings in mutational studies where a marked increase in mutation rates has been
observed in late replicating domains of the human genome [Lawrence et al., 2013;
Stamatoyannopoulos et al., 2009], suggesting a generalised mechanism involving
replication time-dependent damage in both genetic and epigenetic compartments. A
likely explanation for these observations is that modifications in late replicating regions
lack sufficient time to undergo repair or that the mismatch repair systems might have
eroded by this time [Stamatoyannopoulos et al., 2009].
Two indices – Accumulation and Direction - were introduced to assess the extent
and direction of epigenetic drift respectively in the METABRIC cohort. Both indices
were highly heterogeneous across all breast tumours and significantly associated with
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ER status, as well as molecular subtypes of breast cancer, thus indicating the
relationship between genetic, epigenetic and transcriptomic dysregulation in
tumorigenesis. Integrating the tumour’s accumulation index with its mitotic index as
well as gene expression changes confirmed that epigenetic drift is largely a
consequence of the accumulation of passive replication related errors related to the
number of cell divisions (mitotic clock), as initially hypothesised by Yatabe et al.
[2001]. Although this relationship between accumulation of epigenetic drift and
mitotic clock was observed in both ER+ and ER- tumours, it was much stronger in
ER+ tumours in which it was significantly prognostic of lower BCSS. The diminished
relationship in ER- patients raises the interesting postulation that a considerable
proportion of epigenetic drift accumulated in ER- tumours is acquired due to
environmental exposures and not cell-division errors, and will be examined in future
work.
Next, functional regions of the methylome were assessed to identify focal
differential methylation regions (DMRs) and methylation altered regions (MARs) by
comparing tumours and normal tissues. The key distinction between these two
alterations is that DMRs are regions of averaged methylation differences between a
class of tumours and a group of normal tissues, while MARs are tumour-specific.
DMRs can also represent regions of altered methylation between two fixed groups of
tumours, and this is discussed in Section 3.6.
A crucial enhancement to the detection of both DMRs and MARs was the
implementation of the novel DMARC algorithm that has been developed as part of
this thesis. Traditional cancer methylation analyses utilise a uniform methylation
difference threshold across the genome and for all tumours. However, the epigenetic
drift analysis revealed extraordinary variation in background methylation differences
within breast tumours; and in background methylation differences across the genome,
which was strongly correlated with CpG density and DNA replication timing. By
incorporating background methylation heterogeneity into the methylation analyses,
DMARC is able to identify directed methylation alteration regions that are a
consequence of instructive regulatory pathways versus background methylation
alteration that are untargeted and largely associated with cell division errors. The
underlying premise of DMARC is similar to the MutSigCV algorithm for the
identification of mutation driver genes in cancer which is based on the assumption that
cancer driver genes harbour more mutations to that expected for an observed
background rate [Lawrence et al., 2013]. Accordingly, DMARC enabled the explicit
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delineation of the mechanism underlying methylation changes, be it tumour-specific
MARs or class-specific DMRs.
As expected, directed-DMRs were significantly enriched for gene expression
changes in breast cancer compared to background-DMRs. This strongly suggests that
background-DMRs, that have been largely demonstrated to be a consequence of a
stochastic accumulation of cell-division errors are likely to have fewer functional
consequences than directed-DMRs. More stringent thresholds (based on the
background estimates) were used to detect directed-DMRs, and this partially
contributes to the observed enrichment. However, this cannot explain the noteworthy
separation of the biological pathways disrupted at the transcriptional level by the two
distinct methylation mechanisms. Specifically, genes that harboured
background-DMRs as well as concomitant expression changes were more likely to be
involved in pathways elicited by specific cell-extrinsic stresses such as immune
system engagement and hypoxia. Conversely, genes with directed-DMRs were
enriched for altering cell-intrinsic biological signalling pathways such as ER and
NOTCH signalling. Thus, DMARC enables a better understanding of methylation
processes and its role in disease aetiology. However, it is important to note that
bioinformatic approaches go only so far in highlighting important genes and pathways
that might be drivers in pathogenesis. Functional studies are required to validate the
relevance and mechanism underlying the epigenetic events described here.
Although discrimination between directed and background DMRs has proved
extremely valuable for biological interpretation, it would be erroneous to ignore
stochastic DMRs and assume they are functionally irrelevant for two reasons. Firstly,
these stochastic methylation alterations may occasionally hit key genes in cancer-
relevant pathways and be under selection and be identified as directed. Examining
methylation calls aggregated over all cells in the tumour does not allow discrimination
based on selection-related methylation dynamics. However, evaluating methylation
content based on epialleles inferred from single reads can be used to distinguish
methylation alterations that occur in a noisy and stochastic fashion versus those that are
occur in a deterministic manner. This paves the way for a comprehensive analysis of the
role of intratumour methylation heterogeneity in tumour evolution which is conducted
in Chapter 5. Secondly, although the extent of background methylation alterations in a
tumour is undoubtedly associated with CpG density and DNA replication timing, these
two genomic variables are not absolute predictors. Observed methylation differences
(larger than 20%) would always be detected as MARs, however the DMARC algorithm
may suffer from type 1 or type 2 errors in classifying directed from background
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methylation alterations. Shipony et al. [2014] demonstrated that gain and loss of
methylation in somatic cells is also associated with nucleosome occupancy and nuclear
laminal interaction in addition to replication timing. It is likely that integrating these
additional genomic variables into the DMARC algorithm will improve performance.
A caveat in the tumour-normal differential analyses (both DNA methylation and
gene expression) is that the comparisons are conducted against the normal tissue that
is found adjacent to the breast tumour tissue. Teschendorff et al. [2016a] established
that the normal-adjacent breast tissue harbour epigenetic field defects (largely
stochastic age-associated methylation alterations), and consequently, this may reduce
the sensitivity to detect potential regulatory methylation events. However, the authors
also demonstrated that breast tumours exhibit larger methylation differences on
comparison with normal-adjacent tissues at the loci harbouring field defects, and so
this strategy is still appropriate. Moreover, this also raises another advantage of
DMARC since it can discriminate between stochastic age-related methylation
alterations and putative directed events.
Another key benefit of the DMARC algorithm is that it provides a novel way to
account for tumour purity. A critical issue in cancer methylome studies is that tumour
tissues are highly heterogeneous that suffer from contamination from adjacent normal
cells. Consequently, methylation profiles obtained from these tumour tissues are in
fact mixed signals from tumour and normal components depending on tumour purity
[Jaffe and Irizarry, 2014; Zheng et al., 2014]. Although tackling intra-sample cell
heterogeneity has been studied in the context of epigenome-wide association studies
(EWAS) [Houseman et al., 2014; Jaffe and Irizarry, 2014; Rahmani et al., 2016;
Teschendorff et al., 2017; Zheng et al., 2017a], differential methylation analysis
between tumour and normal tissues with the consideration of tumour purity represents
a related but fundamentally distinct challenge and is understudied [Wang et al., 2016].
Consequently, statistical methods for differential methylation analysis implemented in
a vast majority of cancer methylome studies do not account for tumour purity [Akalin
et al., 2012b; Aryee et al., 2014; Assenov et al., 2014] which leads to biased and often
erroneous results [Wang et al., 2016; Zheng et al., 2017b]. For instance, let us assume
two tumours – A and B – with Tumour A having a higher tumour purity than tumour
B. The epigenetic drift analysis revealed that the accumulation index (magnitude of
background methylation alterations) in a tumour was significantly associated with
ASCAT-defined tumour purity estimates (p-value = 7.6×10-23). Consequently, for the
same genomic loci, tumour A would also harbour a higher absolute background
methylation difference (compared to normal tissues) than tumour B on account of its
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higher tumour purity. Using uniform methylation difference thresholds as per
traditional differential methylation analysis would erroneously result in the detection
of a larger number of MARs for Tumour A. Conversely, by incorporating background
estimates into constructing tumour-specific methylation difference thresholds,
DMARC is able to account for purity-based biases. Although there a few methods
available to estimate tumour purity from DNA methylation content, only a few recent
reports have been able to use this information to deconvolute the methylation profiles
of the tumour analysis for downstream differential methylation analysis [Barrett et al.,
2017; Zheng et al., 2017b, 2014]. Interestingly, DMARC does not require explicit
estimates of tumour purity as an input, although the accumulation index is a good
indicator of it, nor does it utilise the epiallelic content obtained from bisulphite
sequencing techniques and thus can be used for microarray techniques as well.
DMARC is suitable for all high-throughput genome-wide cancer methylome
studies, and in principle, it can be applied across all popular methylation profiling
techniques that provide single CpG resolution such as microarrays and bisulphite
sequencing techniques. The benefits of utilising DMARC in cancer methylome
analysis are clearly outlined above, however, it is important to note, that it relies
extensively on accurate estimations of tumour-specific background methylation
differences in distinct genomic contexts. Since theoretically every single CpG is
profiled in WGBS, it is obvious that the implementation of DMARC in WGBS cancer
methylomes is not only highly recommended to deconvolute directed and background
methylation alterations, but the algorithm will also benefit from superior resolution at
all genomic contexts. Although microarray technologies are biased towards
functionally relevant and interesting CpG sites, approximately 50% of the probes
localise in the background or neutral compartment of the epigenome (as defined in
Section 3.2) which points to their suitability in the implementation of DMARC.
Specifically, HM450 and EPIC include 215K CpG sites and 452 K CpG sites
respectively as part of the background CpG universe. RRBS is even more suitable as
demonstrated in this study, with approximately 1816 K background CpG sites assayed.
Moreover, background CpG sites across all above-mentioned methylation platforms
have adequate distributions of DNA replication timing that are similar to the whole
epigenome. However, a limitation of microarray technologies is that both HM450 and
EPIC suffer from inadequate representation of background CpG sites at CpG-rich
regions (HM450 = 13 K, EPIC = 13 K, EPIC = 478 K; CpG Density ≥ 80 CPGs/kbp).
Additionally, despite being depleted for CpG-low regions, the RRBS epigenome
contains a larger number of background CpG sites at CpG-poor regions compared to
microarray technologies (HM450 = 141 K, EPIC = 376 K, RRBS = 849 K; CpG
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Density < 40 CpGs/kbp). Consequently, DMARC may not perform as accurately in
microarray technologies, and future work will assess their utility in pan-cancer
microarray-based methylomes publically available from TCGA [Bass et al., 2014;
Cancer Genome Atlas Network, 2012; Cancer Genome Atlas Research Network,
2016; Collisson et al., 2014; Hammerman et al., 2012; Muzny et al., 2012; The Cancer
Genome Atlas Research Network, 2013a; Weinstein et al., 2014].
Despite multiple studies attempting to map cancer-associated epigenetic changes
at the genome-wide level, one of the shortcomings of previous breast cancer methylome
analyses [Cancer Genome Atlas Network, 2012; Dedeurwaerder et al., 2011; Gao et al.,
2015; Roessler et al., 2015] is that the focus has largely been retained on the promoter
regions due to their established significance as an epigenetic transcriptional repressor.
Although recent reports in breast cancer have progressed to investigating gene body
methylation as well [Fleischer et al., 2014; Györffy et al., 2016], these studies restricted
their analysis to a selected panel of genes. There is also noteworthy absence in the
examination of the epigenetic roles of intergenic distal regulatory regions such as
enhancers and PRC regions in breast cancer. In the current project, the extent of
DNA methylation alterations in breast cancer was assessed in a variety of genomic
features, encompassing both gene-associated elements as well as distal-regulatory
elements. Hyper as well as hypo DMRs in all the genomic features were detected
in this breast cancer methylome study. Notably, these epigenetic differences were
not only incriminated with gene silencing, but in fact a large number of DMRs were
implicated with the upregulation of potential oncogenes as well. Collectively, the
results in this chapter strongly indicate that the activity of major signalling pathways in
breast cancer are at least partly regulated by the epigenome, and more so, by epigenetic
deregulation of not only promoter but also other genomic elements.
The importance of breast cancer stratification is highlighted in Section 3.6, where
ER status was initially used for classification. Some genes such as GATA3 and ESR1
are specifically linked to oestrogen signalling and so may be relevant only in an ER+
context. Conversely, various genes including IDH2 and MAST4 were identified as
subtype specific epigenetic regulators in ER- cancers, and the methylation statuses were
also associated with worse prognosis. GSEA also revealed distinct pathways that were
epigenetically disrupted in ER+ and ER tumours, such as oestrogen-signalling in ER+
tumours and the p53 pathway in ER- tumours. Interestingly, DMRs within enhancers
were largely identified as subtype specific, and hypomethylated enhancers (both within
the gene body and further away) in particular, were demonstrated to have a strong
gene regulatory role. A likely mechanism is that reduced methylation at enhancers
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is associated with increased transcription factor binding which has transcriptional
consequences for the target genes. This has been demonstrated in recent studies
across different cancers [Heyn et al., 2016] and in normal mammary epigenomes
[Pellacani et al., 2016]. ER binding sites are also available from ChIP-Seq experiments
conducted on these tumours [Ross-Innes et al., 2012], and one of the follow-up goals
of this project is to correlate enhancer DMRs in ER+ tumours with differential ER
binding, as was performed in a recent report studying ER+ tumours [Stone et al.,
2015]. Furthermore, motif analysis can be implemented to map putative binding sites
of various transcription factors to activating hypo enhancer DMRs in ER+ and ER-
breast tumours. This would enable the construction of subtype-specific transcription
factor regulatory networks in breast cancer.
The results presented in this chapter also strongly suggested that the epigenome
contributes to defining these subtypes as distinct biological entities that affect the
clinical evolution of the disease. However, these subtype-specific methylation patterns
might be associated with the epigenetic imprints of presumed cellular origins. Recent
reports have explored epigenomic profiles in different cell populations from normal
mammary glands [Gascard et al., 2015; Pellacani et al., 2016] and revealed striking
differences in the degree of epigenomic reprogramming between them. Future
investigations post this thesis are proposed to integrate the METABRIC breast cancer
methylomes with those from the normal mammary subpopulations obtained from the
Roadmap Epigenomics Project [Kundaje et al., 2015] to shed light on epigenomic
reprogramming in normal mammary development and leading to the initiation of
breast cancer.
The DMR and MAR analysis are implemented on SCCRUB – the universe of
spatially coordinated regions defined in Chapter 2. SCCRUB consists of approximately
289K focal regions comprising of 4 CpG sites on average with an average width of 88bp
(see Chapter 2), and this is largely driven by Msp1 sites, the restriction enzyme used in
RRBS. Although differential methylation analyses on SCCRUB regions can identify
focal hypomethylated regions, an alternate approach needs to be employed to detect
long-range methylation alterations such as the recently identified hypomethylated
blocks in various cancers [Berman et al., 2011; Hansen et al., 2011; Hovestadt et al.,
2014]. Future work will identify whether multiple hypo DMRs (from within the
SCCRUB universe) cluster together in specific regions of the genome. This will be
followed by an investigation into whether these epigenetic domains correspond to
large chromatin regions (LOCKs), nuclear organisation (LADs), or DNA repeats and
subtelomeric regions, and whether they have consequences on genome instability.
151
Chapter 3. Identification of DNA methylation alterations in breast cancer
Genetic events might have a dominant role in shaping the epigenome by affecting
cellular components that participate in epigenetic pathways (see Chapter 1). Although
the widely recognised epigenetic modifiers such as DNMT3A, IDH1 and TET1 are
rarely mutated in breast cancer, BRCA1 mutations have been associated with global
DNA hypomethylation [Flanagan et al., 2010]. Conversely, BRCA2 mutations were
linked with promoter hypermethylation [Holm et al., 2010]. While the reasons for
this remain unknown, this suggests that besides their recognised functions in DNA
repair [Joosse, 2012], BRCA family of proteins also participate in regulation of
DNA methylation. A recent computational report using the TCGA consortium breast
cancer data identified three epigenetic modifier genes – UHRF1, WHSC1 and CBX7
– that were universally deregulated across different cancers including breast cancer
and associated with concomitant disruption in global DNA methylation levels [Yang
et al., 2015]. One of the follow-up goals of this project is to integrate the mutational,
transcriptomic and epigenomic data in METABRIC to confirm these findings and
determine additional epigenetic enzymes in breast cancer.
The results in this chapter support the view that altered DNA methylation is
associated with the disruption of key transcriptional pathways in breast cancer.
Although it is possible that the observed methylation alterations instigate concomitant
silencing or upregulation of the gene in question, recent studies have also
demonstrated how the presence or absence of an upstream transcription factor
(through genomic events) can mediate active DNA methylation changes at promoter
and distal regulatory elements [Domcke et al., 2015; Feldmann et al., 2013; Yin et al.,
2017]. This study provides a snapshot of the expression and methylation status of the
breast tumour at the time of surgery. And consequently, the associative statistical
models presented here cannot distinguish between a causative role for DNA
methylation and an effects model, in which the observed methylation modification is a
consequence of an upstream gene deregulation event [Teschendorff et al., 2016b].
However, even in the scenario where DNA methylation alterations follow gene
deregulation, it has been shown to play a critical role in locking this transcriptional
state [Bird, 2002; Lock et al., 1987; Siegfried and Cedar, 1997]. Therefore,
differential DNA methylation marks do not only reflect altered transcription factor
activity [Fleischer et al., 2017; Schübeler, 2015], but as demonstrated in this chapter,
can also serve as powerful biomarkers for breast cancer subtype-specific diagnosis and
prognosis. Collectively, these results have confirmed that DNA methylation alterations
are an extremely informative indicator of the epigenetic disruption of transcriptional
pathways in cancer, and they contribute significantly to breast cancer heterogeneity.
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4.1 Introduction
Genetic alterations such as mutations, copy number changes and epigenetic alterations
such as DNA methylation events represent distinct mechanisms by which gene function
in cancer can be deregulated [Cancer Genome Atlas Network, 2012; Ciriello et al.,
2013; Curtis et al., 2012; Vogelstein et al., 2013]. Genomic and epigenomic profiling
of these alterations have led to the identification of a number of genes that contribute
to tumour progression, but they have mostly been studied in isolation from each
other. Since all these types of events possess gene-regulatory function, it is clear
that there must be an interaction between them during malignant transformation
[Cancer Genome Atlas Network, 2012; Shen and Laird, 2013]. The development of
integrative approaches has allowed discovery of joint patterns across multiple data
types such as DNA methylation, expression and copy number events (iCluster [Shen
et al., 2009], moCluster [Meng et al., 2016], consensus clustering (cluster of clusters)
[Lancichinetti et al., 2009]). However, these methods, involve dimensionality reduction
across multiple molecular landscapes with the primary objective of understanding
the taxonomy of disease; and are not concerned with the identification of the distinct
mechanism (or synergy of multiple mechanisms) associated with deregulation of cancer.
Curtis et al. [2012] successfully bridged the gap between these two objectives by first
identifying 1000 genes in which CNAs influenced expression in cis in breast cancer;
and subsequently conducting integrative clustering on this set of genes. This analysis
revealed 10 (now 11) novel tumour subgroups (the Integrative clusters; IntClusts) with
distinct clinical features and prognosis. However, the DNA methylation landscape has
not been profiled in this METABRIC dataset until now.
In the same year as the METABRIC publication, The Cancer Genome Atlas
(TCGA) presented results for approximately 500 patients with data available on DNA
copy number, DNA methylation, exome, mRNA, microRNA and protein profiles
[Cancer Genome Atlas Network, 2012]. Approximately, 300 breast tumours were
added to the consortium in 2015 resulting in a total of ∼800 breast tumours [Ciriello
et al., 2015]. This represented the first large multiplatform analysis with epigenetic
and genetic data in breast cancer, and was followed by an ER+ breast cancer study (n =
560) conducted by the International Cancer Genome Consortium (ICGC) in 2015 [Nik-
Zainal et al., 2016]. Although, the breast cancer methylome was not explored in depth
in either of these two studies, the public availability of this data, in particular TCGA,
has sparked an interest in integrating data across multiple molecular frameworks to
identify epigenetic drivers of tumorigenesis. Teschendorff et al. [2016b] conducted
a detailed investigation of the multi-omic basis of transcription factor dysregulation
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in cancer using pan-cancer data obtained from TCGA. Excitingly, they revealed that
promoter hypermethylation is a more frequent event than copy number losses or
inactivating mutations, and is the more likely mechanism associated with silencing of
transcription factors in cancer. However, only methylation of the gene promoter was
evaluated, and mechanisms underlying the activation of genes was not investigated;
and notably, breast cancer samples were not included in the study. About the same
time, another pan-cancer report using TCGA data (this time including breast cancer)
revealed that DNA methylation alterations prefer to target genes in the extracellular and
transmembrane domains (enriched for cytokines and growth factors, cell differentiation
markers) rather than intracellular domains (enriched for transcription factors) [Gao and
Teschendorff, 2017]. However, this study too, only focused on promoter methylation
events negatively correlated with expression; and there is a pressing need to expand
cancer methylome analyses beyond this traditional outlook.
The breast cancer landscape has previously been shown to be dominated by copy
number events [Ciriello et al., 2013]. Although, the landmark study [Curtis et al.,
2012] mentioned above also revealed that the breast cancer transcriptome is largely
influenced by acquired somatic CNAs with the identification of 1000 cis-acting CNA
genes, the variation in expression for approximately 60% of genes across the genome
was unaccounted for by CNA. Could a significant contribution of this unaccounted
variation in the transcriptional deregulation be explained by DNA methylation? A
recent demonstration that this was in fact the case in other cancers [Teschendorff et al.,
2016b] suggests that this is a promising hypothesis; although, as mentioned above,
only inactivation of transcription factors was evaluated. In this chapter, the independent
contributions of cis-association of CNA and of DNA methylation in explaining gene
expression were compared in order to identify genes that were regulated by CNA,
DNA methylation or both alterations. Moreover, the contributions of CNA and DNA
methylation alterations in explaining inter patient breast cancer heterogeneity (such as
between ER+ and ER- tumours) were also compared.
Many cancer genes exhibit contradicting expression profiles to what is expected
given the underlying copy number alterations. For instance, tumours with copy
number gains do not show an anticipated upregulation of the underlying gene. The
large number of genes showcasing this abnormality suggests that this is not a technical
artefact. And so, the hypothesis that an alternate mechanism such as DNA methylation
could be used to target specific genes in order to modulate the regulatory role of cis
CNA events is proposed and investigated.
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Finally, the prevalence of methylation altered regions (MARs) and of CNAs were
compared within genes that were differentially expressed in tumours compared to
normal tissues to identify which alteration accounts for a higher fraction of tumours
in these potentially functional genes. This section of analysis helps to support results
from the above comparison of the regulatory roles of DNA methylation and CNA, but
critically also allows investigation of patterns of co-occurrence and mutual exclusivity
between these two distinct mechanisms for the same gene. A biologically plausible
rationale for finding two independent co-occurring events is that they specifically
augment each other’s tumour suppressive or oncogenic roles [Knudson, 1971]. In this
case, the second alteration provides a selective advantage for the cancer cell(s) and
will consequently be observed more frequently than expected by chance. A case in
point is loss of heterozygosity (LOH), a common event in tumour suppressor genes
in cancer (e.g. RB1 in retinoblastoma, BRCA1 in breast cancer), in which a mutation
or an epigenetic hit is accompanied by hemizygous deletion of the non-mutant allele
ensuring that only the function of the mutant allele is observed [Cavenee et al., 1983;
Esteller, 2000; Kawaoi et al., 1992; Merajver et al., 1995]. On the other hand, a pattern
of two mutually exclusive events on the same gene could be an indication that i) both
alterations have the same functional consequence. For instance, loss of an allele would
give the same effect as a dominant negative mutation; ii) the second alteration offers
no further selective advantage than the first hit; or iii) the second alteration leads to
a disadvantage for the cell, eventually leading to cell death. Consequently, they will
be observed less frequently than expected by chance. Identification of methylation
alterations among such patterns of independent cancer mechanisms on the same gene
helps to delineate the functional role of DNA methylation in tumorigenesis, but also
supports the discovery of novel tumour suppressor genes and oncogenes and validation
of previously established ones in breast cancer.
4.1.1 Summary of aims
In the previous chapter, potential functional methylation alterations were identified
using a combination of strategies including accounting for tumour-specific and
context-specific background rates; and subsequently characterising these events using
concomitant changes in gene expression. This chapter extends these findings, and
aims to characterise the regulatory role of methylation patterns and explore the
molecular multi-omic landscape of cis gene deregulation in breast cancer. This is
achieved through the following steps:
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1. Quantification and comparison of the independent contributions of DNA
methylation and CNA alterations to identify the predominant mechanism
driving deregulation of gene expression in breast cancer.
2. Investigation of whether methylation events can modify the effect of copy
number amplifications and copy number losses in a gene.
3. Calculation of the comparative prevalence of MARs and CNAs in differentially
expressed genes in breast cancers. Identification of MARs that co-occur or are
mutually exclusive with CNA events within the same gene, and explore the
regulatory consequences of these configurations.
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4.2 Identification of the principal functional
methylation region (PFMR) of a gene
The purpose of this chapter is to identify the relevant mechanism – Copy number,
mutations, or methylation - that is predominantly associated with cis activation or
silencing of genes in breast cancer. Although definite estimates of CNA, gene
expression and mutation (only 173 genes) information are available per gene (see
Chapter 2), DNA methylation changes are widespread and variable over multiple
regions within the gene body as well as distal cis-regulatory elements (Chapter 3). For
example, GATA3 has 3 promoter regions, 4 exons, 3 introns, 9 introns, 3 enhancers
and 9 polycomb-repressed complex marked (PRC) regions assayed as part of the
SCCRUB universe. For the purpose of identifying the principal functional
methylation region (PFMR) of the genes, the SCCRUB region associated with the
gene having the highest correlation with expression was selected.
To serve the dual objectives of i) evaluating the independent roles of DNA
methylation and of CNA in explaining gene expression; and ii) making an informed
choice for the PFMR per gene, a multivariable regression framework was constructed.
This is similar to expression analysis described in Chapter 3, with the fundamental
difference being that all regions within the SCCRUB universe were considered, and
not just those identified as DMRs. Each gene may be associated with multiple
methylation regions but only single CNA and gene expression estimates are available,
and accordingly multiple tests were performed for each gene using distinct
methylation inputs against the same CNA and expression inputs. For each region-gene
combination, gene expression (normalised log2 intensities, see Chapter 2) was treated
as the independent variable and both DNA methylation (M-value, see Chapter 2) and
CNA (segmented mean log2 ratios, see Chapter 2) as continuous covariates. The
inclusion of both DNA methylation and CNA in the model ensures that their
independent contribution to gene expression can be determined for each gene [Gao
and Teschendorff, 2017]. Tumours that had matched gene expression (microarray, see
Chapter 2), CNA (SNP 6.0 array, see Chapter 2) and DNA methylation data were
considered for this analysis. A total of 15968 genes with gene expression (microarray;
Chapter 2), CNA (array) and DNA methylation data available were used.
The analysis in Chapter 3 examined associations from a DMR and genomic
feature (such as promoters, exons etc) standpoint. In this section, a gene-central
perspective is considered. On average, each gene was associated with 24.6 (SD =
23.2) distinct regions of coordinated clusters of CpG sites as defined by the SCCRUB
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universe (2.3 regions within promoters, 1.4 region within exon, 5.9 regions within
introns, 11.5 regions within enhancers and 3.5 regions within PRC regions; Figure 4.1a
- left). For every gene individually, the partial correlations between methylation and
expression were recorded for each of its multiple regions (rmeth-independent, which is a
measure of the independent strength and direction of this relationship whilst controlling
for the effect of CNA). A key question is whether methylation on intragenic regions
(including promoters) are more likely to be associated with the expression of the
underlying gene than distal regulatory elements? To test this hypothesis, the region
with the highest rmeth-independent was noted for each gene, and a hypergeometric test
was conducted to compare observed vs. expected proportions for each feature. All
three intragenic features (promoters, exons and introns) were significantly more likely
to contain the region in which methylation most correlated with expression; whereas
enhancers and PRC regions were significantly depleted for the strongest methylation
correlation for the gene (Figure 4.1a – middle and right). It is true, however, that
these regions were selected from within the SCCRUB universe and not the entire
genome, which means that the formal comparison of the regulatory roles of different
genomic features cannot be performed. Nevertheless, promoters displayed the highest
enrichment (hypergeometric test: enrichment = 1.69; FDR p-value < 1×10-255) which
strongly confirms previous findings that promoters have the most impact on gene
expression [Jiao et al., 2014].
Although Chapter 3 undoubtedly illustrates that distal cis-regulatory features
such as enhancers and PRC regions are epigenetically altered in breast cancers and
that they also have significant impact on gene expression, it is challenging to prove
these associations without using chromosome conformation capture assays such as
Chromatin Interaction Analysis by Paired-End Tag Sequencing (ChIA-PET)
[Fullwood et al., 2009] or Hi-C [Lieberman-Aiden et al., 2009] to identify distal
cis-interactions with promoters. This, along with the observation that promoter and
gene body regions are more likely to play the strongest methylation-specific
regulatory roles for the underlying gene (Figure 4.1), led to the decision to focus
further investigation in this chapter exclusively on promoters, exons and introns.
However, this does not diminish the importance of understanding the behaviour of
distal regulatory methylation alterations in the presence or absence of other genomic
events; they have been ignored purely for practical purposes.
For each gene, the region (within the three intragenic features) with the strongest
regulatory role (highest rmeth-independent) was selected as a functional region, and its
methylation estimate was used as the representative methylation value for the gene.
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Figure 4.1: Promoters are likely to harbour the PFMR of a gene. (a) Considering
intergenic and distal regulatory elements. (left) Average number of SCCRUB regions
detected per gene per genomic feature. (middle) Fraction of genes that have a specific
genomic feature as the principal functional methylation region. (right) Enrichment (log2)
of a genomic feature to be detected as the principal functional methylation region of a
gene. (b) Considering only inter-genic elements. same as described for (a). PFMR =
principal functional methylation region. The top 2000 variably expressed genes
(VAR2000) were considered.
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Promoters represent the strongest methylation-specific regulatory region for 35% of
the genes; exons for 17% of the genes; and introns for 48% of the genes (Figure
4.1b). Given that there are twice as many intron regions covered in SCCRUB than
promoter regions (1.2 million vs. 0.6 million), promoter regions are the most enriched
(enrichment = 1.44, hypergeometric test: p-value < 1×10-255; Figure 4.1f).
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4.3 Cis-acting DNA methylation and CNA regulate the
breast cancer transcriptome
4.3.1 Inter-patient heterogeneity in breast cancer
Multiple reports have shown that the breast cancer transcriptome is largely influenced
by cis-acting CNAs [Ciriello et al., 2013; Curtis et al., 2012]. In this section, the
contribution of cis-acting DNA methylation in explaining gene expression is
quantified and compared to that for cis-acting CNA. Specifically, for each gene the
partial correlation between methylation and expression (rmeth-independent, a measure of
the strength of the independent contributions of methylation on expression) and
between CNA and expression (rcna-independent, a measure of the strength of the
independent contributions of methylation on expression) are compared. At the outset,
focus was set on the 2000 most variably expressed genes in breast cancer in this
cohort (this gene set will be henceforth denoted as VAR2000), since this represents a
straightforward strategy to enrich for genes likely to explain the considerably
inter-tumour heterogeneity in breast cancer.
Figure 4.2a demonstrates the comparison of the cis-regulatory roles of methylation
and CNA in the VAR2000 gene set. A stringent threshold of 0.40 was applied on
the partial correlation estimates (rmeth-independent and rcna-independent) to select genes in
which CNA (blue points), or DNA methylation (purple points), or both (green points),
were highly correlated with the expression of each gene. This high threshold ensured
that the selected genes had a strong relationship between the respective mechanism and
gene expression. The proportion of genes (out of the 2000 genes in VAR2000) in each
of these 3 categories was plotted (Figure 4.2b – left panel). Similarly, the proportions
were also plotted for the set of all genes (15968 genes) in Figure 4.2b (right panel).
21.7% of VAR2000 genes were methylation-regulated, whereas only 4.9% were CNA-
regulated. A clear preference for methylation control of gene expression was observed
in VAR2000 when compared to the set of all genes (All genes: CNA = 14.2% vs.
Methylation = 5.5%). This corresponds to a substantial increase in the number of
methylation-modulated genes with a simultaneous decrease in the number of CNA-
modulated genes in VAR2000 compared to what is expected. Accordingly, Fisher’s
exact tests were used to formally assess three hypotheses: i) is the proportion of
methylated-regulated genes significantly enriched or depleted in VAR2000 compared
to what is expected based on all genes?; ii) is the proportion of CNA-regulated genes
significantly enriched or depleted in VAR2000 compared to what is expected based on
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Gene Set N (total) N (available) Disease-specific Description
VAR2000 2000 2000 Breast cancer Genes with highest variation in
expression in the METABRIC dataset
[Curtis et al., 2012, this study]
SORLIE 437 392 Breast cancer List of variably expressed genes used to
classify breast tumour into Intrinsic
subtypes [Perou et al., 2000; Sorlie et al.,
2003]
PAM50 50 47 Breast cancer Reduced list of variably expressed genes
used to classify breast tumours into
Intrinsic subtypes [Parker et al., 2009]
IC10 614 528 Breast cancer Genes with high correlation between
gene expression and cis-acting CNA.
Used to classify breast tumours into
Integrative clusters [Curtis et al., 2012]
COSMIC 602 549 All cancers Catalogue of Somatic Mutations in
Cancer [Forbes et al., 2015,
cancer.sanger.ac.uk]
Table 4.1: Definition of 5 gene sets. N (total) represents the number of genes defined in
the gene set. N (available) represents the number of genes profiled in the METABRIC
dataset described in this thesis.
all genes?; and iii) Is the enrichment or depletion in methylation-regulated significantly
different from CNA-regulated genes?
Figure 4.2c illustrates that methylation-modulated genes are significantly enriched
in variably expressed (VAR2000) breast cancer genes (OR = 8.15, FDR p-value =
2.0×10-164) while CNA-driven genes are significantly depleted (OR = 0.28; FDR
p-value = 2.2×10-45). Identical analyses were conducted for four additional gene
sets that are defined in Table 1, comprising of breast cancer specific genes (Sorlie,
PAM50 and IC10), and the Catalogue of Somatic Mutations in Cancer (COSMIC).
The PAM50 gene set of 50 genes (47 genes available in this cohort) which has been
shown to robustly classify breast tumours into the Intrinsic subtypes showed a similar
enrichment in methylation-regulated genes (16 out of 47 genes, OR = 8.88, FDR
p-value = 2.2×10-9) and depletion in CNA-regulated genes (4 out of 47 genes, OR =
0.56, p-value = 0.401). The Sorlie gene set (previous iteration of the PAM50 gene set)
is comprised of approximately equal proportions of methylated-modulated (17.86%,
OR = 3.91, p-value = 2.1×10-18) and CNA-modulated (19.64%, OR = 1.48, p-value =
0.0034) genes, however, the methylation-altered genes are enriched to a considerably
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Figure 4.2: (Caption on next page.)
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Figure 4.2: (Previous page.) Cis-acting DNA methylation events are the predominant
mechanism regulating variably expressed genes in breast cancer. (a) Scatter plot of
the partial correlations between cis-acting DNA methylation and gene expression (x-axis)
and cis-acting CNA and gene expression (y-axis) for each of the 2000 variably expressed
genes in breast cancer (VAR2000). Each point represents one gene. Colour of the points
represents whether the gene can be described as methylation-regulated (purple),
CNA-regulated (blue), both (green), or none (white) using a partial correlation threshold
of 0.40. (b) Proportion of genes that are characterised as methylation-regulated (purple),
CNA-regulated (blue) or both (green) within the VAR2000 gene set (left); and within the
set of all genes (right, ALL gene set). (c) Enrichment analysis to investigate whether the
proportion of methylated-regulated genes and CNA-regulated genes are significantly
enriched or depleted in the gene set of interest compared to what is expected based on all
genes. x-axis represents methylated-regulated genes (left bar - purple) and
CNA-regulated genes (right bar - blue) and the five panels represents the 5 gene sets
considered as defined in Table 4.1. Height of bars on the y-axis represents enrichment
(log2(observed/ expected odds)). Asterisks on the two bars per panel represents FDR
p-values (hypergeometric test) to test if the methylation (left) or CNA (right) regulation
is enriched or depleted. Asterisks between the two bars represents FDR p-values
(hypergeometric test) to explicitly test the difference in enrichment between methylation
and CNA regulation. (. = FDR p-values < 0.1, * = FDR p-values < 0.05, ** = FDR
p-values < 0.01, *** = FDR p-values < 0.001, **** = FDR p-values < 0.0001).
higher extent than CNA-altered genes (p-value = 2.6×10-7). These results provide
substantial evidence that inter-tumour heterogeneity in the breast cancer transcriptome
is largely associated with cis methylation differences, however, as argued in Chapter
3 (and later in Section), correlations between DNA methylation and expression may
not be indicative of causation. Remarkably, COSMIC (the set of commonly mutated
genes in all cancer types) also showed a higher enrichment for methylation-regulated
genes than CNA-regulated genes (OR = 1.54 vs. OR = 1.20, p-value = 0.305),
although a higher absolute frequency of CNA-driven genes were present (8.20% vs.
16.57%). This indicates that DNA methylation and CNA mechanisms interact with
mutations in cancer and warrants the integrative analysis of DNA methylation and
CNA complementing driver mutation genes in breast cancer.
The only gene set that displayed an exception to this pattern was IC10, in which
the majority of genes were CNA-modulated genes (72.54%, OR = 18.80, p = 8.9×10-
212), and showed significant depletion for methylation-modulated genes (2.27%, OR
= 0.38, p-value = 3.1×10-4). However, this observation is undoubtedly driven by the
fact that the IC10 gene selection was purely based on high CNA-expression correlation
for the same cohort [Curtis et al., 2012], and thus does not provide a fair assessment of
the comparative regulatory roles of DNA methylation and CNA.
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4.3.2 Tumour-normal and tumour-tumour differences
Next, the extent of the contributions of CNA and DNA methylation in explaining
tumour-normal differences (in particular ER+ vs. normal and ER- vs. normal) or
tumour-tumour differences (ER+ vs. ER-) were examined. Differential expression
analysis was used to identify genes that were upregulated and genes downregulated in
each of these comparisons separately (using limma: an absolute fold change > 1.5 and
FDR p-value < 0.05 were used as thresholds for significance). A statistical framework
to identify partial-correlations of DNA methylation and CNA (rmeth-independent and
rcna-independent, similar to Section 4.2 and 4.3) was conducted. However, the regression
models were adapted using appropriate sample weights (weighted least squares
regression) to ensure that the two groups being compared contributed equally to the
correlations. For example, for ER+ vs. normal comparisons, the 1124 ER+ tumours
were weighted lower than 237 normal samples to prevent the ER+ tumours from
dominating the results.
Genes downregulated in ER+ tumours vs. normal are largely influenced by
methylation (7.65%) than CNA (5.92%) as illustrated in Figure 4.3a (left). In fact, on
comparison with all genes, methylation-regulated genes were enriched (OR = 1.95,
FDR p-value = 1.6×10-8) and CNA-regulated genes were depleted (OR = 0.42, FDR
p-value = 1.7×10-16) in those silenced in ER+ tumours vs. normals (Figure 4.3b - left).
On the contrary, genes upregulated in ER+ tumours vs. normal are dictated largely by
copy number changes, with 20.51% of the overexpressed genes correlated with CNA,
while only 11.2% correlated with methylation. Nonetheless, upregulated genes showed
a higher enrichment for methylation-regulated genes than CNA-regulated genes (OR
= 3.23 vs. OR = 1.93, FDR p-value = 6.22×10-6).
Gene Set Enrichment Analysis (GSEA: pathways tested included Hallmark,
REACTOME, oncogenic gene sets obtained from the Molecular Signatures Database
[Subramanian et al., 2005, MSigDB]; hypergeometric test) were performed on the
CNA and methylation-regulated genes to identify whether distinct pathways were
disrupted by CNA and methylation alterations. CNA drives increased expression of key
protagonists of cell cycle progression such as AURKA which encodes Aurora kinase A,
a marker of proliferation that facilitates entry into M-phase of the cell cycle [Marumoto
et al., 2005]; CDK4 (Cyclin-dependent kinase 4) which is involved in G1/S phase
cell cycle progression [Dai et al., 2012; Massagué, 2004]; and NEK2, a a cell cycle-
regulated kinase involved in the control of centrosome separation [Fry, 2002]. This
corresponded to significant enrichments of cell cycle progression pathways such as
mitotic cell cycle (enrichment = 3.23, FDR p-value = 1.1×10-5, REACTOME), targets
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Figure 4.3: (Caption on next page.)
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Figure 4.3: (Previous page.) Cis-acting DNA methylation events are the predominant
mechanism associated with silenced genes in breast cancer. (a) Proportion of genes
that are characterised as methylation-regulated (purple), CNA-regulated (blue) or both
(green) in the differentially expressed genes between ER+ tumours and normals (left),
between ER- tumours and normals (middle) and between ER+ and ER- tumours (right).
x-axis represents the direction of regulation. (b) Enrichment analysis to investigate
whether the proportion of methylated-regulated genes and CNA-regulated genes are
significantly enriched or depleted in the gene set of interest compared to what is expected
based on the set of all genes (ALL gene set). x-axis represents methylated-regulated
genes (purple) and CNA-regulated genes (blue) and the six panels represents the 6 gene
sets – 3 differentially expressed gene sets (left, middle, right) x 2 directions of regulation
(top, bottom). Height of bars on the y-axis represents enrichment (log2(observed/
expected odds)). Asterisks on the two bars per panel represents FDR p-values
(hypergeometric test) to test if the methylation (purple) or CNA (blue) regulation is
enriched or depleted. Asterisks between the two bars represents FDR p-values
(hypergeometric test) to explicitly test the difference in enrichment between methylation
and CNA regulation. (. = FDR p-values < 0.1, * = FDR p-values < 0.05, ** = FDR
p-values < 0.01, *** = FDR p-values < 0.001, **** = FDR p-values < 0.0001).
of E2F transcription (enrichment = 5.24, FDR p-value = 4.4×10-9, Hallmark), MYC
targets (enrichment = 5.14, FDR p-value = 6.1×10-9, Hallmark), G2/M checkpoint
(enrichment = 3.91, FDR p-value = 6.6×10-6, Hallmark), S phase (enrichment = 5.05,
FDR p-value = 1.2×10-5, REACTOME). Conversely, methylation was associated with
activation of key regulators of the oestrogen signalling pathway such as ESR1 and
GATA3 [Stone et al., 2015], as well as genes defining early (enrichment = 11.30, FDR
p-value = 1×10-16, Hallmark) and late response to oestrogen (enrichment = 8.94, FDR
p-value = 2.6×10-12, Hallmark). Genes silenced by methylation alterations were also
associated with down-stream modulation of the AKT pathway (enrichment = 9.48,
FDR p-value = 8.1×10-9, Oncogenic signature), and mTOR pathway (enrichment =
5.72; FDR p-value = 8.6×10-5, Oncogenic signature).
Differential expression analysis of ER- vs. normal showed similar results to
ER+ vs. normals, with CNA dominating upregulated genes (CNA = 29.23% vs.
Methylation = 12.74%; Figure 4.3a - middle). However, even though methylation
regulated only 12.74% of overexpressed genes, this was significantly higher than
expected (Methylation OR = 2.60 vs. CNA OR = 1.92, FDR p-value = 1.1×10-4;
Figure 4.3b - middle). CNA-regulated genes were also observed marginally more
frequently in downregulated genes than methylation-regulated genes (12.14% vs.
10.24%) in concordance with the reported high chromosomal instability associated
with ER- tumours [Curtis et al., 2012; Hu et al., 2009]. Nonetheless, methylation-
regulation was observed significantly higher than expected (OR = 1.91, FDR p-value
= 6.5×10-11) in striking contrast to CNA (OR = 0.57, FDR p-value = 4.0×10-13)
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which further substantiates the methylation-associated silencing role in cancer [Baylin,
2005; Herman and Baylin, 2003]. Analogous to the ER+ vs. normal analysis, CNA
directed keys pathways associated with cell-cycle progression including mitotic cell
cycle (enrichment = 5.02, FDR p-value = 1×10-16, REACTOME), mitotic M/G1
phases (enrichment = 5.97, FDR p-value = 2.7×10-15, REACTOME). Conversely,
DNA methylation was involved in modulation of ER- specific pathways including
downregulation of both oestrogen-response and TP53 signalling (enrichment = 6.26,
FDR p-value = 6.0×10-7, Oncogenic signature).
Analysing genes differentially expressed between the two breast cancer subtypes
(ER+ vs. ER-) revealed that methylation-associated epigenetic control of gene
expression (both up and downregulation) dominated the landscape (upregulated genes:
OR = 11.25, FDR p-value = 2.29×10-101, downregulated genes: OR = 11.36, FDR
p-value = 2.9×10-94; Figure 4.3b - right). All together, these results showed that
whereas CNA plays a strong role leading to the divergence of tumours from normal
tissues, DNA methylation, on the other hand, was the preferred mechanism for
refining subtype-specific differences leading to inter-tumour heterogeneity.
Interestingly, in all comparisons conducted, the scatter plots of partial correlations
of CNA and DNA methylation revealed an ‘L’ type shape (not shown, but similar
to Figure 4.2a) which implies that expression of genes highly correlated with DNA
methylation are not likely to be correlated with CNA and vice versa (FDR p-value
for all comparisons < 0.05; Fisher’s exact test). Thus, these two gene regulatory
mechanisms are largely complementary, i.e. they do not commonly target the same
genes.
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4.4 DNA methylation as the CNA-modifier in gene
expression
Although, Curtis et al. identified 2000 cis-acting CNA genes influencing the breast
cancer transcriptome, CNAs did not explain the variation in expression for a majority
of genes across the genome [Curtis et al., 2012]. In fact, results from the previous
section indicated that a large contribution of inter-tumour heterogeneity in the breast
cancer transcriptome can be explained by cis methylation differences. In order to
assess whether DNA methylation adds significant gene regulation in addition to CNA,
a nested regression framework was constructed. In the first iteration (the crude or
unadjusted model), gene expression was treated as the independent variable and CNA
as the dependent variable. For each gene, three statistics were recorded: i) the effect
estimate of CNA (βcna), which indicates the extent and direction of this relationship; ii)
the FDR-corrected regression p-value of the CNA (FDR p-valuecna), which indicates
the strength of evidence for its association with gene expression; and iii) a measure
of the variation in expression explained by CNA (R2cna). In the second iteration of the
regression model (confounder or adjusted model), DNA methylation (M-value) was
added as the second predictor to the regression model. For each gene, the three statistics
mentioned were recorded. i) the independent effect estimate of CNA (βcna-independent),;
ii) the FDR-corrected regression p-value of the independent effect of CNA (FDR
p-value (FDR p-valuecna-independent); iii) and the total variation in expression explained
by the combined CNA and DNA methylation model (R2total). was noted. The additional
variation in expression explained by DNA methylation is (R2addmeth). with
R2total = R
2
cna +R
2
addmeth (4.1)
It has been established that CNAs do not explain the variation in expression
for a majority of genes (only 14.2% of all genes, only 4.2% of VAR2000 genes,
Section 4.3.1) across the breast cancer genome. However, a key question is – are these
non CNA-regulated genes largely diploid or is this a consequence of acquired copy
number aberrations not inducing expected expression changes at the RNA level? As
mentioned earlier, expression of 4.9% (n = 97) of VAR2000 genes in the genome were
significantly regulated by copy number losses or copy number gains/ amplifications
(rmeth-independent ≥ 0.40, FDR p-valuecna < 0.05; linear regression), henceforth known
as CNA-cis genes. 61% (n = 1220) of VAR2000 genes were weakly but positively
significantly associated with CNA (rmeth-independent < 0.40, βcna > 0, FDR p-valuecna
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Figure 4.4: DNA methylation explains significant variation in transcriptional
activity in the top 2000 variably expressed genes in breast cancer. Variation in
expression (y-axis) explained by just CNA (R2cna) and CNA + DNA methylation (R
2
total)
per gene. The slope of the lines connecting the two dots represent the additional variation
in expression explained by DNA methylation. Each line represents a gene. A threshold
of 10% was used to signify genes with significant added contribution (gold). This was
analysed separately across the 4 categories of genes as defined in the text –
CNA-contradictory (left), CNA-independent (middle left), CNA-weakregulated (middle
right) and CNA-cis (right). % of genes with significant methylation contribution is
shown in gold. Total number of genes in each category are shown in brackets in the panel
legend. Only the 2000 variably expressed genes (VAR2000) were considered.
CNA-weakregltd = CNA-weakregulated.
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< 0.05; linear regression), henceforth known as CNA-weakregulated genes. These
represent genes where copy number gains/ amplifications and copy number losses show
mild consequences in transcription. Surprisingly, 4.2% (n = 83) of VAR2000 genes
showed contradictory response to CNA (CNA-contradictory genes; βcna < 0, FDR p-
valuecna < 0.05; linear regression) including genes such as GATA3, CCND2 and TSHZ2
with known tumorigenic roles. The remaining, 28.4% (n = 567) of VAR2000 genes
were largely diploid or those in which CNA did not exhibit a significant (expected or
contradictory) association with CNA (CNA-independent genes; FDR p-valuecna ≥
0.05; linear regression).
Figure 4.4 illustrates the additional variation in expression explained by DNA
methylation across these 4 categories of genes, and a threshold of 10% was used
to signify genes with significant added contribution. CNA-cis genes did not exhibit
significant additional methylation regulation (only 18.6% genes), which was expected
since CNA and DNA methylation do not commonly target the same genes. 32.6%
of CNA-independent genes showed significant contributions by DNA methylation,
suggesting that a large extent of the unaccounted variation in expression reported in the
literature could be explained by epigenetic control. Remarkably, higher proportions of
CNA-weakregulated (39.6%) and CNA-contradictory genes (42.2%) had significant
methylation contributions (p-value = 0.0021; chi-square test). This observation raises
the hypothesis that DNA methylation could be used as a mechanism to modulate the
effect of CNA on the breast cancer transcriptome (deactivate in the case of CNA-
contradictory; enhance in the case of CNA-weakregulated genes).
4.4.1 DNA methylation alterations target potential tumour
suppressor genes in genomic amplifications: TSHZ2
Breast cancer has largely been considered to be a copy number driven disease, where
the normal diploid state of the genome is altered in large chromosomal regions. The
function of copy number gains is exerted through amplifying the number of copies
and thus increasing the expression of the underlying oncogene(s). Identifying the
driver oncogenes within these large genomic regions remains a challenge, as any
given amplification region might harbour several tens or hundreds of genes. Besides
containing an oncogene, the large amplification event might also span genes whose
overexpression is not beneficial or is even toxic for the cancer. Thus, to fully benefit
from an amplification event, cancer cells need to selectively inhibit the expression of
unwanted genes within amplified genomic regions. Is it possible that DNA methylation
alterations could be used to target such genes and silence them within copy number
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alterations? This postulation was explored in frequent amplicons in breast cancer, and
one example is detailed below.
A set of 62 breast tumours have 4 or more copies of the chromosome 20q13
cytoband which consists of several genes (Figure 4.5a). ZNF217, an oncogene, which
has been associated with promotion of Epithelial-to-Mesenchymal Transition (EMT)
as well as the development of metastasis in mice in vivo, is the presumed target for
this amplification [Krig et al., 2010; Vendrell et al., 2012]. In fact, breast tumours
with the amplification exhibited significantly higher expression for ZNF217 (Figure
4.5b). However, the immediate adjacent gene is TSHZ2 (Teashirt zinc finger homeobox
2), which has been identified as a CNA-contradictory gene. The 62 tumours have an
amplification for this gene as well, but they do not report higher expression. Why
is this so? Examining the promoter of TSHZ2 revealed that breast tumours with the
amplification had higher average promoter methylation (Figure 4.5c). In fact, about
64.5% of tumours with amplifications had significant promoter hypermethylation
which is an enrichment of almost 4 times as expected (expected = 33.1%, odds ratio =
3.67, p-value = 1.4×10-6; Fisher’s exact test; Figure 4.5d). Exploring the regulatory
role of TSHZ2 promoter methylation revealed that hypermethylation was associated
with down regulation of the gene in tumours with amplifications (p-value = 0.0024;
linear regression; Figure 4.5e). TSHZ2 has been proposed as a potential tumour
suppressor in breast cancer via regulation of GLI1, the downstream transcription factor
of Hedgehog signalling [Habib and O’Shaughnessy, 2016; Yamamoto et al., 2011].
Collectively, this evidence strongly suggests that by virtue of being located on the
same cytoband as ZNF217, TSHZ2 has been amplified in 62 breast tumours. However,
due to its tumour suppressive properties, promoter hypermethylation has been used as
a mechanism to selectively silence this gene.
The lack of overexpression normally associated with copy number amplification
in TSHZ2 is attributed to the presence of altered DNA methylation, and will be
henceforth termed as a diminishing effect of DNA methylation. The diminishing
effects of DNA methylation manifests in the suppression of the anticipated effects of
CNA in transcription, and therefore can explain the detection of CNA-contradictory
genes such as TSHZ2.
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Figure 4.5: (Caption on next page.)
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Figure 4.5: (Previous page.) Anticipated effect of copy number amplification in
TSHZ2 is buffered by promoter hypermethylation (a) Genes in chromosome 20q13
cytoband. (b) Relationship between ZNF217 gene expression and CNA for all breast
tumours. Gold line represents the loess smoothed curve (95% confidence interval shaded
grey). (c) Relationship between TSHZ2 gene expression and promoter methylation for all
breast tumours. Gold line represents the loess smoothed curve (95% confidence interval
shaded grey). (d) Relationship between TSHZ2 promoter methylation and CNA for all
breast tumours. Blue line represents the linear regression slope (95% confidence interval
shaded grey). (e) Relationship between TSHZ2 gene expression and promoter
methylation for tumours with TSHZ2 amplification (copies ≥ 4). Purple line represents
the linear regression slope (95% confidence interval shaded grey). In (b) (c) and (d)
Dashed vertical lines represents the discrete CNA boundaries as denoted on the x-axis. In
(d) and (e) points are coloured by presence of hyper MAR (red) or not (green) in the
tumour. LOSS = loss of copy number. NEUT = Neutral copy number. GAIN = gain of
copy number. AMPL = Amplification of copy number.
4.4.2 DNA methylation can diminish or enhance the role of CNA
in a subtype specific manner
ER+ and ER- tumours encompass significant differences in the fundamental biology of
breast tumours. Considerable subtype-specific CNAs and DNA methylation alterations
have been associated with differentially genes between ER+ and ER- tumours (Section
4.3). Could a mechanism of DNA methylation alterations modulating the effect of
CNA in targeted genes, as introduced above, contribute to phenotypic differences (at
the level of mRNA) between ER+ and ER- tumours? In order to formally evaluate
this postulation, the extent of DNA methylation modifying the effect of CNA on gene
expression was examined for all genes that were differentially expressed between ER+
and ER- tumours using a nested regression framework, similar to that described in
Section 4.4. A key adaptation to this regression framework was that appropriate sample
weights were used to ensure that the two ER subtypes contributed equally to the models
(as described previously in Section 4.3.2). The crude model (first iteration: mRNA∼
CNA; Section 4.4) delineates the effect of CNA on gene expression without adjusting
for DNA methylation as a confounder. This model represents the observed effect of
CNA on gene expression (βcna), and has been used in previous studies [Curtis et al.,
2012]. The adjusted model (second iteration: mRNA∼CNA+Methylation; Section
4.4) includes DNA methylation as a confounder. This enables the deconvolution of
the independent role of the CNA (βcna−independent). The effect estimates of CNA in
the observed model (βcna) and adjusted model (βcna−independent) were compared as
follows.
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∆= βcna−βcna−independent (4.2)
Delta modification (∆) represents the direction and the magnitude of the
methylation-assisted modification in the role of CNA. GATA3, a gene that is
significantly upregulated in ER+ tumours, exhibited a large negative modification (∆)
in the observed role of CNA, and was explored in detail below.
Figure 4.6: (Caption on next page.)
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Figure 4.6: (Previous page.) DNA methylation at the GATA3 intron produces
subtype-specific consequences in breast cancer. (a) Relationship between GATA3 gene
expression and CNA for all breast tumours. Black line represents the loess smoothed
curve (95% confidence interval shaded grey). (b) Comparison of observed effect of CNA
on gene expression (black) and independent adjusted effect of CNA on gene expression
(red) shown as distinct slopes. The reduced observed CNA role of GATA3 is attributed to
the diminishing influence of DNA methylation. (c) Relationship between GATA3 gene
expression and intron methylation for all breast tumours. (d) Relationship between
GATA3 intron methylation and CNA for all breast tumours. Blue line represents the
linear regression slope (95% confidence interval shaded grey). In (a) (c) and (d) points
are coloured by ER status. In (a) (c) and (d) Dashed vertical lines represents the discrete
CNA boundaries as denoted on the x-axis. In (c) the blue vertical dashed line denotes
boundary for hypo MAR definition, and red vertical dashed line denotes boundary for
hyper MAR definition. In (d) the blue horizontal dashed line denotes boundary for hypo
MAR definition, and red horizontal dashed line denotes boundary for hyper MAR
definition. LOSS = loss of copy number. NEUT = Neutral copy number. GAIN = gain of
copy number. AMPL = Amplification of copy number.
4.4.2.1 DNA methylation at the GATA3 intron produces subtype-specific
consequences in breast cancer
GATA3 is a known cofactor in the ER transcription complex and a marker of
ER+/luminal breast cancer [Takaku et al., 2015]. However, ER+ tumours with copy
number deletions in GATA3 do not present with reduced expression (Figure 4.6a).
Conversely, GATA3 amplification were more common in ER- tumours but the affected
tumours did not reflect an increase in gene expression. Consequently, on fitting the
crude unadjusted model, a negative effect estimate of CNA with gene expression was
observed for GATA3 (β cna = -2.3, as defined in Section 4.4; Figure 4.6b – black line).
Remarkably, examining the methylation status of the GATA3 gene body (intron)
revealed that tumours with amplifications were far more likely to have a higher
methylation status than tumours (Figure 4.6c), and this hyper methylation was
significantly associated with reduced GATA3 expression (Figure 4.6d). This strongly
suggests that hypermethylation in the GATA3 gene body was suppressing the effect of
GATA3 amplifications in the ER- tumours. Adjusting for the suppressing role of DNA
methylation as a confounder, revealed that the independent effect of CNA on GATA3
expression (β cna-independent = 0.2, as defined in Section 4.4; Figure 4.6b – red line)
was much higher than observed effect (β cna = -2.3, as defined in Section 4.4; Figure
4.6d – black line). The reduced observed role of CNA (compared to the
methylation-adjusted effect estimate of CNA, ∆ = -2.5) is clearly attributed to the
diminishing influence of DNA methylation. Specifically, in the presence of a GATA3
intron DNA methylation, ER- tumours with amplifications did not reflect a
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concomitant increase in gene expression. GATA3 has been shown to be involved in
upregulating ESR1 in ER+ cancer, and is not required to be highly expressed in ER-
tumours. Based on this collective evidence, it is possible that the GATA3 amplicon in
ER− tumours encompasses other driver oncogenes, and that suppression of GATA3
expression is mediated by DNA methylation.
4.4.2.2 DNA methylation diminishing CNA function
A substantial decrease in the observed effect estimate (∆ ≤ -0.1) of CNA was used to
identify other potential DNA methylation diminishing agents in the context of
differentially expressed genes between ER+ and ER-. For these genes, in presence of
a DNA methylation diminishing agent, tumours with amplifications do not reflect a
concomitant increase in gene expression, and/ or tumours with copy number losses do
not exhibit an expected reduction. This analysis revealed that 112 genes were
upregulated and 95 genes were downregulated in ER+ tumours potentially as a
consequence of a methylation-associated CNA-diminishing mechanism (Figure 4.7a –
blue bars). Of note, this mechanism was identified in ER+ upregulated genes such as
GATA3 (detailed above), DNALI1 and SPDEF (identified in Chapter 3), a known
transcription factor involved in ER+ breast cancer pathogenesis [Sood et al., 2009];
and in ER+ repressed genes such as IL32, MID1, and the SFRP1 (identified as a gene
with ER+ specific tumour suppressive role, see Chapter 3) (Figure 4.7b – left panels).
Collectively, these results strongly indicate that DNA methylation is being used as a
CNA buffer to target critical regulators, which subsequently leads to subtype-specific
breast cancer pathogenesis.
4.4.2.3 DNA methylation enhancing CNA function
Similarly, a substantial increase in the observed effect estimate (∆ ≥ 0.1) of CNA
implies an enhancing effect of CNA on gene expression, bearing in mind that this
could result in either hyper-activating genes in tumours with amplifications, or further
deactivating gene function in the presence of copy number losses. In ER+ tumours,
139 upregulated genes and 180 downregulated genes were identified with
CNA-enhancing roles (Figure 4.7a – orange bars). For instance, FOXA1, a known
pioneer factor that is a fundamental determinant of ER activity in breast cancer
[Hurtado et al., 2011] was shown to be significantly overexpressed in ER+ tumours as
a consequence of a methylation-associated CNA-enhancing mechanism (Figure 4.7b –
right panels). Conversely, Sry-related HMg-Box genes, SOX10 and SOX11 were
overexpressed in ER- tumours due to CNA-enhancing configurations (Figure 4.7b –
right panels). Fascinatingly, these genes have been shown be transcription factors and
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Figure 4.7: (Caption on next page.)
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4.4. DNA methylation as the CNA-modifier in gene expression
Figure 4.7: (Previous page.) DNA methylation modifies the role of CNA in
differentially expressed genes between ER+ and ER- tumours. (a) Number of genes
with evidence of methylation-associated copy number diminishing (blue bars) and
number of genes with evidence of methylation-associated copy number enhancing
(orange bars) were quantified among genes differentially expressed in ER+ vs. ER-
tumours (downregulated – left panel) and (upregulated – right panel). (b) Genes with
evidence of methylation-associated copy number diminishing were listed in the x-axis on
the left panels (blue) and genes with evidence of methylation-associated copy number
enhancing were listed on the x-axis in the right panels (orange). Additional variation in
expression (R2) contributed by DNA methylation was illustrated on the y-axis, and genes
were ordered by decreasing values of this metric. Only genes with R2 ≥ 20% were
illustrated. The shape of points represented the absolute magnitude of delta (∆) of the
modification in the role of CNA. Only genes that were differentially expressed between
ER+ and ER- tumours were considered. Upregulated genes are represented in the top two
panels and downregulated genes in the lower two panels.
critical regulators exclusively of ER- tumours [Cimino-Mathews et al., 2013;
Shepherd et al., 2016]. These results indicate that both DNA methylation and CNA
are necessary for the regulation of key cancer genes.
This line of analysis raises a closely related question -- how often do DNA
methylation and CNA events co-occur in the same tumour, and what are the regulatory
consequences? This is investigated in detail in the next section.
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4.5 DNA methylation and CNA are complementary
mechanisms in cancer
Conclusions made in the previous sections suggest that DNA methylation events
may act as complementary/ or additive mechanisms to CNA within the same gene in
regulating expression. To formally test this hypothesis, the prevalence of functional
methylation alterations and CNAs were compared. The analysis was focused on genes
that were differentially expressed in tumours compared to normal tissues (separately
conducted for ER+ and ER- tumours, see Section 4.3). Functional methylation events
for a specific tumour were defined as detected methylation altered regions (MARs, see
Chapter 3) in the corresponding principal functional methylation region (PFMR, as
described in Section 4.2) for the differentially expressed genes under consideration.
Functional methylation events could be hyper or hypo MARs. A bipartite strategy
was used for the definition of functional copy number events: for genes that were
downregulated in tumours, homozygous deletions (complete loss of genomic material,
loss) as well as hemizygous deletions (loss of one allele in a diploid gene, irrespective
of number of copies in the other allele, LOH) were defined as functional events. On the
other hand, amplifications (threshold of 4 or more copies) were defined as functional
copy number events for genes upregulated in tumours.
4.5.1 Identification of potential tumour suppressors
Firstly, significantly silenced genes in ER+ and ER- tumours (vs. normal tissues,
separate analysis for ER+ and ER-) were explored in order to identify potential tumour
suppressor candidates. The proportion of tumours with DNA functional methylation
(x-axis) and CNA losses (y-axis) were plotted for downregulated genes in ER+ and
ER- tumours (Figure 4.8). Genes that were recurrently (in more than 25% tumours)
altered due to MARs or CNAs or both were identified. 27.3% of downregulated genes
in ER+ tumours have recurrent MARs (Figure 4.8, purple and green points) compared
to only 15.3% of genes in ER- tumours (Figure 4.8 - purple and green). The opposite
trend is observed for copy number losses with a higher number of ER- downregulated
exhibiting recurrent copy number losses (ER+ = 16.4%, ER- = 56.6%; Figure 4.8, blue
and green points). This parallels findings from Section 4.3.2 where DNA methylation
was revealed to play a stronger role in silencing genes in ER+ tumours compared to
ER- tumours.
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Figure 4.8: Silenced genes in breast cancer exhibit different propensities to DNA
methylation or copy number loss. Scatter plots of the prevalence of MAR events
(x-axis) against copy number loss (y-axis) in differentially downregulated genes in ER+
tumours (left panel) and ER- tumours (right panel). Each point represents a silenced
gene. Colours represent the propensity of the gene for DNA for either MAR events
(purple), CNA events (blue), both (green) or none (grey) based on a recurrence threshold
of 25%. Genes enclosed by the dotted black lines are considered for the co-occurrence
and mutually exclusive analyses as described in the text. Upward triangles represent
genes with co-occurring MAR and CNA events, while downward triangles represent
genes with mutually exclusive MAR and CNA events.
Interestingly, many genes were detected that were intrinsically prone to genomic
loss (Figure 4.8, blue points) i.e. they exhibited recurrent copy number losses in
breast cancer (≥ 25% tumours) but were not commonly altered at the level of DNA
methylation (i.e. < 25% tumours harboured MARs for these genes). Genes exhibiting
this pattern in both ER+ and ER- tumours include CDH5 and CDH13 involved in
cytoskeletal organisation [Berx and van Roy, 2009; van Roy, 2014]. However, ER-
tumours harboured considerably more genes with a propensity for copy number loss
such as NR2F1 and SETBP1. Interestingly these 2 genes also exhibited this pattern
in lung squamous cell carcinoma and colon adenoma carcinoma [Teschendorff et al.,
2016b]. Conversely, genes with a propensity for DNA methylation alterations and
not copy number losses (Figure 4.8, purple points) such as HOXA4 and HOXA5
were detected in ER+ tumours. These HOXA genes encode transcription factors
that have critical roles in embryogenesis and tissue differentiation and evidence for
epigenetic silencing has also been demonstrated in acute myeloid leukaemia [Musialik
et al., 2015] and lung cancers [Teschendorff et al., 2016b]. Interestingly, methylation-
regulated silencing of CDH13 was commonly observed in ER- tumours (compared
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to CNA-regulated silencing in ER+ tumours) indicating the preference of distinct
mechanisms to downregulate this gene in ER+ and ER- tumours.
Several genes undergoing both copy number losses and MARs in tumours were
also identified. A lower threshold of 10% prevalence was used, but for both types
of alteration (Figure 4.8, points enclosed by dotted black lines). These genes were
also investigated for patterns of co-occurrence and mutual exclusivity for the two
mechanisms -- CNA and MARs within the same gene, using a hypergeometric test.
Furthermore, associations with gene expression were also examined for these genes.
One-way ANOVA tests were used to explore expression changes across 4 categories
of tumours: i) tumours that were wild-type (i.e. had no MAR or copy number loss);
ii) tumours that only had MARs; iii) tumours that only had copy number losses; and
iv) tumours in which concomitant MARs and copy number losses co-occurred for
the same gene. Gene expression was z-transformed using the mean and SD of the
wild-type tumours (1st group of samples) such that the wild-type tumours are given
an expression z-score value of 0. This allows straightforward comparisons between
the groups across different genes. Tumour categories with less than 5 samples were
not considered, and ANOVA p-values were corrected for multiple testing (FDR). This
analysis was conducted separately for i) genes exhibiting co-occurrence; and ii) genes
exhibiting mutual exclusivity, and is detailed in the following two sections.
184
4.5. DNA methylation and CNA are complementary mechanisms in cancer
Figure 4.9: (Caption on next page.)
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Figure 4.9: (Previous page.) Silenced genes in breast cancer exhibit co-occurring or
mutually exclusive patterns of DNA methylation and copy number loss. (a) All
silenced genes with significantly co-occurring MAR and CNA events within the same
tumour, detected in ER+ tumours. (b) same as (a) but for ER- tumours. (c) All silenced
genes with significantly mutually exclusive MAR and CNA events within the same
tumour, detected in ER+ tumours. (d) same as (c) but for ER- tumours. In (a), (b), (c)
and (d), each row represents a gene. The coloured squares represent the mean z-scores of
gene expression data for three categories: (blue) tumours that only had copy number
losses; (purple) tumours that only had MARs; (green) tumours in which concomitant
MARs and copy number losses co-occurred for the same gene. The z-scores were
constructed using the mean and SD of wild type tumours as detailed in the text, and the
grey vertical line at 0 represents the mean z-scores of gene expression for wild type
tumours. Tumour categories with less than 5 samples were not considered. In (c) and (d),
tumours with concomitant MARs and copy number losses events are not shown since
this constitutes a rare or significantly depleted category. Tumours with AHNAK MARs
(pink) and those with AHNAK copy number losses (blue) have similar expression on
average which is why the CNA (blue) data point is not visible.
4.5.1.1 Downregulated genes with co-occurring CNA and DNA methylation
profiles
Genes in which tumours harboured MARs as well as CNA losses simultaneously were
observed more than expected by chance (Enrichment > 1.5, FDR p-value < 0.05;
hypergeometric test) were identified and were termed as co-occurring genes. Only
significantly silenced genes in ER+ and ER- tumours, that had a prevalence of 10% or
more for both CNA and MARs were considered (No. of such silenced genes: ER+ =
402, ER- = 501). Co-occurring silenced genes were identified separately in ER+ (n =
8) and ER- tumours (n = 11), and are indicated with upward triangles in Figure 4.8;
and detailed in Table 4.2a and Table 4.2b. These genes might have tumour-suppressive
roles in the respective subtypes and accordingly associations with gene expression
were examined as described above. Figure 4.9a and Figure 4.9b displays the average
expression z-scores across the 4 categories of tumours defined above for the co-
occurring silenced genes. In 7 out of 8 (87.5%) co-occurring silenced genes detected
in the ER+ subtype, the tumours with concomitant MARs and copy number losses
(Figure 4.9a, b – green points) suffered the highest loss in expression compared to
other tumour categories (ANOVA FDR p-value < 0.05). Together with the observation
that this co-occurrence was a significantly enriched event, these finding strongly
imply that the two independent mechanisms augment each other’s silencing roles and
their combination provides a selective advantage for the tumour. These associations
identified for concomitant MARs and CNA events support the classical definition for
loss of heterozygosity (LOH). Similarly, 8 out of 11 (72.7%) co-occurring silenced
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genes detected in ER- tumours demonstrated evidence of loss of heterozygosity. These
15 genes (ER+ = 7, ER- = 8) are put forward as candidate tumour suppressors. Of
note are the transcription factors, PER3 (ER+ tumours, Figure 4.10a) and TBX3 (ER-
tumours, Figure 4.10b).
Gene Feature Methylation CNA Enrichment Expression
Direction (%) CNA (%) Type Extent FDR p* Direction FDR p**
(a) Co-occurring genes: ER+ tumours
MAOA promoter Hypo 16.7 Loss/ LOH 14.2 Co-occurring 1.70 0.0005 Down 0.1246
AHNAK intron Hyper 10.2 Loss/ LOH 16.2 Co-occurring 1.70 0.0061 Down <0.0001
NAV2 intron Hyper 16.2 Loss/ LOH 11.1 Co-occurring 1.67 0.0060 Down <0.0001
AGPAT2 intron Hyper 10.4 Loss/ LOH 14.5 Co-occurring 1.63 0.0205 Down <0.0001
PPP1R1B promoter Hyper 14.1 Loss/ LOH 18.2 Co-occurring 1.55 0.0059 Down <0.0001
PER3 promoter Hyper 25.8 Loss/ LOH 25.1 Co-occurring 1.51 <0.0001 Down <0.0001
MSRA intron Hypo 19.0 Loss/ LOH 40.0 Co-occurring 1.51 <0.0001 Down <0.0001
MTMR9 intron Hypo 15.8 Loss/ LOH 33.5 Co-occurring 1.50 0.0003 Down <0.0001
(b) Co-occurring genes: ER- tumours
WISP2 intron Hypo 12.7 Loss/ LOH 13.5 Co-occurring 2.08 0.0375 Down 0.2706
TBX3 intron Hyper 11.2 Loss/ LOH 32.7 Co-occurring 1.95 0.0044 Down 0.0026
IGSF10 promoter Hypo 23.6 Loss/ LOH 12.8 Co-occurring 1.85 0.0098 Down 0.6289
CTNNAL1 intron Hypo 10.2 Loss/ LOH 35.5 Co-occurring 1.69 0.0121 Down 0.0258
CARD10 exon Hypo 31.9 Loss/ LOH 24.5 Co-occurring 1.68 0.0001 Down <0.0001
GNG7 intron Hypo 13.0 Loss/ LOH 34.1 Co-occurring 1.62 0.0323 Down <0.0001
FAM198B exon Hyper 28.1 Loss/ LOH 37.1 Co-occurring 1.58 <0.0001 Down 0.0001
CA4 exon Hypo 10.6 Loss/ LOH 48.0 Co-occurring 1.56 0.0036 Down 0.0203
TSC1 exon Hypo 13.2 Loss/ LOH 35.5 Co-occurring 1.55 0.0213 Down <0.0001
PNPLA7 exon Hypo 14.8 Loss/ LOH 34.3 Co-occurring 1.53 0.0268 Down 0.0011
OLFML1 promoter Hypo 10.4 Loss/ LOH 38.5 Co-occurring 1.52 0.0469 Down 0.0421
(c) Mutually exclusive genes: ER+ tumours
SRPX intron Hypo 19.6 Loss/ LOH 13.9 Exclusive 0.25 <0.0001 Down 0.0468
PLIN2 intron Hyper 10.3 Loss/ LOH 23.6 Exclusive 0.28 <0.0001 Down <0.0001
TSPAN6 intron Hypo 18.1 Loss/ LOH 17.6 Exclusive 0.30 <0.0001 Down 0.0001
DIAPH2 intron Hypo 15.2 Loss/ LOH 18.1 Exclusive 0.32 <0.0001 Down <0.0001
KLHL13 intron Hypo 20.1 Loss/ LOH 18.8 Exclusive 0.36 <0.0001 Down 0.0002
MAOB intron Hypo 16.8 Loss/ LOH 13.5 Exclusive 0.38 0.0028 Down <0.0001
CITED1 promoter Hyper 13.0 Loss/ LOH 28.3 Exclusive 0.40 <0.0001 Down 0.0120
CFD promoter Hyper 10.5 Loss/ LOH 17.8 Exclusive 0.42 0.0189 Down 0.0001
SSTR2 exon Hypo 13.7 Loss/ LOH 14.4 Exclusive 0.44 0.0118 Down 0.2785
PTCHD1 intron Hypo 17.9 Loss/ LOH 13.4 Exclusive 0.48 0.0087 Down 0.2785
(d) Mutually exclusive genes: ER- tumours
ITGA7 promoter Hyper 15.5 Loss/ LOH 30.4 Exclusive 0.07 <0.0001 Down 0.1149
PDGFRA intron Hyper 12.6 Loss/ LOH 21.5 Exclusive 0.24 0.0379 Down 0.0348
FAM149A promoter Hyper 16.6 Loss/ LOH 36.2 Exclusive 0.29 0.0002 Down 0.0006
MAP1LC3A promoter Hyper 26.2 Loss/ LOH 17.2 Exclusive 0.29 0.0043 Down <0.0001
RBP7 intron Hyper 16.7 Loss/ LOH 34.4 Exclusive 0.37 0.0041 Down 0.0416
SNCA promoter Hyper 17.0 Loss/ LOH 28.4 Exclusive 0.44 0.0379 Down 0.0045
CYP2U1 intron Hyper 18.9 Loss/ LOH 29.6 Exclusive 0.46 0.0323 Down 0.0045
BAG3 intron Hyper 20.1 Loss/ LOH 32.6 Exclusive 0.46 0.0152 Down <0.0001
HBEGF promoter Hyper 28.5 Loss/ LOH 46.6 Exclusive 0.48 <0.0001 Down 0.7440
FBLN5 exon Hypo 12.3 Loss/ LOH 44.7 Exclusive 0.48 0.0479 Down 0.2528
LOXL4 intron Hyper 15.4 Loss/ LOH 36.1 Exclusive 0.48 0.0255 Down 0.2394
FGF2 promoter Hyper 27.7 Loss/ LOH 24.7 Exclusive 0.50 0.0369 Down 0.0006
Table 4.2: (Caption on next page.)
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Table 4.2: (Previous page.) Silenced genes in breast cancer exhibit co-occurring or
mutually exclusive patterns of DNA methylation and copy number loss. (a) All
silenced genes with significantly co-occurring MAR and CNA events within the same
tumour, detected in ER+ tumours. (b) same as (a) but for ER- tumours. (c) All silenced
genes with significantly mutually exclusive MAR and CNA events within the same
tumour, detected in ER+ tumours. (d) same as (c) but for ER- tumours. The direction and
prevalence (%) of the MAR event and the direction and prevalence (%) of the CNA event
(only copy number losses considered) were detailed for each gene. The direction and
extent of enrichment (observed/ expected) and FDR p-value and are indicated based on
the hypergeometric test as defined in the text. For (a) and (b), the co-occurring genes are
ordered by decreasing enrichment (Odds Ratio; OR). The direction of expression change
and the FDR p-value based on the one-way ANOVA of the mean expression z-scores
across the 4 categories of tumours are indicated. For (c) and (d), the mutually exclusive
genes are ordered by increasing enrichment (OR, decreasing depletion). The direction of
expression change and the FDR p-value based on the one-way ANOVA of the mean
expression z-scores across the 3 categories of tumours are indicated. FDR p* = FDR
p-value from the hypergeometric test; FDR p** = FDR p-value from the ANOVA.
4.5.1.2 Downregulated genes with mutually exclusive CNA and DNA
methylation profiles
Genes in which tumours harboured MARs as well as copy number losses in a mutually
exclusive fashion (enrichment < 0.5, FDR p-value < 0.05; hypergeometric test) were
identified. These genes exhibited higher levels of MARs in tumours that had no copy
number losses for the given gene, compared with tumours harbouring copy number
losses for the given gene, and vice versa, and were termed as mutually exclusive genes.
As mentioned above, only significantly silenced genes in ER+ and ER- tumours, that
had a prevalence of 10% or more for both CNA and MARs were considered (No. of
such silenced genes: ER+ = 402, ER- = 501). Mutually exclusive silenced genes were
identified separately in ER+ (n = 10) and ER- tumours (n = 12), and are indicated
with downward triangles in Figure 4.8; and detailed in Table 4.2c and Table 4.2d.
For these genes, a pattern of two mutually exclusive events is an indication that the
second alteration offers no further selective advantage than the first hit, or in fact
leads to a disadvantage for the cell leading to cell death, which explains why tumours
with concomitant MAR and copy number losses were observed less frequently than
expected by chance. Therefore, in these genes, MAR and copy number losses represent
two alternative mechanisms for silencing. Figure 4.9c and Figure 4.9d displays the
average expression z-scores across 3 categories of tumours (tumours with concomitant
MARs and copy number losses are not considered since this constitutes a rare or
significantly depleted category). In 7 out of 10 (70.0%) mutually exclusive silenced
genes detected in the ER+ subtype (8 out of 12 i.e. 66.7% in ER-), tumours with MAR
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events (Figure 4.9c, d – green points) suffered the highest loss in expression compared
to other 2 tumour categories (ANOVA FDR p-value < 0.05) suggesting that DNA
methylation is the predominant mechanism in downregulating these potential tumour
suppressors. These 15 genes (ER+ = 7, ER- = 8) are also put forward as candidate
methylation-regulated tumour suppressors. Of note are CITED1 (ER+ tumours, Figure
4.10c), a transcription factor which is a regulator of oestrogen signalling; and the
fibroblast growth factor, FGF2 (ER- tumours, Figure 4.10d). Expression of both
these genes have been shown to be correlated with good prognosis in breast cancer
[McBryan et al., 2007; Yiangou et al., 1997] thus revealing their potential function as
tumour suppressor genes.
4.5.1.3 BRCA1 demonstrates classical tumour suppressor behaviour
BRCA1 (Breast cancer susceptibility gene 1) is a canonical tumour suppressor gene
that plays a critical role in homologous recombination to repair DNA damage and
prevent tumour development [Easton et al., 1993; Hall et al., 1990; Miki et al., 1994;
Moynahan, 2002; Moynahan et al., 1999]. Germline inactivating mutations in BRCA1
were established to have a strong role in hereditary cases of breast and ovarian cancers
[Castilla et al., 1994; Friedman et al., 1994]; and this first hit was shown to be
accompanied by a second hit through the somatically acquired loss of chromosomal
material on the wild type allele i.e. LOH [Merajver et al., 1995]. Collectively, these
observations supported the identification of BRCA1 as a classical tumour suppressor
gene, based on Knudson’s seminal two hit model for tumorigenesis [Knudson, 1971].
Since then several studies have revealed that other alterations such as somatic mutations
and promoter hypermethylation in BRCA1 can also drive the initiation and progression
of breast cancer [Cancer Genome Atlas Network, 2012; Esteller, 2000; Pereira et al.,
2016; Polak et al., 2017].
The availability of a large cohort of breast tumours with expression, copy
number, mutational and DNA methylation information on BRCA1 (approximately
1344 samples: 1241 breast tumours and 103 adjacent normal breast tissues from the
METABRIC dataset had data on all four platforms) allowed a comprehensive
examination of the different configurations that non-hereditary genetic and epigenetic
events combine with each other to silence BRCA1 in breast cancer. Firstly, BRCA1
promoter methylation was estimated for all 1241 breast tumours and 103 normal
tissues. A 16 CpG SCCRUB region was detected in the promoter of BRCA1
(chr17:41276641 – 41277275). 35 tumours were identified with a significant hyper
MAR at this locus in the BRCA1 promoter (Figure 4.11a). All hyper MARs were
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Figure 4.10: Examples of key genes in breast cancer exhibiting co-occurring or
mutually exclusive patterns of DNA methylation or copy number loss. (a) PER3, a
significantly downregulated gene in ER+ tumours, exhibiting concomitant genomic
losses and promoter hyper MARs. (b) TBX3, a significantly downregulated gene in ER-
tumours, exhibiting concomitant genomic losses and intron hyper MARs (c) CITED1, a
significantly downregulated gene in ER+ tumours, exhibiting mutually exclusive
genomic losses and promoter hyper MARs. (d) FGF2, a significantly downregulated
gene in ER- tumours exhibiting mutually exclusive genomic losses and promoter hyper
MARs. (e) INTS8, a significantly upregulated gene in ER+ tumours, exhibiting
concomitant genomic amplifications and promoter hypo MARs. (f) CDK12, a
significantly upregulated gene in ER- tumours exhibiting concomitant genomic
amplifications and promoter hypo MARs. For each gene, a heatmap representation of the
(top) z-score mRNA change vs. normal, (middle) MAR status – hyper, hypo or none, and
(bottom) CNA status – Loss/ LOH, Gain/ amplification or neutral, is plotted for each
tumour. Tumours are sorted by increasing gene expression.
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Figure 4.11: (Caption on next page.)
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Figure 4.11: (Previous page.) BRCA1 demonstrates classical tumour suppressor
behaviour. (a) DNA methylation estimates for all tumours across the 16 CpG sites at the
BRCA1 promoter region defined using SCCRUB. Each point represents a tumour for a
specific CpG site, coloured by IHC status. (b) Relationship between BRCA1 gene
expression and promoter methylation (mean for the promoter SCRRUB region) for all
breast tumours. Each point represents a tumour, coloured by IHC status. (c) Relationship
between BRCA1 gene expression and promoter methylation for all TNBC tumours. Each
point represents a tumour, coloured by mutation status. (d) BCRA1 promoter methylation
estimates compared between TNBC tumours with and without an inactivating BRCA1
mutation. P-value based on t-test as described in text. (e) Relationship between BRCA1
gene expression and promoter methylation for all TNBC tumours. Each point represents
a tumour, coloured by copy number status. (f) BCRA1 promoter methylation estimates
compared between TNBC tumours with and without a copy number loss. P-value based
on t-test as described in text. (g) No. of inactivating BCRA1 mutation for TNBC tumours
with and without a copy number loss. P-value based on Fisher’s exact test as described in
text. In (a) the blue horizontal dashed line denotes boundary for hypo MAR definition,
and red horizontal dashed line denotes boundary for hyper MAR definition. In (b) (c) and
(e) the blue vertical dashed line denotes boundary for hypo MAR definition, and red
vertical dashed line denotes boundary for hyper MAR definition. BRCA1 = Breast cancer
susceptibility gene 1. TNBC = Triple negative breast cancer. Mut. = Mutation. INACT =
Inactivating mutation. NEUT = Neutral copy number. LOSS = loss of copy number. (. =
FDR p-values < 0.1, * = FDR p-values < 0.05, ** = FDR p-values < 0.01, *** = FDR
p-values < 0.001, **** = FDR p-values < 0.0001).
confirmed as directed-MARs (as defined in Chapter 3), and the methylation status was
significantly associated with silencing of the gene (p-value < 1×10-16; linear
regression; Figure 4.11b). Triple negative breast tumours (TNBC, breast tumours that
are ER-, PR- and HER2-, see Chapter 1) were significantly enriched for the promoter
hypermethylation event corroborating several previous reports [Xu et al., 2013;
Yamashita et al., 2015; Zhang et al., 2015; Zhu et al., 2015], with 30 out of 35 breast
tumours harbouring a BRCA1 promoter hyper MAR, also having TNBC
characteristics (enrichment = 29.7, p-value = 3.8×10-18; hypergeometric test).
Subsequent analysis was focused on the 232 TNBC tumours. Next, the somatic
mutational profiles for these tumours were examined and 6 TNBC tumours with
inactivating BRCA1 mutations were detected (Figure 4.11c). Remarkably, none of
these 6 tumours harboured hyper MARs at the BRCA1 promoter indicating that
inactivating mutations and promoter hypermethylation events are mutually exclusive
in BRCA1 (p-value = 1.4×10-07; t-test; Figure 4.11d). Examining the BRCA1 copy
number landscape revealed that a vast majority of the TNBC tumours (61.2%)
harboured LOH (Figure 4.11e); and that the TNBC tumours with LOH were
significantly enriched for promoter hypermethylation (p-value = 6.9×10-5; t-test;
Figure 4.11f) strongly suggesting a preference for these two BRCA1 events to
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Figure 4.12: Two non-hereditary mechanisms illustrated for BRCA1 silencing in
TNBCs. (a) Status of the 2 BRCA1 alleles in the normal mammary gland. (b)
Mechanism 1 for silencing BRCA1 in TNBCs: LOH is accompanied by BRCA1 promoter
hypermethylation. (c) Mechanism 2 for silencing BRCA1 in TNBCs: LOH is
accompanied by inactivating BRCA1 mutation. BRCA1 = Breast cancer susceptibility
gene 1. TNBC = Triple negative breast cancer.
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co-occur in the same tumour. Integrating the mutational and copy number profiles of
BRCA1 for these tumours revealed the third piece of the puzzle, that is, all 6 tumours
harbouring inactivating BRCA1 mutations also suffered LOH (p-value = 0.0853;
hypergeometric test; Figure 4.11g). Although this was marginally significant in
TNBCs (at alpha = 0.05), expanding this association to all breast tumours revealed a
strong statistical significance (p-value = 0.0003; hypergeometric test) again indicating
a tendency for these two somatic genetic events to occur on the two alleles of BRCA1.
Collectively, this data has revealed two distinct non-hereditary mechanisms that
lead to both alleles of BRCA1 being hit, and supporting its role as a tumour suppressor
gene (Figure 4.12). Firstly, tumours with BRCA1 promoter hypermethylation almost
always harboured LOH (26 out of 30 tumours with hyper MARs also had LOH)
ensuring that only the function of the hypermethylated allele is observed; and secondly,
the 6 inactivating somatic BRCA1 mutations were always accompanied by LOH.
Interestingly, the mechanism involving DNA methylation (n = 26) occurs more than
4 times as frequently as the mechanism involving somatic mutations (n = 6), which
strongly substantiates the crucial role of promoter hypermethylation as a BRCA1
epigenetic silencing event in TNBCs. Fascinatingly, the inactivating BRCA1 mutations
were completely mutually exclusive with promoter hyper MARs suggesting that a
mechanism utilising these two events as distinct hits is not preferred.
4.5.2 Identification of potential oncogenes
Next, in order to identify potential oncogene candidates in breast cancer, genes
significantly upregulated in ER+ and ER- tumours (vs. normal tissues, separate
analysis for ER+ and ER-) were explored. The proportion of tumours with DNA
functional methylation (x-axis) and copy number amplification events (y-axis) were
plotted for upregulated genes in ER+ and ER- tumours (Figure 4.10). Genes that were
recurrently (in more than 25% tumours) altered due to MARs or CNAs or both were
identified. However, although, amplifications induce the activation of a larger number
genes compared to DNA methylation in both ER+ and ER- tumours, (Section 4.3), a
higher number of upregulated genes had recurrent MARs (ER+ = 13.9%; ER- =
11.5%; Figure 4.13, purple and green points) than copy number amplifications (ER+ =
1.6%; ER- = 1.1%; Figure 4.13, blue dots and green points). This contradictory
observation is likely explained by the fact that i) copy number amplifications (Total:
4+ copies) are sufficient to significantly increase the expression of genes, while DNA
methylation plays a weaker/ fine-tuning role; and ii) a gain of 1 copy (total: 3 copies)
in a gene could still increase gene expression, but is ignored in the prevalence analysis
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resulting in the reporting of a lower number of tumours harbouring activating copy
number alterations. Genes intrinsically prone to copy number amplifications (Figure
4.13, blue points) include protein kinases such as MAPKAPK2 and NUAK2 in ER+
tumours; and downstream components of the PI3K/ AKT/ mTOR pathway such as
SQLE, GSDMC and MAL2 in ER- tumours. Conversely, genes with a propensity for
DNA methylation alterations and not copy number losses (Figure 4.13, purple points)
such as ESR1 and TFF1 were detected in ER+ tumours. Both these genes are involved
in oestrogen signalling [Ariazi et al., 2006; Prest et al., 2002].
Figure 4.13: Upregulated genes in breast cancer exhibit different propensities to
DNA methylation or copy number amplification. Scatter plots of the prevalence of
MAR events (x-axis) against copy number amplifications (y-axis) in differentially
upregulated genes in ER+ tumours (left panel) and ER- tumours (right panel). Each point
represents an upregulated gene. Colours represent the propensity of the gene for DNA for
either MAR events (purple), CNA events (blue), both (green) or none (grey) based on a
recurrence threshold of 25%. Genes enclosed by the dotted black lines are considered for
the co-occurrence and mutually exclusive analyses as described in the text. Upward
triangles represent genes with co-occurring MAR and CNA events, while downward
triangles represent genes with mutually exclusive MAR and CNA events. Tumours with
MED1 copy number amplifications (blue) and those with both CNA and MAR (green)
have similar expression on average which is why the CNA (blue) data point is not visible.
Several genes undergoing both CNA amplifications and MARs in tumours were
also identified. A lower threshold of 10% prevalence was used, but for both types
of alteration (Figure 4.13, points enclosed by dotted black lines). These genes were
also investigated for patterns of co-occurrence and mutual exclusivity for the two
mechanisms -- CNA and MARs within the same gene, using a hypergeometric test.
One-way ANOVA tests (see Section 4.5.1) were used to explore expression changes
across 4 categories of tumours: i) tumours that were wild-type (i.e. had no MAR or
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copy number loss); ii) tumours that only had MARs; iii) tumours that only had copy
number losses; and iv) tumours in which concomitant MARs and copy number losses
co-occurred for the same gene. This analysis was conducted separately for i) genes
exhibiting co-occurrence; and ii) genes exhibiting mutual exclusivity, and is detailed
in the following two sections.
4.5.2.1 Upregulated genes with co-occurring CNA and DNA methylation
profiles
A similar analysis as described in Section 4.5.1.1 was conducted to identify
upregulated genes with co-occurring CNA and DNA methylation profiles, separately
in ER+ (n = 12) and ER- tumours (n = 16) (indicated with upward triangles in Figure
4.13; and detailed in Table 4.3a, b). These genes might have oncogenic roles in the
respective subtypes and accordingly associations with gene expression were examined
as described above. Figure 4.14a and Figure 4.14b display the average expression
z-scores across the 4 categories of tumours defined above for the co-occurring
upregulated genes. In all of the 12 co-occurring upregulated genes detected in the ER+
subtype (13 out of 16 in the ER- subtype), tumours with concomitant MARs and copy
number amplification events (Figure 4.13a, b – green points) exhibited the highest
gain in expression compared to other tumour categories (ANOVA FDR p-value <
0.05). This strongly implies that the two independent mechanisms augment each
other’s activating roles and their combination provides a selective advantage for the
tumour. These 25 genes (ER+ = 12, ER- = 13) are put forward as candidate oncogenes.
Of note are INTS8 (ER+ tumours, Figure 4.10e), a key constituent of the RNA
polymerase II mediated transcription machinery which has been shown to be highly
mutated in several cancers [Federico et al., 2017]; and CDK12 (ER- tumours, Figure
4.10f), a regulatory kinase which has been shown to promote breast cancer cell
invasion [Tien et al., 2017].
4.5.2.2 Upregulated genes with mutually exclusive CNA and DNA methylation
profiles
A similar analysis as described in Section 4.5.1.2 was implemented to identify genes in
which tumours harbour MARs as well as CNA amplifications in a mutually exclusive
fashion. Only two such genes, ARHGAP30 and SLA were identified in ER- tumours,
and none in ER+ tumours (indicated with downward triangles in Figure 4.13; and
detailed in Table 4.3c, d).
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Figure 4.14: Upregulated genes in breast cancer exhibit co-occurring or mutually
exclusive patterns of DNA methylation and copy number amplification. (a) All
upregulated genes with significantly co-occurring MAR and CNA events within the same
tumour, detected in ER+ tumours. (b) same as (a) but for ER- tumours. (c) All
upregulated genes with significantly mutually exclusive MAR and CNA events within
the same tumour, detected in ER+ tumours. (d) same as (c) but for ER- tumours. In (a) –
(d), each row represents a gene. The coloured squares represent the mean z-scores of
gene expression data for three categories: (blue) tumours that only had copy number
amplifications; (purple) tumours that only had MARs; (green) tumours in which
concomitant MARs and copy number amplifications co-occurred for the same gene. The
z-scores were constructed using the mean and SD of wild type tumours as detailed in the
text, and the grey vertical line at 0 represents the mean z-scores of gene expression for
wild type tumours. Tumour categories with less than 5 samples were not considered. In
(c) and (d), tumours with concomitant MARs and copy number amplifications are not
shown since this constitutes a rare or significantly depleted category.
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Gene Feature Methylation CNA Enrichment Expression
Direction (%) CNA (%) Type Extent FDR p* Direction FDR p**
(a) Co-occurring genes: ER+ tumours
INTS8 promoter Hypo 22.3 Amplification 16.2 Co-occurring 2.21 <0.0001 Up <0.0001
BCL9 intron Hyper 16.2 Amplification 18.2 Co-occurring 2.16 <0.0001 Up <0.0001
LAD1 promoter Hypo 11.3 Amplification 23.6 Co-occurring 1.95 <0.0001 Up <0.0001
EPPK1 intron Hypo 25.5 Amplification 15.4 Co-occurring 1.91 <0.0001 Up <0.0001
MAFA promoter Hyper 21.2 Amplification 16.6 Co-occurring 1.73 <0.0001 Up 0.0001
ARHGAP39 exon Hyper 20.1 Amplification 14.8 Co-occurring 1.73 <0.0001 Up <0.0001
GOLPH3L intron Hypo 22.0 Amplification 21.4 Co-occurring 1.72 <0.0001 Up <0.0001
CAPN8 exon Hypo 31.3 Amplification 24.2 Co-occurring 1.65 <0.0001 Up <0.0001
POLB intron Hypo 41.3 Amplification 10.3 Co-occurring 1.59 <0.0001 Up <0.0001
TPD52 intron Hypo 46.8 Amplification 14.8 Co-occurring 1.58 <0.0001 Up <0.0001
STAU2 exon Hypo 51.8 Amplification 13.3 Co-occurring 1.56 <0.0001 Up <0.0001
MAL2 intron Hypo 10.4 Amplification 18.2 Co-occurring 1.54 0.0217 Up <0.0001
(b) Co-occurring genes: ER- tumours
ECT2 exon Hypo 10.9 Amplification 11.5 Co-occurring 3.05 0.0055 Up <0.0001
EFNA4 promoter Hypo 11.9 Amplification 12.9 Co-occurring 2.80 0.0003 Up <0.0001
SCRIB exon Hypo 16.6 Amplification 22.5 Co-occurring 2.50 <0.0001 Up <0.0001
PSMB4 promoter Hypo 17.5 Amplification 14.5 Co-occurring 2.35 0.0011 Up <0.0001
STARD3 promoter Hyper 25.9 Amplification 18.0 Co-occurring 2.32 <0.0001 Up <0.0001
MED1 intron Hypo 37.4 Amplification 15.4 Co-occurring 2.22 <0.0001 Up <0.0001
TIGD5 exon Hypo 12.7 Amplification 23.7 Co-occurring 2.18 0.0009 Up <0.0001
DAP3 intron Hypo 10.5 Amplification 11.8 Co-occurring 2.12 0.0492 Up <0.0001
RFX5 exon Hyper 13.5 Amplification 13.9 Co-occurring 2.11 0.0136 Up <0.0001
GRB7 promoter Hypo 32.8 Amplification 21.8 Co-occurring 2.08 <0.0001 Up <0.0001
CDK12 promoter Hypo 36.8 Amplification 18.4 Co-occurring 2.05 <0.0001 Up <0.0001
ERBB2 exon Hypo 40.1 Amplification 18.8 Co-occurring 1.92 <0.0001 Up <0.0001
RAB25 intron Hypo 26.6 Amplification 11.5 Co-occurring 1.83 0.0096 Up <0.0001
ZC3H3 exon Hyper 29.8 Amplification 23.8 Co-occurring 1.65 0.0008 Up <0.0001
EPPK1 intron Hypo 29.8 Amplification 22.0 Co-occurring 1.60 0.0018 Up <0.0001
CDC123 intron Hypo 37.1 Amplification 11.4 Co-occurring 1.51 0.0449 Up <0.0001
(c) Mutually exclusive genes: ER+ tumours
(d) Mutually exclusive genes: ER- tumours
ARHGAP30 promoter Hypo 19.0 Amplification 14.1 Exclusive 0.24 0.0390 Up <0.0001
SLA promoter Hypo 29.9 Amplification 24.5 Exclusive 0.28 <0.0001 Up <0.0001
Table 4.3: Upregulated genes in breast cancer exhibit co-occurring or mutually
exclusive patterns of DNA methylation and copy number amplification. (a) All
upregulated genes with significantly co-occurring MAR and CNA events within the same
tumour, detected in ER+ tumours. (b) same as (a) but for ER- tumours. (c) All
upregulated genes with significantly mutually exclusive MAR and CNA events within
the same tumour, detected in ER+ tumours. (d) same as (c) but for ER- tumours. The
direction and prevalence (%) of the MAR event and the direction and prevalence (%) of
the CNA event (only copy number amplifications considered) were detailed for each
gene. The direction and extent of enrichment (observed/ expected) and FDR p-value are
indicated based on the hypergeometric test. For (a) and (b), the co-occurring genes are
ordered by decreasing enrichment. The direction of expression change and the FDR
p-value based on the one-way ANOVA of the mean expression z-scores across the 4
categories of tumours are indicated. For (c) and (d), the mutually exclusive genes are
ordered by increasing enrichment (decreasing depletion). The direction of expression
change and the FDR p-value based on the one-way ANOVA of the mean expression
z-scores across the 4 categories of tumours are indicated. FDR p* = FDR p-value from
the hypergeometric test; FDR p** = FDR p-value from the ANOVA.
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4.6 Discussion
The copy number and mutational landscapes have been studied extensively in breast
cancer [Cancer Genome Atlas Network, 2012; Ciriello et al., 2013; Curtis et al., 2012;
Nik-Zainal et al., 2016; Pereira et al., 2016], but relatively little is known about the
contribution of DNA methylation events and how they interact with genomic events.
In order to reveal the molecular multi-omic basis of breast cancer, a considerably
large number of tumours needs to be analysed due to the substantial heterogeneity of
the disease. The availability of copy number, gene expression, mutations and now
DNA methylation data across ∼1200 primary breast tumours in METABRIC has
now enabled a large systematic genome-wide exploration into the distinctive roles of
epigenetic and genetic events in breast cancer.
Comparing the contributions of CNA and DNA methylation events breast cancer
revealed a poignant juxtaposition in the regulatory roles of CNA and DNA
methylation. CNA played a stronger role in driving the expression of key protagonists
of cell cycle progression leading to the divergence of tumours from normal tissues.
Conversely, silenced genes in breast tumours were significantly enriched for DNA
methylation alterations, and not cis genomic loss corroborating a previous report
investigating multiple cancers [Teschendorff et al., 2016b]. Moreover, focusing on the
top 2000 variably expressed genes in breast cancer as well as the set of genes
differentially expressed genes between the two ER subtypes established that DNA
methylation was the preferred mechanism for refining subtype-specific differences.
For instance, expression of genes specifically linked to the oestrogen signalling
(overexpressed specifically in ER+ tumours) as well as TP53 signalling
(downregulated in ER- tumours) were demonstrated to be modulated by DNA
methylation alterations. Conversely, the role of gene amplifications or deletions
appears to be much more modest in driving inter-tumour heterogeneity.
A key finding in this chapter was that not all CNA events have the anticipated
consequences in gene transcription, and other mechanisms such as DNA methylation
could be used as a mechanism to modulate (diminish or enhance) the effect of CNA on
the breast cancer transcriptome. Although the detection of copy number amplifications
has become routine in breast cancer [Curtis et al., 2012], overexpression of some
genes within these large amplification domains might not be beneficial for the cancer
cells. DNA methylation was demonstrated as a potential genomic amplification
diminishing agent to selectively inhibit the expression of these genes. This can
lead to the identification of putative tumour suppressors (such as THSZ2) as well as
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genes that are toxic for breast cancer. Multiple genes were identified in which DNA
methylation events modulated the role of CNA. Striking examples include gene body
methylation acting as a diminishing agent in GATA3 resulting in the subtype-specific
downregulation of the gene in ER- tumours; and the CNA enhancing effect of DNA
methylation in FOXA1 leading to its upregulation in ER+ tumours.
The comparison of the prevalence of functional methylation and copy number
events in differentially expressed genes in breast tumours (versus the normal tissue)
demonstrated that probabilistically, DNA methylation is a more likely mechanism
than CNA in deregulation of key cancer genes. Silenced and overexpressed genes
exhibiting a higher propensity for DNA methylation than CNA events, and vice
versa, were identified in ER+ and ER- tumours. Fascinatingly, this also led to the
identification of genes that were recurrently silenced (≥25% tumours) in both ER+
and ER- tumours, but using distinct mechanisms. For instance, STAT5A and HLF
(both genes were MAR-silenced in ER+ tumours, but CNA-silenced in ER- tumours);
and CDH13 (CNA-silenced in ER+ tumours, MAR-silenced in ER- tumours).
However, it is important to note that the associative statistical models presented
here can only demonstrate inferred function of these epigenomic and genomic events
in silencing or over-expressing key genes (as discussed in Chapter 3). Functional
and/ or clinical investigation is required for providing definite evidence of the causal
function of individual alterations in genes, and for labelling the targeted genes as
tumour suppressors or oncogenes [Stricker et al., 2016]. Nevertheless, the analysis
presented here provides convincing evidence that DNA methylation is a superior
indicator of the underlying regulatory activity of the gene than CNA.
The principal objective of quantifying the prevalence of MAR and CNA events
was to identify genes that demonstrated significant configurations of mutual exclusivity
or co-occurrence in these two events for the same gene and in the same tumour. Only 2
genes exhibiting CNA and MAR events in a mutually exclusive fashion were identified
in the context of upregulated genes. Along with the previously noted strong role of
CNA in upregulating genes, this indicates that the occurrence of only MAR events
in the breast tissue may not be dominant enough to sufficiently overexpress the gene
since in the absence of copy number gains (or amplifications), DNA methylation can
only act on a maximum of two alleles, This is why mutually exclusive patterns are
rarely observed in the context of upregulated genes in breast cancer. Conversely, in
the context of silenced genes, 15 genes (ER+ = 7, ER- = 8) with mutually exclusive
patterns for MAR and copy number amplifications were detected, suggesting that
MAR and copy number losses represent two alternative mechanisms for silencing.
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This also indicates that for these genes, one alteration (either MAR or copy number
loss) is sufficient for silencing, or the second alteration is a disadvantage for the cell.
Consequently, tumours with both hits will be observed less frequently than expected
by chance. A previous effort to detecting silenced transcription factors with mutually
exclusive promoter hypermethylation and copy number loss events in multiple cancers
only revealed one gene each in 4 out of the 6 cancer datasets investigated [Teschendorff
et al., 2016b]. The identification of 15 subtype-specific genes in the METABRIC
dataset, demonstrates the benefit of i) evaluating gene body methylation in addition to
promoter methylation and of ii) having high power in integrative molecular analyses.
Detection of co-occurrence patterns strongly imply that the two independent
mechanisms, CNA and DNA methylation, augment each other’s deregulating roles
providing a selective advantage for the tumour. Genes demonstrating classical tumour
suppressor behaviour as described by Knudson [1971] with LOH (and a MAR event
on the present allele(s)) included PER3 in ER+ tumours and TBX3 in ER- tumours.
Interestingly, investigating the mutational profile of TBX3, revealed that tumours with
LOH and inactivating mutations were also associated with a lower expression than
tumours with only inactivating mutations. BRCA1 also demonstrated patterns of co-
occurrence (between CNA and MAR events, and between CNA and mutations), as
well as mutual exclusivity (between MAR and mutations) in TNBC tumours. The
co-occurrence analysis also revealed genes such as INTS8 (ER+ tumours) and CDK12
(ER- tumours) that showcased concomitant MAR and amplification events associated
with high expression. Both genes have previously shown to have oncogenic behaviour
in breast cancer [Federico et al., 2017; Tien et al., 2017]. Therefore, the detection
of non-random patterns of CNA and MAR events in tumours in the same gene has
enabled the identification of potential tumour suppressors and oncogenes in breast
cancer in which DNA methylation has a functional role.
However, a caveat to the mutually exclusivity and co-occurrence analysis is
that mutation events were ignored in this analysis. Consequently, genes in a tumour
which seemed to harbour only one event (among DNA methylation or copy number
alterations), may also be affected by somatic (or germline) mutations. As a result,
many LOH events that occur due to alternate combinations of genetic and epigenetic
are not captured in this analysis. Accordingly, one of the follow-up goals of this project
is to conduct a similar analysis on the prevalence of DNA methylation aberrations,
copy number alterations and somatic mutational events across all genes available in
the METABRIC dataset [Pereira et al., 2016], as well as in the TCGA breast cancer
dataset [Cancer Genome Atlas Network, 2012].
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In a similar vein, mutual exclusivity analysis can also be conducted between
different genes (by any of the genetic or epigenetic events profiled) rather than on
the same gene. This strategy can be used to identify sets of genes belonging to the
same molecular pathway that are recurrently altered in a mutually exclusive fashion.
For instance, the Mutual Exclusivity Modules (MEMo) algorithm [Ciriello et al.,
2012] was implemented in the TCGA breast cancer dataset [Cancer Genome Atlas
Network, 2012] to identify gene modules exhibiting mutually exclusive alterations
across the mutational and copy number landscape. This effort revealed several gene
modules including the receptor Tyrosine kinase (RTK)–PI(3)K signalling pathway;
the p38-Mitogen-Activated Protein Kinase (MAPK) signalling pathway; and the TP53
signalling pathway. Including DNA methylation alterations into such analysis is one
of the future objectives of this project, and this promises to provide new insights into
the pathogenic mechanisms of breast cancer.
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Historically, the main focus of cancer evolution has been on genetic heterogeneity.
Numerous studies have revealed the contribution of genetic intratumour heterogeneity
in clonal evolution in breast cancer [Nik-Zainal et al., 2012; Shah et al., 2012; Wang
et al., 2010], and other cancers [Cooper et al., 2015; Gerlinger et al., 2012; Navin
et al., 2011], as well as its association with poor clinical outcomes [Diaz Jr et al., 2012;
Merlo et al., 2010]. For example, genetic clonal diversity measures were shown to
predict neoplastic progression to oesophageal adenocarcinoma [Maley et al., 2006],
and more recently, deep sequencing analysis revealed that the presence of subclonal
driver mutations was an independent risk factor for rapid disease progression in chronic
lymphocytic leukaemia (CLL) [Landau et al., 2013].
However, in addition to genetic alterations such as somatic mutations, epigenetic
aberrations are also heritable modifications that have been shown to be drivers of
tissue-specific phenotypic differences [Baylin and Jones, 2011; Esteller, 2008,
Chapter 3 and 4]. In 2006, Feinberg et al. [2006] proposed that epigenetic
modifications can disrupt stem and progenitor cells through the aberrant expression of
tumour progenitor genes. These early stage epigenetic cancer alterations were
hypothesised to drive epigenetic plasticity, increase the probability of genetic
mutations and fuel tumour progression. Darryl Shibata’s group were one of the first to
analyse epigenetic intratumour heterogeneity (ITH) by investigating DNA methylation
patterns at neutral loci in colorectal cancer [Kim et al., 2005; Siegmund et al., 2009].
These loci were assumed to have no functional consequences and unlikely to be under
selective pressures, and thus could serve as a molecular mitotic clock to provide an
estimate of the cell divisions (see Chapter 1). A follow-up study utilised deep
methylation sequencing to examine the molecular heterogeneity between and within
individual colorectal cancer glands and simulate the evolutionary history of the
tumour [Sottoriva et al., 2013]. This analysis revealed high ITH at the DNA
methylation level, and advocated the use of neutral genomic features in understanding
the evolution of cancers [Mazor et al., 2016].
Moreover, genetically similar tissues have exhibited variations in phenotypic
outcomes such as tumour propagation potential, survival and response to therapy,
likely indicating the influence of the epigenome to tumour evolution [Kreso et al.,
2013; Shaffer et al., 2017; Sharma et al., 2010], and the necessity for the comprehensive
assessment of ITH at the epigenetic level.
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Recent studies have used genome-wide DNA methylation microarrays to examine
multiple samples of primary tumour and metastatic sites in prostate [Aryee et al., 2013;
Brocks et al., 2014] and brain cancers [Mazor et al., 2015]. These reports revealed
extensive spatial DNA methylation heterogeneity in the solid tumours, and successfully
constructed phylo-epigenetic trees using distance-based clustering of the epigenetic
signatures. Interestingly, in all three studies, evolutionary histories inferred from
genome-wide DNA methylation signatures were highly similar to those constructed
from CNA [Aryee et al., 2013; Brocks et al., 2014] and somatic mutations [Mazor
et al., 2015]. Multiple spatial sample analysis conducted in breast cancer also showed
substantial clonal epigenetic heterogeneity within tumours, although this study was
not genome wide, and only focused on promoter hypermethylation of 24 established
tumour suppressor genes [Moelans et al., 2014].
Sampling multiple regions within a tumour is a powerful approach that has been
used to determine its evolutionary history as described above. However, inferring
clonal dynamics of the epigenome using single samples is still in a formative stage.
One reason for this is that conventional DNA methylation analysis such as microarrays
estimate aggregate methylation values at each CpG site from the population of cancer
cells over a tumour sample. While these technologies easily allow comparison between
multiple samples of a tumour, the evaluation of heterogeneity of individual single
cells within a tumour is not possible. However, the advent of bisulfite sequencing
technologies such as WGBS and RRBS, has enabled the assessment of epigenetic allele
(or epiallele) compositions at single molecules (reads) derived from the population of
cancer cells in a tumour. In a landmark paper, Landan et al. [2012] quite elegantly
introduced the concept of epigenetic polymorphism or epipolymorphism of a given
locus as the “probability that two randomly sampled DNA molecules from the cell
population differ in their methylation pattern”. They used this epipolymorphism scores
to explore the dynamics of the process driving methylation change in cancer tissues,
to distinguish methylation changes that occur in a noisy and stochastic fashion versus
those that are occur in a deterministic manner. Moreover, the epiallelic diversity within
the tumour also provides a measure of overall ITH, and Pan et al. [2015] leveraged
the aggregate epipolymorphism scores in an RRBS analysis of diffuse large B cell
lymphoma (DLBCL) to demonstrate that patients who relapse within 5 years have
higher epigenetic ITH at diagnosis than those who do not relapse. Subsequently,
Landau et al. [2014] developed the notion of proportion of discordant reads (PDR), as
an alternate measure of intratumour DNA methylation heterogeneity, where increased
PDR levels were reflective of stochastic heterogeneity in tumour samples [Landau
et al., 2014]. Through RRBS analysis of CLL, they established that patients with
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higher ITH were associated with lower remission times. Furthermore, the high PDR
levels within an individual lymphoma were highly correlated with the number of
subclonal mutations, further demonstrating the link between epigenetic and genetic
ITH.
Although these reports have attempted to track the evolution of DNA methylation
in tumours by matching DNA methylation ITH scores (such as epipolymorphism and
PDR) in tumours at distinct time points such as diagnosis and relapse [Pan et al.,
2015], Li et al. [2014] argued that a disparity (or similarity) in epipolymorphism
measures between two time points does not necessarily reveal the underlying shift
in epigenetic clonality. They developed an algorithm called methclone to explicitly
compare the epiallelic distributions of a tumour at two distinct disease stages using
a combinatorial entropy change calculation to identify loci that alter significantly
in epiallelic compositions. In a follow-up study by the same group, this method
was applied to a cohort of 138 acute myeloid leukaemia (AML) patients with paired
observations at diagnosis and relapse, and they observed that epiallelic compositions
varied considerably during disease progression, and that a high degree of epigenetic
allelic burden within a tumour was linked with adverse clinical outcomes [Li et al.,
2016b].
While these initial results in leukaemias and lymphomas are promising, it is yet
unclear whether DNA methylation ITH measures are associated with adverse outcomes
in solid tumours [Mazor et al., 2016]. A very recent report utilising RRBS on 140
Ewing sarcomas indicated substantial epigenetic heterogeneity (PDR) within tumours,
however, the PDR levels were not significantly associated with metastatic disease
[Sheffield et al., 2017]. To the best of our knowledge, the above-mentioned study in
Ewing Sarcoma is the only comprehensive (> 50 tumours), genome-wide assessment
of epigenetic ITH in solid tumours, though RRBS (or adapted methods) methylomes
in prostate cancer [Lin et al., 2013] and chondrosarcoma [Lu et al., 2013] have been
made available with approximately 20 tumours each in the two cohorts. Consequently,
the role of methylation disorder in tumour evolution in epithelial tumours including
breast cancer is extremely poorly understood. This is in part due to the fact of high cost
and complexity of genome-wide bisulphite sequencing technologies (such as RRBS,
WGBS), but also due to the relative difficulty in procuring longitudinal solid tumour
samples compared to blood-based cancers.
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5.1.1 Summary of aims
Chapters 3 and 4 investigated the inter-tumour DNA methylation heterogeneity in
breast cancer. In this chapter, the 1482 next-generation sequencing(NGS) breast
cancer and 237 normal methylomes (part of the METABRIC cohort) were reanalysed
to provide the first genome-wide assessment of the role of epigenetic intra-tumour
heterogeneity in breast cancer, and the largest for any single cancer. This is achieved
through the following steps:
1. Characterisation of the epigenetic intratumour heterogeneity within breast
tumours to explain the dynamics underlying methylation changes in breast
cancer tissues.
2. Identification of loci with significant epiallelic compositional changes involved
in the initiation and progression of breast tumours from normal tissues.
Investigation of the association of these epigenetically shifted loci with gene
expression alterations in tumours.
3. Examination of the link between ITH measures inferred from genetic and
epigenetic profiles in breast cancer.
4. Investigation of the prognostic potential of DNA methylation ITH and dynamic
epiallelic composition shifts in breast cancer.
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5.2 Intratumour DNA methylation heterogeneity
The previously established PDR score [Landau et al., 2014] was used to estimate
intratumour heterogeneity of each sample (tumours and normal) from their DNA
methylation profiles.
5.2.1 Calculation of the PDR score
RRBS, being a NGS-based technology, is a powerful tool for examining intratumour
heterogeneity, and each sequencing read captures the DNA methylation information
of one allele of a single cell derived from the population of cells in the tumour. If
there are 4 consecutive CpG sites that are close enough to be captured by a single
read, then given that DNA methylation is a binary mark, there are 24 or 16 possible
methylation patterns, henceforth known as epialleles. Groups of 4 adjacent CpGs
that were frequently covered (at least 20× coverage) by the same read are identified
as loci of interest. The nature of RRBS data makes it an optimal technique for
the identification of such loci since the sequencing reads naturally tend to start and
end at the same DNA coordinates. By reanalysing RRBS data at the read level,
the pattern of epialleles at a locus can be detected which gives a snapshot of the
distinct cellular subpopulations within the tumour. For instance, two 4-CpG loci that
have approximately identical methylation estimates (calculated as the proportion of
methylated CpGs – black circles), conversely, showed distinct patterns of methylation
ITH. The first locus is compatible with a mixture of cell populations with clear but
distinct methylation states, and lower epigenetic ITH (Figure 5.1a). In contrast, the
second locus, is compatible with a mixture of cell populations with locally disordered
methylation resulting in higher ITH (Figure 5.1a).
The PDR (proportion of discordant reads, Figure 5.1b) score has been proposed
as a measure of DNA methylation ITH, where high PDR levels were reflective of
locally disordered DNA methylation in a CpG locus, and low values represent
homogeneous DNA methylation patterns indicative of a selective process. By
reanalysing bisulfite-sequencing (RRBS) data at the read level on all 4-CpG loci
(using the criteria defined above) per tumour, sequencing reads were characterised
into two categories: a) discordant reads, defined as those that contain both methylated
and unmethylated CpG sites; and b) concordant reads, those that contain only
methylated or unmethylated CpG sites. The proportion of discordant reads was
calculated for each CpG locus as described in Landau et al. [2014]. Since the PDR
levels are dependent on DNA methylation levels [Landan et al., 2012; Landau et al.,
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Figure 5.1: Proportion of discordant reads is a measure of intra-sample
methylation heterogeneity. (a) Methylation patterns from two distinct 4-CpG loci. The
locus on the left is compatible with a mixture of cell populations with clear but distinct
methylation states, and lower epigenetic ITH. In contrast, the locus on the right is
compatible with a mixture of cell populations with locally disordered methylation
resulting in higher ITH. (b) DNA methylation and PDR scores for a 4-CpG locus were
calculated using the given formulas. In both panels, each row denotes methylation
information for the 4-CpG locus captured by a single read representing one cell from the
sample. Black circles = methylated CpG sites. White circles = unmethylated CpG sites.
PDR = Proportion of Discordant reads. ITH = Intratumour heterogeneity. Figures
modified from Landau et al. [2014].
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2014], all loci were binned based on average methylation level into 21 bins spanning
0–100% methylation levels. The PDR for each 4-CpG loci (black dot) is displayed as
a function of methylation for a representative ER+ tumour (Figure 5.2). The PDR
levels are clearly dependent on the underlying DNA methylation levels. Loci with
methylation proportions at the two extremes (0% and 100%) are characterised by low
PDR scores. Conversely, loci with intermediate methylation can be achieved via
several methylation patterns, and consequently have higher PDR values. For each
sample, median PDR values were calculated across the 21 bins spanning DNA
methylation levels from 0% to 100% (red line). A sample-specific PDR score was
calculated by determining the area under median PDR line.
Figure 5.2: PDR scores are dependent on underlying DNA methylation levels. PDR
scores and DNA methylation estimates are plotted for all 4-CpG loci obtained from a
representative ER+ tumour. The PDR for each 4-CpG loci (black dot) is displayed as a
function of DNA methylation. Tumour average (median) PDR values (red line) were
calculated across the 21 bins spanning DNA methylation levels from 0% to 100% as
explained in the text. Only 4-CpG loci with coverage greater than 30× are plotted,
although 4-CpG loci with coverage greater than 20× were analysed.
5.2.2 Breast tumours have lower epigenetic intratumour
heterogeneity than normal tissues
The average PDR for each sample was calculated as described above globally
(averaging over all 4-CpG loci in the RRBS universe), and separately across different
genomic features (such as promoters, exons, introns, enhancers and
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polycomb-repressed chromatin (PRC) regions). Next, the tumours were stratified by
ER status and the distribution of PDR scores is illustrated for ER+ tumours, ER-
tumours and normal tissues (Figure 5.3). Notably, the breast tumours were
considerably heterogeneous with respect to the PDR scores (compared to the normal
tissues) suggesting there is potential to link the epigenetic state of a tumour with the
underlying clonal diversity as implemented in previous studies [Landan et al., 2012;
Landau et al., 2014]. On average, breast tumours had a lower average ITH than the
normal tissue (Global median PDR: Tumour = 40.21, Normal = 42.76, FDR p-value =
8.6×10-33; Wilcoxon test) which was also observed in DLBCL [Pan et al., 2015], and
is consistent with a epiclonal selection process underlying tumorigenesis. This could
be explained by the fact the normal mammary epithelial have diverse cell types with
distinct methylation profiles. Furthermore, ER- tumours exhibited lower ITH than
ER+ tumours (Global median PDR: ER+ = 40.63, ER- = 38.78, FDR p-value =
5.9×10-21; Wilcoxon test). ER- tumours display a higher tumour grade than ER+
tumours, and therefore the lower epigenetic ITH could be interpreted as reflecting a
series of recent clonal outgrowths from more diverse cell populations [Mazor et al.,
2016].
Promoters, exons and enhancer regions exhibited the lowest ITH in tumours
compared to other genomic features (Median Tumour PDR: promoters = 37.32, exons
= 37.01, enhancers = 37.61, introns = 39.69, PRC regions = 40.98, global = 40.21), as
was also observed in CLL [Landau et al., 2014]. Since exons are regions that are under
a strong selective constraint, a low epigenetic ITH need not indicate a special function
for CpG methylation [Cohen et al., 2011]. However, the promoters displayed a far
larger ITH loss between tumours and normal tissues than exons or enhancers (median
PDR loss between tumours and normal: promoters = -3.79, exons = -2.86, enhancers
= -1.61, global = 2.55), and also showed the highest divergence in PDR between ER+,
ER- and normal tissues (Kruskal-Wallis test). This indicates that a tumour evolves
under a regime selecting for specific methylation patterns in promoters, thus implying
a functional role of promoter DNA methylation in tumorigenesis.
A subset of ER+ and ER- tumours, with PDR scores that are higher than the
normal tissue, are also clearly identified (outliers with high PDR scores in Figure
5.3). Interestingly, tumours with high epigenetic ITH in one genomic feature were
also likely to have high epigenetic ITH (pairwise correlations of PDR scores between
all genomic features > 0.85). Further characterisation of this group of tumours with
disordered methylation levels (high PDR scores) is conducted in Section 5.4 and 5.5.
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Figure 5.3: Breast tumours have lower epigenetic intratumour heterogeneity than
normal tissues. Distribution of average PDR scores for ER+, ER- and normal tissues
stratified by genomic feature. Separate panels represent different genomic features, and
only loci that overlapped a given feature were considered (the first panel, Global,
represents all loci). For each genomic feature, pairwise Wilcoxon rank-sum tests were
used to compare PDR scores between these three categories. FDR p-values were denoted.
Only 4-CpG loci at 20× coverage were considered. (. = FDR p-value < 0.1, * = FDR
p-value < 0.05, ** = FDR p-value < 0.01, *** = FDR p-value < 0.001, **** = FDR
p-value < 0.0001).
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5.2.3 Late replicating regions are associated with disordered
methylation
Intratumour heterogeneity scores such as PDR for specific regions can also help to
delineate the dynamics of the process driving methylation changes in cancer tissues
from normal tissues. PDR values within CpG loci can distinguish a controlled increase
in the frequency of a specific epiallele (low PDR), from multiple stochastic changes in
the frequencies of many epialleles (high PDR). For each 4-CpG locus, PDR values
were averaged (mean) across all 1482 tumours to give a loci-specific score for breast
cancer, and these regions were stratified by time of replication (TOR) in the cell
cycle (8 groups from early to late: ≥ 80, 70-80, 60-70, 50-60, . . . , 20-30, < 20). As
mentioned in Chapter 3, TOR status for the CpG sites was obtained from previously
published Repli-seq experiments conducted on the Michigan Cancer Foundation-
7 (MCF-7) breast cancer cell line [Pope et al., 2014]. Significantly higher PDR
was observed in regions with later TOR (median PDR scores: earliest TOR group
= 26.4, latest TOR group = 36.1, p-value ≤ 2×10-16, Jonckheere-Terpstra test for
trend, Figure 5.4). An equally strong PDR-TOR relationship (p-value ≤ 2×10-16,
Jonckheere-Terpstra test for trend) was detected in the background epigenome (as
defined in Chapter 3), indicating that regions that replicate later in the cell cycle were
prone to higher stochastic variation in methylation, an observation also reported for
promoter regions in CLL [Landau et al., 2014]. This was in strong concordance with
the findings in Chapter 3, in which regions with later TOR were shown to accumulate
significantly higher DNA methylation related drift. However, much weaker PDR-TOR
trends were observed for promoter, exonic and enhancer regions in this breast cancer
methylome (data not shown), suggesting that highly conserved genes (that replicate
earlier in the cell cycle) may also have high levels of ITH that coud be associated with
tumorigenesis.
5.2.4 Directed-DMRs associated with concomitant expression
changes harbour ordered methylation patterns.
Next, the 4-CpG loci were stratified based on whether they overlapped differentially
methylated regions (DMRs) between tumour and normal tissues as defined in Chapter
3 (≥ 20% absolute difference in average methylation, FDR p-value < 0.05). A lower
degree of PDR was observed at DMRs regardless of whether they were hyper and
hypo methylated compared to loci that were did not undergo methylation change in
tumours (p-value < 2.2×10-16; Kruskal-Wallis test; Figure 5.5a). This implies that
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Figure 5.4: Late replicating regions are associated with disordered methylation.
Distribution of PDR scores for loci within 7 time of replication (TOR) categories from
early to late. The number of loci considered within each TOR category is denoted.
Average PDR scores for each locus is calculated by averaging over all tumours with
available information. Only 4-CpG loci at 20× coverage were considered.
Jonckheere-Terpstra test for trend was used to compare the PDR scores between the
seven categories. FDR p-values were denoted. (. = FDR p-value < 0.1, * = FDR p-value
< 0.05, ** = FDR p-value < 0.01, *** = FDR p-value < 0.001, **** = FDR p-value <
0.0001).
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loci with significant deviations in tumour-averaged methylation underwent ordered
methylation changes indicating positive selection, a finding that was observed in CLL
as well [Landau et al., 2014].
Nevertheless, is it possible to identify DMRs that are a culmination of stochastic
accumulation of methylation changes? Considerable progress in this regard was made
in Chapter 3, in which aggregate (not intratumour) methylation estimates were used to
characterise DMRs into i) directed-DMRs, that were hypothesised to be the result of
targeted methylation differences; and ii) background-DMRs, hypothesised to be the
consequence of accumulation of largely stochastic cell-division related methylation
errors. In this section, intratumour PDR scores were used to further characterise
regions within these two DMR categories (Figure 5.5b). Background DMRs showed
a significantly stronger stochastic component than directed DMRs (median PDR:
directed DMRs = 38.9, background DMRs = 42.1, p-value < 2.2×10-16; Wilcoxon
test) which further supports this DMR classification. Furthermore, directed-DMRs
associated with a concomitant alteration in gene expression (directed expression-
DMRs) had relatively homogeneous methylation patterns compared to those not
associated with expression changes (Figure 5.5c) (median PDR: directed expression
DMRs = 35.3, directed DMRs not associated with expression = 39.1, p-value =
8.3×10-16; Wilcoxon test). This suggests that methylation changes with an apparent
functional role in tumorigenesis (measured at the mRNA level) are more likely to be
selected for and reflect an ordered methylation state across the tumour. A similar trend
of lower PDR scores for directed expression DMRs was also noted when focusing
on loci within promoters (median PDR: directed expression DMRs = 35.1, directed
DMRs not associated with expression = 39.1, p-value = 0.017; Wilcoxon test).
Notably, intra-patient DNA methylation homogeneity was also observed for
promoter methylation differences associated with gene expression in a multiple region
analysis of metastatic prostate cancer [Aryee et al., 2013]. In conclusion, lower PDR
scores within a locus are a good indicator that the methylation status of the
corresponding locus has a potential functional role and has undergone positive
selection.
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Figure 5.5: (Caption on next page.)
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Figure 5.5: (Previous page.) Directed-DMRs associated with concomitant expression
changes have lower intratumour methylation heterogeneity. (a) The relationship
between average PDR scores and DNA methylation was compared for loci within hyper
DMRs, hypo DMRs and for loci not overlapping DMRs. Loess curves are illustrated for
each of these three categories. (b) Distribution of PDR scores for loci within
directed-DMRs and background-DMRs. (c) Distribution of PDR scores for loci within
directed-DMRs that are associated with expression changes and directed-DMRs not
associated with expression changes. In (a) (b) and (c) average PDR scores for each locus
is calculated by averaging over all tumours with available information. Only 4-CpG loci
at 20× coverage were considered. In (a) Kruskal-Wallis test was used to compare PDR
scores between the categories. In (b) and (c) Wilcoxon rank-sum tests were used to
compare PDR scores between the two categories. FDR p-values were denoted. (. = FDR
p-value < 0.1, * = FDR p-value < 0.05, ** = FDR p-value < 0.01, *** = FDR p-value <
0.001, **** = FDR p-value < 0.0001).
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5.3 Evolutionary dynamics of epigenetic changes in
breast cancer
In order to unravel the evolutionary dynamics involved in tumorigenesis from an
epigenetic perspective, an alternate method called methclone [Li et al., 2014] was used
to measure the shifting of epiallelic compositions from the normal tissue to the breast
tumour. This represents an orthogonal approach to the PDR score (which quantified
the epiallelic diversity within individual samples), since it examines the transformation
of epiallelic states between two samples.
5.3.1 Detection of significant epiallelic composition shifts in
breast tumours relative to normal samples
The epiallelic composition shift analysis was performed using methclone, as described
in Li et al. [2014]. Briefly, for each 4-CpG locus (minimum 20 read coverage in both
the tumour and the corresponding normal tissue), the epiallele patterns of
compositional changes between the tumour and the normal tissue was evaluated to
calculate the combinatorial entropy change (∆S) of epialleles (Figure 5.6). Loci with
combinatorial entropy change (∆S) < -90 were identified as undergoing significant
epiallelic composition shifts (henceforth known as eloci). For each tumour, the
number of eloci was normalised to the total number of CpG loci considered in the
analysis, giving rise to an estimate of Eloci Per Million CpGs (henceforth known as
EPM).
The EPM score thus represents a global estimate of epigenetic allelic burden per
tumour. It is important to note that the epiallele composition shift analysis between
a tumour and a normal tissue, can not only detect loci with organised changes in
methylation leading to a substantial difference in mean methylation (such as those
detected using a DMR analysis), but in addition can also detect differential variability
in methylation. Early DNA methylation changes in normal cells at risk of neoplastic
transformation and in early cancers (also called epigenetic field defects) have been
shown to reflect a stochastic nature [Teschendorff et al., 2016a, 2012; Teschendorff
and Widschwendter, 2012]. Therefore, in contrast to a traditional DMR analysis, the
EPM analysis can also detect such stochastic and heterogeneous DNA methylation
pattern changes.
As discussed in Chapter 3, the original normal tissue from which the tumours
arose was not available, and instead the matched adjacent normal tissue was used
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which may contain epigenetic field defects [Johnson et al., 2017; Teschendorff et al.,
2016a] as well as tumour contamination, and thus reduce sensitivity in detecting
eloci in the tumours. Furthermore, not all breast tumours had matched normal tissue
available (only 143 tumours), and so a matched 1-to-1 methclone analysis as described
in the original publication [Li et al., 2014] was not possible. A modified methclone
strategy was developed1 and implemented in the breast cancer cohort as described
below. A panel of 50 reference normal breast samples (out of 237 available) was
randomly selected, and each tumour was linked individually with each of these 50
normal samples leading to 74100 pairwise methclone analyses (1482 tumours x 50
reference normal samples). For each analysis, the list of eloci (significantly shifting
epialleles) was identified and the global EPM was calculated as described earlier.
Accordingly, each tumour had 50 lists of eloci and 50 EPM scores (resulting from
individual comparisons with the 50 reference normal samples). For each tumour,
a consensus list of eloci was determined by identifying loci that were covered by a
minimum of 20 normal samples and consistently met the threshold criteria (∆S < -90 in
≥10% of the normal comparisons; minimum of 5 normal comparisons). Methylation
profiles of normal tissues have been shown to be relatively homogeneous (Chapter
2), thus supporting the suitability of this approach. The global tumour-specific EPM
score was calculated by taking the geometric mean of the 50 individual EPM scores
based on the separate normal comparisons. Similarly, genomic feature specific EPMs
were also calculated for each tumour by focusing the analysis on individual genomic
features including promoters, exons, introns, enhancers and PRC regions.
To further, contextualise EPM shifts in breast tumours with respect to normal
tissues, EPM scores were similarly calculated for the normal tissues. The remaining
187 normal samples, not part of the reference normal panel, were linked with the 50
reference normal samples leading to a further 9350 pairwise methclone analyses (187
normal tissues x 50 reference normal tissues). A similar consensus approach was
utilised to calculate the EPM scores for the 187 normal tissues.
An alternate methclone strategy was also tested in which the ER status of the
tumour and adjacent normal tissue was considered. Specifically, ER+ tumours were
compared only with those reference normal tissues that were adjacent to ER+ tumours,
rather than all 50 reference normal samples, and the same was repeated for ER-
tumours. However, since methylation profiles of normal tissues have been shown to
be homogeneous with respect to ER status of the adjacent tumour (Chapter 2), this
1 This modified methclone strategy was developed by me as part of the PhD thesis, and discussed
with the authors of the original methclone publication [Li et al., 2014] during a visit to their laboratories
at Weill Cornell Medicine, New York.
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alternate strategy did not yield dissimilar results (data not shown) and was not utilised
for further analysis.
Figure 5.6: Epiallelic composition shift detection by methclone. Schematic plot of
epiallelic composition of cells for the same 4-CpG locus in the normal tissue and in the
matched tumour tissue. Each row denotes methylation information for the 4-CpG locus
captured by a single read representing one cell from the sample. Black circles =
methylated CpG sites. White circles = unmethylated CpG sites.
5.3.2 Breast tumours undergo subtype-specific and genome
feature-specific epiallelic composition shifts
The breast tumours were stratified by ER status and the distribution of EPM scores
is illustrated for ER+ tumours, ER- tumours and normal tissues globally and for
specific genomic features (Figure 5.7). Whereas, EPM scores for the tumours largely
represent the degree of epiallelic burden associated with tumorigenesis from the
normal tissue, conversely, EPM scores for the normal tissues likely represents the
inter-patient variation in the degree of epigenetic field defects in normal breast tissues
[Li et al., 2016b]. Globally, breast tumours exhibited higher EPM scores than normal
tissues (Global median EPM (log10): Tumour = 4.08, Normal = 3.78, FDR p-value
= 3.0×10-135; Wilcoxon rank-sum test) indicating that the epigenetic alterations
associated with tumorigenesis are much more dynamic than epigenetic field defects.
The number of eloci captured between the different normal samples is also very stable
(less heterogeneous) suggesting that inter-patient epigenetic variation in normal breast
tissues is low, an observation also noted in an independent study in AML patients [Li
et al., 2014]. This further substantiates the findings in Chapter 2, that adjacent normal
breast tissues have relatively homogeneous methylation profiles.
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Figure 5.7: Breast tumours exhibit high epiallelic composition shifts compared to
normal tissues. Distribution of average EPM scores (log10) for ER+, ER- and normal
tissues stratified by genomic feature. Separate panels represent different genomic
features, and only loci that overlapped a given feature were considered (the first panel,
Global, represents all loci). For each genomic feature, pairwise Wilcoxon rank-sum tests
were used to compare EPM scores between these three categories. FDR p-values were
denoted. Only 4-CpG loci at 20× were considered. (. = FDR p-value < 0.1, * = FDR
p-value < 0.05, ** = FDR p-value < 0.01, *** = FDR p-value < 0.001, **** = FDR
p-value < 0.0001).
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Higher tumour EPM scores were observed across all individual genomic features
as well (FDR p-value < 1.0×10-113 for all comparisons). Interestingly, higher EPMs
were detected in intergenic regulatory regions such as enhancers and PRC regions
compared to genic regions, with the promoters containing the lowest proportion
of average number of significantly deregulated loci (Median Tumour log10 EPM:
promoters = 3.68, exons = 3.85, introns = 4.03, enhancer = 4.05, PRC regions = 4.31).
However, in tumours, promoter as well as PRC loci displayed the highest variability in
EPMs (measured by interquartile range), as well as displaying large departures from
the normal tissues. This suggests that there is potential to link promoter epiallele shifts
in a tumour with its underlying evolutionary dynamics.
5.3.3 High epiallelic composition shifts at promoters are linked
with tumour-specific gene expression changes
Given the high tumour variability in promoter EPM scores (described above) and the
well-recognised and reported role of promoter methylation in regulating transcription
in tumours, the presence of epiallelic composition shifts (eloci) in the promoter of
a gene was investigated for concomitant alterations in its mRNA expression. For
each tumour, genes were classified into whether their promoters harboured eloci
or not. For all genes, log fold changes (LFC) in gene expression were calculated
between the tumour and the 50 reference normal samples. The standard deviation
(SD) in LFC, and the percentage of genes differentially expressed (LFC > 1) were
noted for the two genes categories: i) with promoter eloci; and ii) without promoter
eloci. Figure 5.8a illustrates that on average genes containing substantial shifts in
epiallelic compositions at their promoters showed significantly higher variance in
gene expression alterations in the tumour compared to the normal tissue (p-value =
1.0×10-14; Wilcoxon signed rank test). In addition, genes with promoters harbouring
eloci were also significantly more likely to be differentially expressed (p-value =
2.9×10-6, adjusted for concomitant copy number alterations; Wilcoxon signed rank
test, Figure 5.8b), confirming the contribution of DNA methylation dynamics at
promoters in deregulating the transcriptional landscape in tumours.
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Figure 5.8: High epiallelic composition shifts at promoters are linked with
tumour-specific gene expression changes. For each tumour, genes were stratified into
whether they harboured an eloci in the promoter or not. (a) Boxplot of standard deviation
of LFC in transcript expression in each tumour (log2 fold change versus 50 reference
normal tissues). For each tumour this is calculated for genes with (right) or without eloci
(left) in their promoters. (b) Boxplot of percentage of genes in each tumour that are
differentially expressed (compared to 50 reference normal tissues). For each tumour, this
is calculated for genes with (right) or without eloci (left) in their promoters. In (a) and
(b), Wilcoxon signed rank tests (paired) were used to compare the scores between the
two categories. p-values were denoted. Only 4-CpG loci at 20× within promoters were
considered. (. = p-value < 0.1, * = p-value < 0.05, ** = p-value < 0.01, *** = p-value <
0.001, **** = p-value < 0.0001).
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5.4 PDR and EPM represent distinct properties of the
epigenome
A tumour’s PDR score and EPM score represent two orthogonal measures of its
epigenome. The PDR score represents intra-tumour epigenetic diversity, while the
EPM score represents the magnitude of dynamic epiallelic composition shifting in the
tumour compared to the normal tissue. The relationship of these scores are compared
with the established genetic ITH scores and the epigenetic drift derived Accumulation
index (Chapter 3).
5.4.1 Patterns of genetic and epigenetic intratumour
heterogeneity
The Integrative cluster (IntClust) classification divides breast tumours into 11 tumour
subtypes based on integrating genomic (CNA) profiles with gene expression. The two
epigenetic scores defined above, PDR and EPM are investigated within these clusters.
Since promoter loci displayed the highest divergence in PDR scores between tumour
subtypes and normal tissues (Section 5.2), further investigation of intratumour DNA
methylation dynamics in this chapter is largely focused on the promoter regions. The
distribution of tumour-specific promoter PDR scores across the Integrative clusters
was very heterogeneous (Kruskal Wallis p-value < 2.2×10-16; Figure 5.9a), as were the
promoter EPM scores (Kruskal Wallis p-value < 2.2×10-16; Figure 5.9b), suggesting
that in addition to carrying distinct genetic rearrangements, these tumour subtypes
were also diverse with respect to the dynamics driving methylation changes. Similar
heterogeneity across the subtypes was observed using PDR scores and EPM scores
inferred from 4-CpG loci in other genomic features (data not shown).
But is the level of epigenetic ITH correlated with the level of genetic ITH? The
mutant-allele tumour heterogeneity (MATH) score [Mroz and Rocco, 2013], which
is a tumour-specific score based on the variation in variant allele frequency (VAF) of
all mutations in the tumour, was used to quantify genetic ITH. Only 173 genes were
profiled for mutations, so only these genes were used for calculation of the MATH
score (MATH scores for METABRIC tumours obtained from Pereira et al. [2016]).
Remarkably, a very strong (but negative) correlation was observed between PDR
scores and the MATH scores (rho = -0.82, p-value = 0.0010; spearman correlation
over Integrative clusters weighted by number of tumours in each subgroup; Figure
5.9c). Stratifying by ER status also revealed significant negative correlations (ER+:
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Figure 5.9: (Caption on next page.)
226
5.4. PDR and EPM represent distinct properties of the epigenome
Figure 5.9: (Previous page.) Patterns of genetic and epigenetic intratumour
heterogeneity. (a) Distribution of average promoter PDR scores for the 11 Integrative
clusters. (b) Distribution of average promoter EPM scores (log10) for the 11 Integrative
clusters. (c) Bubble plot of median promoter PDR scores and MATH scores for each
Integrative cluster. Grey lines depict the quartiles for both scores (vertical lines, PDR
quartiles; horizontal lines, MATH score quartiles) in the cohort as a whole. The areas of
the circles are proportional to number of samples in each Integrative cluster. (d) Bubble
plot of median promoter EPM scores (log10) and CIN scores for each Integrative cluster.
In (a) (b) (c) and (d), only 4-CpG loci at 20× within promoters were considered. In (c)
and (d), grey lines depict the quartiles for the two scores in the cohort as a whole. The
areas of the circles are proportional to the covariance between the scores plotted in each
Integrative cluster.
rho = -0.65, p-value = 0.0287; ER-: rho = -0.73, p-value = 0.0159). IntClust 10 that
are predominantly Basal-like tumours and IntClust 5 tumours that are predominantly
HER2+ tumours have relatively high mutation ITH [Pereira et al., 2016], and high
chromosal instability [Curtis et al., 2012]. Conversely, these tumours exhibited the
least ITH at the epigenetic level (Median PDR). This suggests a linked relationship
between genetic and epigenetic heterogeneity, with tumours displaying high levels of
genetic diversity conversely being associated with highly ordered promoter methylation
patterns indicative of selection. The basis behind this relationship can be partially
explained by presence of epigenetic field defects in genetically homogenous tumours.
Chromosomal instability (CIN), is also a tumour-specific score obtained by
calculating the fraction of the genome altered by CNAs was also examined (CIN
scores for METABRIC tumours obtained from Pereira et al. [2016]). Since, breast
cancer is a copy number driven disease, CIN can be used to represent the extent of the
genetic burden in the tumour. Mutational burden cannot be used since the mutational
profiles of only 173 key cancer driver genes are available for these tumours. The
relationship between the EPM score and the CIN score was also investigated since
they represent the epigenetic and genetic burden of the tumour respectively. A weak
positive correlation was observed with the EPM score (rho = 0.36, p-value = 0.2472;
spearman correlation over Integrative clusters weighted by number of tumours in each
subgroup; Figure 5.9d). However, stratifying by ER status revealed mildly significant
positive correlations between epigenetic and genetic burden (ER+: rho = 0.55, p-value
= 0.0773; ER-: rho = 0.69, p-value = 0.0274).
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5.4.2 Epiallelic burden is correlated with epigenetic drift
Given the association of background methylation changes (background DMRs) with a
higher epigenetic ITH (PDR score; Figure 5.5) denoting a stochastic-oriented process
at a region-level, it might be tempting to theorise that a tumour’s global PDR score is
associated with accumulation metric that quantifies the extent of epigenetic drift in
the tumours (calculated in Chapter 3). However, no such correlation was observed
when testing the relationship between two aggregated measures -- PDR score and
the Accumulation index – across all tumours (rho = 0.01, p-value = 0.735, partial
correlation adjusted for ER status; Figure 5.10a). Similar results were obtained for
PDR scores inferred only from promoter loci (rho = 0.02, p-value = 0.470, partial
correlation adjusted for ER status), as well as PDR scores inferred from loci within
the background or neutral epigenome defined in Chapter 3 (rho = 0.04, p-value =
0.107, partial correlation adjusted for ER status). This strongly implies that a tumour’s
tendency to accumulate stochastic related methylation errors is not associated with
the magnitude of functional methylation changes in the promoter that have undergone
positive selection, and that these two independent processes affect distinct loci within
the genome.
Figure 5.10: The degree of epiallelic composition shifting is correlated with
epigenetic drift. (a) Scatter plot of global PDR score and Accumulation metric for the
1482 tumours. (b) Scatter plot of global EPM score (log10) and Accumulation metric for
the 1482 tumours. Each point represents a tumour. In both panels, the black line
represents the loess curve (95% confidence interval in grey) for the relationship. Only
4-CpG loci at 20× within promoters were considered.
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However, both EPM scores and the Accumulation index represent departures
in the tumour tissue compared to normal tissues. Moreover, as mentioned earlier,
the EPM analysis can detect stochastic and heterogeneous DNA methylation pattern
changes that also largely contribute to epigenetic drift. Consequently, a significantly
positive correlation was detected between these two scores (rho = 0.62; p-value =
2.3×10-171; partial correlation adjusted for ER status. Log10 EPM scores were used
for statistical testing; Figure 5.10b). Similar results were obtained for EPM scores
inferred only from promoter loci (rho = 0.53, p-value = 1.07×10-112, partial correlation
adjusted for ER status. Log10 EPM scores were used for statistical testing), as well as
PDR scores inferred from loci within the background or neutral epigenome defined
in Chapter 3 (rho = 0.64, p-value = 3.4×10-187, partial correlation adjusted for ER
status. Log10 EPM scores were used for statistical testing). This suggests that a large
contribution of epiallelic composition shifts in tumours compared to normal tissues
are the consequence of epigenetic drift related methylation errors.
5.4.3 Relationship between PDR scores and EPM scores
The relationship between the two epiclonal measures of the tumour’s epigenome -
PDR score and EPM score - was also of considerable interest, particularly since they
represent orthogonal scores that have never been linked previously. The association
between the scores was investigated in promoters across the 1482 breast tumours
(Figure 5.11a). Given the largely non-linear relationship between the two scores, the
tumours were classified into 4 quadrants based on mean promoter PDR and promoter
EPM (log10) scores for the whole cohort to allow for easier interpretation. However,
an exception to the non-linear relationship was observed within tumours in quadrant 1
(green; Figure 5.11a), that showed a strong correlation between PDR and EPM scores
(rho = 0.47; p-value = 1.3×10-25; partial correlation adjusted for ER status. Log10
EPM scores were used for statistical testing; n = 437). In this subgroup, tumours that
harboured frequent epiallelic composition shifts were also associated with a higher
degree of locally disordered methylation in promoters. This implies that although
these tumours have a large number of epiclonal shifts compared to the normal tissue,
these methylation changes are more likely to be stochastic and heterogeneous, rather
than ordered methylation changes reflective of functional alterations under selection.
Similar correlations between the PDR score and the EPM score were not noted
in the other quadrants. Tumours with a propensity for selection-related methylation
dynamics (lower PDR) were not associated with epiallelic burden and were found to
be similarly distributed across the tumours with a lower epiallelic burden (low PDR
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Figure 5.11: (Caption on next page.)
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Figure 5.11: (Previous page.) Breast cancer subtypes are associated with the 4-group
methylation classifier. (a) Scatter plot of promoter PDR score and promoter EPM
(log10) scores for the 1482 tumours. A 4-group methylation classier was constructed
using mean values (based on the whole cohort) for the two scores. Colours represent
subgroup classification. The black line represents the loess curve (95% confidence
interval in grey) for the relationship. (b) Scatter plot of promoter PDR score and
promoter EPM (log10) scores for the 1482 tumours. Colours represent ER status. (c)
Bubble plot of median promoter PDR scores and median promoter EPM (log10) scores
for each Intrinsic subtype. (d) Bubble plot of median promoter PDR scores and median
promoter EPM (log10) scores for each Integrative cluster. In (a) (b) (c) and (d), only
4-CpG loci at 20× within promoters were considered. Grey dotted lines depict the means
for both scores (vertical line, mean promoter PDR; horizontal lines, mean promoter EPM
(log10)) in the cohort as a whole. In (c) and (d) the areas of the circles are proportional to
the covariance between the PDR and EPM (log10) scores in each subtype.
and low EPM, quadrant 3, purple; Figure 5.11a) or a higher burden (low PDR and
high EPM, quadrant 2, red; Figure 5.11a). This strongly indicates that a tumour’s
propensity for ordered methylation changes (likely reflecting a selection process) in the
promoter is independent of the number of epiallelic composition shifts that it harbours.
This confirms that the PDR score and the EPM score of tumours represent distinct
properties of the epigenome, and the combination of the two scores into 4 categories
(based on mean values of the whole cohort) can be used to discriminate between
tumours into those where these shifts are a consequence of stochastic drift or selection,
as well as between tumours with a low or high epiallelic burden. A description of
this 4-group classifier is detailed in Table 5.1. ER status was significantly associated
with this 4-category epigenetic based classification (p-value = 3.3×10-19; chi-square
test; Figure 5.11b), with ER+ tumours being strongly predisposed to disordered
methylation patterns with enrichments in quadrant 1 (OR = 2.0, FDR p-value =
1.8×10-6; Fisher’s exact test) and more so in quadrant 4 (OR = 3.5; FDR p-value =
4.8×10-10; Fisher’s exact test). Conversely, ER- tumours were enriched in quadrant
3 (OR = 2.6, FDR p-value = 3.1×10-13; Fisher’s exact test) had a tendency for
selection-related methylation dynamics (lower PDR) but with a lower total epiallelic
burden in promoters. This classification was also significantly associated with the
Intrinsic subtype definition (p-value = 2.6×10-58; chi-square test; Figure 5.11c) and
the Integrative cluster definition (p-value = 7.2×10-65; chi-square test; Figure 5.11d).
The strong relationship of this purely epigenetic based classifier with a genetic and
transcriptomic defined classification of breast cancer such as Integrative clusters
strongly confirms its biological significance, and also the linked nature of genetic
and epigenetic dysregulation in tumorigenesis. Moreover, the IntClusts 1,5,6,9 and
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Intrinsic clusters - Luminal B, HER2 and Basal-like, are all associated with poor
prognosis and were also all enriched in quadrant 2 [Curtis et al., 2012; Parker et al.,
2009]. Consequently, the utility of this methylation-based classifier as a prognostic
indicator in breast cancer was formally investigated in Section 5.5.
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5.5 PDR and EPM scores are prognostic in breast
cancer
5.5.1 Construction of survival models
Cox proportional hazard models [Cox, 1972] were used to explore the prognostic
potential of the two epigenetic measures generated in this chapter -- promoter PDR
score and the promoter EPM score. The prognostic value of the CIN score was also
investigated for comparison. Breast Cancer-Specific Survival (BCSS) was explored
for these measures, and accordingly, the endpoint of interest was defined as death due
to breast cancer. Patients with deaths due to other or unknown causes were censored at
the times of those deaths, and all other patients were censored at the time of last contact.
The three continuous predictors (PDR; EPM; CIN scores) were scaled using their
respective standard deviations (SD), such that the hazard ratio (HR) is interpreted as
the ratio of hazard rates corresponding to an increase of one 1 SD of the corresponding
predictor. Higher hazard ratios indicate that tumours with higher values of the predictor
are associated with lower survival times i.e. higher risk of death associated with breast
cancer [Zwiener et al., 2011].
All survival models were adjusted for confounding clinicopathological variables
including ER status, grade, size, lymph node status, and age at diagnosis. Age, Lymph
node status and size of the tumour were treated as a continuous variable; while ER
status (ER+ vs. ER-) and grade (1/2 vs. 3) were treated as binary variables. The effect
of treatment is also important to consider as it may act as a confounding factor in
survival analyses. However, since treatment decisions for early breast cancer were
highly dependent on the standard clinical parameters mentioned above, treatment was
not used as an additional variable in these analyses. As described for the original
METABRIC study [Curtis et al., 2012], nearly all ER+ patients that were lymph node-
negative did not receive adjuvant chemotherapy status; conversely, all ER− patients
that were lymph node-positive patients did. Moreover, the patients with ER+ disease
who did receive chemotherapy were also more likely to have high-grade tumours.
None of the HER2+ patients in the original METABRIC cohort received adjuvant
trastuzumab since they were diagnosed prior to its use in clinic.
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5.5.2 PDR and EPM scores collectively, but not individually are
highly significant predictors of BCSS
Firstly, survival models were constructed to assess the individual contributions of the
two promoter methylation-based scores: PDR and EPM scores. Given the dominance
of copy number events in breast cancer [Ciriello et al., 2013], the prognostic value of
the CIN score was also considered in a third model. Next, to evaluate the combined
contributions of these measures, three pairwise multivariable models, i) CIN +PDR; ii)
CIN + EPM; iii) EPM+PDR; and a final multivariable model with all three predictors,
CIN +PDR + EPM. These seven survival models were also adjusted for the clinical
confounding variables (enumerated above). Further, a likelihood ratio (LR) test was
conducted for each model, to assess whether the described model provides a better fit
than the null-clinical model (comprising of solely the 5 clinicopathological parameters).
The results of the seven models are presented in Table 5.2.
Lower promoter PDR scores were predictive of lower BCSS after adjustment
of clinical parameters (HR = 0.9016, p-value = 0.0497; adjusted Cox proportional
hazards model; Table 5.2) indicating that tumours associated with lower epigenetic
heterogeneity (selection-related methylation patterns) at promoters were associated
with worse outcomes. Conversely, higher promoter EPM scores were not predictive of
lower BCSS (HR = 1.0534, p-value = 0.2934, EPM scores were log10 transformed;
adjusted Cox proportional hazards model; Table 5.2). However, combining these two
scores gave rise to a model where both promoter PDR scores and promoter EPM
scores demonstrated evidence of being prognostic (PDR p-value = 0.0111, EPM p-
value = 0.0587, Model 6 in Table 5.2). Moreover, the likelihood ratio test indicated
that amongst all seven models tested, the combined EPM + PDR model provides
the best goodness of fit (lowest LR test p-value), and was significantly informative
when compared to the null-clinical model (LR test p-value = 0.0236). The partial
hazard ratios (adjusted for each other and clinicopathological variables, Model 6 in
Table 5.2) for promoter EPM and PDR scores are illustrated in Figure 5.12, again
confirming that tumours with higher epiallelic burden and tumours with evidence of
ordered methylation patterns (indicative of a selection process) in promoters were
associated with adverse prognosis (higher hazard ratio; lower BCSS).
Higher CIN scores were mildly predictive individually (adjusted Cox proportional
hazards model: HR = 1.1029, p-value = 0.0764); however, inclusion of CIN with either
of the methylation scores did not yield models with a better fit than the null-clinical
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Figure 5.12: PDR and EPM scores are both prognostic in breast cancer when
combined. (left panel) Hazard ratio for promoter PDR score (partial i.e. adjusted) from
Model 6 in Table 5.2. (right panel) Hazard ratio for promoter EPM (log10) score (partial
i.e. adjusted) from Model 6 in Table 5.2. Survival models constructed as described in text
and Table 5.2. of the circles are proportional to number of samples in each subtype.
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Model Variable HR (scaled) Wald’s test LR Test
Model1: EPM EPM 1.05 0.2934 0.2931
Model2: PDR PDR 0.90 0.0497 0.0482
Model3: CIN CIN 1.10 0.0764 0.0798
CIN 1.10 0.0920Model4: CIN+PDR
PDR 0.95 0.3698 0.1435
CIN 1.10 0.0930Model5: CIN+EPM
EPM 1.02 0.6925 0.1993
EPM 1.11 0.0587Model6: EPM+PDR
PDR 0.87 0.0111 0.0236
EPM 1.05 0.4005
PDR 0.93 0.2423Model7: EPM+PDR+CIN
CIN 1.09 0.1434 0.2042
Table 5.2: PDR and EPM scores are both prognostic in breast cancer when
combined. The first column represents the epigenetic or genetic variables included in the
survival model fitted using Cox proportional hazards, as described in the text. All
survival models were adjusted for clinicopathological variables including ER Status, Age
at diagnosis, No of lymph nodes, Size and Grade of tumour. HR represents the scaled
hazard ratio, and Wald’s test represents the Wald’s test p-value. Both statistical estimates
were adjusted for other variables in the model and calculated as described in the text. LR
test represents the p-value from the likelihood ratio (chi-square) test of the model versus
the null-clinical model.
model, implying that the intratumour promoter methylation measures – PDR and EPM
– have a greater prognostic potential than chromosomal instability.
5.5.3 PDR + EPM methylation classifier is prognostic
Given that PDR and EPM collectively are highly prognostic of BCSS, the utility
of the 4-group classifier based on these two scores (defined in Section 5.4) as a
prognostic indicator in breast cancer was investigated. Kaplan-Meier survival curves
(endpoints: BCSS) were constructed to test the prognostic ability of the promoter
methylation-based classifier in all tumours and this model was highly prognostic (Log-
likelihood test p-value = 1.2×10-6, Figure 5.13a). As expected from the findings in the
previous section, breast tumours with both high epiallelic burden in promoters and low
epigenetic ITH (quadrant 2, red; HR = 2.27; p-value = 1.4×10-6, reference = quadrant
4; Cox proportional hazards model) had the shortest survival times. Conversely
tumours with a low epiallelic burden and high epigenetic ITH in promoters (quadrant
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4, blue (reference): HR = 1) were linked with the best prognosis. The survival
curves were also significantly prognostic in ER+ tumours with quadrant 2 tumours
exhibiting the shortest BCSS times (Figure 5.13b), but not in ER- tumours (Figure
5.13c). However, crucially the 4-group promoter methylation-based classifier was
significantly prognostic within three Integrative clusters (Log-likelihood test p-values
for all < 0.05; Figure 5.13d-f). For instance, IntClust 8 (largely ER+; low grade)
tumours that harbour a high epiallelic burden in the promoters had the worst prognosis
(quadrants 1 (green) and 2 (red)), while IntClust 9 (largely ER+; high grade) tumours
with low epigenetic burden in the promoters were likely to have the worst outcomes
(quadrants 3 (purple) and 4 (blue)). This finding in the IntClust 9 subtype can explained
due to the identified driver role of 8q cis-acting copy number alterations and 20q
amplification in these tumours, indicating that role of epigenetics may not be necessary.
Remarkably, IntClust 10 (predominantly ER-; high grade) tumours with high epigenetic
burden as well as high epigenetic diversity in the promoters were likely to have the
worst outcomes (quadrants 1 (green)). This reflects the extraordinary heterogeneity
observed in the role of epiallelic dynamics in breast tumours, and also indicates
the ability to refine the molecular taxonomy of breast cancer by investigating the
epigenome.
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Figure 5.13: The 4-group methylation classifier is prognostic in breast cancer.
Kaplan-Meier survival curves (endpoints: BCSS) were constructed to test the prognostic
ability of the 4-group methylation-based classifier in (a) all tumours, (b) ER+ tumours,
(c) ER- tumours, (d) IntClust 8 tumours, (e) IntClust 9 tumours, and (f) IntClust 10
tumours. The numbers of samples under consideration in each methylation subgroup are
indicated, and the numbers in brackets represent the deaths occurring in the cohort.
Log-lik p-value represents the significance of the survival curves based on a
log-likelihood test.
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5.6 Discussion
Extensive profiling of cancer methylomes have delineated specific genomic regions that
on average are differentially methylated between cancer and normal tissues. However,
there is insufficient evidence of the dynamics of the process driving methylation change
in cancer tissues. Are these differences a consequence of ordered and regulated changes
in methylation patterns, or rather a result of stochastic and heterogeneous process
occurring independently and non-specifically over the epigenome? This question
was briefly addressed using tumour and region-specific estimates of the background
methylation differences in Chapter 3. However, RRBS, which is an NGS based
methylation profiling platform also allows the capture of the epiallelic composition
from contiguous CpG sites on sequencing reads. Leveraging this information can
provide deeper insights into the role of the epigenome in cancer.
Utilising the proportion of discordant reads (PDR) method [Landau et al., 2014]
enabled the enumeration of epigenetic ITH for the 1482 breast tumours at different
regions of the genome, with lower PDR values within a CpG locus representing a
controlled increase in the frequency of a specific epiallele while higher PDR scores
represent multiple stochastic changes in the frequencies of many epialleles. Therefore,
PDR scores leverage the snapshot of the epigenetic state in a tumour to unravel the
journey that has been traversed ultimately culminating in this state. Late replicating
regions were associated with disordered methylation patterns compared with early
replicating regions, corroborating the findings in Chapter 3 in which these regions
were shown to accumulate significantly higher drift (stochastic) related methylation
errors. Furthermore, directed-DMRs associated with concomitant expression changes
also harboured lower epigenetic ITH than other loci, indicating that these functionally-
marked regions potentially underwent an ordered change in methylation patterns likely
reflecting a positive selection mechanism.
A similar loss in ITH (epipolymorphism scores) was observed in hyper
methylated loci in a study of colorectal tumour-normal pairs, albeit only a select panel
of putative DMRs were assayed [Landan et al., 2012]. However, they demonstrated
that the subpopulation of cells in the tumour with increased methylation levels
actually exhibited high epipolymorphism indicating a strong stochastic component,
and the loss in polymorphism at such loci is actually attributed to a co-existing but
distinct subpopulation of cells that remains completely resistant to methylation.
Consequently, the authors [Landan et al., 2012] made an interesting argument that
although deterministic epigenetic patterns are observed in cancer cells that gain
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resistance to methylation, once this protection is removed, methylation accumulates in
a locally disordered manner leading to an increase in methylation levels (and
consequently identified as a hyper DMR). However, this postulation remains to be
confirmed in other published genome-wide cancer methylome studies, and will be
examined in our breast cancer cohort in the future.
Next, the shifting of epiallel compositions from the normal tissue to the breast
tumour was assessed using methclone [Li et al., 2014]. The methclone algorithm can
not only detect differentially methylated loci, but in addition can also detect
differential variability in methylation that might be a consequence of stochastic
processes. Promoters with evidence of epiallelic composition shifting (eloci) in the
tumour (compared to the normal tissue) were associated with a higher variability in
transcriptional change (compared to the normal tissues), as well as a higher
probability of being differential expressed in the tumour, indicating the utility of this
approach. Interestingly, tumours with a high number of aggregate eloci (calculated as
eloci per million or EPM) also demonstrated evidence of high epigenetic drift
(measured by the Accumulation index, see Chapter 3). This may not be surprising,
given that both EPM and epigenetic drift give an account of the accumulation of
stochastic heterogeneous methylation patterns in tumours compared to the normal
tissue (though EPM does not exclusively detect stochastic changes). However, what is
notable is the fact that methods underlying the calculation of these two scores,
Accumulation index (developed in Chapter 3) and methclone [Li et al., 2014] are
vastly distinct. The former utilises information obtained from average methylation
differences in various genomic contexts while the latter leverages single read
information to detect changes in epiclonal composition.
Epiallelic composition shifting represents an orthogonal approach to quantifying
epigenetic ITH within individual samples, since it examines the transformation of
epiallelic states between two samples. While tumour-specific aggregate EPM scores
represent the overall epiallelic burden of the tumour including ordered methylation
changes as well as stochastic and heterogeneous DNA methylation pattern changes,
the tumour-specific PDR scores contextualises this burden by characterising the level
of epigenetic ITH in these regions.
However, a caveat in the estimation of the two epiallelic (PDR and EPM) scores
is that measurements from tumour samples may include a mixture of tumour and
adjacent normal tissue depending on tumour purity [Jaffe and Irizarry, 2014; Zheng
et al., 2014, also discussed in Chapter 3]. Consequently, this would lead to biased PDR
and EPM scores. Although, a few methods to account for normal tissue contamination
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in cancer methylome studies are available for microarrays and other platforms using
aggregate tumour methylation profiles [Zheng et al., 2017b, 2014, DMARC developed
in Chapter 3], true decontamination at the epiallele level is challenging. A recent
report details a novel Bayesian approach to infer tumour sample purity from bisulphite
sequencing data and incorporate these estimates to deconvolute the tumour epiallele
profiles [Barrett et al., 2017]. Moreover, this method also controls for experimental
noise due to variation in bisulphite conversion. Future work will utilise this protocol
in the RRBS dataset described in this thesis, to allow a more accurate quantification of
the EPM and PDR scores in the 1482 breast tumours.
A limitation of the RRBS protocol (see Chapter 1, 2) is the inability to
discriminate between PCR-induced duplication artefacts or distinct molecular copies
of fragments since the start and end sites of reads are largely driven by restriction
enzyme digestion. This can also distort estimates of intratumour methylation
heterogeneity estimates. This predicament in RRBS can be circumvented through the
use of unique molecular identifiers (UMI) as demonstrated in the quantitative RRBS
(Q-RRBS) method established by Wang et al. [2015]. Future studies using singe-cell
genome-wide bisulphite sequencing techniques [Farlik et al., 2015; Guo et al., 2013;
Smallwood et al., 2014] in breast cancer will be able to generate exquisite measures of
ITH and provide valuable insights into their role in tumour evolution.
Several studies have reported substantial agreement between ITH inferred from
DNA methylation compared with CNAs and somatic mutations [Aryee et al., 2013;
Brocks et al., 2014; Mazor et al., 2015]. However, these studies examined spatial
heterogeneity via overall DNA methylation measurements at CpG sites based on
microarrays, and hence do not completely address the issue of epiclonal heterogeneity.
A recent report in CLL documented high epigenetic heterogeneity that was associated
with a higher number of subclonal mutations [Landau et al., 2014]. However, this
genetic score is not truly reflective of genetic ITH, but rather the degree of mutational
burden. The link between genetic and epigenetic ITH remains to be fully understood.
In this chapter, measurements of genetic and epigenetic intratumour heterogeneity
(MATH score and PDR score respectively) across more than 1000 tumours were
compared and remarkably, a significant negative correlation between the two was
observed. Higher genetic ITH has been associated with adverse clinical outcomes in
breast cancer [Pereira et al., 2016] and other cancers [Landau et al., 2013; Merlo et al.,
2010] while lower epigenetic ITH was associated with shorter survival times in the
breast cancer dataset described in this chapter. This may reflect that epigenetic and
genetic routes to malignancy in breast tissues are related but longitudinal experiments
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examining de novo genetic and epigenetic alterations in cancer cells would be required
to shed further light into this interesting relationship.
This chapter presents the first investigation of the interplay between the two
intratumour DNA methylation scores – PDR (epigenetic ITH) and EPM (epigenetic
burden) -- in cancer, as well as the first examination of the prognostic value of these
indices in breast cancer (or in any epithelial malignancy). Interestingly, EPM scores
were not prognostic individually (in addition to clinicopathological variables), but
when combined with PDR scores, both scores were prognostic (in addition to
clinicopathological variables) with tumours demonstrating evidence of higher
epigenetic burden and lower epigenetic heterogeneity associated with worse outcomes.
The resulting model using the two orthogonal epigenetic scores was the most
significantly prognostic model when compared to models with the individual scores as
well as models with CIN (chromosomal instability index). Given that breast cancer is
dominated by copy number alterations, the superior prognostic potential of the
epigenetic scores indicates the strong role of the epigenome in breast cancer.
The prognostic potential of the PDR and EPM scores supported the construction
of a simple methylation-based classifier based on the mean values of these scores in
the whole cohort. This classification was not only highly prognostic in all breast
tumours, but crucially also explained different phenotypes within established breast
cancer subtypes. Tumours with high epigenetic burden within IntClust 8 and tumours
with low epigenetic ITH in IntClust 9 were associated with worse outcomes compared
to other tumours within the respective subtypes. These tumours were largely ER+, and
consequently when considering all ER+ tumours, the combination of higher epiallelic
burden and lower ITH in promoter regions (quadrant 2, red) were demonstrated to
have the shorter breast cancer-specific survival times. Although, the higher epiallelic
burden (EPM score) in promoters have also been previously linked with adverse
outcomes in AML [Li et al., 2016b], the findings that lower DNA methylation ITH in
promoters is associated with worse prognosis is novel. Lower DNA methylation ITH
is an indicator of ordered methylation patterns that may reflect a selection process of
methylation alterations which enhance tumour fitness through the aberrant expression
of tumour suppressors and oncogenes (directed ex-DMRs have lower PDRs, Section
5.2). Tumours with lower ITH also have a higher grade, and so it could be argued that
they represent recent epiclonal expansions in which the fittest subclone emerged
resulting in lower ITH. In fact, the study in DLBCL [Pan et al., 2015] also reported
decreased methylation ITH at diagnosis compared to the normal cell population from
which they arose, and a further decrease in methylation ITH at relapse corroborating
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the postulation that as a cancer progresses, the epiclonal state rapidly becomes
homogeneous.
In sharp contrast, to the ER+ subtypes (IntClust 8 and 9), tumours within
IntClust 10 that had high epigenetic burden as well as high epigenetic diversity were
associated with worse prognosis. These tumours are predominantly ER-/ Basal-like,
thus reflecting the extraordinary distinction in the role of epiallelic dynamics in
different breast cancer subtypes. The observation that higher epigenetic heterogeneity
is associated with worse outcomes corroborates findings from the seminal study that
established PDR scores and applied them in CLL [Landau et al., 2014]. They also
reported that tumours with higher DNA methylation ITH at diagnosis correlated with
shorter progression-free survival in CLL suggesting that higher epigenetic diversity
could enhance phenotypic plasticity, thus enabling superior tumour evolution.
This 4-group methylation classifier was constructed using two tumour-specific
epigenetic indices that were calculated by aggregating scores over all 4-CpG promoter
loci (at 20×) within the RRBS universe. However, the epiallele dynamics measured by
the PDR and EPM scores can be retained at the single locus level allowing the discovery
and prioritisation of epiclonal selection and epiallele composition shifting in key cancer
genes. It is anticipated that this effort will substantially improve the understanding of
the role of stochastic drift, phenotypic plasticity and natural selection in evolution of
tumours, as well as result in the development of an enhanced methylation classifier
with superior prognostic ability.
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Summary and Perspective
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The investigation of the DNA methylation landscape in the METABRIC cohort
comprising of 1482 breast tumours and 237 matched adjacent normal tissues using
RRBS is described in this thesis. This constitutes the largest single cancer methylome
study yet, and being a next-generation sequencing (NGS) technique, represents a
significant development in the field of breast cancer.
In Chapter 2, a robust RRBS bioinformatics pipeline that is not only suitable
for high-throughput, but also maximises the information content yield was developed
and implemented. This pipeline was also validated by comparing with microarray
profiling performed on some of the samples, as well as with an external dataset
[Cancer Genome Atlas Network, 2012]. Quantitative methods for RRBS are currently
undeveloped due to the specific complexities this protocol, and to address this, a
novel algorithm called SCCRUB (Spatially Coordinated CpG-sites within the RRBS
Universe in Breast cancer) was constructed and implemented to define a functionally
relevant RRBS universe of regions comprising of spatially coordinated CpG sites in
breast cancer. The dataset generated in this thesis represents the methylation profiles
of a large number of breast tumours, and consequently will be of great value to the
breast cancer community. It has already been used as a validation dataset in a recent
report investigating germline and somatic alterations underlying deficient homologous
recombination repair in breast cancer [Polak et al., 2017].
In Chapter 3, the epigenetic drift defined as the extent of background or neutral
DNA methylation changes in breast tumours (compared to the normal tissues) was
quantified. This represents the first characterisation of genome-wide epigenetic drift
in a large cohort of primary breast tumours, and was found to be highly context
specific with methylation gains largely observed in CpG rich regions and losses in low
CpG regions. Moreover, late time of replication regions demonstrated a remarkable
predisposition for accumulating both methylation changes (gains and losses) in breast
cancer. The extent of epigenetic drift was also found to be highly heterogeneous
between the breast tumours and was sharply correlated with the tumour’s mitotic index.
This confirmed that epigenetic drift is largely a consequence of the accumulation of
passive replication related errors related to the number of cell divisions as postulated
by Yatabe et al. [2001]. The presence of these methylation alterations, that are
largely stochastic and non-specific in nature, can make the identification of epigenetic
alterations, that are truly associated with the initiation and progression of tumours,
quite challenging; an obstacle that is rarely considered in previous cancer methylome
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studies. Accordingly, the background methylation differences in tumours were utilised
to feed the development of a novel algorithm called DMARC (Directed Methylation
Altered Regions in Cancer) to detect directed and background DNA methylation
alterations in tumours. In addition, to illuminating the mechanism underlying an
observed methylation difference in a tumour, directed methylation alterations identified
by the algorithm were significantly enriched for putative functional (gene expression)
changes in breast cancer compared to background alterations.
Another key benefit of the DMARC algorithm is that it provides a novel way
to account for tumour purity. Moreover, DMARC is suitable for all high-throughput
genome-wide cancer methylome studies, and in principle, it can be applied across all
popular methylation profiling techniques that provide single CpG resolution such as
microarrays and bisulphite sequencing techniques. Future work will assess their utility
in pan-cancer microarray-based methylomes publically available from TCGA [Bass
et al., 2014; Cancer Genome Atlas Network, 2012; Cancer Genome Atlas Research
Network, 2016; Collisson et al., 2014; Hammerman et al., 2012; Muzny et al., 2012;
The Cancer Genome Atlas Research Network, 2013a; Weinstein et al., 2014].
Chapter 3 concluded with the implementation of the DMARC algorithm in the
large cohort of breast tumours and normal tissues. Collectively, the results strongly
indicated that the activity of major signalling pathways in breast cancer are at least
partly regulated by the epigenome, and more so, by epigenetic deregulation of not
only promoters but also other gene-associated elements as well as distal-regulatory
elements. Functional characterisation of differentially methylated regions in ER+ and
ER- tumours, also led to identification of subtype-specific candidate targets that were
not only incriminated with gene silencing, but also implicated with the upregulation of
genes. For instance, SPDEF and TFF3 both harboured directed-DMRs specifically
linked to differential regulation in ER+ tumours and were also associated with worse
prognosis. On the other hand, genes including IDH2 and MAST4 were identified
as subtype specific epigenetic regulators (both harboured directed-DMRs) in ER-
breast cancers and were also associated with worse prognosis. Furthermore, gene set
enrichment analysis revealed distinct pathways that were epigenetically disrupted in
ER+ and ER- tumours. For instance, oestrogen-signalling was epigenetically disrupted
in ER+ tumours and the p53 pathway in ER- tumours, thus revealing the heterogeneity
in epigenetic programming in distinct breast cancer subtypes.
Comparing the contributions of CNAs and DNA methylation events breast cancer
in Chapter 4, revealed a poignant juxtaposition in the regulatory roles of CNA and
DNA methylation. CNA played a stronger role in driving the expression of key
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protagonists of cell cycle progression leading to the divergence of tumours from normal
tissues. Conversely, silenced genes in breast tumours were significantly enriched for
DNA methylation alterations, and not in cis genomic loss. Moreover, focusing on
the top 2000 variably expressed genes in breast cancer as well as the set of genes
differentially expressed genes between the two ER subtypes established that DNA
methylation was the preferred mechanism for refining subtype-specific differences.
The crucial role of DNA methylation as a mechanism to target the silencing of
specific genes within copy number amplifications is also explored. This led to the
identification of a putative tumour suppressor gene, THSZ2, which lies within the
amplified 20q13 cytoband but is silenced potentially as a consequence of promoter
hypermethylation. Several genes were identified in which DNA methylation events
modulated the role of CNA in a similar manner. Striking examples include gene body
methylation acting as a diminishing agent in GATA3 resulting in the subtype specific
downregulation of the gene in ER- tumours; and the CNA enhancing effect of DNA
methylation in FOXA1 leading to its upregulation in ER+ tumours. The large number
of samples also allowed for the detection of mutually exclusive or co-occurring patterns
between epigenetic (DNA methylation) and genetic (CNA) alterations, that led to the
identification of genes with putative tumour suppressive roles (such as CITED1 in
ER+ tumours and FGF2 in ER- tumours) or oncogenic roles (such as INTS8 in ER+
tumours and CDK12 in ER- tumours).
Although, it is possible that the DNA methylation alterations detected in this
thesis may actually instigate the silencing or overexpression of a gene that is also
observed, recent studies have also shown that the concomitant deregulation in
expression and methylation patterns can be a consequence of an upstream
transcription factor inactivation event [Domcke et al., 2015; Feldmann et al., 2013;
Yin et al., 2017], or due to an alteration in the chromatin structure [Ohm et al., 2007;
Schlesinger et al., 2007; Widschwendter et al., 2007]. The associative statistical
models presented in the thesis cannot identify which is the causal modification and
can only demonstrate inferred function of DNA methylation events in silencing or
over-expressing key genes. Functional investigation such as epigenome editing is
required for providing definite evidence of the causal function of individual alterations
in genes, and for labelling the targeted genes as tumour suppressors or oncogenes
[Stricker et al., 2016]. However, irrespective of whether DNA methylation plays an
initiating or a reinforcing role in gene regulation, the detection of this modification
provides an extremely informative readout of the underlying epigenetic state of the
tissue. Differential DNA methylation marks do not only reflect altered transcription
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factor activity [Fleischer et al., 2017; Schübeler, 2015], but as demonstrated in this
thesis, they can also serve as powerful biomarkers for breast cancer subtype-specific
diagnosis and prognosis.
The results presented in Chapter 4 underscore the multiplicity of mechanisms
by which key cancer genes may be deregulated. However, it is also evident that a large
component of the variation in the breast cancer transcriptome is still unaccounted for
(only ∼25% of the top 2000 variably expressed genes were significantly regulated by
DNA methylation or CNA). This implies that a majority of gene expression variation
is still to be explained by other events such as microRNA [Dvinge et al., 2013],
somatic mutations [Nik-Zainal et al., 2016; Pereira et al., 2016] that have been shown
to play an important role in breast cancer. Other epigenetic events such as histone
marks [Kondo et al., 2008; Seligson et al., 2005] and chromosomal interactions
[Dryden et al., 2014; Rousseau et al., 2014; Zeitz et al., 2013] are also altered in
cancer with devastating transcriptional consequences. A complete comprehension of
the mechanisms underlying breast pathogenesis and tumour heterogeneity can only
be achieved when all events have been characterised. Information generated from
different molecular interrogations can be used to feed an integrative network analysis
to identify specific molecular pathways that are disrupted in breast cancer that are
indistinguishable if studied at a single gene level. For instance, integrating the DNA
methylation, copy number, mRNA and microRNA expression using PARADIGM
(Pathway recognition algorithm using data integration on genomic models) algorithm
[Vaske et al., 2010] emphasised the importance of FOXM1 and ERBB4 signalling
in breast cancer [Kristensen et al., 2012]. Furthermore, combining the genomic and
transcriptomic landscapes using the METABRIC dataset has already revealed 11 novel
molecular subgroups with distinct clinical features and prognosis [Curtis et al., 2012].
It will be interesting to see whether reconciling the tumour methylomes generated in
this thesis with mRNA expression, microRNA expression, somatic mutation and copy
number landscapes would identify therapeutically tractable signatures and improve
classification towards a driver-based taxonomy.
In Chapter 5, the 1482 RRBS breast cancer and 237 normal tissue methylomes
were reanalysed at the single read level to provide the first genome-wide assessment
of the role of epigenetic intratumour heterogeneity in breast cancer, and the largest for
any single cancer type. In ER+ tumours, a higher epigenetic burden but lower DNA
methylation intratumour heterogeneity was associated with worse prognosis. This
indicates that ordered methylation patterns that may reflect a selection process of
methylation alterations in these tumours which enhances tumour fitness through the
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aberrant expression of tumour suppressors and oncogenes. Conversely, in IntClust
10 tumours (that are largely ER-/ Basal-like tumours), a higher epigenetic burden
but higher DNA methylation intratumour heterogeneity was associated with lower
survival, implying that in these tumours, higher epigenetic diversity could enhance
phenotypic plasticity, thus enabling superior tumour evolution. These findings reflect
the extraordinary distinction in the role of epiallelic dynamics in different breast cancer
subtypes, and provide deep insights into the role of the epigenome in cancer, that
cannot be captured by other methylation platforms such as immunoprecipitation-based
sequencing or microarray technologies.
The existence of another cytosine modification, 5-hydroxymethylcytosine
(5hmC), was discovered in nuclear DNA in the brain [Kriaucionis and Heintz, 2009].
Subsequently, the TET family of proteins were revealed as hydroxylating enzymes
that were responsible for the enzymatic conversion of 5-methylcytosine (5mC) to
5hmC resulting in DNA demethylation [Iyer et al., 2009; Tahiliani et al., 2009].
Hydroxymethylcytosine has since been proposed as a predominantly stable epigenetic
modification with crucial roles in embryonic development, cellular differentiation and
stem cell reprogramming [Bachman et al., 2014; Hackett et al., 2013]. Several studies
have also demonstrated that hydroxymethylcytosine is positively associated with
transcriptional activity [Ito et al., 2010] and is enriched at regulatory elements and
within gene bodies of actively expressed genes [Madzo et al., 2014; Stroud et al.,
2011]. 5-hydroxymethylcytosine levels are dramatically reduced compared to the
normal tissue [Haffner et al., 2011; Song et al., 2011; Yang et al., 2013]. The global
loss of hydroxymethylcytosine is an epigenetic hallmark of cancer mediated by the
tumour suppressive role of TET2, and this phenotype has been observed in various
malignancies including myeloid leukemias [Delhommeau et al., 2009; Langemeijer
et al., 2009], melanoma [Lian et al., 2012] and glioblastomas [Johnson et al., 2016;
Raiber et al., 2017], but remains understudied in breast tumours.
Although RRBS has been utilised to comprehensively map DNA methylation
alterations in this breast tumour dataset, this methylation technology (along with other
bisulphite conversion methods such as WGBS and Infinium microarrays) suffer from
the inability to distinguish between 5-methylcytosine and 5-hydroxymethylcytosine.
Consequently, the biological interpretations provided for DNA methylation might
be confounded by DNA hydroxymethylation levels. However, this is not likely to
alter major conclusions drastically, since hydroxymethylation levels are much rarer
in the genome than methylation levels in cancer [Li et al., 2016a]. Nevertheless, a
comprehensive genome-wide profiling of hydroxymethylcytosine in breast cancer
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is warranted since it is a distinct epigenetic modification with an alternate role in
pathogenesis. Fortunately, a new technique called oxidative bisulphite sequencing
(oxBS-seq) has been developed with an additional oxidation step prior to bisulfite
conversion which allows for 5-methylcytosine and 5-hydroxymethylcytosine to be
distinguished [Booth et al., 2012, 2013]. One of the immediate future goals of this
project is to utilise whole genome oxBS-seq in breast tumours from the METABRIC
dataset presented here to fulfil two principal objectives. Firstly, since the whole
epigenome will be profiled rather than a reduced fraction, this investigation will
enable us to confirm, refine and expand the role of DNA methylation in breast cancer.
Secondly, this will provide a comprehensive account of the DNA hydroxymethylation
landscape at different genomic features and specific loci in breast cancer, and expand
the view of this epigenetic modification beyond the well-reported global reduction of
its levels observed in cancer.
DNA methylation signatures potentially offer key advantages over transcriptomic
profiles as biomarkers in cancer. While gene expression profiles provide a snapshot of
the transcriptional activity at a particular time, DNA methylation depicts a more robust
characterisation of the long-term epigenetic and transcriptional state [Szyf, 2012].
Moreover, DNA methylation is a much more robust and stable marker than mRNA
and therefore could serve as excellent molecular biomarkers for prediction, prognosis,
monitoring and stratification of breast cancer. Spatially and temporally repeated
biopsies are unfeasible for monitoring of patients’ response to therapy, particularly for
metastatic lesions. An emerging alternative is the detection of circulating tumour
DNA (ctDNA), enabling the possibility of a liquid biopsy for systemic non-invasive
monitoring of the disease [Dawson et al., 2013; Esposito et al., 2014; Murtaza et al.,
2013]. Information collected by mining methylomes of the METABRIC dataset
presented here will be instrumental to predict the best collection of methylation
signatures to be assessed in ctDNA. Two clinical studies (DETECT, metastatic breast
cancer patients; and NEO-TANGO, early breast cancer patients) have been established
in collaboration with the Caldas laboratory, which could potentially be used to
investigate the feasibility of the implementing methylation-based liquid biopsies.
A lack of good pre-clinical models, faithfully reflecting clinical response to
therapies has brought about a high attrition rate in both drug and biomarker
development. A large bio-bank of PDTX models obtained by subcutaneous
implantation of surgical tumour sample cores from the Breast Cancer Unit at the
Addenbrooke's Hospital into immune-compromised mice has been generated by the
Caldas laboratory [Bruna et al., 2012]. These models represent breast cancer
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inter-patient and intra-tumour heterogeneity, constituting the best preclinical model
available today. They are deeply characterised with multi-dimensional molecular data
including methylation profiling using RRBS, and ex vivo high-throughput screening of
clinically approved treatments, new anti-cancer drugs and new drug-drug
combinations. Work done in parallel to this thesis and in collaboration with the PDTX
consortium [Bruna et al., 2012] has led to the development and optimisation of the
bioinformatics RRBS pipeline with the crucial added capability of deconvoluting
mouse stromal contamination in the PDTXs [Callari et al., 2017, in preparation].
The well-known paradigm of promoter hypermethylation of the BRCA1 gene
conferring sensitivity to poly (ADP-ribose) polymerase family (PARP) inhibitors
[Veeck et al., 2010] has already been detected in one of the PDTX models. This
indicates the potential of epigenetic biomarkers as powerful targets for therapeutic
intervention in the clinical setting. It is anticipated that further integration of
methylation profiles and drug sensitivity data in the panel of PDTXs can lead to the
identification of new predictive epigenetic biomarkers in breast cancer, which will
move us closer towards tailoring treatments to the patient’s molecular profile.
Moreover, comparison of drug sensitivity in matched primary and metastatic tumours,
as well as serial passaging of the same PDTX tumour model, conjugated with
epiclonal architecture modelling, can give insights into mechanisms of intrinsic and
acquired resistance. Preliminary analysis of the epigenetic intratumour heterogeneity
(PDR score) in the PDTXs have revealed that that higher epigenetic heterogeneity can
drive variable response to drug therapy (PDR score vs. standard deviation of area
under the curve response across all drugs tested: correlation = 0.70, p-value = 0.0037).
Given, the important role of DNA methylation changes in cancer, there has been
much excitement regarding potential therapeutic interventions based on reversing these
epigenetic abnormalities. The predominant approach for targeting DNA methylation is
the utilisation of DNA methyltransferase (DNMT) inhibitors like 5-azanucleosides in
order to obtain tumour suppressive effects [Barletta et al., 1997; Daskalakis et al., 2002;
Jones and Taylor, 1980]. However, the unspecific nature of the DNA methyltransferase
(DNMT) inhibition induced by 5-azanucleosides proved to be too toxic for clinical
therapy initially. Seminal clinical work in adjusting the dose of the 5-azacytidine
treatment regimen demonstrated that its use in conjunction with standard chemotherapy
had significant improvements in survival [Fenaux et al., 2009; Silverman and Mufti,
2005] and led to its adoption in the clinic, although only for leukaemia [Kaminskas,
2005]. Identification of breast cancer subtype-specific methylation signatures in
this thesis can pave the way for further research into incorporating the utility of the
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CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-Cas9)
system towards the development of gene-specific and patient-targeted demethylating
agents as a potential cancer therapy in breast cancer [Choudhury et al., 2016; Liu et al.,
2016; Xu et al., 2016].
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Figure A.1: Supervised analysis of DNA methylation profiles reveal distinct
epigenetic landscapes in breast cancer subtypes. (a) Distribution of average
methylation estimates for the breast cancer Intrinsic subtypes and normal tissues
stratified by genomic feature. For each sample, the median methylation level across each
genomic feature, and the resulting distributions were plotted. For each genomic feature,
methylation estimates between these three categories were compared using the Kruskal
Wallis test. FDR p-values were denoted. (b) Same as (a) but for the breast cancer
Integrative clusters. (N.S.= FDR p-value < 0.1, * = FDR p-value < 0.05, ** = FDR
p-value < 0.01, *** = FDR p-value < 0.001, **** = FDR p-value < 0.0001).
Heterochrmtn = Heterochromatin.
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Figure A.2: (Previous page.) Hyper and hypo DMRs detected in the Intrinsic
subtypes. (top panel) The proportion of hyper and hypo DMRs within each genomic
feature, relative to the total number of SCCRUB regions within the respective genomic
feature (the total number is noted in the boxes at the top), detected across the Intrinsic
subtypes. x-axis represents the tumour subtype and the five panels represent the
individual genomic features. Analyses were conducted separately for the 6 tumour
subtypes and 5 genomic features resulting in 30 bars. Positive bars on y-axis represents
hyper DMRs and negative bars represents hypo DMRs. (middle panel) The ratio
between the number of hyper and hypo DMRs detected for each genomic feature which
represents the inclination of a tumour subtype to significantly gain or lose methylation in
a specific genomic feature. (bottom panel) Enrichment analysis of hyper and hypo
DMRs across the 5 genomic features conducted separately for each tumour subtype, as
explained in the text (hypergeometric test). Top squares represent enrichment of hyper
DMRs and bottom represent enrichment of hypo DMRs. Colour of the squares represent
level of enrichment (observed/ expected). Red represents enriched (enrichment > 1), blue
represents depleted (enrichment < 1) and white represents no enrichment (enrichment =
1). Square boundaries represent whether the enrichment was significant (solid lines =
FDR p-value < 0.05; dotted lines = FDR p-value > 0.05). LUMA = Luminal A. LUMB =
Luminal B. HER2 = HER2-enriched. BASAL = Basal-like. CLAUDIN = Claudin-low.
NORMAL = Normal-like.
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Figure A.3: (Caption on next page.)
310
Figure A.3: (Previous page.) Hyper and hypo DMRs detected in the Integrative
clusters. (top panel) The proportion of hyper and hypo DMRs within each genomic
feature, relative to the total number of SCCRUB regions within the respective genomic
feature (the total number is noted in the boxes at the top), detected across the Integrative
clusters. x-axis represents the tumour subtype and the five panels represent the individual
genomic features. Analyses were conducted separately for the 11 tumour subtypes and 5
genomic features resulting in 55 bars. Positive bars on y-axis represents hyper DMRs
and negative bars represents hypo DMRs. (middle panel) The ratio between the number
of hyper and hypo DMRs detected for each genomic feature which represents the
inclination of a tumour subtype to significantly gain or lose methylation in a specific
genomic feature. (bottom panel) Enrichment analysis of hyper and hypo DMRs across
the 5 genomic features conducted separately for each tumour subtype, as explained in the
text (hypergeometric test). Top squares represent enrichment of hyper DMRs and bottom
represent enrichment of hypo DMRs. Colour of the squares represent level of enrichment
(observed/ expected). Red represents enriched (enrichment > 1), blue represents depleted
(enrichment < 1) and white represents no enrichment (enrichment = 1). Square
boundaries represent whether the enrichment was significant (solid lines = FDR p-value
< 0.05; dotted lines = FDR p-value > 0.05).
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TOR −→ Very Early Early Neutral Late Very Late
CpG density ↓ Diff N Diff N Diff N Diff N Diff N
0 - 5 -9.49 1016 -7.70 610 -6.71 337 -3.02 104 -14.95 1849
5 - 10 -9.07 14077 -6.94 9906 -4.77 6532 -4.00 2760 -14.76 19712
10 - 15 -9.17 21826 -6.63 18700 -4.85 14370 -3.79 7468 -15.05 23989
15 - 20 -9.13 48224 -6.34 44653 -4.73 41368 -3.59 26598 -15.06 46273
20 - 25 -8.74 35667 -6.07 35414 -4.44 35726 -3.38 27410 -14.61 32595
25 - 30 -8.15 47105 -5.68 49684 -4.02 53150 -3.05 48707 -13.88 44795
30 - 35 -7.67 25091 -5.38 27303 -3.79 29757 -2.68 30991 -12.67 25849
35 - 40 -7.08 29444 -4.91 30075 -3.44 33591 -2.38 39613 -11.80 32544
40 - 45 -6.32 14150 -4.70 14049 -2.87 15503 -1.61 20257 -10.93 16318
45 - 50 -5.21 14926 -3.50 15041 -2.31 15764 -1.07 22816 -9.44 15960
50 - 55 -3.49 6885 -2.22 6870 -1.44 7329 -0.52 11049 -7.36 7117
55 - 60 -1.57 7810 -0.75 7914 -0.11 8032 0.23 12337 -4.77 7782
60 - 65 0.32 4562 0.70 4322 0.86 4616 1.06 6370 -2.09 4397
65 - 70 1.49 5590 2.32 5621 1.92 5769 1.27 7645 0.41 5298
70 - 75 4.15 3316 3.59 3435 3.35 3475 1.61 4350 3.64 2858
75 - 80 5.67 4781 5.29 4605 4.50 4838 3.11 5483 6.86 3539
80 - 85 6.59 2650 7.00 2942 5.72 2859 3.64 3238 7.88 1888
85 - 90 7.65 3686 7.25 4224 5.48 3865 4.07 4415 9.30 2744
90 - 95 8.04 2140 7.79 2495 5.36 2236 4.23 2670 10.06 1637
95 - 100 8.13 2693 7.90 3285 6.21 3007 5.10 3614 10.34 2093
100 - 105 8.29 1536 7.36 2015 6.12 1715 5.19 2242 11.79 1243
105 - 110 8.34 2105 7.27 2516 6.22 2423 4.71 2777 12.01 1611
110 - 115 7.77 1054 6.83 1422 6.54 1303 5.59 1522 12.19 846
115 - 120 7.34 1515 6.33 2032 5.95 1679 5.14 1920 13.04 1071
120 - 250 6.87 4332 6.66 6343 5.38 5590 5.67 7477 12.98 3077
Table B.1: Details of the 125 CpG density/ time of replication bins. The mean
background methylation difference between all tumours and the normal tissues across all
CpG sites (Diff), and the number of CpG sites (N) is calculated for each of the 125 CpG
density/ Time of Replication bins. CpG density (25 rows) is measured as number of
CpGs/ kbp. TOR = Time of Replication. TOR is stratified based on 20th percentiles (5
columns).
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13
5 ,
P
IT
X
11
*,
F
O
X
C
11
,G
C
N
T2
1 ,
X
P
O
51
,M
B
21
D
13
,S
N
X
83
,N
F
E
2L
33
*,
N
F
E
2L
33
,M
G
C
72
08
03
,A
C
TR
3B
2 ,
E
IF
4E
B
P
13
,G
SD
M
C
2 ,
TO
P
1M
T3
,C
A
LM
L5
2 ,
H
SP
A
14
4 ,
R
P
P
38
4 ,
M
A
ST
L4
*,
R
P
S2
44
,C
E
P
55
3 ,
D
D
X
11
3 ,
TF
D
P
15
,P
LK
13
*,
C
E
N
P
N
2 ,
SL
C
7A
53
,F
A
M
64
A
4 ,
M
R
P
L1
24
,A
F
G
3L
23
,S
LM
O
13
*,
SL
M
O
13
,D
D
X
39
A
4 ,
D
D
X
39
A
4 ,
D
D
X
39
A
4 ,
P
D
C
D
2L
3 ,
C
D
C
25
B
3 ,
FA
M
83
D
3 ,
R
B
M
38
2 *
,T
YM
P
4 *
,T
YM
P
4 *
In
tC
lu
st
10
D
ow
n
15
13
D
N
A
LI
11
,R
H
O
B
4 ,
A
F
F
33
,I
R
S1
2 ,
IR
S1
2 ,
W
F
S1
3 ,
TF
A
P
2B
2 ,
G
AT
A
32
,A
R
R
B
13
,C
16
or
f4
53
,P
A
LM
3 ,
P
TP
R
T3
*,
P
TP
R
T3
,P
TP
R
T3
*,
C
LI
C
61
Ta
bl
e
B
.3
:(
C
ap
tio
n
on
ne
xt
pa
ge
.)
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Chapter B. Supplementary tables
Ta
bl
e
B
.3
:(
Pr
ev
io
us
pa
ge
.)
G
en
es
ha
rb
ou
ri
ng
su
bt
yp
e-
sp
ec
ifi
c
ex
pr
es
si
on
-D
M
R
si
n
th
e
In
te
gr
at
iv
e
cl
us
te
rs
.F
or
ea
ch
su
bt
yp
e,
ge
ne
s
ha
rb
ou
ri
ng
ex
pr
es
si
on
-D
M
R
s
th
at
fu
lfi
lle
d
th
re
e
cr
ite
ri
a
w
er
e
id
en
tifi
ed
as
fo
llo
w
s:
i)
D
M
R
w
ith
a
m
et
hy
la
tio
n
di
ff
er
en
ce
of
at
le
as
t2
0%
vs
.
no
rm
al
tis
su
e;
ii)
D
M
R
w
ith
a
m
et
hy
la
tio
n
di
ff
er
en
ce
of
at
le
as
t2
0%
ve
rs
us
ot
he
rt
um
ou
rs
;a
nd
iii
)D
M
R
is
as
so
ci
at
ed
w
ith
al
te
re
d
ex
pr
es
si
on
of
th
e
ge
ne
:P
ar
tia
lc
or
re
la
tio
n
be
tw
ee
n
m
et
hy
la
tio
n
an
d
ex
pr
es
si
on
,|r
ho
m
et
h-
in
de
pe
nd
en
t
>
0.
40
,a
nd
F
D
R
p-
va
lu
e
<
0.
05
.T
he
su
pe
rs
cr
ip
t
de
ta
ils
th
e
ge
no
m
ic
fe
at
ur
e(
s)
in
w
hi
ch
th
e
ex
pr
es
si
on
-D
M
R
w
as
fo
un
d.
1
=
pr
om
ot
er
;2
=
ex
on
;3
=
in
tr
on
;4
=
en
ha
nc
er
;5
=
PR
C
re
gi
on
.I
f
m
or
e
th
an
ex
pr
es
si
on
-D
M
R
w
as
fo
un
d
in
on
e
ge
ne
,t
he
n
al
lg
en
om
ic
fe
at
ur
es
w
er
e
de
ta
ile
d
in
or
de
ro
fd
ec
re
as
in
g
m
et
hy
la
tio
n
di
ff
er
en
ce
(v
s.
ot
he
rt
um
ou
rs
).
’*
’r
ep
re
se
nt
s
B
ac
kg
ro
un
d
D
M
R
.A
bs
en
ce
of
’*
’r
ep
re
se
nt
s
D
ir
ec
te
d-
D
M
R
.
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